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SUMMARY
Left ventricular hypertrophy (LVH) is accepted as an important independent predictor of 
adverse cardiovascular outcome; the aetiology includes a number of well-recognized causes 
but there is considerable interest in the genetics underlying cardiac hypertrophy. Data from 
several twin studies indicates that left ventricular mass index (LVMl) has a significant 
genetic basis that is most likely polygenic. Given the heterogeneity of the human 
condition, there has been little progress made towards identification o f the genes involved, 
in this now common disease state. As an adjuvant to current human studies, inbred animal 
models have been developed which in turn have led to the identification of quantitative trait 
loci (QTL), via investigation using a genome wide strategy. This generally involves high 
fidelity phenotyping o f large segregating F2 populations, derived by crossing inbred strains 
of sufficiently differing phenotype and subsequent genotyping using a wide selection of 
polymorphic microsatellite markers spread across the entire rat genome.
The research described in this thesis incorporated an improved analysis of a previous 
genome wide scan, to confirm and identify QTL containing determinants of left ventricular 
hypertrophy in the Glasgow SHRSP x WKY F2 cross. This genome wide scan was carried 
out in 134 F2 hybrids (male: female = 65:69). Systolic and diastolic blood pressure was 
measured by radio-telemetry at baseline and after a 3 week 1% salt challenge in addition to 
heart rate, motor activity and pulse pressure. Other phenotype data included body weight, 
heart and LV weight and plasma renin activity. QTL affecting a given phenotype were 
mapped relative to an improved genetic linkage map for rat chromosome 14, with the aid of 
JoinMap 3.0, MapManager QTXb and Windows QTL Cartographer software. The original 
method of single marker analysis was used initially to test previous and newly acquired 
genotype data and confirm the cited LVMl QTL on rat chromosome 14. More stringent 
and complex statistical approaches were integrated in analysis resulting in detection of a 
second QTL for LVMl at marker DI4Got33 and a single QTL for cardiac mass at marker 
D14Woxl4.
XV
The identification of QTL, although a fundamental process, is only the initial step towards 
the end objective of gene identification. The next logical step is the physical capture and 
confirmation of QTL with the production of congenic strains and substrains. In this thesis, 
the process of verifying the chromosome 14 QTL began with the generation of congenic 
strains, using a marker assisted ‘speed’ congenic strategy, previously validated in rats by 
our group. This was achieved by backcross breeding two inbred rat strains (SHRSP X 
WKY) and introgression of marker delineated regions of chromosome 14, from one 
background into the recipient genome and vice versa. Complete homozygosity of the 
background genetic markers (n-168) was achieved after 4 backcross generations. In the 
time line allowed, it was not possible to achieve a fixed congenic line however based on 
data provided from QTL analysis it was possible to generate and analyse preliminary 
phenotype data from backcross 4 males on the SHRSP background. The initial readings 
from this pilot study provide physical evidence that substituting a portion of WKY 
chromosome 14 with SHRSP results in a reduced LVMl, despite equivalent systolic blood 
pressure.
An essential component of a successful QTL and congenic strategy is an accurate and 
reliable method of phenotyping. Simple post mortem measurement of heart and LV weight 
is satisfactory for end evaluation, but this method does not permit continuous or 
longitudinal studies in the animal. Echocardiography provides an inexpensive and accurate 
means to investigate LVMl in vivo however reproducibility of data can be poor and 
reliability of LVMl estimation varies between strains, primarily due to differences in heart 
shape. A current ‘gold standard’ method of cardiac imaging in the human clinical setting is 
magnetic resonance imaging (MRI). Although this technique has been used successfully 
for several years in therapeutic and diagnostic applications, the scope of MRI in small 
animals has not been fully investigated. With this aim, MRI was used to measure LVM 
and cardiac function in SHRSP, WKY and a chromosome 2 congenic strain 
(SP.WKYGla2a) with a significantly reduced systolic blood pressure. The in vivo use of 
MRI in this study provided 3-D images, which allowed for an accurate, highly reproducible 
and superior method of LVM estimation, applicable in a rat model of hypertension and 
cardiac hypertrophy. Furthermore, MRI was shown to be a sensitive technique, able to
XVI
discern subtle changes in ventricle shape, size and relative wall thickness (RWT) in small 
subject groups, not possible by simple post mortem or 2-D echocardiographic evaluation; a 
significant difference in RWT between the congenic strain and SHRSP was demonstrated 
for the first time.
In addition to QTL analysis, supplemental tools of investigation such as comparative 
mapping provide an inexpensive and relatively easy method o f isolating large conserved 
regions o f synteny between species. While this is still a relatively young field of research, it 
does provide insights into evolutionary aspects of gene hierarchy and provides a means of 
selecting genes o f positional interest for further investigation. Candidate genes {Corin and 
Dbp) with shared synteny between rat, mouse and human were identified within LVMl 
QTL borders (on chromosome 14) for rat. It is important, however to conduct studies to 
confirm a functional role of candidate genes in cardiac hypertrophy. With the use of real 
time polymerase chain reaction (RT-PCR), cardiac mRNA was quantified and differential 
expression o f candidate genes in parental strains was confirmed. The impact of blood 
pressure on these genes was further tested using mRNA taken from heart, after 
anti hypertensive pharmalogical intervention. Despite a reduction in SHRSP blood pressure 
to equivalent WKY levels, the results of this study did not reflect a change in candidate 
gene expression comparable with WKY.
A two-factor microarray study of cardiac tissue in 21 week old SHRSP and WKY +/- salt 
was also undertaken in order to examine strain differences between SHRSP and WKY, as 
well as the effect of environmental stimuli on genotype. The high volume of data generated 
from this investigation required several filtering applications to reduce the number of 
significant differentially expressed genes. This was achieved initially by normalising the 
data for variation affects and partition clustering of groups into genetic profiles. Secondly, 
two different analytical approaches were used to determine genes o f significance for follow 
up study on chromosome 14 regions of interest, in addition to genes determined as 
‘interacting’ between strain and environment. The majority o f genes identified as 
differentially expressed between strains were contractile proteins such as actin {Actal, 
Acta2, Act/J), myosin heavy chain (Myh6, MyhT) and related proteins such as tropomyosin
XVII
alpha (Tpm la). Genes identified as differentially expressed post 3 week 1% salt challenge 
were mainly cell signaling kinases, growth factor receptors (Egfr) and transcriptional 
regulators {Hesl, Hop). Five genes were identified within the QTL regions on 
chromosome 14, of which two are functionally associated with cardiac hypertrophy; Egfr 
and Hop. The results from this microarray study offer several candidate genes for 
continued investigation in addition to providing a base of data in which to add further 
datasets, e.g. a chromosome 14 congenic.
In summary, this thesis describes the detailed investigation of the underlying genetic 
components and improved phenotypic analysis of left ventricular hypertrophy in the stroke 
prone spontaneously hypertensive rat, focussing in particular on the identification of 
candidate genes within an implicated region on rat chromosome 14.
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CH APTER 1 
INTRODUCTION
1.1 Complex Genetic Cardiovascular Traits
Cardiovascular disease (CVD) is the main cause of death in the UK accounting for 
39% of all deaths (British Heart Foundation Statistics, 2005). The major forms of CVD 
are coronary heart disease (CHD) and stroke with around half o f all deaths from CVD 
attributed to CHD and about a quarter from stroke. In the last decade, the number of men 
living with CHD has increased to 7.4% of the adult population, from 6% and from 4.1% to 
4.5% in women. These statistics indicate that there are now approximately 2.6 million 
people in the UK facing life with heart disease (British Heart Foundation Statistics, 2005). 
The cardiovascular disease epidemic has progressed from Western civilizations to the 
developing countries and despite healthcare advances the percentage of all deaths 
attributable to cardiovascular causes are estimated to rise from 25% in 1990 to 40% in 
2020 (Reddy, 2004). The risk factors relating to cardiovascular disease extend from 
hypertension, insulin resistance and type 2 diabetes, obesity and hyperlipidaemias through 
traits such as metabolic syndrome and atherosclerosis to disease phenotypes including 
myocardial infarction, heart failure, stroke, left ventricular hypertrophy, peripheral 
vascular disease, and renal failure (Dominiczak & McBride, 2003).
Most cardiovascular diseases are complex, multifactorial, polygenic disorders, exhibiting 
the simultaneous effects of several genetic and environmental influences (Figure 1.1). A 
complex genetic trait can be described as a trait in which a simple one-to-one relationship 
between genotype and phenotype, as in classic Menedelian inheritance does not exist 
(Lander & Schork, 1994). The genetics of multifactorial diseases in human populations are 
particularly difficult to dissect due to the multiplicity of genes involved in complex 
phenotypes. Gene-gene (epistatic), gene-environment (ecogenetic) interactions, gender, 
discrete effects of each gene and heterogeneity within human populations are all factors 
influencing complex diseases (Stoll et a l,  2000). Despite these difficulties, identifying 
and understanding the principal genes underlying polygenic diseases can lead to improved 
methods of predicting inherited susceptibility and provide opportunities for the 
development of genome specific treatments (Lifton, 1995).
Gender ?[ Environmental Influence 1
 ^ I
Comolex Trait
m ^BMI
Environmental 
Influence 2
Gene 3
Î \ i Age
Gene 2 Gene 1
Figure 1.1 Illustration of the polygenic, multifactorial nature of a complex trait. *BMI 
body mass index (Adapted from Lifton, 1995).
1.1.1 Blood pressure: regulation and maintenance
Blood pressure is the hydrostatic force blood exerts against the vascular walls and 
is determined by the amount of blood ejected from the heart and the resistance of arterioles 
to blood flow (Schork, 1997). Ventricular contraction (systole) ensures continuous flow to 
the periphery with forward propulsion of blood during ventricular relaxation (diastole), A 
sequence illustration of events during the cardiac cycle is shown in Figure 1.2. The 
physical relationships between the factors governing pressure and flow in a circulatory 
system are defined by Poiseuille’ Law, which describes how flow relates to perfusion 
pressure, radius, length, and viscosity. Ffowever, flow in the body does not necessarily 
conform quantitatively to this relationship, which assumes long, straight tubes (not blood 
vessels), a Newtonian fluid (e.g., water, not blood which is non-Newtonian) and steady, 
laminar flow conditions. Nevertheless, this equation serves to demonstrate the dominant 
influence of vessel radius on resistance and flow (Figure 1.3).
Hormonal mechanisms act in concert with neuronal controls to regulate blood pressure via 
several methods, including vasoconstriction, vasodilation and alteration of blood volume. 
The reflex control of blood pressure is mediated by the medulla and to a higher degree by 
the hypothalamus, which acts neurally through the medulla, hormonally via vasopressin 
and consciously by creating a thirst drive (Burnstock 1986). A decrease in blood pressure 
results in sympathetic nervous system (SNS) activation leading to increased contractility of 
the heart (pj-receptors) and vasoconstriction of both the arterial and venous side of the 
circulation (a-receptors). Stimulation of the parasympathetic system works in opposition 
to the SNS by slowing heart rate and causing vasodilation through release of acetylcholine 
(Benarroch, 1993). Whilst, all regulatory components influencing blood pressure are 
important, the renin angiotensin system (RAS) is considered a key modulator of blood 
volume, arterial pressure and sodium balance, the physiology of which continues to be a 
major source o f investigation (Helmer, 1965; Meyer, 1965; Dzau, 1988). Figure 1.4 
outlines the RAS; Table 1.1 summarizes the principal hormones and neurotransmitters 
involved in blood pressure regulation.
Late diastole-both sets of chambefs relaxed. Passive ventricular filling.
Isovolumic ventricular relaxatlon-aa ventricles relaxErassure In ventricles drops, lood flows back Into cups of semllunar valves and snaps them closed.
Atrial systole- atrial contraction forces a small amount of additional blood Into ventricles.
ESV = end-systollc volume, or minimum amount of bio In ventricles. ESV = 65 mL
Ventricular ejection- * as ventricular pressure rises and exceeds pressure In the arteries, the semllunar ^  valves open and blood la ejected
EOV = end-dlastollc volume.The maximum amount of blood In ventricles occurs at the end of ventricular relaxation. EOV = 135 ml_
Isovolumic ventricular contraction-first phase '  ' — of ventricular contraction pusfies AV valves closed but does not create enough pressure to < ^ n  semllunar valves.
Figure 1.2 Diagram outlining the sequence of events during a heartbeat (taken from Berne 
& Levy, 1997).
Rate of flow = tiR (^P., -  P )^
8tiL
Figure 1.3 The rate at which a viscous fluid flows through a cylindrical shaped pipe. 
Poiseuille' Law, for laminar flow rate, where the velocity of blood in a smaller vessel is 
larger than that in a larger vessel with the same flow. R=radius, V=velocity, r|=blood 
viscosity, L=length, P=pressure; increase radius, increase blood flow (adapted from Berne 
& Levy, 1996)
Atrial natriuretic peptide (ANP) was first identified 25 years ago as a cardiac peptide 
involved in the regulation of blood pressure (de Bold et a l, 1981). A physiologically 
inactive precursor to ANP, specifically pro-ANP, is stored and secreted from the atria and 
ventricle (Ogawa et a l,  1991) to high blood pressure. ANP acts to reduce water, sodium 
and adipose loads on the circulatory system, thereby reducing blood pressure and is an 
important regulator of homeostasis in the body. Recently a newly characterised serine 
protease, Corin was identified as the pro-ANP converting enzyme (Yan et a l 1999; Wu & 
Wu, 2003) involved in cleaving pro-ANP to the cardiac active hormone.
1.1.2 Human Essential Hypertension
The provision of a blood pressure level at which adequate tissue perfusion is 
maintained reflects the countless interactive neural, hormonal and circulatory systems and 
sub-systems (Schork, 1997). Hypertension refers to the maintenance o f excessively high 
blood pressure (Pickering, 1965; Swales, 1994), which applies to elevations in mean 
arterial pressure, diastolic pressure, or systolic pressure and is often defined as a diastolic 
pressure of 90 mmHg or above, or a systolic pressure of 140 mmHg or above (Table 1.2) 
(Mikhail & Cope, 2004). Although without obvious symptoms, hypertension can have 
severe effects on a number of important tissues in the body including the heart, kidney and 
brain (Figure 1.5). In most individuals (90-95%) presenting with hypertension, the cause 
is unknown - essential (or primary) hypertension. In the remaining 5-10% of subjects with 
hypertension, it is secondary to renal disease, endocrine disorders, or other identifiable 
causes - secondary hypertension. As the core determinants of essential hypertension are 
unidentified, the efficacy of any preventative therapeutic measures is hampered 
(Dominiczak & Lindpaintner, 1994).
Blood pressure has a unimodal distribution in the general population with a strong 
positive and continuous correlation between blood pressure and cardiovascular disease
Sympathetic Stimulation 
Hypotension
D ecreased  Sodium Delivery
A ngiotensinogenRenin,
AI Adrenal
Cardiac & Vascular 
Hypertrophy
# Systemic 
Vasoconstriction
^  Pituitary
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;J n c æ a s e d  ^Blood
«Volume
\
A ld o ste ro n e/
Renal 
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Figure 1.4 A diagrammatic outline of the RAS regulatory cascade in blood pressure 
regulation. The RAS pathway is common to many tissues however the most notable 
occurrence of this pathway is in the kidney. Sympathetic stimulation, renal artery 
hypotension, and decreased sodium delivery to the distal tubules stimulate the release of 
renin from the kidney, which then acts upon a circulating substrate, angiotensinogen. 
Proteolytic cleavage of angiotensinogen results in formation of the deca-peptide 
angiotensin 1 (AI). The vascular endothelium, particularly in the lungs, secrete angiotensin 
converting enzyme (ACE), which cleaves two amino acids from AI to form the octa- 
peptide, angiotensin II (All) (modified from Zaman et a i, 2002).
Table 1.1. Key regulatory hormones and neurotransmitters involved in the regulation
and maintenance of blood pressure
Neuronal/Hormonal
Regulator
Site of 
Production/Secretion
Function
Renin and angiotensin Kidney Production is stimulated by decreased 
blood pressure (hypotension). Blood 
pressure modulation via control of 
blood volume, also stimulate 
production of aldosterone from the 
adrenal cortex (which also decreases 
urinary fluid and electrolyte loss from 
the body).
Natriuretic peptides: 
atrial natriuretic 
peptides (ANP) 
brain natriuretic 
peptides (BNP)
Atria (ANP) 
Ventricles (BNP)
Play a role in the regulation of blood 
pressure homeostasis and salt and 
water balance via diuretic, natriuretic 
and vasorelaxant effects.
Catecholamines: 
adrenaline, 
noradrenaline and 
dopamine
Adrenal Gland Secreted in response to sympathetic 
nervous system stimulation and act 
rapidly to increase cardiac output and 
cause vasoconstriction.
Acetycholine Cholinergic nerve 
(e.g. vagus)
Act to depress cardiac activity by 
slowing heart rate and causing 
vasodilation.
Vasopressin Posterior Pituitary An important hormone regulator of 
water balance.
Taken from Espiner et al, 1995; Rubattu & Volpe, 2001.
Table 1.2. The JNC-7 guidelines for blood pressure classification
Blood pressure Classification »SBP
(mmHg)
tDBP
(mmHg)
Normal <120 <80
Prehypertensive 120-139 80-89
Stage 1 Hypertension 140-159 90-99
Stage 2 Hypertension >160 >99
systolic blood pressure 
tDBP- diastolic blood pressure 
Adapted from Mikhail & Cope, 2004.
Heart Kidney
Figure 1.5 Organ damage resulting from elevated blood pressure -  Injury to the brain 
due to haemorrhage or thrombosis, causing stroke. The vasculature of the kidney can 
become dramatically constricted restricting urine output and causing proteinuria. The 
heart can become hypertrophied and compromised in function, leading to heart failure. 
Hypertensive rentinopathy is a further complication of extremely high blood pressure 
where blood vessels in the eye become blocked or rupture, causing damage to the 
surrounding eye tissues.
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risk and mortality, even in the normotensive range (Merlo et a l ,  2004). Oldham et a l  
(1960) proposed that high blood pressure is an extreme of normal blood pressure 
distribution, which suggests that hypertension is influenced by several independently 
segregating genes, each exerting subtle effects on blood pressure. This hypothesis was 
quickly extended to five or six individual genes, contributing approximately 30% - 
50% of observed variation in blood pressure in the general population (Ward, 1983).
1.1.3 Left Ventricular Hypertrophy
The cardiac muscle responds to chronically increased volume (preload) or 
pressure (aherload) by compensatory growth of the myocardium (Messerli, 1983). 
Ventricular hypertrophy is an adaptation by the ventricle that enables the heart to 
manage increased stress (Figure 1.6). At the cellular level, this involves a swelling of 
the myocyte cross-sectional area (hypertrophy), with the actual number of myocytes 
increasing (hyperplasia) when the heart reaches a critical weight of approximately 
500g (Linzbach, 1960) or 7.5g/kg bodyweight (Dickhuth et a l ,  1985). The process of 
hypertrophy is also linked to a cellular shift in expression of adult contractile proteins, 
to foetal isoforms (Durand et a l ,  1999).
If the precipitating stress is volume overload, the ventricle responds with the addition 
of new sarcomeres in-series with existing sarcomeres resulting in ventricular dilation 
while maintaining normal sarcomeric lengths, thus wall thickness increases 
proportionally with chamber radius - eccentric hypertrophy (Koren et a l ,  1991). In the 
case of chronic pressure overload, the chamber radius may not alter; however the wall 
thickness greatly increases as new sarcomeres are added in parallel to existing 
sarcomeres - concentric hypertrophy (Koren et a l ,  1991) (Figures 1.6 & 1.7). This 
latter type o f hypertrophy is capable of generating greater forces and higher pressures, 
while the increased wall thickness maintains normal wall stress however, over time the 
ventricle becomes "stiff (i.e., compliance is reduced) and consequently less able to 
relax resulting in impaired filling and diastolic function (Gaasch et al, 1976).
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Figure 1.6 In contrast to skeletal muscle, cardiac muscle has a number of unique features 
that reflect its function of pumping blood. The myofibrils of each cell (cardiac muscle is 
made of single cells, each with a single nucleus) are branched and the branches interlock 
with those of adjacent fibres by adherens junctions. These strong junctions enable the heart 
to contract forcefully without ripping the fibres apart. Cardiac muscle is striated. Each 
cardiac muscle cell contains sarcomeres with sliding filaments o f actin and myosin. 
Sarcomeres represent the minimal contractile unit of a muscle. Sarcomeres in a myofibril 
shorten resulting in shortening of the myofibril and in turn, the muscle fibre (electron 
micrograph, Porter & Bonneville, 1973).
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Figure 1.7 Left ventricular (LV) geometric patterns, consequences of different 
combinations of pressure and/or volume overload. Left ventricular mass index (LVMI) 
describes left ventricle mass relative to height; relative wall thickness (RWT) refers to LV 
wall thickness/LV radius. (Bottom left), the normal condition with normal LVMI, normal 
RWT, normal cardiac output (CO), total peripheral resistance (TPR) and end-systolic ( e s )  
and end-diastolic ( e d )  wall stress ( o ) .  (Top left) concentric LV remodelling and (bottom 
right), eccentric LV hypertrophy. (Top right) concentric LV hypertrophy, (adapted from 
Ganau et al., 1992).
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Systemic perfusion is maintained until the development o f ventricular dysfunction, leading 
to heart failure, myocardial infarction or arrhythmia (Pfeffer et a l ,  1982; Devereux & 
Roman, 1995; Frohlich, 2001).
There is an approximate 60% increase in the incidence of coronary heart disease in men 
and 45% in women for every 50g rise in left ventricle mass (LVM), therefore left 
ventricular hypertrophy (LVH) is considered an important independent risk factor for 
cardiovascular morbidity and mortality (Kannel et a l ,  1970; Levy et a l ,  1990; Devereux 
et a l ,  1994; Dominiczak et a l ,  1997; Schillaci et a l ,  2000). The intrinsic factors adding 
to risk (i.e. the pathophysiologic mechanisms by which hypertrophic remodelling of the 
myocardium contributes to cardiovascular related death) remain unknown (Devereux & 
Roman, 1995; Frohlich, 2001). One cause may be increased prevalence of ischaemic 
damage - enlarged myocardium leads to higher oxygen consumption while at the same 
time reducing coronary blood flow reserve, resultant in impaired blood delivery to the 
affected region (Schwartzkopff & Strauer, 2000).
Although elevated blood pressure is an important determinant of LVH (Kannel, 1983) the 
intensity of blood pressure load does not always correspond to the degree of hypertrophy 
observed in humans (Dominiczak ef al., 1997), indicating a more complex relationship 
than a simple dose-response effect. The distribution of cardiac mass within populations of 
unselected normotensive or hypertensive individuals appears to be largely continuous 
(Nunez et a l , 1996), with some studies reporting no indication of cardiac hypertrophy in 
50% of hypertensive subjects (Devereux et a l,  1987).
1.2 EVIDENCE FOR GENETIC EFFECTS
1.2.1 Mendelian Forms of Hypertension
Evidence to support essential hypertension and LVH as a genetically determined 
disease is based on observations of a number of rare syndromes which display a Mendelian
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inheritance pattern indicative of a monogenic disorder. Although these syndromes are 
uncommon, considerable effort has been spent to identify the genes responsible. There are 
several reasons for this; firstly, the effects o f segregation of single alleles in families can be 
easily distinguished, thereby simplifying the molecular genetic analysis necessary. 
Secondly, these disorders often result in a severe disease state allowing for easier 
phenotypic selection. Finally, it is anticipated that the biochemical pathways and genes 
involved in these severe forms may also be implicated in the cardiovascular disease states 
more commonly seen in the general population. It then follows that understanding these 
disorders may not only be o f value to the affected families but could also provide more 
broadly applicable diagnostic and therapeutic tools (Karet & Lifton, 1997).
There are currently at least six monogenic or Mendelian forms of human essential 
hypertension known to harbour mutations which impose large effects on blood pressure 
levels and are characterised by affecting sodium and water reabsorption in the kidney -  
Glucocorticoid remediable aldosteronism (GRA), apparent mineral corticoid excess 
(AME), Fiddle's syndrome, Gordon's syndrome, hypertension accelerated by pregnancy 
and hypertension with brachydactyly (see table 1.3) (Lifton, 1996).
a) Glucocorticoid-remediable aldosteronism (GRA) - a rare autosomal dominant 
form of primary aldosteronism in which aldosterone secretion is solely under the 
control of adrenocorticotropic hormone (ACTH). GRA is caused by a chimeric gene 
in which the ACTH- responsive 5'-promoter of the 11 beta-hydroxylase gene is fused 
to coding sequences o f the aldosterone synthase gene resulting in ectopic expression 
of aldosterone synthase activity in zona fasciculata cells o f the adrenal cortex under 
the regulation of ACTH, with consequent hyperaldosteronism and suppression of 
angiotensin Il-stimulated aldosterone production in the zona glomerulosa (White, 
1988). Affected subjects have variable elevated plasma aldosterone levels in 
conjunction with suppressed plasma renin activity (PRA) and secrete high levels of
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Table 1.3. Mendelian forms of hypertension, mutations and molecular mechanism 
involved in blood pressure modulation
Syndrome Mutation Mechanism
Glucocorticoid 
remediable 
aldosteronism (GRA)
Chimeric gene of 
aldosterone and 11-(3- 
hydroxylase
Aldosterone synthase gene 
expression hormone instead 
of angiotensin II
Liddle’s syndrome Gain of a function 
mutation, of p and y 
subunit o f epithelial 
sodium channel (ENaC)
Reduction in ENac 
clearance and increased 
channels o f ENac activity
Gordon’s syndrome 
Psuedohypoaldosteronis 
m typell (PHA II)
Mutations in WNKl and 
WNK4 genes
Increase reabsorption of 
chloride in the distal renal 
tubule
Apparent
mineralcorticoid excess 
(AME)
Homozygous loss of 
function mutation of 11-p- 
hydroxysteroid 
dehydrogenase type 2
Reduced conversion of 
cortisol to cortisone
Hypertension 
accelerated by 
pregnancy
Missense mutation in the 
ligand binding domain of 
the mineralocorticoid 
receptor
Activation o f receptor by 
progesterone
Hypertension with 
brachydactyly
Syndrome mapped to 
12p ll.2-12.2
Unknown, but complex 
chromosome rearrangement 
reported
Adapted from Dominiczak et al, 2004
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18-oxocortisol, produced in negligible amounts in unaffected individuals (Sutherland 
et a l ,  1966, Ulick et a l ,  1990). Using 18-oxocortisol secretion as a phenotype, 
linkage to a genomic segment of chromosome, 8 harbouring CYPl 1B2 (aldosterone 
synthase gene) has been established (Lifton et a l ,  1992). This gene is 95% identical 
in DNA sequence to another involved in steroid biosynthesis, the 11 beta-hydroxylase 
gene (C Y P llB l), which also lies on chromosome 8 (Lifton et a l ,  1992).
b) Apparent mineral corticoid excess (AME) - an autosomal recessive form of 
Mendelian hypertension associated with defects in steroid metabolism. Inactivating 
mutations in the renal isozyme of the 1 Ibeta-hydroxysteroid dehydrogenase 
(HSDl 1B2) gene, which normally converts cortisol to cortisone, create hypertension 
by failing to provide affected subjects with protection against the potent 
mineralocorticoid effect of cortisol (Mune et a l ,  1995).
c) Liddle’s syndrome - an autosomal dominant form of hypertension related to 
abnormalities in renal ion transport and clinically characterised by the suppressed 
secretion of aldosterone, suppressed PRA and hypokalaemia (Shimkets et a l ,  1994). 
Initially linked to a short segment o f human chromosome 16, subsequent research 
identified that constitutive over-activation of the aldosterone-regulated epithelial 
sodium channel (expressed in the renal nephron) arises from a mutation in the b 
subunit (SCNNIB) of this channel (Shimkets et a l ,  1994) and/or a mutation 
truncating the carboxy terminus of the gamma subunit (SCNNIG) of the channel 
(Hansson et a l ,  1995). Both lead to hypertension via increased renal salt and water 
absorption independent of mineralocorticoid action.
d) Gordon’s syndrome or pseudohypoaldosteronism type II (PHA-II) - an 
autosomal-dominant disorder that features hyperkalemia and hyperchloremic 
metabolic acidosis, together with hypertension and hypercalciuria. Two genes WNKl 
and WNK4 located in human chromosomes 12 and 17, respectively, are responsible 
for PHA-II. Immunohistochemical analysis revealed that WNKl and WNK4 are 
predominantly expressed in the distal convoluted tubule and collecting duct.
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Physiological studies have shown that WNK4 down-regulates the activity of ion 
transport pathways expressed in these nephron segments, such as the apical thiazide- 
sensitive N a^-Cr cotransporter and apical secretory channel ROMK, as well as up 
regulates paracellular chloride transport and phosphorylation o f tight junction 
proteins such as claudins. In addition, WNK4 downregulates other CP influx 
pathways such as the basolateral Na'^-K'*'-2Cr cotransporter and CP/HCO]" 
exchanger. WNK4 mutations behave as a loss of function for the Na'^-CP 
cotransporter and a gain of function when it comes to ROMK and claudins. These 
dual effects of WNK4 mutations fit with proposed mechanisms for developing 
electrolyte abnormalities and hypertension in PHA-II and point to WNK4 as a 
multifunctional regulator of diverse ion transporters (Gamba, 2005).
e) Hypertension caused by gain-of-function mutation in the mineralocorticoid 
receptor - this missense mutation causes constitutive mineralocorticoid receptor 
activity and altered receptor specificity, so that progesterone and other steroids 
lacking 21-hydroxyl groups become mineralocorticoid receptor agonists. Pregnancy 
causes an extreme elevation of already increased blood pressure (Geller et a l ,  2000).
f) Hypertension with brachydactyly - mapped to a region on the short arm of 
chromosome 12 (12p) (Chitayat et a l ,  1997). Affected persons are shorter than 
unaffected individuals and not exhibit volume expansion-induced hypertension. The 
underlying mechanism o f the hypertension is unknown. This syndrome has been 
described in several families; the hypertension follows an autosomal dominant mode 
of inheritance and cosegregates 100% with short stature and type E brachydactyly 
(Chitayat et a l ,  1997).
1.2.2 Mendelian forms of Cardiac Hypertrophy
There are several inherited disorders associated with cardiac hypertrophy 
independent of secondary stimuli such as hypertension (Nunez et al., 1996). Much of the
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knowledge of familial hypertrophie cardiomyopathy (FHC), a genetically heterogeneous 
autosomal dominant disorder linked to cardiac contractile proteins (outlined in Table 1.4) 
is the result of molecular genetic studies (Ahmad, Seidman & Seidman, 2005). These 
genes encode components o f the myofibril and so it has been proposed that sacromere 
disorganisation may play a role in the pathogenesis of the disease with impairment of 
correct protein packaging into functional macromolecular structures due to the abnormal 
protein (Nunez et a l ,  1996). Whilst classic FHC causes death at an early age, several 
studies have shown that some FHC causing mutations are compatible with a long lifespan 
(Watkins et a l ,  1993; Anan et a l  1994). In 1995 Maron et a l  reported the prevalence of 
echocardiographically defined hypertrophic cardiomyopathy was as high as 0.2% in a large 
cohort of apparently young healthy adults selected from a community-based general 
population. It follows that carriers of mutations of the FHC type may be more common in 
the general population than previously appreciated.
All of the rare mutations discussed so far, corroborate beyond doubt that genetic defects 
can result in human cardiovascular disease. The question now stands as to whether these 
same genes play a role in the more common forms of each disease. The next logical step is 
to investigate their impact on clinical outcome by studies in the heterogeneous general 
population.
1.2.3 Human Studies of Hypertension
There are several lines of evidence in support of a genetic component contributing 
to the aetiology o f human essential hypertension. Epidemiologic studies have revealed 
highly significant familial segregation of blood pressure. Individuals with essential 
hypertension are twice as likely as normotensive individuals to have a parent who is 
hypertensive and hypertension is 2-8 fold more common in the offspring of hypertensive 
parents than in the offspring of normotensive individuals (Perera et a l ,  1972; Ibsen, 1984). 
Monozygotic twins (identical genetic profiles) demonstrate higher blood pressure 
correlations than dizygotic twins (50% genetically identical) (Feinleib et a l ,  1977). 
Correlations are similarly high for first degree relatives such as sib-sib and child-parent
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Table 1.4. Disease genes involved in Familial Hypertrophic Cardiomyopathy (FHC)
Gene FHC Locus Protein Expression in Adult 
Striated Muscle
MYH7 14qll.2 -q l2 Myosin heavy chain 
polypeptide 7 ((3-MyHC)
Cardiac muscle and 
slow-twitch skeletal 
muscle
MYH6 14ql2 Myosin heavy chain 
polypeptide (a-MyHc)
Cardiac muscle and 
slow-twitch skeletal 
muscle
MYL3 3p21.2-
3p2l.3
Myosin light chain 
polypeptide 3 (MLC-ls/v)
Cardiac muscle and 
slow-twitch skeletal 
muscle
MYL2 12q23-q24.2 Myosin light chain 
polypeptide 2 (MLC-2s/v)
Cardiac muscle and 
slow-twitch skeletal 
muscle
TNNT2 lq3 Troponin T2 (cTiiT) Cardiac muscle
TNNI3 19pl3.2-
ql3.2
Cardiac troponin I (cTnl) Cardiac muscle
TPMl 15q22 Tropomyosin q (a-TM) Cardiac muscle and 
slow-twitch skeletal 
muscle
MYBPC3 l l p l l . 2 Myosin binding protein 3, 
cardiac (cMyBP-C)
Cardiac muscle
ACTC 15ql4 a  cardiac actin Cardiac muscle
TNNCl 3p21-pl4 Cardiac troponin C Cardiac muscle
T IN 2q31 Titin Cardiac muscle and 
slow-twitch skeletal 
muscle
Adapted from Ahmad, Seidman & Seidman, 2005
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pair than for more distant relatives. Whilst these findings estimate 20-40% of blood 
pressure variation is attributable to genes (Annest et a l ,  1979; Mongeau, 1989), the results 
also imply the multifactorial nature of essential hypertension. Blood pressure does not 
segregate in families in a way consistent with Mendelian transmission as spouses of 
hypertensive individuals also show significant correlations despite sharing no genetic 
component (Mongeau et a l ,  1986). A range of other factors have been shown to impact 
on blood pressure levels, including high salt, low calcium and low potassium intake, 
limited physical exercise, exposure to noise and stress, age, gender and body mass and 
demographics (Horan & Lenfant, 1990). It is likely that an increase in blood pressure is 
only observed when genetically determined susceptibility is a factor, indicating a 
relationship between environment/demographic factors and certain allelic variants. A 
classic illustration o f genetic heterogeneity is the consistent response of blood pressure to 
dietary salt intake; sensitivity or resistance to blood pressure increasing effects of salt 
intake have been demonstrated in both normotensive and hypertensive human subjects 
(Weinberger, 1996).
The prevalence and onset of hypertension in men and women is disparate, with males at 
greater risk for cardiovascular disease than pre-menopausal females (Kannel et a l ,  1995). 
Although the underpinning mechanisms responsible for the sexual dimorphism of blood 
pressure control are not clear, there is significant evidence that androgens, such as 
testosterone, play an important role in gender-associated differences in blood pressure 
regulation. Studies using ambulatory blood pressure monitoring techniques in children 
have shown blood pressure increases in both boys and girls with age however, after the 
onset of puberty, boys exhibit higher blood pressure than age-matched girls (Bachmann et 
a l,  1987; Harshfield et a l  1994). Harshfield et a l  (1994) noted higher systolic blood 
pressures o f approximately 4 mmHg in boys aged 13 to 15 years, rising to differences of 
10 to 14 mmHg at 16 to 18 years of age. In addition, women with polycystic ovary 
syndrome (characterized by elevated testosterone levels), experience hypertension, which 
further emphasises the importance of androgens and blood pressure regulation.
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In women, menopause is characterized by increases in blood pressure (Kannel et a l ,  1995; 
August & Oparil, 1999), with the incidence of hypertension in women doubling post 
menopause, leading to the suggestion that the loss of female gonadal steroids caused by 
menopause is a risk factor for post-menopausal hypertension (Staessen et a l ,  1989;
Marcus et al. 1994). Additionally, oestrogen has been shown to stimulate nitric oxide 
(NO) production (Weiner et a l ,  1994; Goetz et a l ,  1994) and may be protective of blood 
pressure increases in pre-menopausal women. However, since oestrogen replacement 
therapy has not been shown to decrease blood pressure, it is doubtful that the effect of 
estrogen on NO is the protective mechanism acting to lower blood pressure in pre­
menopausal women (Akkad et a l ,  1997; Pripp et a l ,  1999).
Tingleff al. (1996) examined the role of both hypertension and gender in the prevalence 
of an additional cardiovascular risk factor (LVH) with reference to a normotensive group 
across several age clusters. They demonstrated rates of 14% (males) and 20% (females) in 
normotensive subjects. Higher percentages of LVH (25% and 26% respectively) were 
apparent in hypertensive subjects. Therefore, the conclusions drawn from this study 
predict the probability of observed variance in LVH is not entirely attributable to 
haemodynamics, but is also subject to both unidentified genetic and non-genetic 
determinants (Nunez et a l ,  1996).
1.2.4 Human Studies of LVH
The quantitative distribution of cardiac mass within human populations supports 
the view that any heritable effects are likely to be polygenic. However, there is a deficit of 
strong data supporting the extent and importance of inherited variability, in response of the 
heart and hypertrophic stimuli, such as hypertension (Nunez et a l ,  1996). As many studies 
comprise of hypertensive families investigated with respect to blood pressure rather than 
cardiac hypertrophy, this is not unexpected. Twin studies can provide persuasive data for 
the heritability of cardiac mass in humans (Nunez et a l,  1996).
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Ill a large twin study by Verhaaren et al. (1991), involving 254 pairs of 11 -year old 
Caucasian school children, univariate analyses documented that genetic variance in boys 
(63%) and girls (71%) explained a significant proportion of LVM variability. The group 
determined that genes controlling LVM included those regulating LVM only and other 
genes concerned were common to both LVM and body weight. After removing the effect 
of weight and sexual maturity by regression methods, the influence of genetic effect 
continued to be important in determining LVM. Bivariate genetic analyses of their data 
demonstrated that genes common to LVM and weight significantly influence the 
covariation of these variables and that > 90% of the correlation of these traits is due to 
common genes. This study served to demonstrate that LVM was genetically determined in 
childhood and further emphasised the existence of several genes acting to modify cardiac 
mass including the multifactorial effect of environment and demographics.
Swan et al. (2002) determined the degree of LVM heritability and tested the association of 
three candidate genes (G protein beta-3 subunit, aldosterone synthase, and beta-1 
adrenoceptor genes) in an adult population-based twin study. Their analysis demonstrated 
the genetic determination of various aspects of LV structure in middle-aged adults, with 
LVM shown to have approximately 50% heritability unexplained by any known 
confounding elements. They were able to demonstrate significant heritability indicative of 
an underlying genetic effect, in that correlations in monozygotic twins was greater than 
dizygotic twins, for LVM, LV diastolic dimensions, left atrial size, and LV systolic 
function. However, although there appeared to be a heritable component contributing to 
LV mass in this adult twin population, the group failed to show any association with the 
candidate genes assessed.
More recently, Sharma et al. (2006) used a large prospective twin database to establish 
heritability of LVM; a total of 376 normotensive Caucasian twin pairs (182 monozygotic 
and 194 dizygotic) aged 25-79. In this study, heritability estimates suggested that the 
genetic variance of LVM is 59%, with no common overlapping environmental effects 
identified between subjects, suggesting LVH has a substantial genetic basis that is likely to 
be polygenic. The results from this group, forms one of the largest normotensive twin pair
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studies to date and adds further weight that development of LVH is independent of a blood 
pressure effect and is influenced by several underlying genetic components.
Similar to the observed blood pressure increases in menopausal women, there is a growing 
population of post menopausal women with target organ damage such as LVH (Gordon et 
a l ,  1978; Stober et a l ,  1985; Colditz et a l ,  1987). Hinderliter et a l  (2002) evaluated 
cardiovascular changes related to menopause, in a cohort of both pre- and post-menopausal 
women o f similar age, race, weight, and blood pressure. The group showed that despite 
similar blood pressures, post-menopausal women had a higher indexed peripheral 
resistance and a lower cardiac index than pre-menopausal women. In association with this 
greater haemodynamic load, post-menopausal women also showed evidence o f early 
concentric left ventricular remodelling, determined by increased relative wall thickness, in 
comparison to pre-menopausal women. This study further highlights the association of the 
menopause with both haemodynamic changes and left ventricular remodelling, in 
agreement with previous research (Pines et a l ,  1996; Schillaci et a l  1998), however the 
results from these studies do not offer any insight into the mechanistic processes 
contributing to LVH as a consequence of the menopause.
In addition to gender, ethnicity and socioeconomic status has been shown to be predictive 
epidemiologic indicators in LVH. This is probably due in part to both demographics and 
elevated risk of hypertension associated with individuals of African descent. The results of 
the Evans County, GA heart study showed an almost 4-fold increase in the incidence of 
LVH in Black individuals versus White individuals (Arnett et a l ,  1992). Even after 
adjusting for age, systolic blood pressure, weight, and change in weight/change in blood 
pressure, Black men still had an Odds Ratio for LVH of 3.0 (Arnett et a l ,  1996). More 
recently, Rodriguez et a l  (2004) produced data from a population-based sample of 1916 
subjects living in Northern Manhattan, USA. The group showed that LVM varied 
according to race (blacks 48.9 g/m2.7, Hispanics 48.4 g/m2.7, whites 45.6 g/m2.7) in 
hypertensive and normotensive subjects, with an inverse association between mean LVM 
and socioeconomic status for the total cohort. These results suggest that both low social 
status and race are independent factors contributing to LVM in a heterogeneous population
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and further indicate that, in consideration of the independent risk associated with LVH, the 
socio-economic aspects as well as the pathology of disease should be a target of treatment 
and prevention (Rodriquez et a l ,  2004).
1.3 EXPERIMENTAL ANIMAL MODELS
1.3.1 Animal Models of Cardiovascular Disease
Animal models, in particular rodents, offer numerous advantages for genetic 
research. The low cost, ease of handling and breeding, access to sophisticated 
measurements, short generation time, complete environmental control and large litters all 
function to eliminate some of the complexity inherent in human studies (Lovenberg, 1987). 
This has been further extended with the production of inbred genetically homogeneous 
rodent models of hypertensive cardiovascular disease including congenic lines, transgenic 
animals and recombinant inbred strains. Each of these models are designed to express a 
variety of phenotypes, including spontaneous hypertension, salt sensitivity, LVH, stress 
sensitivity, stroke and susceptibility to end-organ damage (Dominiczak & Lindpaintner, 
1994).
1.3.2 Mouse Models of Cardiovascular Disease
Currently the mouse is the preferred mammalian system for genetic manipulation. 
This is mainly due to the extensive knowledge o f the mouse genome, with over 10 000 
genetic markers including in excess of 6000 microsatellite sequences that are critical to 
genetic studies (Hoit & Walsh 1998; Mouse Sequencing Consortium, 2004). To date, a 
number o f diverse modifications of the mouse genome have resulted in mice with both 
cardiac hypertrophy and altered cardiovascular function. These studies include loss/gain 
of function analysis using cardiomyocyte ligands and receptors, G proteins, signal 
transduction pathways, calcium cycling proteins, sarcomeric or structural proteins and or
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sub-cellular components. Of particular note, in vivo studies involving transgenic mice 
emphasize the application of transgenic mouse models as an effective analytical tool to 
investigate molecular alterations of specific genes in the whole animal. Nonetheless, in 
order to understand the processes and genes involved in the development and pathogenesis 
of disease, it is necessary to study mammalian physiology and pathophysiology rather than 
the single gene approach. For this reason the production and use of animal strains 
permissive to the investigation of several candidate genes in situ, is central to the initial 
investigation o f complex polygenic diseases.
1.3.3 Rat Models of Hypertensive Cardiovascular Disease
Cardiovascular disease has been widely investigated in rat models, with more than 
one model representing a genetic aetiology. The number of rat strains commonly in use 
(Table 1.5) offers a useful parallel to the multiplicity of human cardiovascular disease.
Each of these rat strains has distinctive pathophysiological features linked to disease 
development and bears a similarity to disorders found in subgroups o f hypertensive 
subjects worthy of independent genetic investigation, including left ventricular 
hypertrophy and stroke (Ganten, 1987). The Spontaneously Hypertensive Rat (SHR) is the 
most commonly employed model of cardiovascular disease, with over 4000 published 
articles in the last 10 years. In particular, developments of rat models derived from the 
SHR are now widely used for hypertension related diseases (Yamori & Swales, 1994).
A common used approach in developing inbred models of hypertensive cardiovascular 
disease has been to measure blood pressure in a large number o f out-bred animals and then 
selectively breed those with the highest blood pressures (Kurtz et a l ,  1994). In each 
successive generation, offspring with the highest blood pressures are brother X sister 
mated to produce an inbred strain. After 20 generations of brother X sister mating, the 
offspring should be homozygous at >99% of loci and therefore all animals within the strain 
are nearly isogenic (Rapp, 1983). This resolves problems o f aetiological heterogeneity 
observed in humans, while also producing large number of progeny. Moreover, under 
conditions of standardised animal husbandry, the ability to control environmental factors
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offers the prospect of investigating more complex genetic interactions than is possible in 
even the most closely managed clinical trials (Dominiczak & Lindpaintner, 1994).
1.3.4 The Stroke Prone Spontaneously Hypertensive Rat
In 1963, Okamota and Aoki produced a colony of spontaneously hypertensive rats 
(SHR) by selective in-breeding of individual normotensive Wistar-Kyoto (WICY) rats with 
elevated blood pressure from the Animal Center Laboratory, Kyoto University Faculty of 
Medicine, Japan (Yamori & Lovenberg 1987). Typical lesions often associated with 
human hypertensive cardiovascular disease, including cerebral (infarction, haemorrhage), 
myocardial (infarction, fibrosis) and nephrosclerotic (benign, malignant) were all observed 
in SHR after three months of age and potentiated the use of SHR as a model of the human 
condition (Okamoto & Aoki, 1963).
In 1971, SHR were separated into 3 main substrains, at which time it was confirmed the 
incidence of spontaneous cerebrovascular disease was different among them; high in 
substrain A (80%) and low in substrains B and C (50%), despite similarity of blood 
pressure measurement the 3 substrains. Suspecting the involvement of independent 
genetic factors in the pathogenesis of stroke, Okamoto and co-workers selectively bred 
substrain A by maintaining offspring from SHR dying from stroke, resulting in the 
generation of a stroke-prone spontaneously hypertensive rat, or SHRSP (Okamoto et a l,  
1974).
The SHRSP displayed a rapid onset of hypertension after birth in comparison to SHR and 
by twelve weeks o f age had a systolic blood pressure of 230mmHg. The SHRSP had a 
high tendency to naturally develop cerebrovascular lesions, particularly in the antermedial 
and occipital cortex and the basal ganglia with over 90% of all males suffering stroke 
while on a Japanese diet o f high salt, low potassium and protein (Nagaoka et a l ,  1976). In 
contrast to regular SHR strains, which were known to be resistant to salt, the SHRSP were 
found to be salt sensitive (Yamori et a l ,  1981).
27
Table 1.5 Genetically inbred rat strains in common use for cardiovascular research
Name of Straiu Origin of Strain SB?
(mmHg)
Spontaneously Hypertensive Rat 
(SHR)
Kyoto, Japan 200
Stroke-Prone Spontaneously 
Hypertensive Rat (SHRSP)
Kyoto, Japan 230
Milan Hypertensive Rat (MHS) Milan, Italy 175
Dahl Salt-Sensitive Rat (Dahl S) Brookhaven, USA 170
Lyon Hypertensive Rat (LH) Lyon, France 180
Sabra Hypertensive Rat (SBH) Jerusalem, Italy 185
Genetically Hypertensive Rat 
(GH)
Dunedin, New Zealand 185
Fawn Hooded Hypertensive Rat 
(FHH)
The Netherlands 150
Wistar Kyoto Rat (WKY) Kyoto, Japan 120
Dahl Salt Resistant Rat (Dahl R) Copenhagen, Denmark 125
Sprague Dawley (SD) Hoechst, Frankfurt 110
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Given the distinctive traits of the SHRSP, the strain was distributed within a selection of 
high profile research groups for use in study of hypertension and stroke. This circulation, 
prior to complete in-breeding (F2 0  required at least), resulted in significant genetic 
heterogeneity between different colonies (Matsumoto et a l ,  1991; S am an i et a l  1989; 
Nabika et a l ,  1991). Whilst this does not affect the use of SHRSP as an experimental 
model for study, it does call for an awareness o f the source of the SHRSP, SHR or WKY, 
when making comparisons of results obtained by different research groups.
There are several pathophysiological similarities between hypertensive cardiovascular 
disease in SPlRSPs and humans, which encourage the use of SHRSPs in genetic research. 
For example, male SHRSPs have higher blood pressures than females, in common with 
human essential hypertension (Yamori et a l ,  1976). Whilst the most preponderant site for 
stroke in SHRSP is the cortical region (69.8%), the basal ganglia, is next highest (24.5%) 
in common with humans. Indeed, a branch of the middle cerebral artery (the 
lenticulostriate artery) is responsible for basal ganglia lesions in both the SHRSP and 
humans. In addition to hypertension and stroke, the SHRSP also displays cardiac 
hypertrophy and LVH.
It then follows that a suitable in-bred model of human hypertensive cardiovascular disease 
in which to begin analysis of the genetic determinants of hypertension, left ventricular 
hypertrophy and cerebrovascular disease, is the SHRSP. However, as indicated by the 
studies of Mendelian forms of human hypertension, any success in dissecting out common 
underlying determinants is dependant on strong, defined and uniform phenotyping. For 
this reason, an error free, high fidelity method of blood pressure and left ventricle mass 
measurement and assessment of cardiac function is essential.
1.3.5 Studies in Animal Models
The use o f experimental animals offers a useful supplementary to genetic study in 
humans. These animal models not only preserve the polygenic nature o f the disorder but 
are not compounded by genetic heterogeneity and are easily subject to a controlled
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environment (Dominiczak & Lindpaintner, 1994). Additionally, the use of animal models 
affords the applicability of high fidelity phenotyping. Indeed, crude biometric estimates 
from breeding experiments in various hypertensive rat strains have shown the number of 
independent genes affecting blood pressure control to be between two and six (Rapp,
1983). This moderately low number of loci implies the feasibility o f identifying these 
genes as well as gene(s) independently influencing left ventricular hypertrophy in such 
models (Harrap, 2002).
Traditionally genetic research using inbred hypertensive rat strains was undertaken in a 
solely comparative fashion using a control reference strain (Lander & Schork, 1994). An 
assortment of biochemical, anatomic and histological characteristics, were used as 
phenotypic parameters for this approach, with >100 differences determined (Dominiczak 
& Lindpaintner, 1994). However, in all likelihood this variance is probably unrelated to 
the pathogenesis of hypertension and has evolved as a corollary of random allelic fixation 
(genetic drift), during the process of selective breeding and inbreeding (Rapp, 1983).
In order to address some of these issues, Rapp (1983) devised a set of criteria, applicable to 
quantifiable differences between normotensive and hypertensive strains. The most 
prevailing of these being the requirement that the trait under investigation (or the 
intermediate phenotype) must cosegregate in an F2 backcross population of rats derived 
from a cross between phenotypically divergent strains thus, allowing random associations 
to be distinguished from evidence of a causal relationship (Rapp, 1983, Dominiczak & 
Lindpaintner, 1994). A case in point is noradrenaline induced oscillatory activity and 
increased lymphocyte potassium efflux, shown to cosegregate with blood pressure in the 
SHRSP (Dominiczak & Lindpaintner, 1994). Unfortunately, there is still the question as 
to whether the cosegregating trait signifies a primary, causative factor or is simply a 
secondary effect of hypertension.
There are several examples of cosegregation analysis studies, notably four independent rat 
F2  populations have been tested for cosegregation between a polymorphic marker on the 
renin gene and blood pressure. In one study, using a cross between the Dahl salt-sensitive
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(hypertensive) and salt-resistant (normotensive) strains, a co-dominant effect of the 
hypertensive allele on blood pressure was shown (Rapp, 1989), although in a SHRSP- 
Wistar-Kyoto (WKY) cross, no such effect could be established (Lindpaintner, 1991). The 
third study, performed on a cross between SHR and Lewis rats, observed an association 
relating the presence of the hypertensive renin allele and blood pressure in animals 
heterozygous at the renin locus (Dominiczak & Lindpaintner, 1994). Yu (1998) identified 
co-segregation of the renin allele with higher systolic blood pressure in male rats aged 8-24 
weeks and in females aged 12-24 weeks, in a cross between SHR and WKY rats. In this 
study, the SHR renin allele was also associated with higher mean arterial pressure in older 
rats and co-segregated with body weight males rats aged 12-24 weeks, but not with 
females, indicative o f both an age and gender effect.
In considering if the same genes involved in blood pressure regulation also influence 
cardiac hypertrophy, Zhang (1996) analysed a cosegregating Fi population of SHR and 
WKY strains. The group provided evidence of a chromosomal region close to the ANP 
locus determining mean blood pressure, although found no indication that the same region 
influenced heart weight. These results suggest that blood pressure and heart weight may 
be independently controlled by different genetic mechanisms in the SHR. Several years 
later, Masciotra (1999) carried out cosegregation analysis in genetic crosses of WKY- 
derived hyperactive (WKHA) and WKY and WKY-derived hypertensive (WKHT) and 
SHR strains to assess increased ventricular mass and association with expression of the 
ANP gene. The abundance of ventricular ANP mRNA and peptide was shown to correlate 
inversely with LVM, in contrast to the positive correlation observed with a-myosin heavy 
chain mRNA (Masciotra, 1999). Data from the equally hypertensive SHR and WKHT 
strains showed LVM was larger in SHR than in WKHT, yet ventricular ANP mRNA was 
significantly less in SHR than in WKHT. These results provide evidence that low 
ventricular ANP gene expression can be linked genetically to high cardiac mass 
independently of blood pressure and are consistent with the hypothesis that ANP may offer 
protection against hypertrophy.
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Results from studies using transgenic mice over expressing ANP suggest ANP gene 
expression is inversely related to cardiac growth, with transgenic animals exhibiting lower 
heart weight and blood pressure than wild type mice. Conversely, transgenic mice with 
homozygous disruption of the pro-ANP gene (Nppa) or the natriuretic peptide receptor 
(NPR-A) exhibit significant cardiac enlargement, proportionally disparate with observed 
increases of blood pressure in these models (John et a l  1995; Kishimoto et a l ,  2001; 
Knowles et a l  2001). More recently, Mori et a l  (2004) investigated the effect of ANP 
deficiency in response to volume overload and observed exaggerated increased heart and 
LV weight in response to volume overload, which was not prevented by normalization of 
blood pressure (Mori et a l ,  2004).
However, raised circulating levels of ANP and pro-ANP are associated with (i) reduced 
ventricular systolic and diastolic function; (ii) presence of left ventricular hypertrophy (and 
possibly geometric form); and (iii) severe myocardial infarction (Sagnella, 1998).
Recently, Tran et a l  (2004) demonstrated upregulation of the pro-ANP convertase Corin 
gene in hypertrophic cardiomyocytes and failing myocardium. Conversely Lanenickel et 
al  (2004) demonstrated downregulation of atrial Corin mRNA expression in an 
experimental heart failure model. Although these data are conflicting, they do indicate an 
important role for both ANP and Corin, in the hypertrophic response.
In 2005, Chan et a l  produced a Corin knockout mouse model, which compared to wild 
type animals exhibited spontaneous hypertension (increased after dietary salt 
manipulation), and cardiac and LV hypertrophy. The effects of hypertrophy in this model 
eventually led to a decline in heart function over time, characterised by a reduced 
fractional shortening in animals aged 35 weeks. However, the group also established that 
Corin was not a fundamental requirement to ensure embryonic development or postnatal 
survival, as Corin deficient mice developed normally with no abnormal pathology noted in 
other major organs such as the brain, kidneys, lung, liver and spleen.
In another study using angiotensin II (ATII) knockout mouse, it was established that the 
ATz receptor is essential for cardiac hypertrophy induction from pressure overload
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(Senbonmatsu et a l ,  2000; Ichihara et a l ,  2001). These results contradict earlier findings 
employing AT% antagonists, which showed anti growth effects exerted by the AT2  receptor 
(Booz and Baker, 1996), Furthermore, a different strain of ATII knockout mice generated 
independantly did not exhibit any difference in cardiac hypertrophy development after 
pressure overload however vascular hypertrophy was enhanced in these mice (Brede et a l , 
2001). Accordingly, a transgenic mouse over-expressing the AT2 receptor in the heart was 
less susceptible to AT [-mediated actions compared to controls (Masaki et a l ,  1998) and 
developed less fibrosis after ATII infusion (Kurisu et a l ,  2003), whereas hypertrophy 
induction was equal (Sugino et a l ,  2000). ATII induced fibrosis was reduced in these 
animals by a mechanism involving the kallikrein kinin system (Kurisu et a l ,  2003), which 
has been shown to have anti hypertrophic and antifibrotic actions in the heart by the use of 
tissue-kalliki’ein overexpressing transgenic rats (Silva et a l ,  2000). These findings 
together not only suggest a possible role for ATII as a physiologic modulator of cardiac 
hypertrophy, independent of a blood pressure effect but also the utility of experimental 
animals in cardiovascular research.
There is also an accumulating body of evidence to suggest a role for steroid hormones in 
cardiovascular disease, such as vitamin D (Zitterman, 2006). Abnormal vitamin 
metabolism, through deficiency of the active form of 1,25-dihydroxyvitamin D3, and 
acquired vitamin D resistance through a uraemic state, have been shown to be important in 
end stage renal disease (Andress, 2005). Vitamin D deficiency has long been known to 
affect cardiac contractility, vascular tone, cardiac collagen content, and cardiac tissue 
maturation. Recent studies using vitamin D receptor deficient mice as a model 
demonstrate a crucial role of vitamin D in regulation of the RAS (Xiang et a l ,  2003). 
Additionally, there is emerging evidence linking treatment with vitamin D to improved 
survival on haemodialysis and improvement in cardiac function.
1.3.6 Gender Differences
The differences in blood pressure levels documented in human studies, between 
males and females, have also been reported in various animal models (Masubuchi et a l .
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1982; Ganten et a l ,  1989). In hypertensive rat strains, many investigators have found 
increased systolic blood pressure in SHR males in comparison to age matched females 
(Masubuchi et a l ,  1982; Ganten et a l ,  1989). Similar gender differences in the 
development o f hypertension are also found in Dahl salt sensitive rats, SHRSP and the 
New Zealand genetically hypertensive rat (Ashton & Balment, 1991). A number of groups 
have reported blood pressure differences in SHRSP and SHR rat strains, consistent with a 
Y chromosome effect (Ely & Turner, 1990; Hilbert et a l ,  1991; Jacob et a l ,  1991). 
Concordant with these findings, Davidson et a l  (1995), using a genetic cross between 
WKY and SHRSP, established that male offspring originating from a SHRSP progenitor, 
had significantly higher average systolic, diastolic, and mean arterial pressures at baseline 
compared with male F2 hybrids from a WKY grandfather. There are, however conflicting 
reports with regards the effect of the Y chromosome in other rat SHR strains, for example 
studies using the Charles River SHR (SHR/crl) strain of rat (Vincent et a l ,  1994, Ely & 
Turner, 1995) show no Y chromosome effect on systolic blood pressure.
Studies carried out in female SHR support the view that female hormones do not play a 
protective role against development of blood pressure similar to levels noted in male SHR. 
Ovariectomised female SHR at 4 to 5 weeks of age does not result in higher blood 
pressures than in intact females at 18 to 20 weeks of age (Reckelhoff, 1998; Reckelhoff,
2000). However, androgen treatment of ovariectomized female SHR causes an increase in 
blood pressure that is dose dependent (Reckelhoff, 1999), suggesting lack of testosterone 
may protect female SHR from the higher blood pressure found in males rather than female 
hormones. Similarly, studies have shown castration of male SHR results in reduced blood 
pressure, to the equivalent level of female SHR (Chen & Meng, 1991; Reckelhoff, 1998). 
The combined results of these studies are unclear as to the role of the Y chromosome in 
blood pressure regulation and the question still remains whether there is a cost to being 
male or simply a consequence to not being female.
Similar to gender associated effects observed in animal models of hypertension, a study by 
Vincent et a l  (1996) illustrates the involvement of sex chromosome loci and heart weight 
in LH rats using reciprocal back-crosses between Lyon hypertensive (LH) and Lyon
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normotensive (LN) rats. In populations where all rats carry an LH X chromosome, left 
ventricular weight was shown to be significantly higher than in groups where only 50% of 
rats carried the chromosome. Based on these results, they suggest that relative left 
ventricular weight in this animal model is genetically determined (estimated at 41%) with 
partial contribution by a locus on the X chromosome that is independent of blood pressure.
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1.4 GENETIC MARKERS/MAPS
1.4.1 Genome Wide Quantitative Trait Loci Analysis
A quantitative trait is a trait that is continuously distributed within a population and 
is measurable by phenotypic variation due to genetic and/or environmental effects. 
Quantitative trait loci (QTL) are specific chromosomal region(s) which contain genes that 
have a significant effect on this variation and are generally identified by comparing the 
linkage (degree of covariation) of polymorphic molecular markers and phenotypic trait 
measurements. Much of genetic variation underlying disease susceptibility and 
morphology is, however complex. The ultimate goal of complex trait dissection is 
identification of the actual genes central to the trait and an understanding o f the cellular 
roles and functions of these genes in vivo. Theoretically, by scanning the entire genome 
(genome-wide scan) in search o f putative QTL, genes not previously implicated in 
pathways related to trait variation can be detected. Thus, QTL analysis is a phenotype 
driven means of identifying genomic regions that contain polymorphisms affecting the 
distribution o f a measurable trait in a mapping population.
Genetic linkage is measurable by the recombination fraction .(number of recombinants 
observed divided by the total number of meiotic events (progeny). If loci are unlinked 
(whether on different chromosomes or distanced on the same chromosome), approximately 
half of the progeny will be recombinants (50%). If genes are linked (less than 50%) 
parental combinations will predominate and in the case of closely linked genes (where no 
recombination has occurred) the percentage equals 0%. As the frequency of 
recombination between two loci is a function of physical distance on a chromosome, the 
recombination fraction may be converted into distance and expressed as centiMorgan 
(cM), where one cM represents 1% likelihood of recombination, corresponding to 
approximately 1-2 million base pairs of the mammalian genome (Lindpaintner, 1992).
Gene-gene and gene-environment interactions add to difficulty of QTL identification and 
detection. An important development in complex trait analysis is the use of
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molecular/genetic markers, which are used to construct detailed genetic linkage maps. The 
accuracy and precision o f locating these loci is partly dependant on the density o f the 
linkage map created; the higher the map density, the more precise the location of the 
putative QTL. However, heritability of the trait, genetic nature (dominant, recessive or 
additive) and the number o f genes involved also affect the likelihood o f success in QTL 
mapping. For any given QTL, the mapping resolution depends on the number of 
recombination events in the mapping population as well as the type o f population studied.
Progress in human QTL mapping is more slow-moving than in animal counterparts, 
mainly due to the constraints involved in human analyses, for example ethical 
considerations, recruitment of data subjects and limitations presented by outbred, 
heterogeneous population strata. Therefore, the use of experimental inbred animals is 
frequently the first step in QTL-mapping and so will be the focus o f this section.
Statistical associations between the markers and quantitative traits are established through 
statistical approaches ranging from simple techniques, such as analysis of variance 
(ANOVA), to models that include multiple markers (composite interval mapping) and 
interactions (epistasis). The advantages of experimental designs and statistical genetic 
approaches to efficiently map QTL in experimental line-crosses are numerous.
Simpler statistical approaches to QTL detection are methods that assess differences in 
phenotypic means for single-marker genotypic classes (single marker analysis), however 
this type of analyses focus on detecting individual markers rather than genomic regions. A 
more sophisticated method of QTL analysis, which relies on the estimated order of 
markers and map distances, is interval mapping. The additional information gained from 
understanding the relationships between markers is essential to QTL methodologies aiming 
to locate QTL, as the linear arrangement of markers into linkage groups, produces a 
genetic map for locating QTL relative to marker intervals (or statistically related sets of 
markers). In addition to providing a structure in which to search for QTL, the estimated 
genetic map allows for the approximation of missing marker information by using flanking 
marker genotypes to infer information for missing marker genotypes. The intervals 
defined by ordered pairs of markers are searched in increments (for example, 2 cM), and
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statistical approaches are used to test the likelihood that a QTL is present at the location 
within the interval or not. It is important to note that interval mapping, statistically tests for 
a single QTL at each increment across the ordered markers in the genome. Results of the 
tests are expressed as LOD (logarithm of the odds) scores, which compare the evaluation 
of the likelihood function under the null hypothesis (no QTL) with the alternative 
hypothesis (QTL at the testing position) for the purpose o f locating probable QTL.
Jansen (1993) and Zeng (1994) independently proposed the combination of interval 
mapping with multiple regression analysis -  composite interval mapping. This approach 
tests for QTL at an interval, whilst using other markers as covariates to control for other 
QTL outside this defined window of analysis, thus reducing residual variance. The 
criticism o f this method is the limitation to one-dimensional scans across the genetic map, 
which is challenged at times by the multiplicity of several interacting QTL effects (Piepho,
2001). Examples of analyses using these three QTL analysis techniques are depicted in 
Figure 1.8. Clearly, the quality of genome coverage by molecular markers (i.e. even 
distribution o f markers) can also critically affect the chances of success in any mapping 
project, therefore it is important to achieve even spacing of markers before undertaking 
any QTL analysis (Rapp, 1991).
Hilbert et al. (1991) and Jacob et a l (1991) independently completed a genome wide QTL 
analysis in search of hypertension genetic determinants in a SHRSPneideibergX WKY F2 
cross. Three chromosomal loci with LOD scores of over 3.0 were identified, leading to the 
mapping of locus (BPl or BP/SP-1) on rat chromosome 10, where the candidate gene 
angiotensin converting enzyme (ACE) is positioned. A second locus (BP2) was mapped to 
a second locus by Jacob et a l (1991) to chromosome 18 and linked to baseline diastolic 
blood pressure with a significant LOD score of 3.23, whilst Hilbert et a l (1991) mapped 
an X-linked locus contributing to high blood pressure. Subsequent, blood pressure QTL 
have been identified in the SHRSPizumo (Nara et a l, 1993; Nabika et a l,  1997) on 
chromosomes 1 (basal blood pressure) and 3 (basal and salt-loaded blood pressure).
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Figure 1.8 Choices of analysis for quantitative trait locus mapping - QTL analysis carried 
out using several different approaches: single-marker analysis using a t-test (black 
diamonds); interval mapping (blue line); and composite interval mapping (green line). The 
red line represents the 95% significance level on the basis of 1,000 permutations of the 
phenotypic data. Single-marker t-tests identify one significant marker, interval mapping 
locates four maximum QTL locations on the LOD profile, and composite interval mapping 
finds two significant QTL. Differences between single-marker analysis, interval and 
composite interval mapping result from using an estimated genetic map. The difference 
between interval mapping and composite interval mapping is the result of composite 
interval mapping’s use of a ‘window’ or genomic region that allows other effects that are 
outside the window, but associated with the quantitative trait, to be eliminated from the 
analysis point under consideration. The benefit of defining a window is that the variation 
associated with the point of analysis is confined to the QTL effects within the window and 
not outside this field of view, thereby reducing the effects of linked and ‘ghost’ QTL.
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As various groups have also identified the same loci in other experimental crosses, this 
result suggests that they are o f general significance in rats. Since a QTL allele may have 
differing effects when bred onto a different genetic background (Rapp & Deng, 1995), 
genetic mapping results need not be consistent among different crosses and for that reason 
is exemplar of the polygenic nature of hypertension.
1.4.2 Comparative Genome Analysis
The suggestion that genomic organisation may be evolutionarily conserved between 
species was postulated in the early 1900s (Castle and Wachter 1924; Haldane 1927). 
Studies linking banding conservation and chromosome painting (ZOO-FISH) have since 
shown that considerable stretches of DNA are conserved in mammalian species as 
divergent as drosophila and humans (Nash and O'Brien 1982; Sawyer and Hozier 1986; 
Scherthan et al. 1994; Weinberg and Stanyon 1995). Although these studies showed a 
degree o f genome commonality between species, precise high resolution gene order was 
only achieved through genetic/physical mapping. Several groups have established that 
gene order tends to be conserved between mammals (Oakey et al. 1992; Stubbs et al.
1994), which in turn has lead to the concept of constructing and using maps based on 
genetic sequence and map information between multiple species (Nadeau 1989; Lyons 
1997). Comparative genomics was successfully applied in cardiovascular research, by 
Julier et a l (1998) and Baima et a l (1999) with the identification o f a region involved in 
blood pressure regulation on rat chromosome 10 and a susceptibility locus for human 
hypertension on human chromosome 17q.
1.4.3 Candidate Gene Analysis
Candidate gene analysis is a key step in current strategies used for disease gene 
identification and is used widely to investigate the genetics of hypertension and 
cardiovascular disease, with case-control association analyses among the most common 
study design (Dominiczak et a l, 1994). Selection of a candidate gene generally requires 
prior understanding of the physiologic pathways acting to influence the disease state 
(Dominiczak & Lindpaintner, 1994) and therefore is based either on the known or
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suspected function of the gene, sequence homology with other known gene(s) interaction 
of the protein product with another protein or tissue specificity of gene expression. In the 
post genomic era, investigating genetic variation by sequence comparison of candidate 
genes is becoming an increasingly important and feasible tool to study phenotypic 
variation.
In addition, detection of single nucleotide polymorphisms (SNPs, pronounced “snips”) has 
permitted the identification of groups of SNPs that move simultaneously in families and 
populations; haplotype blocks, characterized by a relatively small number of SNPs (tag- 
SNPs). Regardless of these major advances and constantly improving genetic markers, the 
problems concerning statistical power remain an issue. With these difficulties forefront, 
prospective studies should take account and include a sufficient sample size to detect small 
genetic effects and gene-gene and gene-environment interactions. One such study is the 
UK Biobank, who potentially may be one of the best DNA resources available for 
candidate gene studies in cardiovascular and other complex traits. Other approaches to 
tackle candidate genes is to limit investigations to positional candidate genes currently 
emerging from genome wide scans or alternatively reproduce the QTL containing region in 
a whole organism.
1.4.4 Coiigenic Strains and Substrain Production
The initial screening of the genome yields only approximate locations of QTL, 
therefore it becomes necessary to confirm and refine these locations. One strategy is the 
use of congenic strains (Figure 1.9), in which a chromosomal segment from one strain 
(recipient) is selectively replaced through breeding, by the homologous portion of the same 
chromosome from another strain (donor). If the preferred phenotype, for example cardiac 
hypertrophy, of the congenic strain is significantly different from the recipient strain, it is 
then assumed that this particular chromosomal fragment contains a QTL contributing to 
this phenotype. Congenic strains are traditionally developed through a series of 
backcrosses - the donor strain (which contains the genomic region of interest) with the 
recipient inbred strain, together with selection for progeny heterozygous for the desired 
region in each backcross generation (Wakeland et a l,  1997). Essentially, this leads to a
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‘dilution’ of the donor genome into the recipient genome, with continuous maintenance of 
the QTL. The introgressed region is fixed homozygous by intercrossing and the resulting 
congenic strain has a genetic background identical to that of the recipient inbred strain with 
the exception of the introgressed region.
Whilst the protocol for breeding congenic strains is straightforward, the main constraint of 
this strategy is time limitation, with at least 2 Va - 4 years required to achieve background 
purity. Continual additions of microsatellite markers to rat maps provide an opportunity to 
reduce this time constraint with the application of a ‘speed congenic’ approach. This 
requires analysis of polymorphic marker loci distributed throughout the genome, in order 
to allow specific selection o f male progeny carrying the target genomic region, whilst also 
retaining the lowest background heterozygosity throughout the remaining genome, at each 
successive backcross generation. Selective breeding with these ‘best’ males accelerates 
the elimination of unwanted donor genome, thereby reducing the number of backcross 
generations required to successfully construct a congenic strain to typically 4 - 5 
backcrosses.
1.5 GENE EXPRESSION PROFILING
1.5.1 Microarray analysis and real time RT-PCR
Gene expression profiling at the RNA level has been significantly facilitated by microarray 
analysis and quantitative real-time-PCR (RT-PCR). Micro array analysis is a powerful 
technique for high-throughput, large-scale profiling of gene expression allowing 
investigation o f several thousand genes simultaneously, both in diseased and non-diseased 
tissues and/or cell lines. Although RT-PCR analysis provides precise quantification over a 
wider dynamic range of expression levels, this technique is not suited for simultaneous
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X
Serial backcrossing of F, 
offspring to recipient strain
V
Congenic strain
Figure 1.9 A cartoon representing the basic principals behind the production of congenic 
strains. Selective introgression of a chromosomal region from a donor to a recipient strain. 
Typically, the production of a congenic line can take between 8-10 serial backcrosses, to 
ensure elimination o f background heterozygosity (adapted from McBride et a l ,  2003).
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analysis o f large numbers o f genes, genome wide. Therefore, array analysis is often used 
as a tool for screening target genes that are differentially expressed between biological 
samples, and quantitative RT-PCR allows for precise quantification and validation of the 
microarray results.
Although microarray is most commonly equated with DNA microarray, the history of 
microarray began with oligopeptides in the context of immunoassays (Etkins, Chu & 
Micallef, 1989). In the late to mid-eighties, the concept was tendered that sensitivities of 
immunoassays could be dramatically increased using chemiluminescent and fluorescent 
substanees even when the reaction is localised in “microspots” distributed on an inert solid 
support. Several years later. Pease et al. (1994) reported the development of densely 
packed arrays o f oligonucleotide probes. These probe arrays, termed DNA chips, were 
used for hybridization to target DNA sequences. The scope o f microarray has since been 
extended to include other biologically important entities, such as protein, carbohydrate and 
RNA interference (RNAi) microarray and has enabled a paradigm shift in research biology 
from the traditional hypothesis-driven research to a more data-driven research.
From inception, microarray technology has expanded into several supplementary tracks. 
One of the most widely used approaches, first developed by Stanford University and sold 
commercially by sources such as Agilent, uses complimentary DNA (cDNA) clones as 
probes (Schena et a l,  1996). The most frequently used competing method developed by 
Affymetrix employs the use o f short, 25mer DNA oligonucleotides as probes that are 
chemically synthesized using sequence information from genomic databases (Lipshutz et 
a l, 1999). More recently, Illumina has provided an assay for multiplex SNP genotyping 
for high-throughput genetic analysis of large populations using a bead array platform. 
Arrays are made of beads located on silicon slides, which are multi-channel pipette 
compatible for loading multiple samples onto a single silicon slide. This format allows 
many samples to be processed in parallel and differs from Affymetrix, which operates a 
single channel approach i.e. a single sample per chip (Shen et a l,  2005).
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Numerous groups have used microarray technology to aid gene identification at the genetic 
and physical level, and are agreed that gene order is relatively unchanging, with conserved 
synteny between mammalian species. Aitman et ah (1999) identified a gene responsible 
for defective fatty acid metabolism in the SHR strain (Cd35) using cDNA microarrays and 
rat chromosome 4 congenic animals. McBride et al. (2003) investigated differential gene 
expression in whole kidney RNA isolates from parental SHRSP, WKY and congenic strain 
(hypertensive background, introgression of WKY chromosome 2 segment). By taking 
advantage o f the genotypic similarities and differences between the congenic and parental 
strains, they were able to reduce the number of differential genes under investigation and 
identify glutathione S-transferase mu-type 1 (Gstml), a positional and physiological 
candidate gene involved oxidative stress.
Recently, Kong et al. (2005) considered gene expression in Dahl salt-sensitive rats, during 
physiological hypertrophy, pathological hypertrophy, and heart failure. They noted 
increased expression of stress response genes (e.g., heat shock proteins) and inflammation- 
related genes (e.g., pancreatitis-associated protein and arachidonate 12-lipoxygenase) in 
the pathological processes but not in physiological hypertrophy. Expression differences in 
ANP and BNP were also evident dependant on specific conditions, indicating that these 
genes may influence cardiac pathological hypertrophy or simply be markers for 
hypertrophic response and heart failure. This study demonstrates gene regulations specific 
to distinct hypertrophic stimuli and provides evidence of gene alterations as well as 
significantly altered pathways during various forms of cardiac hypertrophy.
DNA microarrays have also been used to define comprehensive gene expression profiles in 
SHR strains aged between 12 and 20 months, during the development o f LVH and in the 
transition to diastolic heart failure (Jaana et a l,  2005). Consistent with previous reports, 
the group observed a progressive LVH and a thickening o f LV walls leading to diastolic 
heart failure with preserved systolic performance. The relatively small number o f known 
altered genes (ninety two) corresponds with previous observations indicating that more 
genes alter in response to acute rather than chronic overload. Many o f the genes identified 
are known contributors o f LVH and heart failure in SHR. A key finding from the study by
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Jaana et al. was a lack of immediate gene expression shift when diastolic dysfunction 
progressed to diastolic heart failure. Instead, significant changes in gene expression 
developed over time and were associated with hypertrophic process and development of 
heart failure. In addition, upregulation of several inhibitors of proteolytic enzymes (tissue 
inhibitor of metalloproteinase-1, plasminogen activator inhibitor-1) and cysteine 
endoproteases (cathepsin K and cathepsin S) suggests dynamic regulation of matrix 
degradation and deposition during the LV remodelling process in hypertrophic heart 
failure (Jaana et a l,  2005) in this hypertensive rat strain.
The studies discussed thus far, serve to demonstrate the inherent genetic complexity of 
hypertension and LVH, which involves a complicated pattern of altered gene expression 
between hypertensive rat strains of varying ages and sex. Although the collective data is 
difficult to interpret, the results emphasize the complex genetic nature o f hypertension and 
LVH and illustrate the importance of the genetic cross studied and almost certainly the 
conditions and method of phenotyping.
1.6 HIGH FIDELITY PHENOTYPING
1.6.1 Haemodynamic Profiling
The goal o f any genetic mapping experiment is to detect and localise the genetic 
elements responsible for the variation in a phenotype of interest. Therefore, careful 
selection of the type o f species examined, cross, sex, parental strains and methods used for 
measuring the phenotype is crucial to the design o f the mapping experiment.
Traditionally, genotyping and phenotyping strategies have been evaluated in terms of their 
power to detect a genetic effect, which depends on the size of the genetic effect and the 
phenotypic information collected in the experiment. In general, a researcher has little 
control over the former, but phenotype and genotype strategies can be designed to extract 
maximum information, subject to cost or other constraints.
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There are various ways in which to determine haemodynamic parameters in experimental 
animals. The most common system currently employed for monitoring blood pressure in 
conscious rats and mice is the tail cuff (Bunag, 1983; Bunag, 1991; Van Vliet et a l,  2000). 
Another, less common but more invasive method, is the exteriorized catheter, which feeds 
a pressure transducer located outside the cage. There are however, considerable 
drawbacks associated with these procedures, which in many respects make each of these 
techniques undesirable as a wholly exact means of obtaining pressure measurements (Van 
Vliet et a l,  2000). Recent studies have shown measurements of physiological variables, 
such as heart rate, and body temperature and activity, from freely moving animals by using 
an implantable radiotelemetry transmitter is more efficient, reliable, less labour intensive 
and permits continuous monitoring of blood pressure (allowing for diurnal variation 
analysis) (Hess, Clozel & Clozel, 1996; Van Vliet et a l,  2000). Several groups have 
validated radiotelemetry as a quantitative method for acquisition of blood pressure data in 
both mice and rats (Brockway, Mills & Azar, 1991; Hess, Clozel & Clozel, 1996). More 
recently, non-invasive techniques for the evaluation of functional and dynamic processes 
such as cardiac function and ventricular remodelling are increasingly preferred, in 
particular when serial measurements is required on living animals during development, 
genetic manipulation and/or in response to pharmacological or surgical interventions.
1.6.2 Cardiac Imaging Techniques
High spatial and temporal resolutions are required to preserve signal fidelity when 
imaging small mammals, which poses a problem on a technical level. Several groups have 
developed cardiovascular imaging modalities suitable for rodent applications, with 
ultrasound techniques such as echocardiography currently the most widely used. With 
constant advances in medical imaging diagnostics, magnetic resonance imaging (MRI) is a 
non-invasive exact technique which offers new insights into cardiac remodelling 
processes. These non-invasive methods are convenient, easy to apply and have been used 
successfully to detect and evaluate numerous cardiovascular phenotypes in small mammals 
such as mice and rats.
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Cardiac echocardiography is a non-invasive procedure that makes use of ultrasonic waves 
directed over the chest wall to obtain a graphic record of the heart's position and size, 
motion of the walls, or internal parts such as the valves (Feigenbaum, 1996). Sonar or 
diagnostic ultrasound was initially a crude, two-dimensional scanning technique, with A- 
mode examinations merely offering a location and amplitude of the returning ultrasonic 
signal. But it was Edler and Hertz (Edler and Hertz, 1954) who are accredited with the 
first use of cardiac echocardiography as the method is currently applied.
In validation studies, M-mode echocardiography has been shown to measure LVM with 
reasonable accuracy (r > or = 0.90 versus post mortem values) in rats ranging in body size 
and age, however reproducibility of these results can vary due to several factors including 
respiratory depression caused by anaesthesia, the position and shape of the heart (dense 
bone matter can obscure view) and quick heart rate averaging 350-400bpm (de Simone et 
a l,  1990; Devereux et a l, 1994; S lama et a l ,  2005). Recent research indicates that the 
level of LVM measured in humans by M-mode echocardiography is a stronger predictor of 
subsequent morbid events and death than blood pressure or other conventional risk factors, 
except age (Devereux et a l, 2003). For these reasons, accurate, quick and reproducible 
evaluation of LVM in experimental animals is important to the study of cardiovascular 
research with respect to identification of genetic components involved in the pathogenesis 
of LVH and the development of pharmacological agents which prevent or reverse the 
phenotype.
Over the past ten years, magnetic resonance imaging (MRI) has rapidly progressed from a 
purely anatomical imaging technique to one that reports on a wide variety of tissue 
functions (Higgins et a l,  1988; Gibbons & Araoz, 2005). Cardiac magnetic resonance 
(CMR) is currently the ideal method of choice for precise measurements of ventricular 
volumes, function and left ventricular mass in humans (Watzinger et a l ,  2005). This is 
due to high spatial resolution, excellent delineation of endocardial and epicardial borders, 
good image quality and ability to reconstruct the heart shape in three dimensions. Results 
are not only independent of geometrical assumptions but are highly reproducible and 
accurate (Bastarrika et a l,  2005). CMR is particularly useful in research, as it is highly 
sensitive to small changes in ejection fraction and mass, and a relatively small number of
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subjects are required for study. Also, due to the excellent reproducibility of data, temporal 
follow-up of any individual in the clinical setting is a more realistic possibility.
Irrespective of current imaging fashions, in vivo assessment of cardiac morphology and 
function in experimental animals using ultrasound imaging techniques such as 
echocardiography suffer from high signal to noise ratio. High fidelity, non-invasive 
imaging methods such as CMR offer desirable option to evaluate and monitor even 
fractional changes in heart weight and function in order to characterize fully the influence 
of pharmacological and/or surgical interventions and genetic manipulation.
Validation of MRI to measure cardiac function and mass has been shown in mice with 
numerous MR studies performed using transgenic animals (Franco et a l,  1999; Woodman 
et a l 2002; Schlieper et a l ,  2004). More advanced techniques like perfusion imaging, 
delayed enhancement or tag imaging are now emerging (Waller et a l , 2000; Zhou et a l , 
2003). Nevertheless, more effort is required to standardize acquisition protocols such as 
obtaining a reliable cardiac trigger, type of anaesthesia used, acquisition time and more 
uniform method of data analysis. In this respect, more improved ‘gold standard’ methods 
to measure cardiac parameters are necessary. Regardless of this, the results generated so 
far from CMR, indicate that this technique can be applied to various aspects of cardiac 
research using small animals.
1.7 AIMS
In a previous genome wide scan using an F2  cross, our group identified a QTL for 
heart weight on chromosome 14 in a Glasgow colony of SHRSP. The overall aim of this 
study was to improve the current genetic linkage map of rat chromosome 14 to confirm 
this QTL and combined with high fidelity phenotyping identify QTL determinants of left 
ventricular mass in the SHRSP.
In order to achieve this aim, it was necessary to carry out the following steps:
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I. Confirm QTL previously identified using an improved genetic map and genotyping. 
Construct congenic strains using speed congenic strategy, in both directions, i.e., by 
(A) transferring a large region of chromosome 14 from the SHRSP to the WKY 
genetic background and looking for an increment in phenotype and (B) transferring 
the ‘minus’ allele from the WKY to the SHRSP and looking for a decrement in 
phenotype.
II. High fidelity phenotyping using echocardiography and MRI to detect differences in 
LV geometry and mass in congenic and parental strains.
III. Comparative mapping to identify candidate genes in the QTL region and differential 
expression analysis in parental and congenic strains using, microarray and RT-PCR 
gene expression assay techniques.
IV. Direct sequencing of candidate genes to supplement genetic mapping and gene
expression analysis and identify any single nucleotide polymorphisms (SNPs) in both 
exonic and upstream gene regions that may be of important functional relevance in 
relation to phenotype.
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CHAPTER 2 
METHODS
2.1 GENERAL LABORATORY PRACTICE
Reagents and equipment used were of the highest quality commercially available. 
During all laboratory procedures, laboratory coat and powder-free latex gloves were worn. 
Reagents deemed hazardous were dealt with appropriately as described in the Control of 
Substances Hazardous to Health regulations by the wearing of laboratory spectacles, 
facemasks and use of a fume hood (Holliday, Fielding & Hocking, Ltd., UK). Appendix I 
lists the suppliers of all chemicals and reagents used and protocols followed in the 
preparation of solutions.
Standard laboratory glass wear was washed in Decon 75 detergent, rinsed with distilled 
H2 O and dried in a 37°C oven. Reagents were weighed using a Mettler P2000 balance (up 
to 3 decimal places) or a Mettler AT250 balance (up to 5 decimal places) both obtained 
from European Instrument Sales. The pH of solutions was obtained using a CO720 digital 
pH meter (WPA Cambridge, UK), which was calibrated on a regular basis with solutions of 
pH7.0 and 4.0 prepared from buffer tablets (Sigma, Europe). Volumes between 0.1 pi and 
5,000 pi were dispensed using appropriate Gilson pipettes (Gilson Medical Instruments, 
USA) and pipette tips (Alpha Laboratories Ltd, UK). Unless stated otherwise, autoclaved 
distilled H2 O was used to prepare aqueous solutions. To dissolve solute in appropriate 
solvents a H E502 stirrer with hot plate capabilities was used (Barlow-world Scientific Ltd., 
UK). Centrifugation of up to 14,000 rpm was used for small samples (maximum of 2,000 
pi) using a Centrifuge 5420 (Eppendorf, UK). Larger samples were centrifuged using an 
lEC centra-GP8R centrifuge (Life Sciences International Ltd, UK).
2.2 ANIMAL STRAINS
All animals were housed under controlled environmental conditions. Temperature 
was maintained at 21°C, 12-hour light/dark cycles were from 7am to 7pm and rats were fed 
standard rat chow (rat and mouse N o.l maintenance diet, special diet services) and H2O 
provided ad libitum. Offspring were weaned after 3 weeks of age when they were sexed,
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ear-tagged (National Band and Tag Co., USA) and caged (maximum 3 animals per cage) j
according to sibling group and sex. |
All procedures carried out on experimental animals were in accordance with the Animals ]
(Scientific Procedures) Act 1986 under the project licence held by Prof. A.F. Dominiczak. 1
Inbred colonies o f the SFIRSP and WKY strains have been maintained in Glasgow by j
brother-sister mating since 1991, when 6 males and 7 females of each strain were given as a j
gift by Dr. D.F. Bohr from the Department of Anatomy and Cell Biology at the University 
of Michigan, USA. Prior to this, the colonies were maintained as inbred for over 15 years 
in the National Institutes of Health, Bathseda, USA. Maintenance of the colony integrity as 
well as the hypertensive and normotensive phenotypes was achieved by selecting SHRSP 
adult breeders with blood pressure values between 170-190 mmHg (males) and 130-150 
mmHg (females), and WKY adult breeders with blood pressure values between 
<140mmHg (males) and <130mmHg (females). Routine microsatellite screening was used 
to confirm homozygosity of all loci within groups of animals from each strain, selected at 
random.
2.2.1 Fi and F% Strain Production
An p2 cohort was previously produced in 1996 from two reciprocal Fi genetic 
crosses. One male SHRSP was mated with 2 WKY females (in cross 1) and 1 male WKY 
was mated with 2 SHRSP females (cross 2) to produce the F; generation. Three Fi males 
and 6 females were then mated from each cross to produce an F2 generation. Reciprocal 
crosses were produced in order to ensure representation of the Y chromosome from both 
hypertensive and normotensive strains.
2.2.2 Congenic Strain Production
The traditional development of a congenic strain requires 8-12 backcross generations and 
therefore takes over 4 years. To reduce the time taken to produce congenic strains a speed 
congenic approach was implemented (Figure 2.1). By using this breeding
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Figure 2.1 Diagram depicting congenic strain production. The traditional method of eight 
backcrosses (BX) versus the speed strategy previously used to produce rodent congenic 
strains (Markel et al., 1997; Jeffs et al. 2000). The dashed arrows indicate the theoretical 
backcross stage at which background heterozygosity is the same.
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strategy, the transfer of regions indicated in the genome-wide scan as QTL for LVMI on rat 
chromosome 14, was initiated. Regions of rat chromosome 14 were transferred from the 
donor SHRSP strain to the genetic background of the recipient WKY and vice versa within 
4 to 5 backcross generations (Figure 2.1).
The Fi population was generated by mating 1 SFIRSP male with 2 WKY females (cross 1) 
and mating 1 WKY male with 2 SFïRSP females to produce the reciprocal lines (cross 2). 
The first backcross consisted o f Fi generation males mated with females of the recipient 
background strain. Thirteen microsatellite markers were genotyped throughout the 
chromosome 14 region as well as 168 background microsatellite markers spanning the rest 
of the genome. Background markers were selected based on optimal coverage of the rat 
genome (Clark et al. 1996, Jeffs et al. 2000), using a variety of rat genome databases 
available on-line - Ratmap: The Rat Genome Database, Sweden at http://ratmap.gen.gu.se/; 
The Whitehead Institute Center for Genome Research Rat Mapping Project, Boston, USA 
at http://www.genome.wi.mit.edu/rat/public/ and the Wellcome Trust Centre for ITuman 
Genetics Genetic Linkage Maps of the Rat Genome, Oxford, UK at 
http://www.well.ox.ac.uk/~bihoreau.
The “best” males were selected at this stage for use in the next round of backcrossing.
These animals are defined as having heterozygosity of the donor strain genotype at the QTL 
region on chromosome 14 (as indicated by the genotypes of the chromosome 14 
microsatellite markers) and least heterozygosity of donor alleles in the genetic background 
(indicated by the genotypes obtained from the background microsatellite markers). This 
procedure was repeated for 4-5 backcrosses, until all the background microsatellite markers 
showed no contamination of the donor genome. At this stage one male and one female 
with heterozygosity at the QTL of interest were mated to fix the QTL region in a 
homozygous state. These fixed congenic strains are maintained through intercross brother- 
sister mating.
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2.3 PHENOTYPIC ANALYSIS
2.3.1 TaiI“CuIf Plethysmography
This procedure was performed on rats heated to 30°C, wrapped in a cloth, and an 
inflatable cuff placed on their tail along with a piezoceramic transducer (Hartmann &
Braun type 2) for pulse detection. The pressure in the cuff could be controlled in ImmHg 
steps over a 300mmHg range and the resulting pulsation detected by the transducer was 
amplified and filtered before being displayed on computer using IBM compatible software. 
This signal was visualised as a function of pressure and an estimation of the systolic 
pressure was marked. An average of twelve readings were taken for each rat per sitting and 
a mean value was calculated around a standard deviation o f approximately lOmmHg, 3 
sittings were taken for each rat and the average of all three sittings was taken for the true 
systolic blood pressure value for that age.
2.3.2 Radio-telemetry
To directly measure systolic pressure, diastolic pressure, mean arterial pressure, 
heart rate and motor activity the Dataquest IV telemetry system (Data Sciences 
International, USA) was utilised. Prior to implantation of the radio transmitter, calibrations 
were verified to be accurate within 3mmHg. Each transmitter could be used a maximum of 
three times following re-sterilisation in Terg-A-Zyme, an enzyme activated powdered 
detergent (Alconox Inc, USA).
Implantation was performed using halothane (2.5-3%) anaesthetised animals at 12 weeks of 
age, under standard sterile conditions. Temporary externalisation of intestines allowed 
access to the abdominal cavity where silk sloops were placed at the aorta below the renal 
arteries and around both iliac arteries. The sloops were held to temporarily occlude blood 
flow to the area and an incision if approximately 1mm diameter was made in the aorta 
using a 21 G needle, just above the bifurcation point of the iliac. The catheter of the 
transmitter was then inserted into the hole, against the flow of pressure and held in place
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with a sterilised cellulose patch (Data Sciences International, USA) and Vet Bond 
biological glue (Data Sciences International, USA). Sloops were removed from the arteries 
and intestines were returned to the abdominal cavity and the transmitter was sutured to the 
abdominal wall.
Each animal was placed in an individual cage, placed over a receiver which was connected 
to a computer for data acquisition. Haemodynamic data was obtained every 5 minutes for 
10 seconds. As stabilisation of measurements postoperatively required 7 days, day 7 to day 
42 were considered as baseline measurements. From day 43, until sacrifice on day 64, 1% 
NaCl was administered in their drinking H2 O (salt-loaded period).
2.3.3 Body and Cardiac Measurements
The body weight of each rat was measured using a CT200V portable balance 
(Ohaus Corporation UK). Cardiac weight was measured using a Mettler AT250 balance 
after removal and blotting on tissue paper to remove excess blood. Both atria and right 
ventricle were removed prior to weighing o f left ventricle and septum. Ratios of heart 
weight to body weight (cardiac mass index; CMI) and left ventricle plus septum weight to 
body weight (left ventricular mass index; LVMI) were determined and expressed as mg/g 
to correct for differences in body size.
2.3.4 Echocardiography
All animals were examined using a Medison Sonoace SA8800 (Diagnostic Sonar, 
Livingston, UK) interfaced with a JVC Super-VHS video recorder for continuous 
monitoring and recording of moving images. The transducer was a 7.5MHz, 128 line 
phase-array system, with an adjustable 60° imaging angle and a 2cm footprint with an 
imaging depth of up to 7.5cm and an accuracy o f 10% in distances between l-60mm.
Animals were sedated by intraperitoneal injection of Hypnorm (approx. 0.1-ml of Hypnorm 
per lOOgram body weight) and the chest was shaved. Ultrasound gel was used to dispel
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any pockets of air trapped in the fur. The rat was positioned to lie in the left lateral 
position, short-axis 2-dimentional B-mode and corresponding M-mode images were 
obtained through the left parasternal window at the level of the papillary muscles. Images 
were adjusted in order to obtain the optimal dynamic range of the displayed image (Figure 
2.2a). Data from six consecutive cardiac cycles from each M-mode tracing was used in the 
following equation for the calculation of left ventricular mass -
LV mass = 0.8{1.04[(EDD + PWT + AWT)^ -  EDD^]}+0.6.
Where PWT = Posterior wall thichiess (mm); AWT = Anterior wall thickness (mm); EDD 
= End diastolic dimension (mm).
Each echo examination consisted of 3-5 sets of images from both B-mode and M-mode and 
lasted for 5-10 minutes. The M-mode images were selected based on good edge definition 
when both the anterior and posterior cardiac wells were clearly visible, and when there was 
a regular cardiac cycle with very little change in the dimensions between beats. Within 24 
hours of echocardiographic examination, animals were transported to 7T MRI unit in 
Garscube for a cardiac magnetic resonance imaging (MRI) scan.
2.3.5 Magnetic Resonance Imaging
Cine MRI was performed on a 7 T-Biospec (Bruker, Germany) using an ECG-triggered 
FLASH-sequence. For rat imaging a rat size whole body coil was used as a transmitter and 
a surface coil as a receiver, with the animal placed in a small cradle and lightly anesthetised 
with halothane gas administered in nitrous oxide/oxygen (70:30). An EGG- fast gradient 
echo (FLASH) cine sequence was used. A flip angle of 30 - 40 degrees, echo time of 
1.1ms and repetition time of 3.2ms was used. A total of 12 frames per heart cycle was 
obtained, resulting in a total acquisition time (TAT) for one cine sequence of 4 minutes 
depending on heart rate (TAT =128 phase encoding steps X averaging steps X length of 
one heart cycle).
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Figure 2.2 (a) Representative echocardiogram. Anterior wall thickness (AWT), end 
diastolic dimension (EDD) and posterior wall thickness (PWT), as well as epicardial (epi) 
and endocardial (endo) boundaries is indicated, b) Correlation of echocardiograph 
estimated LVM and post mortem evaluation (n=58).
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Measurements were averaged four times to increase signal-to-noise ratio with a total of 12 
-  16 contiguous ventricular short axis slices of 1 mm thickness required to achieve 
coverage of the entire heart. Total scan time was 1 V2 - 4 hours. The acquisition matrix used 
was 256 X 192, with a spatial resolution in a plane of 195 X 260. A field of view of 3 -  4 
cm in plane resolution was 230 -  310 mm, scaled to 5.12 pixels / mm. Data was visualized 
and analysed using Image! acquired from http://rsb.info.nih.gov/ij/ (see Figure 2.3a-b). 
Estimation of LVM was calculated as follows -
LVM = (epicardial boundary -  endocardial boundary) x 0.1 (slice thickness) x 1.05
(myocardial density)
2.4 GENETIC ANALYSIS
2.4.1 DNA Extraction
Genomic DNA was extracted from tissue using the Nucleon extraction kit for soft 
tissue (Tepnel life sciences, UK). Tissue was defrosted and <0.25g was added to 2.5ml of 
reagent A, and homogenised using the conventional rotor-stator homogenize!" polytron 
PT2100 (Kinematica, Luzern, Switzerland). The solution was centrifuged at 1300g for 10 
minutes and the supernatant discarded. Cell lysis was undertaken by adding 0.5ml of 
Reagent B to the pellet and vortexing briefly. De-proteinisation was performed by adding 
150pl of sodium perchlorate and inverting at least seven times by hand. Chloroform 
(0.5ml) was added and mixed by inversion to emulsify the phases. To this 150pl of 
Nucleon resin was added and mixed by rotation for 5 minutes. The solution was 
centrifuged at 350g for 1 minute. The upper phase was removed into a microfuge tube to 
which 2 volumes of cold absolute ethanol was added. This was centrifuged at 4000g for 2 
minutes to pellet the DNA and the supernatant removed. Cold 70% ethanol (1ml) was 
added, the sample was re-centrifuged and supernatant discarded. The pellet was air-dried 
for 10 minutes to ensure removal of all ethanol. The DNA was re-dissolved in 50pl of TE/ 
H2 O and stored at 4°C
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All DNA extracted was quantified using aN anoD rop' ND-1000 UV-Vis 
Spectrophotometer (Nanodrop Teclmologies, USA). With the sampling arm open, 2p,l 
o f the extracted DNA was dropped onto the lower measurement pedestal. The 
sampling arm was closed and a spectral measurement was initiated using the operating 
software. The optical density o f the sample was determined in triplicate at 260nm and 
280mn against a blank calculated for each sample. The ratio o f the absorbance at 
260:280mn was a measure of the purity o f the sample. A ratio o f between 1.8 and 2.0 
was considered ideal and these samples were diluted to a concentration of 20ng/pl and 
stored at 4°C. Ratios above 2.0 and below 1.8 indicated contamination by phenols or 
proteins and these samples were discarded.
2.4.2 Polymerase Chain Reaction
Polymerase chain reaction (PCR) is an in vitro method o f specific nucleic acid 
amplification using oligonucleotide primers designed to hybridise to the opposite 
nucleic acid strand and flank the target region of interest. Originally described by Saiki 
et a l  (1985) the protocol involves a series o f template dénaturation, primer annealing 
and elongation o f amiealed primers by a thermostable recombinant Hotstart Taq DNA 
polymerase, which results in exponential accumulation o f a specific fragment. The 
primer extended amplicon synthesised in one cycle serves as template in the next series 
resulting in a doubling of target DNA with each consecutive cycle. Thus 20 cycles of 
PCR yields around a million-fold increase in copy number.
Owing to the large number of samples to be genotyped, 96-well skirted ABgene 
Thermo-Fast plates (Abgene, UK) were used in an MJ Research tetrad thermocycler 
PTC225 (Genetic Research Instrumentation Ltd.). Each reaction was set up by first 
aliquoting 5pi o f each DNA sample (20ng/ pi) into a 96-well skirted PCR plate using a 
multichannel pipette (ensuring no cross contamination). Once all samples were added 
to the plate, a mastermix (including l.OpM of each primer, hotstart Taq DNA 
polymerase, lOX buffer and H 2 O) was added to each well and a adhesive PCR sealing 
sheet (Abgene, UK) was used to cover the plate and prevent evaporation.
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2.4.3 Gel Electrophoresis using Agarose
If  polymorphic differences between the WICY and SHRSP alleles where in the 
order o f 10-15bp for a given marker, high resolution agarose gels were prepared to 
resolve the products and facilitate genotyping the animals. Approximately 400ml o f IX  
TBE buffer was added to a IL  beaker with 4g o f agarose powder and stined rapidly 
with a teflon stir bar. The agarose solution was heated in a microwave oven on high 
power for 3 minutes. Wliile the agarose solution was cooling, ethidium bromide was 
added to a final concentration o f 0.2pg/ml, the solution cooled to 50-60°C and poured 
into a gel casting tray containing the appropriate combs.
After the gel was poured, the agarose was allowed to set and reach room temperature 
(approximately 40 minutes). Approximately lOpl of PCR product mixed with 2X 
formamide loading buffer was loaded onto the gel and run against a DNA size ladder 
marker at 120V for 2 hours (according to the size difference o f alleles) to allow for 
separation and resolution. Gels were then scored by two independent observers.
2.4.4 Gel Electrophoresis using Polyaciylamide Gels and Autoradiography
Polymorphic markers with allelic differences <10bp (between SHRSP and 
WKY) were resolved by polyacrylamide gel electrophoresis using standard denaturing 
sequencing gels, blotting onto a nylon membrane and visualised by autoradiogi'aphy.
An 8% polyacrylamide gel was prepared using the SequaGel sequencing system 
solutions (National Diagnostics, UK). Polymerisation was initiated with 60pl of 
TEMED (Sigma Aldrich, USA) and 700pl of 10% ammonium persulfate (APS). After 
the addition o f these reagents the gel was poured immediately. A small volume o f the 
gel mixture was left in the beaker to test for setting (approximately 1 hour). Once set, 
the gel was placed into a vertical STS-45 standard thermoplate sequencer gel 
electrophoresis unit (Kodak International Biotechnologies Inc, UK) with both buffer 
resei-voirs filled with IX  TBE. A 60 well comb (Kodak International Biotechnologies 
Inc, UK) was inserted into the top o f the gel and the gel pre-run at 2000V (40mA, 70 W)
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for approximately an hour to heat it to around the optimum temperature for loading o f 
55®C. Alternatively, a temperature probe was used and fixed into the glass plate to allow 
the gel reaching automatically the optimum temperatuie when a Power Pac 3000 power 
supply (Bio-Rad, USA) was used.
Prepared PCR samples were denatured at 94”C for 4 minutes prior to loading and 7pi of 
each sample was loaded in the gel. The orientation was aimotated to enable genotyping. 
The time for the optimum separation between the different PCR products was calculated 
as follows to allow for optimum gel usage; products o f approximately lOObp were run 
until the slowest component of the loading dye had ran down the gel 30cm, products of 
approximately 150bp were 40cm, and those o f approximately 200bp were 50cm.
After electrophoretic separation, the gel was cooled and the glass plates split. A 28 x 28 
cm Hybond-N^ nylon membrane (Amersham Biosciences, UK) was placed on the gel, 
followed by two pieces o f absorbing paper, the gel-free glass plate, and weights to allow 
southern blotting overnight. Once blotting was completed, the membrane was carefully 
removed and placed in a tray with 500ml o f 0.4M sodimn hydroxide for 20 minutes, 
followed by 2 X 10 minute washes in 2X SSC (300mm sodium chloride; 30mm sodium 
citrate, pH 7.0), during which the membrane was shaken. The membrane was placed in 
a hybridisation tube (Stuart Scientific Co. Ltd, UK). The forward primer was 
radiolabelled with [a-^^P] dCTP, and the reaction completed as follows: 12.5pl of 
distilled water, Tpl o f terminal transferase buffer (Promega, UK), IpL  of forward 
primer, pi o f [a^^P]dCTP, and 0.5pl o f terminal deoxynucleotidyl transferase (TDT) 
followed by incubation at 37°C for 30 minutes and 10 minutes at 68®C to stop the 
reaction. Once the reaction was completed, a pre-hybridisation solution was prepared 
(24ml sterile water; 12ml 20X SSC; 4ml lOX SDS; 0.1 g powdered milk to prevent non­
specific binding) and the radiolabelled primer added. This mixture was poured into to 
the hybridisation tube containing the membrane for hybridisation at 55°C for 2 hours or 
at 42°C overnight. On completion o f hybridisation, the membrane was washed twice 
with IL o f post-hybridisation solution (0.2% SDS; 2X SSC), dried between two pieces 
of absorbent paper, wrapped in Saran wrap (Dow Chemical Company, Europe) and 
placed in a special cassette (Bio-Rad, USA) against an imaging screen K (Bio-Rad, 
USA). This screen reduced the exposure required with normal film up to ten times due
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to its increased sensitivity to An image was acquired using the Molecular Imager 
FX System (Bio-Rad, USA) which scamied the screen with a dual wave-length laser.
To re-probe the membrane with different primers, the membrane was washed twice in 
boiling 0.4% SDS followed by two washes in 2X SSC.
2.4.5 Fluorescent PCR
Using the PCR method described above, polymorphism o f microsatellite 
markers can be read a non-radioactive PCR protocol. The 5’-end o f the forward primer 
was labelled with a fluorescent dye (FAM, TET, PET and NED dyes) and subsequently 
analysed with an automated ABI 3730 DNA sequencer (Applied Biosystems, USA).
The PCR reaction was carried out in a total volume of 20pl as before but with the 
following reagents: 5 pi o f DNA template (lOOng), 2 pi o f lOX buffer (Qiagen, USA) 
containing tris-HCL, KCL, (NH4 )2 S0 4 , and 15mm MgCL2  pH 8.7; IpL  of 
polyoxyethylene (Life Teclmologies Inc., UK); 200 pM of each dATP, dCTP, dGTP, 
and dTTP; 0.5 pi o f each labelled primer (MWG Biotech, USA) and 0.4U HotStart Taq 
polymerase (Qiagen, USA) and GeneScan 500 ROX size standard (Applied Biosystems, 
USA). Further optimisation was required for some primers where amiealing 
temperatures varied from 50°C to 68“C in increments o f 1°C to find optimal conditions 
for amplification. The fluorescent PCR fragments were pooled according to size and 
fluorescent label used. The use of several fluorescent dyes allows high tlu'oughput 
analysis o f different markers even if  allele size is similar. Each marker can be identified 
according to the fluorescent tag by the DNA sequencer and analysed using GeneMapper 
v3.7 software (Applied Biosystems, USA). Figure 2.4 is an example of the data output 
from GeneMapper.
2.5 QTL ANALYSIS
2.5.1 JoinMap 3.0
JoinMap 3.0 was used to calculate a genetic linkage map for diromosome 14 based on 
the genotype datasets. A new project was created and a locus genotype file containing
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Figure 2.4 An example o f output from GeneMapper v3.7. Allele sizes are input, with 
corresponding tagged fluorescent dye. From this, the output from the 3730 DNA 
analyser can be visualised and genotypes assigned.
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genotype codes were prepared in order to generate locus genotype frequencies and 
calculate linkage groups. Loci were determined to be significantly associated at the 
current LOD thi'cshold with at least one member of a group. The map calculated was 
based on the selected set of loci. The mapping procedure was a process o f building a 
map by adding loci one by one, starting from the most informative pair o f loci. For each 
added locus the best position is searched and a goodness-of-fit measure is calculated. 
When the goodness-of-fit reduces too sharply (too large a jump), or when the locus 
gives rise to negative distances, the locus is removed again. This was continued until all 
loci had been handled at least once.
2.5.2 MapManager QTXb20
Map M anager QTXb20 provides two fimctions, which can be used for QTL 
detection; marker regression and interval mapping. Marker Regression specifically tests 
the association o f the trait values with the genotypes o f single loci and can be applied to 
multiple chromosomes. Intei*val mapping cheeks the same dataset for QTL when 
markers are spaced >20cM apart.
b = (X'^X)'lX’'y
Where b represents a vector, which gives the estimated constant term and a regression 
coefficient estimate for each locus, indicates the transpose o f matrix X, and X-1 
indicates the inverse o f X.
Interval mapping was performed by QT>lntei-val Mapping command. The target locus 
was replaced by a position in a target interval (Lander & Botstein, 1989; Knapp & 
Bridges., 1990; Haley & Knott, 1992; Markel el a l, 1996). The expected effect of a 
hypothetical QTL at this location was estimated from the genotypes at marker loci 
flanking the interval. QTX allows a choice of mapping functions; ITaidane, Kosambi, or 
Morgan.
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Composite intentai mapping (Jansen, 1993; Zeng, 1993) adds background loci to simple 
inteiwal mapping. The design matrix X is expanded to include a column for each 
background locus, with the genotype of that locus expressed in the code appropriate for 
an additive model. QTX always includes the effect o f background loci according to an 
additive model, even in intercrosses, in which there would be a possibility of using 
different models for each background locus.
Permutation tests were performed on the dataset to establish empirical significance 
tlnesholds for significance o f QTL mapping results (Churchill & Doerge, 1994; Doerge 
& Churchill, 1996). QTX uses the same routines for a permutation test as for inteiwal 
mapping, but it permutes the trait values among the progeny before calculating the X 
matrix and fitting the regression. This permutation destroys any relationship between 
the trait values and the genotypes o f the marker loci. The regression model was fitted 
for the permuted data at all positions in the genome and the maximmn likelihood ratio 
statistic (LRS) and p value is recorded. This procedure was repeated one thousand 
times, giving a distribution of LRS values expected if there were no QTL linked to any 
of the marker loci and was represented as tlneshold values -  suggestive, significant and 
highly significant.
The LRS was converted to the conventional base-10 LOD score by dividing the value 
by 4.61 (twice the natural logarithm o f 10). Confidence intervals were estimated by 
bootstrap analysis (Visscher et a l,  1996), which creates multiple bootstrap datasets by 
randomly choosing individuals with replacement from the original dataset. Each 
bootstrap dataset was used for QTL mapping, and the location of the strongest QTL for 
each set recorded. These locations are summarized in a histogram showing the size of 
the region in which the QTL is expected.
2.5.3 W indows QTL Cardographer 2.5
Locus data and genotype/trait data is imported into Windows QTL Cartographer 
(WinQTLCart) from Map Manager QTXb20 as exported map.inp and cross.inp files. 
The datasets are also saved as text files to check locus, genotype and trait information.
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Results are displayed in graphical and statistical view windows with calculation of a 
chi'omosome map/ QTL map based on the dataset input.
2.6 QUANTITATIVE RT-PCR
2.6.1 RNA Extraction
Total RNA was extracted from tissue using RNeasy Maxi kit (Qiagen, UK) 
Frozen tissue was placed in 5ml o f RLT buffer (containing lOpl o f (3-mercaptoethanol) 
and quickly homogenized using a conventional rotor-stator homogenizer polytron 
PT2100 (Kinematica, Luzern, Switzerland) until the sample was uniformly 
homogeneous (usually 45-60seconds at 20,000ipm). The lysate was then transferred to 
a sterile 50ml falcon tube containing 15ml o f nuclease free H 2 O (Ambion Europe Ltd) 
and 250pl o f 20mg/ml proteinase K (Qiagen, UK). The cocktail was incubated in a 
hybaid mini hybridization oven at 55°C for 20 minutes. Following proteinase K 
digestion, the sample was centrifuged at 5000g for 6  minutes until formation o f a small 
pellet at the bottom of the tube. The clear supernatant was transferred to a fresh 50ml 
falcon tube and mixed with 1 1 ml cold absolute ethanol.
Approximately 12ml o f the sample was loaded onto an RNeasy Maxi column, placed in 
a fresh 50ml falcon tube and centrifuged at 5000g for 5 minutes. The flow tlnough was 
discarded and the procedure repeated several times until the entire elear supernatant 
sample has been passed thr ough the cohrnin. 15ml of RW l buffer was then added to the 
RNeasy column and centrifuged at 5000g for 5 minutes and the flow through discarded. 
10ml o f RPE buffer diluted with 4 volumes o f absolute ethanol was added to the 
RNeasy column and centrifuged at 5000g for 2 minutes and the flow through discarded. 
Approximately 10ml o f RPE buffer diluted with 4 volumes absolute ethanol was added 
to the RNeasy column and centrifuged at 5000g for a further 15 minutes until the 
membrane on the column was dry. The column was transferred to a fresh 50ml 
collection tube and total RNA was eluted by pipeting 800pi o f nuclease free H 2 O 
direetly onto the column and centrifuged at 5000g for 6  minutes. To obtain a higher 
concentration o f RNA, a second elution step was performed using the first eluate.
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All RNA extracted was quantified using the NanoDrop ND-1000 UV-Vis 
Spectrophotometer (Nanodrop Teclmologies, USA). With the sampling arm open, 2 pi 
of RNA was pipetted onto the lower measurement pedestal. The sampling arm was 
closed and a spectral measurement was initiated using the operating software. The 
sample column automatically sets between the upper and lower measurement pedestals 
and the spectral measurement was taken and output as a concentration in ng/pl and a 
ratio of the absorbance at 260:280mn. A ratio between 1.9 and 2.2 was considered ideal.
2.6.2 DNAse Treatment of RNA
In order to prevent any contaminating DNA providing false positive results, total 
purified RNA was treated using DNA-free (Ambion) to digest DNA. 44pi of RNA was 
pipetted into a 0.5ml RNase free microfuge tube (Ambion, UK) with 0.1 volume (5pi) 
o f 1 Ox DNase I buffer and 1 pi o f DNasel then vortexed to mix. The mixture was 
incubated at 37°C for 30 minutes. Following incubation, 5pl o f resuspended DNase 
inaetivation reagent was added and the mixture vortexed every 2 0  seconds for 2  
minutes. In order to pellet the DNase inactivation reagent, the RNA was centrifuged at 
10,000g for 1.5 minutes and then transferred to a clean 0.5ml RNase free microfuge 
tube.
2.6.3 Quality Assessment of RNA
RNA was assessed for quality using an agilent bioanalyzer 2100.
Approximately 1.5 pi o f total RNA was spotted onto a specialised agilent chip and RNA 
was quality check referenced withlSS and 28S ribosomal RNA. Samples were rejected 
if  the fluorescent amplitude o f the RNA measured lower than average for total RNA and 
ribosomal RNA.
2.6.4 Two Step RT- PCR Taqman
The technique consists o f two parts: synthesis o f cDNA from RNA by reverse 
transcription, and amplification of a specific cDNA by polymerase chain reaction 
(PCR). The method requires very little RNA and differs from Northern blotting because 
it is somewhat tolerant o f degraded RNA, as long as the RNA is intact within the region
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of interest. First strand cDNA was synthesized using RT-for PCR kit (BD Biosciences, 
USA). Approximately 1 pg of DNase treated RNA was pipetted into an RNase free 0.5- 
ml microfuge tube and diluted to a total volume of 13.5pi with DEPC-treated H2 O and 
ip l o f oligo (dT) primers. The reaction mixture was then heated to 70°C for 2 minutes 
then placed on ice immediately. 6 .5pi of a reagent master mix composed o f 4pi 5X 
reaction buffer, Ip l dNTP (10mm each), 0.5pi recombinant RNase inliibitor and Ip l of 
Moloney Murine Leukemia Virus (MMLV) reverse transcriptase was added per 
reaction, vortexed and incubated at 42°C for 60 minutes on an MJ DNA engine tetrad 
(PTC 225). To stop the eDNA synthesis reaction and to destroy any DNase activity, the 
reaction was heated to 94°C for 5 minute then diluted to a final working volume of 
lOOpl.
RT-PCR was performed using the ABI prism 7900HT Sequence Detection System and 
Taqman Gene Expression Assay probes (Applied Biosystems, USA). Housekeeping 
genes, Glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) and p-Actin were 
selected as controls. Consistent expression o f the selected endogenous controls was 
then verified in the sample set (heart, liver and aorta). The endogenous control 
normalizes differences in the amount of cDNA loaded into PCR reaction wells, 
therefore endogenous control expression must be uniform across all samples in the 
study. Comparison o f the housekeeping gene expression o f several samples was used as 
a test o f uniform expression o f the endogenous control. Gene expression of endogenous 
controls should vary only slightly, therefore any statistical differences in gene 
expression across the samples tested was taken as an unstable housekeeping gene in the 
tissue type analysed and the housekeeping gene was rejected as an endogenous control.
The endogenous control and target assays must have identical PCR efficiency in order 
to obtain a comparative cycle tlneshold (CT) value. To ensure the target gene(s) and 
endogenous control had identical PCR efficiency, a series o f serial dilutions o f the 
cDNA sample was carried out. A constant CT difference across a range o f at least 3 
logs (1000-fold) of initial template concentration was used to verify identical PCR 
efficiency in the target gene(s) and the endogenous housekeeping gene.
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The PCR step for the multiplex assay was carried out in a 96-well format using PCR 
reaction mix components -  1 pi o f 20x Taqman Gene Expression Assay probe, 4 pi of 
cDNA diluted in 5 pi o f H 2 O and lOpl o f Taqman 2x Universal PCR Master Mix. All 
reaction mix components were vortexed prior to use and mixed by pipeting. Each 
reaction was replicated 3 times and the reaction plate was covered with an optical 
adhesive cover and pulse centrifuged at 10 OOOg for 5 seconds. The reaction plate was 
then placed in the sequence detector and the thermal cycling conditions were set using 
the standard run conditions o f 40 cycles with a 95°C denature step for 1 second and 
60 C extension for 20 seconds.
Data was analysed using the comparative CT method, which involves comparing the CT 
values o f the sample(s) o f interest with a control or calibrator RNA from normal tissue. 
The real-time PCR system is based on the detection and quantitation o f a fluorescent 
reporter (Lee, 1993; Livak, 1995). This signal increases in direct proportion to the 
amount o f PCR product in a reaction. By recording the amount o f fluorescence emission 
at each cycle, it is possible to monitor the PCR reaction during exponential phase where 
the first significant increase in the amount o f PCR product correlates to the initial 
amount o f target template. The CT values of both the calibrator and the samples of 
interest were normalized to a pre-selected endogenous housekeeping gene with identical 
amplification efficiency to the target gene. The comparative CT method is also known 
as the CT method, where
[delta][deltajCt = [deltajCt,sample - [delta]Ct,reference
[delta]CT sample is the CT value for any sample normalized to the endogenous 
housekeeping gene (target CT -  endogenous CT) and [delta] CT, reference is the CT value 
for the calibrator also normalized to the endogenous housekeeping gene.
2.7 SEQUENCING CANDIDATE GENES
2.7.1 Cleaning PCR Product
PCR fragments were cleaned using an AMPure Purification Kit (Agencourt 
Bioscience, USA). AMPure was added according to PCR reaction volume (36pl for
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20pl PCR reaction). The AMPure resin binds to fragments >100bp. The solution was 
vortexed and centrifuged for 1 sec at 2 0 0 0 g then allowed to incubate at room 
temperature for 5 minutes. The reaction was then incubated at room temperature for a 
further 10 minutes on the SPRI magnet plate (Agencourt Biosciences, USA). The plate 
was then tipped to remove the cleared solution. 200pl o f 70% ethanol (Sigma Aldrich, 
USA) was added and to allow precipitation o f fragments. The solution was discarded 
after 30 sec by inverting the plate, which was left to air dry for 35 minutes at room 
temperature. Once all ethanol had evaporated, 40ql o f distilled water was added to the 
reaction, which was sealed using an adhesive PCR film lid (Abgene, UK), vortexed and 
centrifuged for 1 sec at 2000g. Cleaned products were then transferred to a fresh skirted 
96-well PCR plate (Abgene, UK).
2.7.2 Sequencing of Candidate Genes
Sequencing o f the clean PCR products required use o f BigDye Terminator v3.1 
sequencing kits (Applied Biosystems, UK). The 20pl sequencing reaction contained
0.5-1.0pl o f template, 3.2 pmol o f primer (forward or reverse), 3.75pl of 5x sequencing 
buffer, 0.5ql o f ready reaction mix and autoclaved distilled H 2 O. The sequencing 
reaction program was as follows: 45 seconds at 96*^0 and 24 cycles o f 25 seconds at 
50°C and 4 minutes at 60°C. To remove unincorporated BigDye ddNTPs and primers 
the sequencing reaction was cleaned by CleanSeq Dye Terminator Removal Kit 
(Agencourt Bioscience, USA). lOpl of Cleanseq was added to lOpl o f each sequencing 
reaction . 42pi o f 85% ethanol was added and the reaction was centrifuged at 2000g for 
1 sec. The PCR plate was placed on a SPRI magnet plate for 4 min until the solution 
was clear. The following steps occur on the SPRI magnet. The cleared solution was 
removed by inversion o f the plate and 150pl o f 85% ethanol added to each reaction and 
allowed to incubate for 30 secs. The plate was then inverted and centrifuged at 2000g 
for 1 sec to remove all ethanol and air dried for 35 minutes at room temperature. The 
cleaned sequencing products were then re-suspended in 40pl of nuclease free H 2 O and 
transferred to a Thermo-Fast 96-well barcoded Detection Plate (Abgene, UK) and 
resolved on the 3730 DNA analyser using the manufacturers recommended run 
conditions, POP-7 polymer and a 36 cm capillary array. Data was analysed using
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Sequence Analysis software version 5.0 and results compared to published sequence 
using BLAST
2.8 MICROARRAY
Affymetrix Gene Chip® probe arrays are made using spatially patterned, light- 
directed, combinatorial chemical synthesis, and contain thousands of different 
oligonucleotides on a glass surface.
2.8.1 Target Tissue Preparation
Target preparation involves the preparation o f biotinylated target RNA sourced 
from a total RNA sample obtained from whole heart (described in detail in Chapter 
2.6.1). Double-stranded cDNA was synthesized using a T7-(dT)24 oligomer (5’ -G GC 
CAG TGA ATT GTA ATA CGA CTC ACT ATA GGG AGG CGG -  (dT) 24-  3’) to 
prime first-strand cDNA synthesis, which was HPLC-purified. First strand cDNA 
synthesis reactions were carried out in 1.5ml polypropylene RNase-free tubes. Second 
strand cDNA was synthesized by adding reagents listed in Appendix I, to the first strand 
reaction tube (briefly centrifuged), which were placed on ice. The tube was tapped 
gently to mix the reagents and incubated at 16°C in a water-bath for approximately 2 
hours. Approximately 2pl (lOU) o f T4 DNA Polymerase was added and incubated for 
5 minutes at 16°C. lOpl o f 0.5M EDTA was added to stop DNA synthesis and the 
mixture was stored at -20°C.
RNA transcripts were labeled using Enzo Bioarray HighYield RNA Transcript 
Labelling Kit; all reagents were supplied with the kit except DEPC-treated, sterile, de­
ionized water. The following reaction components were added in order to RNase-free 
microfuge tube: Template DNA (variable volume to give Ipg  o f cDNA), deionised 
water (variable to give a total reaction volume o f 40pi), lOX HY Reaction Buffer (vial 
l)(4pl), lOX biotin labelled ribonucleotides (vial 2)(4pl), lOX DTT (vial 3)(4pl), lOX 
RNase inliibitor mix (vial 4)(4pl) and 20X T7 RNA polymerase (vial 5)(2pl). After a 
brief centrifugation to collect all reagents at the base of the tube, it was immediately 
placed in a 37°C water bath and left to incubate for 4-5 horns, gently mixing the
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contents of the tube every 30-45 minutes. Following incubation the RNA produced 
either purified immediately or at -70°C. IVT products were purified using RNeasy 
Mini spin columns (Qiagen) to remove unincorporated NTPs to accurately determine 
the quantity o f cRNA.
Depending on recovery, ethanol precipitation was required to concentrate cRNA. 0.5 
volumes of 7.5M NFl4Ac and 2.5 volumes o f absolute ethanol (stored at -20°C) were 
added to the sample, which was then vortexed. The solution was allowed to precipitate 
for one hour to overnight at -20°C prior to centrifugation at >12.000 x g for 30 minutes. 
The resulting pellet was washed twice with 0.5ml of 80% ethanol (stored at -20°C) and 
air dried before resuspension in 10-20pl o f RNase-free water. Quantification o f cRNA 
(cleaned IVT product) was done using a NanoDrop® ND-1000 spectrophotometer, as 
outlined previously {Chapter 2.6.1). An adjusted cRNA yield is calculated to include 
any unlabelled total RNA. The starting amount o f total RNA (pg) can be multiplied by 
the fraction o f cDNA used in the IVT and subtracted from the amount o f cRNA 
measured after IVT (pg) to give an adjusted cRNA yield.
2.8.2 Target Hybridisation
Frozen stocks o f GeneChip® eukaryotic hybridization control cocktail were 
heated to 65°C for 5 minutes to completely re-suspend cRNA before aliquoting. Target 
purification and hybridization, using a probe array (at room temperature) was carried 
out prior to use. As the hybridisation cocktail was heated to 99°C for 5 minutes, the 
array was wet by filling via one o f the septa (see Figure 2.5) using an appropriate 
volume o f IX  hybridisation buffer (standard aixay -  200pl, midi array = 130pl and mini 
array = 80pi) using a micropipettor and corresponding tips. Wlien filling the probe 
array cartridge, two pipette tips are used; one for filling and the second to allow air 
venting from the hybridisation chamber. After incubation at 99°C, the hybridisation 
cocktail was heated to 45°C for 5 minutes using a heat block and then spun at maximum 
speed in a microcentrifuge for 5 minutes to remove any insoluble material from the 
hybridisation mixture. The buffer solution was removed from the probe array cartridge 
and replaced with the appropriate volume (total fill volumes are: standard array = 250pl,
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midi array = 160pl and mini array = 1 OOpl) o f clarified hybridisation buffer. Probe 
arrays were placed in a balanced configuration in the 45°C hybridisation oven for 16 
hours.
2.8.3 Fluidic station and probe array setup
Probe information, fluidics protocols and experimental data were entered and 
then checked in the file locations window. The experiment name and probe array type 
were defined and other optional parameters entered, i.e. sample for resei"voir A was 
changed to non-stringent wash buffer (wash buffer A) and intake buffer reservoir B to 
stringent wash buffer (wash buffer B) prior to priming (see Appendix I for preparation 
of buffers). After 16-hour hybridisation o f the probe, the hybridisation cocktail was 
removed from the probe array and set aside in a microcentrifuge tube (stored at -20°C). 
The probe array temperature was reduced to room temperature before washing and 
staining. It was then filled completely (250pl) with non-stringent wash buffer. The 
GeneChip® fluidics station 400 was used to wash and stain the probe arrays, which was 
operated using the GeneChip® software. Priming of the fluidics station ensured that the 
lines cormected to it were filled with the appropriate buffers and that the station was 
ready to run the protocols. The intake buffer Washing and staining for antibody 
amplification was then carried out using strepdavidin phycoerytlnin (SAPE) stain 
solution. SAPE solution was prepared immediately prior to use and wrapped in foil to 
protect from light penetrance. For a 1200|_il solution the following reagents were mixed 
together: bOOpl o f 2X Stain Buffer, 540pl water, 48jul o f 50mg/ml acetylated bovine 
serum albumin (BSA), 12pi o f 1 mg/ml SAPE. These were divided into two aliquots of 
600pl each to be used for stains 1 and 3 respectively. Antibody solution was prepared 
by mixing 300pl o f 2X Stain Buffer, 266.4pl water, 24pi of 50mg/ml acetylated BSA, 
6.0pl o f lOmg/ml normal goat IgG and 3.6pl of 0.5mg/ml biotinylated antibody. The 
appropriate antibody amplification protocol was selected on the workstation to control 
the washing and staining o f the probe an*ay. The appropriate probe arrays were inserted 
into the designated modules in the fluidics station. The 600pl of SAPE solution in a 
microfuge tube was placed into the sample holder, ensuring that the sampling needle is 
in the tube with its tip at the bottom. When indicated, the next solution of 600pl of 
antibody stain solution was applied in the same manner. Again, this was then replaced
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Probe array on 
glass substrate
plastic cartridge
septa
front back
Figure 2.5 Diagram o f the GeneChip® Probe Array.
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with the last 600jal o f SAPE solution. When the protocol was complete the software 
indicated to eject the cartridge containing the array. An empty microcentrifuge tube 
was placed on the sampling needle and the probe array checked for bubbles. If  bubbles 
were present, the array was placed back into the cartridge and the station will drain and 
refill the array with the last buffer used. Once no bubbles were present the probe array 
was ready to be scamied, or could be kept in the dark at 4°C.
2.8.4 Data Analysis
Low-level normalization o f data was carried out using the Robust Multichip 
Average (RMA) method (Irizany et a l ,  2003), which performs several operations 
including:
i. probe-specific backgroimd correction, to compensate for non-specific 
binding
ii. probe-level multichip quantité normalization to unify distributions across 
all chips
iii. robust probe-set summary o f the log-normalized probe-level data by 
median polishing.
Cluster analysis was used to identify and classify samples on the basis of similarity, to 
minimize within-group variance and maximize between-group variance. Probe sets 
were identified as differentially expressed using the rank product (RP) method of 
analysis, a novel approach based on calculating RP from replicate experiments, 
providing a straightforward and stringent way to determine the significance level for 
each gene, which allows for flexible control o f the false-detection rate (Breitling et a l ,
2004). Genes were defined as differentially expressed with a p < 0.05 (p<0.01 and 
p<0.1 were also tested). Ingenuity Pathways Analysis (https://analysis.ingenuity.com) 
software was employed to gain functional and network information from RP data. Two- 
way analysis of variance (ANOVA) was used as an additional analytical method, to test 
for interactions between strain and environmental stimuli.
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CHAPTER 3
IDENTIFICATION OF LEFT VENTRICULAR HYPERTROPHY IN SHRSP
3.1 INTRODUCTION
Current major strategies developed for gene identification in humans (linkage 
analysis in families segregating for rare Mendelian forms of cardiac hypertrophy and a 
candidate gene approach) are limited due to the complex, multifactorial and polygenic 
nature of the common disease form (Brand et a l, 1998). To some degree, a number of the 
inherent complexities encountered in the study of human subjects can be circumvented with 
the use of inbred rat models. The main advantages to using experimental animals are the 
ability to study large numbers o f homogenous progeny under controlled environmental 
conditions and the application of standardised and uniform high fidelity phenotyping 
methods. The stroke prone spontaneously hypertensive rat (SHRSP) is one of the best 
animal models available for the study of cardiovascular disorders, as it is characterised by a 
number of vascular complications including left ventricular hypertrophy and salt-sensitivity 
in common with the human disease state (Okamoto & Aoki, 1963; Yamori, 1982). Indeed, 
several studies have confirmed the polygenic inheritance of left ventricular mass (LVM) 
with the use of inbred SHRSP (Tanase et a l, 1992; Clark et a l,  1996; Inomata et a l,
2005).
The main impetus to these investigations is the ultimate goal of gene identification. In the 
SHRSP, quantitative trait loci (QTL) are detected from the results of a complete genome 
wide scan in a segregating F2  population, obtained by cross breeding the SHRSP with the 
normotensive reference strain Wistar Kyoto rat (WKY). As early as 1982, Tanase et a l 
demonstrated the heritability o f heart weight in the rat and suggested the effect of genetic 
factors influencing cardiac mass is larger than that of blood pressure alone. From this 
study, the extent o f genetic influence was estimated to be 45%-65% (by strain comparison) 
and 35%-60% (by cross analysis) (Tanase et a l,  1982). Following on from these results, 
genome wide scans carried out in a variety of inbred rat strains have led to the identification 
of QTL for LVM independent of blood pressure, on rat chromosome 17 (Pravenec et a l , 
1995; Tsujita et a l  2000), chromosome 3 (Sebklii et al., 1999), chromosome 5 (Deschepper 
et a l 2001) and chromosome 2 (Innés et a l, 1998).
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Pravenec et al. (1995) used recombinant inbred strains initially derived from the SHR and 
normotensive Brown Norway strain (HXB and BXH). In this genome wide scan, they 
found the genetic marker for dopamine lA  receptor (DrdlA) on chromosome 17 showed a 
high correlation for LVM irrespective o f blood pressure values. Similarly, Tsujita et al. 
(2000) identified a blood pressure independent locus for left ventricular mass index (LVMI; 
LVM indexed to body weight) on chromosome 17 in an F2  cross between SHR and the 
Lewis rat. This locus was not in the same region identified by Pravenec et al., however it 
does illustrate the importance of strain differences and the requirement to examine a variety 
of strains. Innes et al. (1998) used 182 F2  male animals derived from a cross between SHR 
and normotensive Donryu rats. The group identified a locus on chromosome 2 (lvm-1) 
with linkage to relative LVMI but showed no evidence of linkage to mean arterial pressure. 
These results further indicate that LVM is influenced by parameters other than blood 
pressure in hypertensive rat crosses and the genetic factors relating to cardiac mass may not 
be the same genes controlling blood pressure. In order to investigate this hypothesis 
further, several studies have been carried out in normotensive rat crosses. Sebkhi et al. 
(1999) examined 126 F2  male rats obtained from a normotensive WKY and Fischer 344 rat 
cross. They identified a QTL on chromosome 3, accounting for 16.5% of the total variance 
of LV weight. This QTL was also found to be significantly linked to total heart weight. 
Deschepper et al. (2001) investigated LVM using a normotensive cross between the WKY 
and WKHA (WKY hyperactive) rat. From this study, they identified 2 contiguous QTL on 
chromosome 5, with linkage to either LVM or ANP, suggesting a possible correlation 
between ANP levels and LVM in normotensive animals. However, in order to support this 
hypothesis, further investigation to discount other physiological factors relating to ANP 
levels and the biochemical pathways involved in both normotensive and hypertensive 
strains is required.
QTL analysis itself can have a number of limitations with several factors influencing 
results, for example, the population under investigation, polymorphic marker loci and 
number, missing genotype/phenotype data, the location, number and interaction of QTL 
and of course human error. For these reasons, more refined statistical approaches to QTL 
mapping have been developed. Broadly speaking, there are three different types of
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statistical analysis that can be used in the search for QTL; single-marker tests, interval 
mapping and composite interval mapping. The advantage of composite interval mapping 
methods is that they accommodate multiple QTL. Llowever, none o f the current available 
methods can accommodate fully the complexity of multifactorial traits that arise from gene- 
gene and gene-environment interactions.
With multiple traits and multiple environmental factors involved in a QTL mapping 
experiment, the estimation of pleiotropic effects and QTL-environment interactions is 
fundamental as is the understanding and estimation of the structure and genetic make-up of 
quantitative traits. With the advent of well-saturated genetic maps, it is possible to single 
out major structural components of the genetic architecture o f quantitative traits and 
estimate the associated parameters. Multiple interval mapping is a well adapted statistical 
approach to identify and estimate these parameters, which include QTL number, genomic 
positions, effects and interactions of significant QTL and their input on genetic variance. 
Published studies over the last decade have provided a large number of newly developed 
microsatellite markers, which have vastly improved the density o f the rat genetic linkage 
map (Jacob et al., 1995; Pravenac et a l,  1996; Bihoreau et al. 1997; Brown et a l, 1998). 
These markers, together with refined statistical analysis should allow a more complete 
mapping of heart weight in the SHRSP.
Previously, our group identified two blood pressure QTL on rat chromosome 2, a single 
QTL for pulse pressure on rat chromosome 3 and a suggestive QTL for LVMI on rat 
chromosome 14, using F2 genome wide analysis of a SHRSPoia x WKYoia cross (Clark et 
a l,  1996). The aims of this study were to perform an improved QTL analysis scan in both 
male and female F2 hybrids produced from this cross, using phenotypic data collected from 
the previous F2  genome wide scan (detailed in Appendix II; Clark et a l,  1996) and an 
improved genetic linkage map for rat chromosome 14.
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3.2 METHODS
3.2,1 Experimental Animals and Genetic Crosses
Inbred colonies o f SHRSP and WKY rats have been established at the University of 
Glasgow since 1991. Two reciprocal crosses were previously produced in 1996, 1 male 
SHRSP was mated with 2 WKY females (cross 1) and 1 male WKY was mated to 2 
SHRSP females (cross 2). From the Fi generation of each cross, 3 males and 6 females 
were brother-sister mated to produce Fi rats (57 in cross 1 with a male; female ratio of 
28;29 and 83 in cross 2 with a male; female ratio of 37;46). Phenotypic data was previously 
obtained for 140 Fz (male; female = 65; 75) rats at 21 weeks of age, including 
radiotelemetry data (SBP, DBP, heart rate and activity) over a 5-week baseline period and 
after a 3- week salt challenge (1% NaCl in drinking water) (Clark et a l,  1996).
Gravimetric measurements of cardiac mass index (CMI; heart weight to body weight ratio) 
and left ventricular mass index (LVMI; left ventricle mass relative to body weight) were 
calculated from post mortem values (see Chapter 2.3.3), following a 3-week 1% salt 
loading period. Liver DNA used for analysis was extracted and stored at -20°C (see 
Chapter 2.4.1).
3.2.2 Genotyping, Improved Genetic Linkage Map and QTL Analysis
A total o f 24 new microsatellite markers in addition to the original 5 previously 
used by Clark et a l,  (1996) were screened and 8 of these were found to be polymorphic 
between SHRSP and WKY. Genotyping was performed by PCR amplification of DNA 
around all 13 microsatellite markers for chromosome 14 (Table 3.1). The PCR primers for 
typing the microsatellite markers were obtained from MWG Biotech, UK and have been 
previously published by the Welcome Trust Centre for Human Genetics 
(hftp;//www.well.ox.ac.uk/). PCR products were separated by agarose gel elecrophoresis, 
analysed using bioanalyzer (Bio-rad, USA) and scored by two independent operators, 
unaware of the phenotypic data.
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Genotype results gained from these additional genetic markers were added to data 
previously collected and mapped relative to each other using JoinMap 3.0 (Van Ooijen and 
Voorrips, 2001). The genetic linkage map generated by JoinMap 3.0 was used to analyse 
genotype and phenotype data for QTL on rat chromosome 14. Software packages used to 
analyse QTL included Windows QTL Cartographer and MapManager QTXb40. In order to 
account for missing genotype and trait data, several QTL analyses were performed, 
including interval mapping, composite interval mapping and multiple marker mapping 
using both software packages. Data was permutated 10000 times in order to obtain a more 
robust dataset and set significant threshold levels unique to the trait under analysis. The 
likelihood ratio statistic (LRS) was converted to the conventional base-10 LCD score, 
which varied for each trait analysed.
3.2 RESULTS
Raw genotype data acquired for this study is listed in Appendix II as well as the raw 
phenotype data used to re-analyse LVMI QTL on rat chromosome 14. Twenty four 
markers were tested in addition to the five used in the original genome wide scan (Clark et 
a l, 1996), o f which eight markers were polymorphic and agarose gel resolvable. Figure
3.1 is an example o f PCR fragments amplified from F2 DNA using a polymorphic marker 
{D M arbl7) and visualised using a 1% agarose gel. Figures 3.2a-b illustrates an improved 
genetie linkage map for rat chromosome 14, generated by genotyping F2 DNA samples 
(11= 134) for 13 polymorphic microsatellite markers. Initially, LOD scores and pairwise 
recombination frequencies between markers was calculated, however due to a region of 
approximately 20 centiMorgans (cM) between Dl4rat41m\d D 14ratll0 , two distinct 
genetic linkage groups were created. Linkage group 1, comprised o f 12 microsatellite 
markers (excluding D14RatllO) was integrated and recombination values converted to 
genetic distances using the Kosambi mapping function. This improved rat chromosome 14 
genetic linkage map is in correct orientation and corresponds well with physical distances 
cited on online databases (http://www.ensembl.org;).
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Table 3.1 Polymorphic microsatellite marker oligonucleotide sequences.
Marker Left Sequence Right Sequence
D14Rat54 AGGCGTGCACACACATAAAC TTGGGCAGAGTATAGGGGTG
D14Rat75 GCACACTGCAGTGAGACAAA
A
TGAGGGTTGAGTTGGAAATTG
D14Woxl8 GAGTTTTCTTGCTGTCCAGAT
T
TGAGAATGGGTATGGGTTTAG
D14WoxlO TCCTTTGGTGATGATTAATAT
GAG
ATAAGGATTGTGAGATGGAAATG
D14Wox8 AAGGATAGGAGTGAATTGGT
G
TTGATGATGGTTTCATAAAGGG
D14Arbl7 AGTGAGGAATGGTGTGGTGA
GG
TAAGTGGGAGTAGGTGAGTTGG
D14Mgh3 GAAGGAGAGGGTAGTAGAGG
G
AATGGGTAGGTATGTATTGTGGG
D14W oxl2 GGAAGTGGTATGAGAGGAGG AAGTGGGAGTAGGTGAGTTGG
D14W oxl4 AGTTGATTAGAGAGAGAAAG
AGAGA
GTTTGCTTTGTTTTAGGGATTT
D14Got33 TGGATGAGATTTGGTGTGAG AGAGAAATGAGGGAAGGGTTG
D14Rat41 TTTGGAAAGTGATGGGGGT TGCGGTTGAGAGGAGATAATG
D14Rat24 GGAGAGGGGAGAGGTAATAA AAGGGTGGTGGAGTGGAG
D14RatllO AAGATTGTGTTGGTTAGGGTG
A
GTGGAGGGAGAGAGGAGG
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Figure 3.2 (a) Chromosome 14 map generated by Clark et a l  (1996). Microsatellite 
markers correspond to a region of approximately lOcM, as defined by the addition of 
further polymorphic microsatellite markers, (b) Improved genetic linkage map generated 
using JoinMap 3.0 and 8 additional polymorphic microsatellite markers; D 14ratlI0  is not 
shown on this linkage map as this marker forms a linkage group unlinked to the 12 markers 
shown.
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In order to confirm the suggestive QTL for LVMI, previously identified by Clark et a l 
(1996), simple interval mapping was used to analyse the entire F2 group including males 
and females (n=134) for all traits. A QTL for CMI was identified, LOD = 4.0 (Figure 3.3a) 
and a QTL for LVMI, LOD = 2.8 (Figure 3.4a). Clark et a l (1996) reported a possible 
gender bias specific for males therefore the 69 females were removed from techniques; 
composite interval mapping and multiple interval mapping (Figures 3.3b, 3.3c, 3.4b, 3.4c, 
3.5b, 3.5c, 3.6b, 3.6c, 3.7b, 3.7c).
In each dataset, analysis was initially performed using the simple statistical approach of 
interval mapping. With the application of more complex QTL analyses, generally the QTL 
region was more defined. Figures 3.3-3.7 illustrate the increasing complexity of the QTL 
region as more sophisticated statistical analysis methods are used. For example, in Figure 
3.3a, a broad QTL peak for LVMI is visualised by simple interval mapping. Re-analysis 
using a composite interval mapping strategy results in a reduced QTL spread (Figure 3.3b). 
Further analysis using multiple interval mapping (Figure 3.3c) produces two distinct QTL 
peaks linked to markers D14Woxl4  (QTLl) and D14Got33 (QTL2). For this reason, the 
likelihood-ratio statistic (LRS) and therefore logarithm of the odd score (LOD) varied for 
each trait analysed, however the location of the QTL was consistent regardless of the model 
tested. Furthermore, the suggestive QTL identified for PRA by simple interval mapping 
analysis is lost when re-analysed by more composite statistical methods (Figure 3.7). There 
were no QTL identified for any trait by subsequent analysis in the female subset of animals, 
suggesting a possible gender specific effect for CMI and LVMI observed only in males.
Variance in LVMI between heterozygote (WS) and homozygote (WW, SS) genotypes was 
examined using single factor (one-way) ANOVA, for polymorphic marker loci underlying 
the peak o f LVMI QTLl {DI4Woxl4) and QTL2 (D14Got33) in groups separated by sex. 
The results shown in Figures 3.8a-b (male) and 3.9a-b (female) respectively indicate both 
DMWox and D14Got33 loci affect LVMI in a recessive manner in males only.
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Figure 3.8 Single factor ANOVA analyses of LVMI in males at polymorphic marker loci 
(a) D14Woxl4 between heterozygote (WS, n=27) and homozygotes (WW, n=10; SS, n=26) 
and (b) D14Got33 between WS (n=30), WW (n=12) and SS (n=21). Between WW and SS 
there is a significant difference in LVMI of 1.44 (♦, P<0.0001) and 1.22 
(*, P<0.001) at markers D14Woxl4 and D14Got33 respectively. As WW and WS rats have 
equivalent LVMI, both marker loci affect LVMI in a recessive manner. There is no 
statistical difference in LVMI between WW and WS at both polymorphic loci. Data shown 
is mean iSEM ,^^^^ hoc Bonferroni adjustment.
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Figure 3.9 Single factor ANOVA analyses o f LVMI in females at polymorphic marker loci 
(a) D14W oxl4  between heterozygote (WS, n=30) and homozygotes (WW, n=16; SS, n=19) 
and (b) D14Got33 between heterozygote (WS, n=30) and homozygotes (WW, n=19; SS, 
n=18). There is no statistical difference in LVMI between the three genotypes WW, WS 
and SS at both polymorphic loci. All data shown is mean ±SEM.
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with no corresponding QTL identified in the female subgroup, thus confirming a sex 
difference between males and females.
p 2 data was further analysed by linear regression to test the null hypothesis, LVMI in males 
is independent o f SBP (after 3-week 1% salt loaded period), shown in Figure 3.10. There is 
a suggested relationship between SBP and LVMI; SBP accounted for between 2I%-27% of 
observed variance in LVMI, determined by linear regression. In Figure 3.10, SHRSP 
homozygotes (labelled ‘S’) tend to have higher LVMI compared to animals with genotypes 
“W” (WKY homozygote) or ‘H ’ (WKY/SHRSP heterozygote); the percentage variation 
explained by the D14Got33 genotype is estimated between 11% and 19%. By fitting a 
regression model with LVMI as the response and SBP as the predictor and including 
SHRSP homozygous as a factor, resulted in significant coefficients for both SBP 
(coefficient±SE=0.010±0.002, P=1.2xl0‘®) and SHRSP homozygous (0.233±0.067, 
P^O.OOl); these regression lines are also plotted on Figure 3.10. There was no evidence 
that the relationship between SBP and LVMI was different for SHRSP homozygotes 
compared to animals with other genotypes (i.e. there is no evidence that the slope of the 
SHRSP homozygotes’ regression line differed from the slope for the other animals; 
coefficienttSE=-0.0024±0.0037, P=0.519).
Statistical interpretation within the male subgroup was broadened to include student t-test 
analyses of Y chromosome origin (SHRSP grandfather versus WKY grandfather) and 
LVMI and SBP (after 3-week 1% salt loading period). From the data, the SFIRSP derived 
Y chromosome segregates with an increased LVMI and SBP (Figures 3.11,3.12) 
confirming previous findings by Davidson et a l (1995) with respect to blood pressure. 
Figure 3.11 shows the mean LVMI values separated by Y chromosome origin and a 
regression analysis plot is shown in Figure 3.12. From the data, males with a SHRSP 
grandfather have both larger LVMI and increased SBP compared to males with a WKY 
grandfather. In both cases this difference is statistically significant when compared using a 
unpaired t-test (LVMI difference=0.35mg/g, 3.7x10“^ ; SBP difference^!8.SmmHg, 
P=3.2exI0'^). The Y chromosome effect percentage variation on LVMI and SBP is 
approximately 29% and 27% respectively.
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Figure 3.10 Graph showing SBP and LVMI values for male rats. The D14Got33 genotype 
is shown: ‘S’ = SHRSP homozygous, ‘ W’ = WKY homozygous and “H” = WKY/SP 
heterozygous; missing genotypes are shown as Regression lines for the model of 
LVMI using SBP (coefficient±SE=0.0I0±0.002, P= 1.2x10'^) and the SHRSP homozygous 
factor (0.233^0.067, P=O.OOI) as regressors are shown; adjusted R^= 0.47, F=25.8I with 2 
and 54 d.f., P = L 4xI0t
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Figure 3.11 Analysis of the Y chromosome effect in male data subset. Animals are 
grouped according to Y chromosome origin: WKY grandfather (n=37) and SHRSP 
grandfather (n=28). LVMI was highest in males derived from SHRSP progenitor with a 
difference o f 0.35mg/g (P=3.7xl0‘^ , F=27.27). Data shown is mean ±SEM using unpaired 
student t-test.
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Figure 3.12 Graph showing SBP and LVMI values for male rats separated by Y 
chromosome origin. The D14Got33 genotype is shown: “S” = SHRSP homozygous, “W”
= WKY homozygous and “H” = WKY/SHRSP heterozygous; missing genotypes are shown 
as Animals with SHRSP grandfathers are coloured green and those with a WKY 
grandfather are coloured blue. Unpaired student t-test analysis F=27.27, P=3.7xlO'^, n=65).
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3.3 DISCUSSION
With the addition of a further eight microsatellite markers, the number of 
polymorphic loci was increased from five to thirteen, resulting in a more improved 
coverage of rat chromosome 14 and a genetic linkage map spanning 63cM in the correct 
orientation, in comparison to the previous map generated (Clark et a l,  1996). In this study, 
a QTL for LVMI (QTLl) in males, identified by Clark et a l (1996) was confirmed and 
additional QTL for LVMI (QTL2) and CMI were identified using a dense genetic linkage 
map and three independent analysis methods.
Regardless of how the data was interrogated, a consistent single QTL linked to marker 
D14W oxl4 was identified and segregated with LVMI. The application of more complex 
and strict conditions identified a second QTL for both LVMI and CMI linked to D14Got33, 
which was not previously identified in the original F2 genome wide scan carried out by 
Clark et a l (1996) and at the time of writing this thesis there were no other cited QTL for 
CMI or LVMI on rat chromosome 14.
Continued analysis of the data to include all traits, using simple interval mapping, identified 
an additional QTL for PRA. However, this QTL was completely lost after re-analysis using 
both composite interval and multiple interval mapping approaches. These findings would 
suggest that application of a stringent and more refined statistical approach can reduce or 
completely eliminate artefacts associated with QTL identification, however these results 
also raise questions regarding gender within an inbred population and how sex can mask 
the effect of QTL leading to a complete loss or reduction of effect due to the simplicity of 
the statistical approach used. A further point to note with regards the results of this study is 
the gender bias toward males for the identified LVMI QTL. Comparisons between LVMI 
and linked polymorphic marker loci DMWox 14 and D14Got33 within the male and female 
subgroups showed statistical relevance in the male subset only. There was a higher 
standard error of the mean (SEM) in LVMI within the female group compared to the males.
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which may be a result of population size or simply higher intra-group variability, although 
SEM by itself is difficult to interpret.
Many compounding factors can affect QTL analysis, for example the number and 
interaction of QTL. LOD score-based (likelihood ratio statistic) methods were used by 
Lander & Botstein (1989) to define an approximated confidence interval of an estimated 
QTL position; "support interval” mapping. Jiang and Zeng (1995) also used the likelihood 
ratio statistic approach to test hypotheses such as close linkage vs. pleiotropy.
Consequently, the actual drop-off required in the likelihood ratio statistic to define support 
intervals varies with both each study and QTL. This problem becomes further complicated 
when other markers are fitted in a model, in addition to the markers flanking the interval 
under investigation. In particular, when extra markers are added to a genetic linkage map, a 
sharp rise or conversely fall, in the likelihood ratio curve at some marker loci is often 
observed. Assuming the QTL exists, increasing the complexity o f the statistical analysis 
and applying a more stringent criterion, can therefore result in a more refined model of the 
QTL. This study demonstrates that application of composite statistical analysis methods 
result in more delimited QTL, ineluding the identification of an additional QTL (QTL2) 
and the reduction o f a suggestive QTL, for PRA.
It is has previously been established that male SHRSP have higher blood pressure in 
comparison to females (Davidson et a l,  1995), therefore to test the variance of LVMI with 
SBP (after 3-week 1% salt challenge) as a variable, stepwise linear regression analysis of 
the data was performed. The results for genotypes WKY/SHRSP heterozygote and SHRSP 
homozygote at markers underlying the peak of QTL2 showed a statistical relationship 
between LVMI and blood pressure, indicating that LVMI is influenced by blood pressure, 
but genotype is not linked to blood pressure, as there is no blood pressure QTL identified 
on rat chromosome 14 in this study. This relationship is not surprising given that a 
correlation with blood pressure and LVMI has previously been shown in SHR and other rat 
models (Cicila et a l,  1999; Rapp, 2000; Aiello e ta l ,  2004).
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The same analysis in the WKY homozygote genotype showed a trend towards a blood 
pressure effect and LVMI, but this did not reach a level of significance and may simply be 
due to a lack o f power due to a lower number of animals in this subgroup. From Figure 
3.10 differences within the genotypes groups are also apparent, most notably half of the 
SHRSP homozygotes seem to have higher LVMI compared to almost all the animals with 
the other genotype groups. This difference leads the linear regression model with the 
binary factor “SHRSP homozygote” to find a significant increase in LVMI for animals 
which are SHRSP homozygotes. However, the bimodal nature of the SHRSP homozygote 
genotype suggests that there may be some other factor(s) involved. This could be due to 
operator differences in data acquisition or seasonal/time differences as animals used in the 
study were bred over one year period.
Another possibility for the observed gender effect is a Y chromosome/autosome interaction. 
When the data was analysed using linear regression, there is a SHRSP derived Y 
chromosome effect with respect to LVMI and SBP. These results do not necessarily 
implicate an epistatic Y chromosome-autosome interaction, as SBP is a dependant variable 
and previous data by Davidson et a l (1995) confirmed SBP in the SHRSP is influenced by 
loci on the Y chromosome. It is also important to note that there was no significant linkage 
between genotypes underlying the QTL2 peak and SBP and that LVMI variance is greater 
than that of blood pressure effects alone, which account for between 21%-27% variance in 
this study.
Recently, Inomata et al. (2005) carried out genome-wide screenings in two F2  populations 
bred from the SHRSP X WKY (110 male and 110 female rats) and SHR X WKY (151 
male rats; 1% salt loading), which showed consistent linkage to cardiac mass on rat 
chromosome 3, in the vicinity o f D3M ghl6 (LOD = 4.0 to 6.6 across the F2 populations). 
The QTL was defined in a relatively narrow region <25 cM in both F2 cohorts and despite 
confounding factors such as differences in haemodynamic overload and dietary 
manipulation (with or without salt-loading), was highly reproducible. In addition, the 
group identified a high degree of gender specific linkage from their data, with the genetic
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percentage impact on QTL variance in both sexes estimated to 23% (males) and 17% 
(females).
Deschepper et al. (2005) mapped the progeny of an F2 inter-cross between normotensive 
WKY and WKHA rats, showing male-specific linkage between locus Cm 24 and LVMI. 
Genome wide expansion o f their analysis detected additional loci, all linked to LVMI in a 
sex-specific manner, regardless of the autosomal location - a locus (Lvm-8) on 
chromosome 5 (LOD=3.4), two loci (Lvm 13; LOD=4.5 and Lvm 9; LOD=2.8) on 
Chromosome 17, and on chromosome 12 (Lvm 10; LOD=4.2). These results indicate that 
LVMI in normotensive rats is influenced by genes separate to those controlling blood 
pressure, with the suggestion that these genes may also act in a gender-specific manner 
possibly via sex-specific gene-gene-protein interactions.
Altogether, these studies provide further evidence that genes underlying LVMI QTL 
influence heart weight in both hypertensive and normotensive rat strains and support the 
hypothesis that sexual dimorphic effects are important with regards genetic susceptibility of 
cardiac hypertrophy. In conclusion, this current study is notable for the use of several 
statistical applications for localisation o f LVMI QTL on rat chromosome 14, though these 
analyses only refine the region of interest and do not reduce the QTL peak to the inclusion 
of a single gene. The outcome of this statistical breakdown resulted in confirmation and 
identification of QTL for LVMI and CMI in SHRSP X WKY cross, which showed no 
linkage with genotypes underlying the QTL2 peak and SBP in SHRSP or WKY F2 animals. 
In particular, the relative prevalence of sexual dimorphic QTL was highlighted in males, 
which may be masked in data produced by groups performing analyses exclusively in male 
only populations. Whilst no obvious physiological candidate genes have been identified 
within the QTL regions, there are a number of positional candidates with functional 
relevance to the phenotype which will be discussed in detail in results Chapter 4. In spite 
of this and due to the large area delimited by QTL regions, the generation of congenic 
strains is required in order to either confirm or refute the putative QTL and further dissect 
the region further {Chapter â).
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CHAPTER 4
COMPARATIVE MAPPING AND IDENTIFICATION OF CANDIDATE GENES
4.1 INTRODUCTION
The candidate gene approach focuses on specific genes, based on some a priori 
knowledge regarding loci or system(s), which at a functional level may be expected to 
show significant differences in animal models. Comparative mapping efforts, whereby 
regions of conserved synteny in different species are investigated and combined with QTL 
analysis data, can provide candidate genes of interest within a specific region, in the 
absence of gene profiling data. This strategy has several advantages such as lower cost, 
ease of use and the relatively high number of candidate genes identified. There are several 
disadvantages however, including the limitations of gene mapping resources and 
restrictions in available knowledge and understanding of gene function, which is required 
when filtering candidate genes to take forward to quantitative expression analysis. In order 
to maximise the potential of comparative mapping, QTL with shared commonality between 
rodent strains should also be seen as important candidate loci for the disease under 
investigation.
One such example o f this is the QTL identified on rat chromosome 10, which provides a 
paradigm and highlights the importance of conserved regions of synteny between 
chromosomes. This particular QTL was reported in several rodent crosses, including - 
SHRSPHd X WKYHd cross, (Jacob et a l,  1991; Hilbert et a l,  1991) Dahl S x MNS cross, 
(Deng et a l,  1991; Deng et a l,  1995) Dahl S x LEW cross, (Garrett et a l, 1998) GH x BN 
cross, (Harris et a l,  1995) and SHR x WKY cross (Zhang et a l ,  1996). In addition, Julier 
et a l (1997) investigated both the QTL region on rat chromosome 10 and a homologous 
region of conserved synteny on human chromosome 17. The same region has also been 
linked to a monogenic disorder, pseudohypoaldosteronism type II or Gordon’s syndrome, 
in a subset o f families (Mansfield et a l, 1997). In 1999, Baima et a l confirmed these data 
in another population of patients with essential hypertension and further clarified the region 
of interest. These studies (Julier et a l ,  1997; Baima et a l,  1999) provide classic evidence of 
the proof of concept that a QTL identified in a rodent species can be translated directly to a 
QTL in humans and set a precedent for similar studies for other cardiovascular QTL.
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Once a positional candidate gene has been identified, it is important to investigate 
functional roles both in vitro and in the whole animal at different stages in development in 
order to assess how the gene(s) impact on the phenotype of interest. There are a number of 
investigative approaches to this. For example, at the molecular level expression of specific 
genes in a target tissue can be examined using techniques such as real-time PCR with 
pharmacological intervention and dietary manipulation studies as well as protein analysis at 
the physiological and biochemical level. Pharmacologieal intervention studies involving 
antihypertensive drugs allow a route for investigation of candidate gene expression in 
response to chemotherapy and provides some insight into both biochemical 
pathways/interactions and pharmacogenetics in experimental animal models. A recent 
example of this comes from Zhou et a l, (2006) who demonstrated the long-term regulation 
of cardiac channel gene expression could be controlled by the gene activation of AT, 
receptors, by angiotensin II.
Identified QTL regions still contain a large number of potential candidate genes and in the 
absence o f high-throughput genotyping methods, comparative mapping techniques rely on 
bioinformatic methods such as data mining to reduce the number of potential gene 
candidates. In this study, the primary objective was to narrow the QTL region further by 
mapping conserved regions of synteny between the rat, mouse and human. In doing so, 
putative genes o f interest can be identified and taken forward for further analysis including 
tissue specific mRNA quantification and sequencing. Additionally, the functional role of 
candidate genes was investigated by gene expression analysis at different stages in the 
development of hypertension. Furthermore, the impact of pharmacological intervention on 
the expression of candidate genes identified will be investigated with the use of drugs 
previously demonstrated to affect blood pressure and LVM via different mechanisms.
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4.2 METHODS
4.2.1 Comparative Mapping
Data mining using online databases was carried out and data used to build 
comparative maps for mouse, rat and human (http://www.ensembl.org; 
http://www.ncbi.nih.gov; http://www.softberry.com/). Regions of synteny were mapped 
concordantly and known genes identified within defined regions o f synteny between the 
chromosomes of rat, mouse and human.
4.2.2 Pharmacological intervention
ATi receptor antagonist (olmesartan) and a vasodilator + diuretic combination 
(hydralazine + hydrochlorothiazide) were administered to 16-wk old SHRSP males (n=9) 
over a 4 week period by mixing with banana custard baby food. Daily doses - olmesartan 
(20mg/kg/day; n=3), hydralazine (16mg/kg/day; n=3) + hydrochlorothiazide (16mg/kg/day; 
n=3) (Sigma, UK). Control animals were fed vehicle only (WKY, n=3; SHRSP n=3). 
Blood pressure measurements were recorded on a weekly basis by tail cuff 
plethysmography. Hearts were removed at sacrifice for RNA extraction (n=3 per group) 
and quantitative analysis as follows.
4.2.3 RNA extraction and cDNA synthesis
Liver, aorta and whole hearts were removed at sacrifice from SHRSP and WKY 
animals: ages 6 weeks (n=3 respectively), 16 weeks (n=3 respectively), 21 weeks (n=3 
respectively) and 21 weeks after 1% dietary salt manipulation (n=3 respectively). In 
addition, heart tissue was removed from animals receiving pharmacological intei*vention 
treatment. The heart was blotted and weighed; the LV was dissected free from right 
ventricle and atria and weighed. LVMI was calculated from LVM indexed to body mass 
(mg/g). The liver was sliced and aorta left intact. All tissues were snap frozen using liquid 
nitrogen. RNA was extracted as described in Chapter 2.6.1 using Qiagen RNeasy Maxi kit
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(heart and liver) and Qiagen RNeasy mini kit (aorta). Single stranded cDNA was 
synthesised using 1 pg o f total RNA and the Advantage RT for PCR kit from Clontech.
4.2.4 Real-time PCR Quantification
With the purpose o f identifying differential gene expression patterns between 
SHRSP and WKY parental strains, tissue from aorta and whole heart were examined from 
animals aged 6wk (prior to the onset of significant hypertension), 16wk (when significant 
hypertension is established), 21wk and 21wk (‘S’, 3 week, 1% salt in drinking water). 
Additionally, heart RNA was examined from animals in the drug intervention study. RNA 
was quantified by real-time PCR (RT-PCR) using TaqMan® Gene Expression Assays 
(Applied Biosystems, Foster City, CA) as detailed in Chapter 2.6.4. A  concern with the 
use of certain housekeeping genes in RT-PCR, is non specific binding of contaminating 
DNA, which can interfere with the measure of fluorescence from both target and control 
gene probes, therefore DNA digestion was carried out on all RNA samples prior to use. In 
order to assess the possibility of relative quantification, singleplex and multiplex reactions 
were tested to examine PCR efficiency for both the gene(s) of interest and appropriate 
housekeeping gene. All gene expression PCR was carried out on an ABI prism 7900HT 
Sequence Detection System using a 96-well plate format.
4.2.5 Sequencing Candidate genes
Candidate genes were sequenced from PCR products obtained from genomic DNA 
extracted from 3 SHRSP, 3 WKY, 1 Brown Norway (BN) and 3 (WKY/SHRSP) 
heterozygote rats’ liver tissue using the method described in Chapter 2.4.1. The inclusion 
of heterozygote DNA was to provide further confirmation o f SNPs identified, as 
heterozygote animals will possess both alleles. Forward and reverse primers were designed 
in house to cover exon/intron boundaries as well as 5' flanking regions of the genes, to 
include approximately 1500 bases upstream of the initiating methionine codon of the open 
reading frame. Primer sequences used to sequence Dhp and Corin are listed in Tables 4.1 
& 4.2 respectively.
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Table 4.1 PCR and sequencing primers for Dbp.
Primer Sequence (5'-3') BP# GC% Coverage
Dbp OIF ACCACTTTACAACTTGAAGCGGG 23 47.8 Exon 1
D6;?_01R GGAAACAGAAATGCGCAGTTGT 22 45.5
Dbp 02F CAATTCTCCCTCCCACATTGG 21 52.4 Exon 2
Dbp 02R TGGGTGAGGCTGTGAAGGAA 20 55
Dbp 03F AAGGGCATCTGAACACACTCTGA 23 47.8 Exon 3
Dbp 03R TCAAGGTTTTATGCATCCCCAG 22 45.5
Dbp 04F TTCAAGCATCAGGAAGCCCTG 21 52.4 Exon 4
Dbp 04R CTACCGGATCATAGCATGGCTC 22 54.5
Dbp 05F GTATTTGCCAGGACGTGCTTCA 22 50 Exon 5
Dbp 05R TGTGGTGATGGAGCACGTTTAG 22 50
Dbp 06F GATACTTGACCTTTCCCGAGTGC 23 52.2 Exon 6
Dbp 06R GCCTTGTAGCCATGACATTGCT 22 50
Dbp 07F GCTCTCACAGACCGATAGCAATG 23 52.2 Exon 7
D bpJD K GAATCGCAGTGGGGACTAAAATC 23 47.8
Dbp 08F CAACATGAAGTGGAGAACTC 20 45 Exon 8
Dbp 08R CCAGTGGTTCTCAATCTTC 19 47.4
Dbp 09F ACCCACCTCAAGTGGAATTTTG 22 45.5 Exon 9
Dbp 09R TCTGGGAATGGAGTTGTTGGTC 22 50
D bpJQ V AAGTGTCTACTATCGCTATTGGAC 24 41.7 Exon 10
Dbp lOR TGCATGTGTGTTTTTTACAGAGCC 24 41.7
Dbp IIF TTGTTGGACAAGTAGAGGAC 20 45 Exon 11
D b p J lK GGTTTGGAGCAAGAAGATAG 20 45
Dbp 12F TTGCTGAGTCCCCTGAAAAC 20 50 Exon 12
Dbp U K CTTCTCTGTATCTGCAACATGGGT 24 45.8
D /jp u p O  1F GACACCAGCTATTTACTGTC 20 45 U p -7 5 0
Dbp up OlR AGAAAGCTGCCTCCAGCAATG 21 52
Dbp up 02F CCCAAGGGAAAGAAGATCATGG 22 50 Up 750 - 1500
D/)p_up_02R AACGCTGTGGTTCCTGAACTGT 22 50
All primers were designed in house using reference sequences taken from Ensembi 
database (http://www.ensembl.org). F refers to a forward strand primer and R refers to a 
reverse strand primer (reverse primers are in reverse complement format). Base pair 
number (BP), G (guanine)/C (cytosine) percentage and primer coverage is listed.
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Table 4.2 PCR and sequencing primers for Corin.
Primer Sequence (5'-3') BP# GC% Coverage
CRNOIF CTTGGAGTCGGAGGCTCGGAC 21 47.8 Exon 1
CRNOIR TTACCATAGAGCTCCAGATGTCTC 23 45.5
CRN02F CAATTCTCCCTCCCACATTGG 20 52.4 Exon 2
CRN02R TGGGTGAGGCTGTGAAGGAA 20 55
CRN03F TTCCTCCTGCTTGTGCTCATC 20 47.8 Exon 3
CRN03R CTTGTCCACACAGTCATGGTC 21 45.5
CRN04F GTGGAATGCAGAAGTGGACAG 22 52.4 Exon 4
CRN04R GTGCTCCCATTGAGATTCTC 20 54.5
CRN05F CAAATTCTGCCCTACCACAGCAC 23 50 Exon 5
CRN05R GGCGTCGCTGTTATTCTCAGTG 22 50
CRN06F GATACTTGACCTTTCCCGAGTGC 23 52.2 Exon 6
CRN06R GCCTTGTAGCCATGACATTGCT 22 50
CRN07F GCTCTCACAGACCGATAGCAATG 23 52.2 Exon 7
CRN07R GAATCGCAGTGGGGACTAAAATC 23 47.8
CRN08F CAACATGAAGTGGAGAACTC 20 45 Exon 8
CRN08R CCAGTGGTTCTCAATCTTC 19 47.4
CRN09F ACCCACCTCAAGTGGAATTTTG 22 45.5 Exon 9
CRN09R TCTGGGAATGGAGTTGTTGGTC 22 50
C R N upO lF GACACCAGCTATTTACTGTC 20 45 Up -  750
CRNup OIR AGAAAGCTGCCTCCAGCAATG 21 52
CRNup 02F CCCAAGGGAAAGAAGATCATGG 22 50 Up 750 - 1500
CRNup_02R AACGCTGTGGTTCCTGAACTGT 22 50
All primers were designed in house using reference sequences taken from Ensembi 
database (http://www.ensembl.org). F refers to a forward strand primer and R refers to a 
reverse strand primer (reverse primers are in reverse complement format). Base pair 
number (BP), G (guanine)/C (cytosine) percentage and primer coverage is listed.
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PCR (20|al) product was purified to facilitate elimination of dNTPs and primer 
oligonucleotides. Sequencing reactions were performed, cleaned and run on an ABI 3730 
(Applied Biosystems, UK) as described previously in Chapter 2.7.2
4.2.6 Sequence analysis
Candidate gene sequences were analysed using Seqscape version 2.1 (Applied 
Bio systems, USA), which is designed for reference-based analysis such as mutation 
detection and analysis, SNP discovery, validation and sequence confirmation. Data was 
input in text file format and sequences aligned against a reference sequence dataset 
downloaded from Ensembi database (http://www.ensembl.org). Detection of SNPs was 
carried out manually with two independent observers and automatically, using Seqscape 
console commands. Short sequences including SNPs were then re-aligned against 
reference databases of transcription factors and corresponding binding sites with 
commercially available software TFSearch© (Yutaka Akiyama, 2002), rVista version 2.0 
and GeneQuest version 5.05 (Dnstar, USA).
4.2.7 SNP Genotyping
Re-genotyping o f Fz animals was carried out by sequencing DNA of each animal 
using primers designed against a named SNP identified from candidate gene sequencing. 
As all animals used to produce the Fi progeny are inbred, linkage disequilibrium of SNPs 
identified in candidate genes will be high therefore only one SNP was used for genotype 
analysis.
4.3 RESULTS
Comparative mapping strategies aim to identify putative candidate genes based on 
conserved regions o f synteny between species. Figure 4.1, is an illustration of a 
comparative map based on data from identified orthologous regions between rat 
chromosome 14, mouse and human. Mouse chromosome 5 and human chromosome 4
111
Human
Chromosomes
0 Mbr
2S m
5» Mb
78 Mb
100 Mb
Rat Mouse
Chromosome 14 Chromosomes
I4A1
14A2
14A3
14B -
14C1
14C2
I4C3
1403 -
14C1
14C2*1
0 Mb
28 Mb
84 Mb
78 Mb
144 Mb
It M 2 4 m% 7 # 1 1  # 2 2
Figure 4.1 Comparative map for rat chromosome 14 (centre). Regions of common synteny 
between the mouse and human are colour coded, with corresponding chromosome 
indicated. Chromosomes identified in mouse are 5, 11,4 and 7. Chromosomes identified 
in human are 4, 2, 7, 22 and 1.
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approximated to QTL regions identified in Chapter 3. Selection o f two candidate genes 
was based on a combination of cross-referencing literature with available online databases 
for functional relevance to cardiac hypertrophy and narrowing the regions of interest to the 
underlying QTL peaks; listed in Appendix III. In addition, data from a previous microarray 
study carried out by our group (McBride et a l,  2003) in kidney tissue was used as an initial 
reference to gauge differential expression of putative candidate genes of interest.
The selected genes were then tested by pairwise display to check for sequence percentage 
homology, using a simple model designed by Jukes and Cantor (1969) to adjust for the 
number of differences observed between sequences. This corrective formula, D=-3/41n (1- 
(4p/3)), explains the relation between the percent difference and the genetic distance (the 
fraction of expected substitutions) between sequences. If the genetic difference ‘D’ is 
increased between sequences, the percentage of dissimilarity will also increase. Table 4.3 
details the pairwise alignment scores obtained from NCBI Homologene, for candidate 
genes Corin and Dbp in human, mouse and rat. From the data, it can be seen that Dbp has 
a more highly conserved inter species amino acid sequence homology (92.3%) than Corin 
(83%) and a relatively shorter evolutionary genetic distance; D= 0.157-0.162 in Dbp 
compared to 0=0.187-0.193 for Corin.
Both candidate genes were further investigated using relative quantification real time PCR 
(RT-PCR), which allows for detection of changes in steady-state mRNA levels across 
multiple samples relative to an endogenous control, which is constitutively and uniformly 
expressed. Calculations are based on cycle threshold (CT) value comparisons at a constant 
level of fluorescence from the gene expression probes using a method assuming 
-100%  PCR efficiency of reaction between the target and reference gene. Therefore, in 
order to quantify mRNA of a target gene relative to an endogenous control, efficiency of 
PCR is first examined in a multiplex reaction using mRNA from 16wk heart tissue. Figure 
4.2a shows the relative CT values (y-axis) obtained for candidate gene Corin and reference 
housekeeping gene (3-actin, plotted against the log of cDNA (x-axis) and Figure 4.2b 
illustrates the relative PCR efficiency plot for both genes. Expression o f -actin was 
identified as unstable in heart tissue with an unacceptable level of inter-strain variability
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Table 4.3 Pairwise analysis of candidate genes
Species Gene aa%ID nt%ID D Ka/Ks Knr/Knc
H. sapiens
CORIN
vs.
M.musculus Corin 83 83.5 0.187 0.128 0.786vs.
R.norvegicus Corin 82.7 83 0.193 0.128 0.968
H.sapiens
DBP
vs.
M.musculus Dbp 92.3 85.4 0.162 0.067 0.763vs.
R.norvegicus Dbp 92.3 85.8 0.157 0.071 1
A pairwise score display gives a table of pairwise statistics for a ‘Homologene’ group, that 
includes percent amino acid (aa%) and nucleotide identities (nt%), the Jukes-Cantor 
evolutionary genetic distance parameter (D) (Jukes and Cantor; 1969), the ratio ofnon- 
synonymous to synonymous amino acid substitutions (Ka/Ks) for predicted proteins, and 
the ratio of radical to conservative changes in the transcript (Knr/Knc). Sequences input for 
HomoloGene processing comprise o f the proteins from input organisms compared to one 
another (using blastp) and then paired and grouped, using a tree built from sequence 
similaiity, where closer related organisms are matched first, and then further organisms 
added as the tree is navigated in the direction of the root. Protein alignments are mapped 
back to their corresponding DNA sequences, where distance metrics are calculated (e.g. 
molecular distance, Ka/Ks ratio). Sequences are paired using syntenic regions where 
applicable, with the remainder o f sequences matched by application of an algorithm used to 
maximize the score globally, rather than locally, in a bipartite matching. Cutoffs on bits per 
position and Ks values are set to avoid improbable "orthologs" from being grouped together 
(NCBI HomologGene).
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Figure 4.2 CT values for positional candidate gene corin. The CT and ACT (y-axis) 
is plotted against the log of cDNA (x-axis) and the equation calculated by linear 
regression analysis, (a) Plot of CT values for Corin and housekeeping reference 
gene f5 -actin. (b) Relative multiplex PCR efficiency plot o f Corin and p  -actin.
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detected; a higher level o f (3-actin gene expression was observed in SHRSP in comparison 
to WKY (Figure 4.3). An alternative endogenous control was selected - Glyceraldehyde-3- 
phosphate dehydrogenase {GAPDH). Relative PCR efficiency o ï Corin and Dbp was then 
tested in a multiplex reaction with G A P D H the endogenous reference housekeeping gene 
(Figure 4.4a-b). GAPDH  remained stable in both strains and various tissues at different 
time points; tabulated in Appendix IV.
Gene expression analysis o f Corin was examined in aortic and heart tissue and the results 
are shown in Figures 4.5 and 4.6. In aorta, gene expression does not vary between WKY 
groups, with a 6-fold increase observed in SHRSP at ages 16, 21 and 21 weeks (S). A 
different pattern of gene expression was noted in heart tissue with an initial 3-foId increase 
observed in SHRSP age 6 weeks, no significant difference between the strains at the 16 
week time point and an approximate 6-fold increase in WKY versus SHRSP at age 21 week 
and 21 week (S). There was no significant difference in gene expression observed in 
SHRSP across all age groups, regardless of dietary salt manipulation.
It was not possible to assess Dbp gene expression in aortic tissue, as the level of gene 
expression in SHRSP was consistently below the threshold intensity o f detection; Ct values 
for WKY are shown in Appendix IV. In Figure 4.6, at age 6 weeks Dbp gene expression in 
heart tissue is significantly increased in WKY by approximately 5-fold, rising to 6-fold at 
16 weeks and 17-fold at 21 weeks in comparison to age matched SHRSP. After a 3 week 
1% salt challenge, the level of gene expression observed in WKY drops from a fold change 
of 17 to 3. Dbp gene expression in SHRSP was consistently low across all age groups and 
dietary manipulation.
The results of pharmalogical intervention to reverse LVH in mature SHRSP are given in 
Figures 4.8a-b and 4.9a-b. The effects of olmesartan (ATi receptor antagonist) and 
combined hydralazine and hydrochlorothiazide (vasodilator and diuretic) on systolic blood 
pressure over a 4 week period are shown in Figure 4.8a. SBP is significantly reduced in 
SHRSP to levels comparable with age matched WKY in both drug treated groups. The 
effect on LVMI, of a 4 week drug regimen is described in Figure 4.8b.
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Figure 4.3 CT values for p  -actin. There was significant inter-strain variability (P^O.Ol) 
for p -actin CT values in a multiplex reaction, with an increased expression of p  -actin 
observed in SHRSP versus WKY heart tissue. Analysis by unpaired student t-test.
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Figure 4.4 Ct values for Dbp, Corin and GAPDH. (a) Illustrates the relative Ct values for 
positional candidate genes Dbp and Corin with reference housekeeping gene GAPDH. (b) 
Relative PCR efficiency plots for both candidate genes in a multiplex reaction with 
housekeeping gene GAPDH.
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Figure 4.5 TaqMan gene expression in aorta - Corin. All data shown was normalised to 
SHRSP 6 weeks for 2'"^^^. At 16 week, 21 week and 21 week (S) there was an 
approximate 6-fold increased gene expression in SHRSP compared to WKY (n=3, 
P=0.002; n=3, P=0.003, P=0.003 respectively). There was no significant difference 
observed in WKY strains across all age groups. All data shown is mean ±SEM, analysed 
by unpaired student t-test.
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Figure 4.6 Taqman gene expression in heart - Corin. Ail data shown was normalised to 
WKY 6 weeks for In WKY, a significant increase of approximately 3-fold was
noted at ages 21 week and 21 week (S) respectively (n=3, P=0.006; n=3, P= 0.005) with an 
approximate 3-fold decrease compared to SHRSP at 6 weeks of age. There was no 
significant difference detected between the strains at 16 weeks of age and no significant 
difference was noted in SHRSP across at any time point. Data shown is mean ±SEM 
analysis by unpaired student t-test.
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Figure 4.7 TaqMan gene expression in heart - Dbp. All data shown was normalised to 
SHRSP 21 weeks (S) for 2'^ ^^ .^ In WKY, at ages 6 week, 16 week and 21 week, Dbp gene 
expression was increased approximately 5-fold (P=0.0003), 6-fold (P=0.0004) and 17-fold 
(P=3.2xl0'^) respectively compared to age matched SHRSP. There was a drop in gene 
expression at 21-wk (S) in WKY to an approximate 3-fold increase versus 21 week (S) 
SHRSP (P=0.01). There was no statistical difference in Dbp gene expression in SHRSP 
across all time points. Data shown is mean ±SEM, analysis by unpaired student t-test.
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Figure 4.8 Pharmalogical intervention study. Olmesartan (Olm) or combinded hydralazine 
and hydrocholorothiazide (H+H) administered over 4 weeks, (a) Averaged weekly daytime 
SBP is significantly reduced in Olm (n= 7; *, P<0.001) and H+H (n=7; *, P<0.001 ) treated 
SHRSP versus untreated SHRSP (n=7). (b) Gravimetric LVMI is significantly reduced in 
Olm (n= 7, *P=0.001) and H + H (n=7, *P<0.01) treated SHRSP versus untreated SHRSP 
(SHRSP, n=7). LVMI was reduced further in Olm treated animals (t, P<0.05) versus the 
group receiving H+H. All data shown is mean +SEM, single factor ANOVA with post hoc 
Bonferroni adjustment for multiple comparisons.
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Figure 4.9 Pharmacological effects on gene expression in (a) Corin and (b) Dbp. All data 
shown was normalised to Olm treated SHRSP for 2'^ ^^ (as this was the lowest expression 
group). There is no statistical difference in candidate gene expression in heart tissue of 
Olm (Olm, n=3) or hydralazine hydrochlorothiazide (H + H, n=3) treated SHRSP versus 
untreated SHRSP (SHRSP, n=3). Data shown is mean ±SEM, analysis by unpaired student 
t-test.
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observed in AT] receptor antagonist group. Body weight and cardiac parameters are 
tabulated in Appendix VI. The effect of drug treatment on candidate gene expression levels 
is illustrated in Figures 4.9a-b. Although there is a trend towards a reduced expression of 
both genes in treated animals, this was not significantly different to the untreated SHRSP 
group.
Single nucleotide polymorphisms (SNPs) found within the promoter or coding region of a 
gene may explain differences in gene regulation, therefore sequencing was carried out on 
both candidate genes in SHRSP, WKY and BN liver DNA. There were no SNPs detected 
from sequencing the rat Corin gene in either exonic or upstream regions. In exons 3, 4, 5 
and 13 of rat Dbp, synonymous SNPs were identified. A graphical representation of raw 
data output shown in Figure 4.10. All SNPs identified in rat Dbp (with the exception of 
one exon 4 SNP at position 14505) are novel. In addition to exonic polymorphisms, a SNP 
located at position -1244 was detected in the proximal 5' region. Analyses with 
transcription factor binding sites and promoter sequence software predicted an unusual 
TGTAAA motif located at position -1244, which may serve as a proxy TATA sequence. 
Figure 4.11 illustrates the structure of the rat Dbp gene and putative binding transcription 
factors based on sequence data. Further analysis of the predicted promoter region identified 
a cap signal for transcription initiation and several putative binding transcription factors -  
globin transcription factor 1 {GATAI), globin transcription factor 2 (GATA2), activator of 
nitrogen-regulated genes 2 (NIT2) and cyclic AMP response element binding protein 
{CREE).
Genotyping F2 animals was repeated for the D6pexon-4 SNP. Re-analysis with additional 
genotypes improved the QTL region marginally but not significantly. Linear regression 
analysis showed no difference between Z>èpexon-4 SNP genotypes and D14Got33 
genotypes with respect to LVMI; P=0.679 for the difference in SS intercepts for D14Got33 
(0.233) and DbpQxonA (0.195), therefore data is not shown. These data also demonstrate 
high linkage disequilibrium between D14Got33 and Dbp^xowA, which is expected in an 
inbred homogeneous population.
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Figure 4.10 Raw data output from SeqScape version 2.1 sequencing analysis software. 
The data shown here is a SNP located in exon 13 of rat Dhp. The reference sequence for 
alignment is from Brown Norway (BN) rat sequence downloaded from Ensembi database. 
The SNP at position 35979 is highlighted by two black parallel lines with nucleotide 
substitution shown by colour changes from reference colour yellow (G) to red (T). 
Homozygote WKY (WW) and SHRSP (SS) are shown as yellow and red respectively; 
WKY/SHRSP heterozyote (WS) is obvious from the presence of both yellow and red 
colours.
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Figure 4.11 Graphical representation rat Dbp gene structure. SNPs were identified at 
position -1244, exons 3, 4, 5 and 13 (indicated by grey arrows). The putative TATA 
sequence, position o f the cap initiation signal and promoter region, is shown in the 5' region 
of the gene. From cross-referencing bioinformatic databases, transcriptions factors GATAI, 
GATA2, N1T2 andCREB  were identified. Synonymous exonic SNP nucleotide changes are 
shown in light grey boxes with the intronic SNP nucleotide changes shown in dark grey.
1 2 6
Â
4.4 DISCUSSION
From this study, two positional candidate genes {Corin and Dbp) were identified 
based on comparative mapping of syntenic regions in mouse, rat and human. Subsequent 
pairwise analysis confirmed sequence homology between species. Differential gene 
expression patterns in SHRSP and WKY strains were detected in cardiac tissue and aortic 
tissue for Dbp and corin respectively, by RT-PCR. Further analysis of the candidate genes 
by sequencing identified 4 novel SNPs in Dhp, in particular a 5' SNP located at postion -  
1244, in a putative promoter sequence and thus transcription factor-binding site, with no 
SNPs identified in Corin.
Dbp also known as group-specific component of serum (Gc-globulin) is a member of a 
multigene family that includes albumin, a-fetoprotein and a-albumin/afamin (Cook & 
David, 1985) and is the major plasma carrier protein of vitamin D and binds monomeric G- 
actin, released during cell lysis or injury, thus preventing polymerisation to F-actin (Van 
Baelen, Boullion & De Moor, 1985; White & Cook, 2000). In this study, a highly 
significant drop in Dbp gene expression was observed in WKY 21-week (S) compared to 
21-week, suggesting an inhibitory effect of dietary salt intake in WKY animals. In 2004, 
Thierry-Palmer et al. demonstrated, using the Dahl salt-sensitive (S) and salt resistant (R) 
rat, similar levels o f protein-bound 25-hydroxy vitamin D (25-OHD) in urine, when rats are 
fed a low salt (0.3%) diet. However, in older S rats fed a high salt (3%) diet, lower plasma 
25-OHD concentrations are found than in S rats compared to levels detected in R rats, with 
concentrations of PTH in S rats twice that o f R rats (Thierry-Palmer et a l,  2004).
Although WKY is not classically defined as salt sensitive, the inhibitory effects of a 
sustained salt intake over a long period of time in this rat strain have not been studied. 
Fuithermore, the relatively low levels of Dbp gene expression observed in SHRSP in this 
study may be indicative of low vitamin D status and consequentially an altered calcium 
homeostasis. Although the SHRSP was described in one study as a model of spontaneous 
osteoporosis in man (Yamori et a l,  1991), vitamin D status is yet to be fully investigated in 
this strain. Figure 4.12 illustrates the process of vitamin D production, transport and
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metabolism. Sequencing o f Dbp has led to the discovery of novel SNPs identified in exons 
3, 4, 5 and 13 (which includes the 3' untranslated region; UTR) and a putative promoter 
site.
In 1991, Ray et al. sequenced the entire rat Dbp gene, which is approximately 35 Kbp and 
contains 13 exons with the transcription cap site located 62 bp upstream from the translation 
start codon (Ray et a l ,  1991). From the sequencing data presented by Ray et al. (1991), it 
appears introns within the coding regions of the Dbp gene are highly conserved between 
other members of the albumin gene family (albumin and a-fetoprotein genes). The primary 
role of Dbp is the transport of vitamin D sterols, which are involved in calcium homeostasis 
along with calcitonin and parathyroid hormone (PTH). Calcium modulators have been 
shown previously to have vascular actions in rat and may be important in humans (Gairard 
et a l,  1994; Bukoski RD, Ishibashi K, Bian K, 1995; Levin & Li, 2005). In particular there 
is strong evidence for the role of vitamin D in the pathogenesis of cardiovascular disease 
from patients with end-stage renal disease (Foley et a l, 1998). In patients undergoing 
hemodialysis, 1 a-vitamin D and the vitamin D analogue paricaicitol are highly effective in 
reducing the risk of death from cardiovascular disease (Shoji et a l,  2004; Teng et a l,
2005). In addition, there are several studies reporting an association between PTH and 
LVMI (London et a l,  1987; B au wens et a l  1991), with a study by Hara et al. (1995) 
demonstrating a regression of ventricular hypertrophy and improvement in cardiac 
contraction after parathyroidectomy in 10 patients on maintenance haemodialysis, and 
similar results reported by Park et a l  (1999) who used intravenous calcitriol The possible 
functional role of calcium modulators is further, strengthened by in vitro studies, where 
PTH appears to have chronotropic, inotropic as well as hypertrophic effects on rat 
cardiomyocytes (Bogin et a l,  1981; Katoh et a l,  1981; Schulter et a l,  1995).
Dbp also known as group-specific component of serum (Gc-globulin) is a member of a 
multigene family that includes albumin, a-fetoprotein and a-albumin/afamin (Cook & 
David, 1985) and is the major plasma carrier protein of vitamin D and binds monomeric G- 
actin, released during cell lysis or injury, thus preventing polymerisation to F-actin (Van 
Baelen, Boullion & De Moor, 1985; White & Cook, 2000).
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In this study, a highly significant drop in Dbp gene expression was observed in WKY 21- 
week (S) compared to 21-week, suggesting an inhibitory effect of dietary salt intake in 
WKY animals. In 2004, Thierry-Palmer et a l demonstrated, using the Dahl salt-sensitive 
(S) and salt resistant (R) rat, similar levels of protein-bound 25-hydroxyvitamin D (25- 
OHD) in urine, when rats are fed a low salt (0.3%) diet. However, in older S rats fed a high 
salt (3%) diet, lower plasma 25-OHD concentrations are found than in S rats compared to 
levels detected in R rats, with concentrations of PTH in S rats twice that of R rats (Thierry- 
Palmer et a l, 2004). Although WKY is not salt sensitive, the inhibitory effects of a 
sustained salt intake over a long period of time in this rat strain have not been studied. 
Furthermore, the relatively low levels of Dbp gene expression observed in SHRSP in this 
study may be indicative of low vitamin D status and consequentially an altered calcium 
homeostasis. Although the SHRSP was described in one study as a model of spontaneous 
osteoporosis in man (Yamori et a l, 1991), vitamin D status is yet to be fully investigated in 
this strain. Figure 4.12 illustrates the process of vitamin D production, transport and 
metabolism. Sequencing o f Dbp has led to the discovery of novel SNPs identified in exons 
3, 4, 5 and 13 (which includes the 3' untranslated region; UTR) and a putative promoter 
site.
The UTR of mRNAs can determine gene expression by influencing mRNA stability and 
translational efficiency, with recent reports demonstrating gene expression regulation by 
the differential use of alternative 3' UTR (Hughes, 2006). An example o f this is 
demonstrated by Kloss et a l, (2005) who showed reduced expression of soluble guanylyl 
cyclase subunits was mediated by downregulation of the mRNA-stabilizing protein human- 
antigen R, emphasising the importance o f 3' UTR binding proteins in mRNA stability. The 
regulation of PTH gene expression by Ca2+ is also post-transcriptional and affects mRNA 
stability mediated by the binding of protective trans acting factors to a cis acting instability 
element in the 3' UTR. Indeed, in hypocalcemia there is increased binding that protects
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Figure 4.12 Illustration of Vitamin D biosynthesis pathway. Vitamin D is produced in the 
skin of mammals when light energy is absorbed by a precursor molecule 7- 
dehydrocholesterol and by dietary sources of Vitamin D (egg yolk and fish oils) Each of 
the various forms of vitamin D are lipophilic and are transported in blood bound to carrier 
proteins; the major protein is Dbp.
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PTH mRNA from degradation by cytosolic ribonucleases resulting in higher levels of PTH 
mRNA, whereas in hypophosphatemia there is decreased binding, with a subsequent 
increased degradation of the PTH mRNA resulting in low levels of PTH mRNA (Naveh- 
Many et a l, 2002).
In this study, Corin gene expression in SHRSP heart tissue remains unchanged across all 
time points, in contrast to WKY where expression is increased with age and consequently 
body size. In aorta, gene expression increases in SHRSP as blood pressure rises, but 
remains unaltered in WKY. This observed difference may be the result of reduced and 
impaired atrial stretch in SHRSP, due to concentric remodelling of the left ventricle and 
could also explain why a different gene expression profile is seen in aortic tissue. The 
suggestion that a local release of Corin is important to ensure the required hypertrophic 
response is supported by Langenickel et a l  (2003). Using an experimental model of heart 
failure, atrial Corin mRNA was decreased in parallel to a blunted ANP release upon stretch 
(Langenickel et a l ,  2003) offering corroboration that Corin released upon atrial stretch may 
be a rate-limiting mechanism for ANP release in vivo. Lanenickel et a l (2004) also 
sequenced the Corin and determined a high degree of homology between rat Corin, mouse 
(93,6%) and human (85%); the latter confirmed by pairwise sequence homology in this 
study.
In order to investigate the significance of blood pressure reduction on candidate gene 
expression, pharmalogical intervention using three different classes o f anti-hypertensive 
drugs was used to reverse the effects of high blood pressure in the SHRSP. It should be 
noted that although both drug treatments reduced SBP to an equivalent WKY level, this 
was not sufficient to reverse LVH, as LVMI was still significantly increased in drug treated 
animals compared to WKY. Although there appears to be slight downward trend in 
expression of both genes with drug treatment, the results were not significant. The overall 
lack of increased gene expression in SHRSP to equivalent WKY levels by anti­
hypertensive treatment suggests that reduced gene expression observed in SHRSP is not 
simply a secondary response to elevated SBP, as there is no significant change in gene 
expression after SBP reduction. The results of this study are in contrast to findings of
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Kaganovsky et al. (2001) who showed a positive correlation between levels of ANP 
granularity and myocyte size in SHR, which was significantly reduced after treatment with 
hydralazine. Similarly, Ohta et a l ,  (1995) demonstrated reduced ANP gene expression in 
10-wk SHR heart after treatment with an ATI receptor antagonist although they observed 
no suppression o f ANP gene expression with the use of hydralazine.
To date, there is a reported single QTL on mouse chromosome 5 and QTL for blood 
pressure, heart rate and myocardial infarction susceptibility on human chromosome 4, 
which are syntenic to rat chromosome 14. There is currently no reported LVMI or CMI 
QTL on either mouse chromosome 5 or human chromosome 4. The identification of 
candidate genes based on comparative mapping is laborious as many genes within syntenic 
regions require screening as well as determination of functional impact on the phenotype of 
interest as well as proximal distance to the QTL. There is also a certain element of 
guesswork in identifying candidate genes from comparative mapping resources as the 
function of many genes is still unknown with numerous genes still uncharted in the rat.
The combined strategies of congenic breeding with high throughput gene expression 
analysis methods, such as microarray should provide a more robust approach to candidate 
gene identification offering insight into the intricate network o f molecular pathways.
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CHAPTER 5
MRI AS A METHOD FOR IN VIVO LYM QUANTIFICATION AND 
ASSESSMENT OF LV GEOMETRY
5.1 INTRODUCTION
Over the past ten years, magnetic resonance imaging (MRI) has rapidly progressed 
from a purely anatomical imaging technique to one that reports on a wide variety of tissue 
functions. Cardiac magnetic resonance is currently the ideal method of choice for precise 
measurements of ventricular volumes, function and left ventricular mass in humans (Sola, 
White & Desai, 2006). This is due to high spatial resolution, excellent delineation of 
endocardial and epicardial borders, good image quality and ability to reconstruct the heart 
shape in three dimensions. For these reasons, results are not only independent of 
geometrical assumptions but are highly reproducible and accurate. CMR is particularly 
useful in research, as it is highly sensitive to small changes in ejection fraction and mass, 
and a relatively small number of subjects are required for study. In addition, due to the 
excellent reproducibility of data, temporal follow-up of any individual in the clinical setting 
is a more realistic possibility.
Following the release of the rat genome sequence there has been a forward, steady trend 
towards the use of the rat in cardiovascular research. In vivo assessment of cardiac 
morphology and function in rodents is hampered by both the small size and rapid action of 
the heart therefore high fidelity phenotyping techniques such as CMR are desirable to 
monitor even fractional changes in heart weight and function, in order to characterize fully 
the influence o f genes and pharmacological and/or surgical interventions.
In 1990, Manning et a l investigated the capacity of electrocardiogram (ECG)-gated MRI to 
assess in vivo LVM in the rat in comparison to gravimetric dry weight values. In this study, 
healthy Sprague-Dawley and Fischer 344 were imaged pre and post volume overload 
induction by aortic leaflet disruption. The group demonstrated a high correlation between 
MRI-estimated LVM quantification and post mo7'tem LVM values and showed a 40% 
increased mass in animals after aortic leaflet disruption. These preliminary results 
demonstrated both the feasibility and precision of MRI for in vivo assessment of LVM in 
the adult rat.
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Following on from the work of Manning et a l, Laurent, Allergrini & Zierhut (1995) 
showed a difference in left ventricular remodelling and function between the renal 
hypertensive rat (RHR) and SHR, despite similar SBP and LVM, using cardiac MRI. 
Several years later, Al Shafei et a l  (2002), developed a cine MRI technique to allow 
detection and characterization of chronic changes in myocardial tissue volume in the 
normotensive WKY rat. This was closely followed in 2003 with the application of single­
shot ultrafast spin-echo (Parzy et a l, 2003), to determine and evaluate left ventricular 
hypertrophy in hypertensive rats.
More recently, MRI has become a valuable, non-invasive technique in the characterisation 
of pathological changes in the heart during the progression of disease and as a tool for the 
evaluation of new therapies in left ventricular hypertrophy (Nahrendorf et a l, 2003; Schalla 
et a l,  2004; Loganathan et a l,  2005). Further exploration of theses studies not only allows 
an understanding of the requirement for high fidelity phenotyping in experimental animals 
but also helps examine how animal models can be of clinical benefit to humans.
Nahrendorf et a l (2003) studied the feasibility of cine MRI for assessment of infarcted rat 
and mouse heart, compared to established methods previously used for the prediction and 
prevention o f heart failure in patients. They did this by testing cine MRI in studies 
investigating interventions to alter the path of the remodelling process. MRI was used to 
establish left ventricular volumes and mass, myocardial infarct size and cardiac output and 
compared to left ventricle wet weight and conventional haemodynamic measurements for 
determination of cardiac output and LV volumes by electromagnetic flowmeter and 
pressure-volume curves. They were able to show a high concordance between LVM 
assessed by MRI and wet weight and in the MRI- and flowmeter measurements of cardiac 
output. From these initial results, it can be concluded that cine MRI is a valuable non- 
invasive diagnostic tool for use in rat and mouse to assess cardiac function, which may 
offer new insights into remodelling processes.
Collectively, these studies highlight the use of MRI as an invaluable, non-invasive 
technique to monitor changes in heart geometry and physiology (Loganathan et a l,  2005)
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and demonstrate the viability and utility o f MRI in the study of experimental animal 
models. O f course the translation of these investigations to the human clinical platform is 
invaluable from both a diagnostic and investigative standpoint.
This study aims to develop a MRI imaging protocol to compare 3-dimensional 
quantification o f LVM with 2-dimensional conventional methods such as echocardiography 
and simple post mortem evaluation in SHRSP, WKY and SP.WKYGla2a (a congenic strain 
with a reduced SBP compared to SHRSP). In addition, it is anticipated that MRI evaluation 
will allow the detection of subtle differences and changes in heart physiology in these 
strains.
5.2 METHODS 
5.2.1 Experimental Animal Strains
Inbred colonies o f SHRSP and WKY rat strains have been maintained at the 
University o f Glasgow since 1991 as described in section 2.2. The previously generated 
SP.WKYGla2a congenic strain (Jeffs et al., 2000) has an approximate 65cM homozygous 
WKY region o f rat chromosome 2, containing 2 blood pressure QTL (minimum boundary 
markers; D2Woxl3, D2Ratl57) intro grossed into the SHRSP background; a graphical 
representation is shown in Figure 5.1. The strain is characterized by a reduced SBP in 
comparison to the SHRSP parental strain (approximately 20 mmHg), but is not 
normotensive (Figure 5.2).
5.2.2 Echocardiographic LV Determination
Thirty rats, ranging from 8 weeks to 21 weeks of age per strain group, were 
assessed by echocardiography (SHRSP n=10; WKY n=10; SP.WKY.Gla2a n=10) as 
described in Chapter 2.3.3. Posterior wall thiclcness and LV internal dimensions were
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Figure 5.1 Graphie illustration of SP.WKYGIa2a congenic strain. A genetic linkage map 
for rat chromosome 2 genetic is shown on the right. The approximate locations o f 2 blood 
pressure QTL identified from a previous genome wide scan (Clark et a l ,  1996) are 
highlighted in blue. The SP.WKYGla2a congenic strain is shown on the left -  the yellow 
block represents a 65 cM WKY chromosome 2 segment introgressed onto a SHRSP (red) 
background (McBride et al. 2003).
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Figure 5.2 Representative radiotelemetry data for averaged daytime and night time SBP. 
F-statistics and P-values are for relevant main effects from repeated measures analysis of 
variance. The congenic SP.WKYGla2a strain has a reduced SBP in comparison to the 
parental SHRSP strain (F=15.8, P<0.0001) but is not normotensive (McBride et al. 2003).
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measured according to the leading edge method of the American Society of 
Echocardiography (ASE) at end diastole, with all measurements performed by two 
observers (Sahn et a l,  1978); Figure 5.3. LVM was calculated first using three statistical 
methods for comparison:
1. ASE-cube formula (Sahn et a l , 1978)
- LV mass (g) = 1.04 (IVSd + LVIDd + PWTd) 3 -. LVIDd3)
2. Troy formula (Troy, Pombo & Rackley, 1972)
- LV mass (g) -  1.05 (4/37t[(EDD/2+PWT)2(EDD+PWT)]-[(EDD/2)2-EDD])
3. Devereux correction factor (Devereux et a l,  1984)
- LV mass (g) = 0.8 (1.04 (IVSd + LVIDd + PWTd) 3 -. LVlDd3) + 0.6
Relative wall thickness (RWT) was estimated using the formula RWT = AWT + PWT / 
EDD.
5.2.3 Animal preparation for MRI imaging
Twelve 16-week-old male rats (WKY n=4; SHRSP n=4; SP.WKYGla2a n=4) 
examined by echocardiography approximately 24hrs previously, were anaesthetized with 
halothane in nitrous oxide: oxygen (70:30) prior to MRI scanning. An exchangeable 
radiofrequency (RF) birdcage was used as a transmitter and a 32mm diameter surface coil 
as the receiver (Bruker Biospin MRI, Germany). In addition, an animal cradle designed 
specifically to accommodate rodents, was optimized for use in the RF resonator (Bruker 
Biospin MRI, Germany) and facilitated monitoring of ECG, heart rate, respiration rate, and 
temperature. The animal’s chest and leg was shaved to allow adhesion of 8-lead ECG pads. 
The animal was positioned horizontally in a Bruker animal thermal cradle and then placed 
in the magnet (Bruker Biospin MRI, Germany) and sagittal images o f the thoracic cavity 
were obtained. A 70/30 USR 7 Tesla Biospec system (Bruker Biospin MRI, Germany) and 
Bruker software Paravision 3.0.2 was used for image acquisition with the following 
parameters: Single slice Flash cine, TE^lOSms, TR=14ms, Averages=6, field of 
view=50X50mm, image matrix=256X192, flip angle=10°. The entire volume of the heart
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was scanned by acquiring 1mm slices. ECG gating was carried out using the Biotrig 
monitoring system (SpinSystems LTD, Australia) with image sequences triggered in 
synchrony with the R signal o f the QRS waveform. MR images were analysed using 
ImageJ (NIH).
5.2.4 MRI Assessed LV determination and calculations
Using a sagittal image with the clearest representation of the heart, short axis multi 
slice images were acquired. The images in Figure 5.3a-b demonstrate how the plane is 
angled between transverse and coronal orientations. The contours of the left ventricle were 
determined by delineation of the epicardial and endocardial boundaries. The endocardial 
value was subtracted from the epicardial value, multiplied by slice thickness and then 
multiplied by 1.05 (density of the myocardium). Multi-slice values were calculated, 
summed and divided by 1000 (IKg). Measurements were taken separately at both systole 
(ESV) and diastole (EDV). Stroke volume (SV) was defined as EDV - ESV, and ejection 
fraction (LVEF) was defined as SV/EDV. Relative wall thickness (RWT) was calculated 
as RWT = AWT + PWT / EDD from a single MRI slice at the level of the papillary 
muscles. A compact disc (CD) of moving rat hearts (at mid-ventricle) is included inside the 
front cover. The images are in AVI format and represent a complete cardiac cycle for each 
strain.
5.2.5 P ost mortem  evaluation
After MRI examination, animals were euthanized under halothane anaesthesia. The 
hearts were removed; pericardium, fat and blood vessels were trimmed. The whole heart 
was blotted and weighed using an analytical balance. The atria and the right ventricular free 
wall were then carefully removed and the LV + septum was blotted and weighed to obtain 
LVM value; LVM index (LVMI) was calculated by indexing LVM to body weight.
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Figure 5.4 Pilot images. Sagittal (a) and transverse-coronal (b) pilot images were used to 
establish the cardiac axes and to position the transverse cardiac sections used in image 
acquisition.
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5.3 RESULTS
The main parameter o f the experimental protocol was to acquire MRI images of the 
entire heart at 1mm intervals through a complete cardiac cycle beginning with the heart at 
end diastole. Figure 5.5 displays a time series of MRI images at the level of the papillary 
muscles. All images show a clearly demarcated ventricular wall, ventricular lumen and the 
thoracic cavity. From Figure 5.5 (panel a) a fully dilated ventricle can be seen in the image, 
triggered by the R wave with a progressive decrease in luminal diameter in subsequent 
images (panel b-j). Both epicardial and endocardial surfaces of the left ventricle retained 
circular cross-sections throughout the cardiac cycle, in contrast to the crescent cross-section 
of the right ventricle (highlighted by white arrow).
From the MRI images, left ventricle quantitative analysis was carried out for each strain 
and compared directly with obtained gravimetric values. The mean values for this data 
show no significant difference between MRI derived LVM and LVM determined at autopsy 
(Figure 5.6a). Means and standard error of means (SEM) for haemodynamic measurements 
are shown in Table 5.1. Acquisition time was heavily dependent on both a steady heart rate 
synchronized with a stable ECG trace and was therefore affected by inter and intra-strain 
heart rate variability. From the analysis of MRI images, LVEF was not significantly 
different between all three strains. The results of linear regression analysis of MRI 
estimated LVM and echocardiographic analysis, compared to gravimetric values at post 
mortem (PM) and are shown in Figure 5.7. There is a good correlation between MRI 
derived LVM and post mortem weight (R^= 0.56; P= 0.008) shown in Figure 5.7, however 
echocardiographic assessment of LVM in small animal number groups (n=12) showed a 
poor correlation with gravimetric values.
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Figure 5.6 Comparison o f MRI, echocardiography and post mortem  (PM) for LVM in 16 
week old males. In comparison to PM, echocardiographic estimated LVM was 
significantly increased in SHRSP, WKY and SP.WKYGla2a (*, P>0.05, Cl -0.103 to 0.052; 
n=4 ♦, P>0.05, -0.148 to 0.071, n=4; ♦, P>0.05, Cl -0.091 to 0.059, n=4, respectively).There 
was no statistical difference between the MRI estimated LVM and PM values, grouped 
according to strain. All data shown is mean ±SEM, single factor ANOVA and post hoc 
Bonferroni adjustment for multiple comparisons.
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Table 5.1 MRI summary data for animals
Strain LVEF
(%)
HR (beats min'^) Weight (g)
SHRSP (n=4) 45.1±1.0 249±10 289.9±29.0
SP.WKYGla2a (n=4) 51. Ii6 .0 190±7 28L5±3.4
WKY (n=4) 41.7±5.6 195±5 335.6±29.3
Data shown is mean ±SEM
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Figure 5.7 Linear regression analysis of LVM. Calculations from MRI (n=l2) and 
echocardiographic (n=9) images compared with post mortem weight of the left ventricle. 
The results demonstrate a good correlation between MRI derived LVM and gravimetric 
values (black squares, line), with no statistical relationship observed between 
echocardiographic estimated LVM (calculated using Devereux modified ASE-cube 
formula) and post mortem LV weight (red circles, line).
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In order to compare calculation estimates for LVM as determined by echocardiography, 
three different formulae were used and the results contrasted. Figure 5.8a illustrates the 
results of this statistical comparison in thirty animals. The Troy formula and ASE-cube 
formula overestimate LVM significantly with a more accurate estimation of LVM using the 
Devereux modified ASE-cube equation. When animal numbers are increased, estimated 
LVM is in higher concordance with gravimetric values; a correlation of R^=0.S4, P<0.001 
(Figure 5.8b). In Figure 5.9a, MRI derived RWT mean values for the three strains are 
shown. From the data, RWT is significantly increased in SHRSP (P<0.001) versus WKY, 
SHRSP versus SP.WKYGla2a (P<0.05) and SP.WKYGla2a (P<0.05) versus WKY. RWT 
values obtained from echocardiographic images did not show any significant variation 
between the three strains (Figure 5.9b).
5.4 Discussion
The principal aims of this study were to develop MRI techniques to image a moving 
rat heart for accurate quantitative analysis of LVM and in addition compare the method 
directly with post mortem LV weight and echocardiography. In this study, MRI analysis 
was sufficiently sensitive to detect significant differences in RWT between the 
SP.WKYGla2a and the parental SHRSP strain, indicating concentric remodelling, 
undetected by simple LVM quantification. Previous assessment using echoeardiography 
and simple post-mortem evaluation has shown no statistically significant difference in 
either LVM or LV dimensions between the SP.WKYGla2a congenic and the SHRSP 
parental strain, despite an approximate SBP difference of 20mmHg. This is the first 
instance LVM, relative wall thickness (RWT) and left ventricular ejection fraction (LVEF) 
have been measured using MRI in the SP.WKYGla2a congenic strain.
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Figure 5.8a Comparison of echocardiographic statistical evaluation. Post mortem (PM) 
weight contrasted with three statistical formulae for calculation o f LVM, derived from 
echocardiography in SHRSP (n=10), SP.WKYGla2a (n=10) and WKY (n=10). There is no 
significant difference between Devereux modified ASE-cube formula and post mortem 
LVM (p>0.05). Application o f the Troy and ASE-cube formulae resulted in a respective 
34% and 15% overestimation of LVM compared to gravimetric values (p<0.001). All data 
shown is mean ±SEM, single factor ANOVA and post hoc Bonferroni adjustment for 
multiple testing.
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Figure 5.8b Linear regression analysis plot of echocardiographic derived LVM with post 
mortem (PM) values. LVM was assessed in thirty animals ranging in age and weight from 
8-21 weeks and 115-340g respectively using echocardiography. Devereux modified ASE- 
cube formula was used to quantify LVM and directly compared to gravimetric values 
obtained at sacrifice. Correlation between both methods was achieved; R^= 0.84, P< 0.001, 
n=30).
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Figure 5.9 Relative wall thickness (RWT) calculated at end diastole from (a) MRI images 
n=12) and (b) echocardiographic images (n=9). From MRI analysis, there is a significant 
increased RWT observed in SHRSP versus WKY and SP.WKYGla2a (P<0.001, P<0.05, 
respectively) and SP.WKYGla2a versus WKY (p<0.05). There is no significant difference 
in RWT observed between strains by echocardiographic estimation (p>0.05). In addition, 
RWT is consistently overestimated by echocardiographic evaluation versus MRI derived 
values (P>0.001). All data shown is mean ±SEM, single factor ANOVA with post hoc 
Bonferroni adjustment for multiple testing.
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MRI correlates well with gravimetric post mortem values, providing qualitative images 
which allow identification of differences in LV morphology, not apparent from 
echocardiographic imaging or simple post mortem evaluation. This study is novel, in that 
high fidelity phenotyping of the rat is taken to a further level of in vivo assessment, 
facilitating detection o f subtle changes in left ventricle geometry and remodelling, 
demonstrating significant differences between parental and congenic strains, even in small 
number groups. Moreover, MRI imaging allowed for an improved characterization of the 
congenic rodent strain, which demonstrates concentric remodelling versus concentric 
hypertrophy as seen in the SHRSP parental, which was not possible with echocardiography 
or simple post mortem evaluation.
Whilst several groups have validated the use of echoeardiography as a means of estimating 
LVM in the rat (Devereux et al., 1994; Graham et a l,  2004), estimations are based on 
geometric assumptions (Jones et a l 1992). Previously, our group showed a good 
correlation between post mortem and echocardiographic estimated LVM (n=58), calculated 
using the ASE-cube formula (Graham et a l,  2004). In this study (n=30), use of the 
Devereux modified ASE-cube formula results in a higher correlation between 
echocardiographic estimated LVM and gravimetric values. Despite these improvements in 
LVM calculation, use of echocardiography for analysis in the small subset of animals used 
in the MRI study provided a poor correlation and did not allow for anatomical differences 
such as heart shape, which is assumed to be the same in every subject. Similarly, cardiac 
remodelling events such as wall thickening are over estimated with echocardiography in 
comparison to MRI, which provided a precision of analysis sufficient to detect discrete 
changes in LV geometry between the SP.WKYgla2a and SHRSP for the first time.
More precise and exact correction factors could of course be derived for individual strains 
to circumvent the issue or strain variation and LVM estimation, although this introduces a 
further element of guesswork, which detracts from the accuracy o f results obtained and 
does not aid in identification of subtle inter strain LV geometric variations. MRI analysis 
of the rat heart provided a precise estimation of LVM in small animal groups (n=4), in 
accordance with data obtained from other groups investigating murine and rat heart mass
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by means of MRI analysis (Siri et al. 1997; Crowley et a l,  1997; Wise et a l,  1999) and 
demonstrates the potential utility of MRI to assess LVM quantification and structure in 
small sample groups.
LVEF was also measured from MRI images using data from both systole and diastole.
From the results it appears that the method of anaesthesia used in this study may have 
reduced cardiac output in these animals, as LVEF values for normotensive WKY hearts are 
somewhat lower in comparison to hypertensive SHRSP hearts and differ from MRI derived 
values obtained from other groups (Wise et a l,  1998). Although the effects of inhalant 
anaesthesia were not assessed in this study, other groups have reported cardiac depressant 
effects associated with use of halothane, in both humans and rodents (Merin, 1975; Friesen, 
Wurl & Charlton, 2000), which may indicate a requirement to change the anaesthetic used.
The actual time involved in optimisation of the MRI protocol was increased due to several 
factors, including heart rate variation between strains and signal interference associated 
with the ECG wires inside the magnet. In comparison to 2-dimensional techniques, such as 
echocardiography, MRI requires an initial set up period to optimise the stability of the 
animal and procedures such as motion gating. Standardising image acquisition is also 
fundamental in development of a MRI protocol in order to achieve precise and reproducible 
data, which ultimately leads to an overall increase in cost and time.
Crowley et al. (1997) devised a strategy to reduce the time of cardiac MRI image 
acquisition by application of an empirical formula to provide a more economical 
reconstruction of ventricular volumes at end diastole and end systole from a limited number 
of strategic images over a shortened image time. Following on from the work of Crowley 
et a l. Wise et a l,  (1999) developed an ellipsoid of revolution predictor for accurate 
determination of epicardial and endocardial geometries across the cardiac cycle using a 
reduced set of imaging planes and imaging times. The application of a reduced imaging 
protocol such as described requires time to validate the method fully and the introduction of 
additional MRI related equipment and therefore was not attempted in this study. Although, 
the utility of analysis approximating the ellipsoidal model could demonstrate further inter
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strain differences at different time points throughout the cardiac cycle and may be 
applicable to studies assessing cardiac function.
In conclusion, despite the fact that MRI imaging is costly in terms o f time and technical 
input, the advantages gained in using 3-dimensional imaging over 2-dimensional imaging 
are numerous. MRI provides good soft tissue contrast and temporal image resolution with 
improved accuracy o f LVM estimation. In addition, it was possible to identify cardiac 
structures and detect discrete changes not easily distinguished using 2-dimensional imaging 
or simple post mortem evaluation. MRI is an extremely powerful tool for cardiac imaging 
in relatively small animal gi'oups, offering unrestricted multi-planar imaging and as such 
provides a more advanced and superior method of experimental animal model phenotyping; 
in particular when the detection o f subtle changes and slight differences are important. In 
addition, the reproducibility o f results from MRI analysis is more consistent than 2- 
dimensional echocardiography, allowing for repeated acquisition of identical imaging 
planes and a more concise method o f serial imaging, which will be of particular benefit in 
longitudinal studies.
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CHAPTER 6
CONSTRUCTION OF SPEED CONGENICS I
6.1 INTRODUCTION
The identification o f chromosomal regions harbouring quantitative trait loci (QTL) 
is only the initial step towards gene identification (Rapp & Deng, 1995), mainly due to the 
relatively broad QTL regions implicated from analyses which in general do not underpin a 
single gene relating to a phenotype of interest. In addition, there is a requirement to 
validate statistical QTL analyses, by physical confirmation or ‘capture’ o f the QTL in a 
whole organism. Therefore in order to verify the existence of a QTL and narrow the 
chromosomal region of interest, thereby facilitating gene identification, a more definitive 
and stringent genetic test is required, in the form o f congenic strain production.
Traditionally congenic strains are developed by serial backcrossing a donor strain 
(containing the genomic region of interest) with the recipient inbred strain, then selecting 
for progeny heterozygous for the desired region in each backcross generation (Wakeland et 
a l,  1997). Essentially, this leads to a successive dilution of the donor genome into the 
recipient genome, with continuous maintenance of introgressed region containing the QTL. 
According to Mendel’s laws, it is expected that half of the unrelated genetic material will 
be transmitted to a subsequent backcross generation, 8-10 generations of backcross mating 
should result in a congenic strain in which more than 99% of the genome unlinked to the 
target gene(s) will be o f recipient strain origin. The introgressed region is then ‘fixed’ 
homozygous by intercrossing and the resultant congenic strain theoretically contains a 
genetic background identical to that of the recipient inbred strain with the exception of the 
introgressed region.
Whilst this breeding protocol is theoretically straightforward, in practice several years are 
required to ensure the recipient background homozygosity of the new congenic strain. The 
completion of the rat genome sequence in the Brown Norway strain (Gibbs et a l,  2004) in 
addition to concerted efforts to revise and update microsatellite based rat maps, provides 
the opportunity to reduce time taken to produce congenic strains, via a DNA marker 
assisted or congenic ‘speed’ strategy. This approach involves the analysis of polymorphic 
marker loci distributed throughout the genome in order to specifically select male progeny
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carrying the genetic region o f interest, whilst also retaining the lowest background 
heterozygosity at each backcross generation. Breeding with these ‘best’ males accelerates 
elimination of the donor genetic segment thereby reducing the number of generations 
necessary to produce a congenic strain.
There are many examples of rat congenic strains successfully produced using both the 
traditional and speed congenic breeding approach (Deng et a l,  1997; Zhang et a l, 1997; 
Rapp et a l,  1998 Cicila et a l,  1999). In 2000, our group (Jeffs et a l,  2000) were the first 
to successfully produce reciprocal congenic strains, via a speed congenic protocol. This 
was achieved by introgressing segments of chromosome 2 containing 2 blood pressure 
QTL between WKYoia and SHRSPoia rats, using 83 background genetic markers. Baseline 
and salt-loaded systolic blood pressure was reduced by approximately 20 and 40 mmHg 
respectively in male congenic rats with a SHRSP background compared with the SHRSP 
parental strain. This study not only confirmed QTL for blood pressure on chromosome 2, 
but supported the application and validity of this strategy.
Boutin-Ganache et a l  (2002) produced a normotensive congenic strain from WKY and 
WKY hypertensive (WKHA) rats, which exhibited differences in LVMI in the absence of 
high blood pressure. Their data implicated a region on chromosome 5 showing linkage to 
both LVMI and atrial natriuretic protein (ANP), in males only. These results formed the 
basis of further investigative studies examining the association between chromosome 5 and 
heart weight. Souzeau et a l (2006) recently identified alleles at a specific locus (locus 
Cm24) on chromosome 5, which may be responsible for the observed differences in LVMI 
between WKY and WKHA rats. The group also suggest, that this genetic locus induces 
either mild or no concentric LV remodelling in male rats and is associated with LV 
dilatation and dysfunction when hearts are subjected to volume overload. These data 
provide evidence, which clearly demonstrates the involvement of a strong genetic element 
affecting cardiac weight and LV geometry, which although influenced to some extent by 
volume overload, is independent of a blood pressure effect.
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The aim of this current study was to generate reciprocal congenic strains from SHRSP and 
WKY parental stock, in order to investigate genetic linkage (identified in chapter 3) 
between cardiac and LV weight and rat chromosome 14. It is expected that congenic 
strains produced will be hypertensive (SHRSP background) and normotensive (WKY 
background), as no blood pressure QTL was identified on rat chromosome 14 from the F2 
genome wide linkage analysis study. Production of these congenic strains will not only 
allow for investigation of genes underlying the QTL peaks, but will provide insights into 
heart weight and cardiac remodelling in the presence and absence o f high blood pressure.
6.2 METHODS
6.2.1 Congenic Strain Production
Congenic strains were constructed by introgressing approximately a 64cM region 
of chromosome 14 (boundary flanking markers ~ DI4Rat54, D14Ratl 10) from SHRSP into 
the genetic background o f WKY and vice versa, using a previously tested DNA marker 
assisted protocol as outlined in Chapter 2.2.2. The actual number of backcrosses required 
was dependant on the rate at which heterozygosity was reduced in the genetic background, 
as well as litter size and male: female ratio. Once a suitable male and female were 
identified, in which all background heterozygosity was eliminated, they were intercross 
mated to obtain offspring homozygous for the donor alleles throughout the chromosome 14 
region o f interest. Congenic lines were then maintained via brother-sister mating. Care 
was taken to ensure the correct Y chromosome was paired with the relevant genetic 
background i.e. WKY background males retain the originating WKY Y chromosome and 
vice versa, as is illustrated in Figure 6.1.
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Figure 6.1 Cartoon of congenic breeding strategy and correct Y chromosome orientation in 
a WKY background congenic strain. To ensure the correct Y chromosome is paired with 
the appropriate genetic background, a parental male from the donor strain (WKY) is mated 
with a recipient parental female (SHRSP) to produce Fi offspring. All Fi males will have a 
correctly paired WKY Y chromosome. As the majority of the Y chromosome does not 
recombine, the origin of the male F| progenitor will determine the Y chromosome in all Fi 
hybrid males and male offspring.
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6.2.2 Tail-Tipping and DNA extraction
Animals were lightly anaesthetized at 6-weeks of age with halothane and less than 
5mm tip was removed from the tail end and placed into a 1.5ml microfuge tube. The 
wound was immediately cauterized electronically (Engel Loter lOOS) and the tail tips 
stored at 4°C. Genomic DNA was extracted from using a simplified mammalian DNA 
extraction kit (Nucleon), described in Chapter 2.4.1. All DNA samples were stored at - 
20°C prior to PCR analysis.
6.2.3 PCR and Genotyping
PCR was performed as previously described in Chapter 2.4.2, using fluorescent 
markers provided by MWG Biotech. Genotype analysis was carried out by two 
independent observers, using GeneMapper v.3.0 software (Applied Biosystems, USA). 
Genotype data was exported in text file format and imported to an in-house designed 
Microsoft Access database for further analysis. Animals were selected for breeding on the 
basis o f a ‘preferred’ genotype -  heterozygous (WS) for chromosome 14 polymorphic 
markers and mostly homozygous (WW or SS) for the recipient alleles (WKY and SHRSP 
respectively) on the remaining genetic background. Chromosome 14 polymorphic 
microsatellite markers used are detailed in Chapter 3, Table.3.1 with background 
microsatellite markers shown in Appendix V.
6.2.4 Design of Microsoft Access Database
A relational database system was designed using Microsoft Visual Basic Code 6.0 
and structured query language (SQL). The database was designed to (i) retain breeding 
information for all animals held at the facility (ii) link to an in-house designed genotype 
database. The genotype database was optimised to facilitate upload of breeding data and 
indexing for quicker searching and data output. Consistency between both databases was 
achieved by ineluding declared constraints (a logical schema) in the database design. This
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involved ‘normalization’, with the desirable properties of both databases selected from a set 
of logically equivalent alternatives to prevent overlap and improve overall efficiency (E.F. 
Codd, 1979). A visual representation of logical schema relations is shown in Figure 6.2 
and the GUI search facility is shown in Figure 6.3.
6.2.5 Phenotype Measurements
Tail-cuff plethysmography was used to obtain blood pressure measurements from 
animals at ages 10 and 18 weeks, as detailed in Chapter 2.3.1. Left ventricular mass and 
geometry were evaluated by echocardiography and gravimetric values recorded at post 
mortem. Echocardiographic measurements were carried out at 10 weeks of age for baseline 
measurements and repeated again at 18 weeks. For a detailed discussion of this method see 
Chapter 2.3.3. Immediately post exsanguination, the thorax was opened and the heart 
removed, blotted and weighed to within three decimal places. Both atria and right ventricle 
were removed free and the left ventricle and septum weighed. The indices of cardiac mass 
(heart weight to body weight ratio) and LVM (left ventricle weight to body weight ratio) 
were calculated and determined.
6.2 RESULTS
A breakdown of background heterozygosity, determined from genotype analysis of 
168 background microsatellite markers, is shown in Table 6.1. The percentage of 
heterozygosity progressing from the initial backcross 1 stage to backcross 4, demonstrates 
the effective dilution of donor genetic background to that of a homozygous recipient origin. 
Three fixed congenic females were identified; one female matching to a WKY background 
and two females correspondent to a SHRSP background. There were no appropriate 
genotype males identified for interbreeding with females to achieve a founder congenic
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(  Sex
RATS
( R a t i o )
Chromosome 
marker
LITTER
Marker
position c Rat enotype
GENOTYPE
(  DOB )  C Parents)
Breeding 
cage
Figure 6.2. Conceptual relationship schema joining breeding and genotype database 
systems. Entities are shown in boxes with attributes shown in ovals. In this integrated 
schema, relationships are represented as one - many (genotype - rats) or many - many (rats 
- litter).
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Figure 6.3 Search GUI for the breeding database. Search queries are based on Input of one 
or more identifiers. A quick indexed return of animals is output with options to link to 
individual animal data.
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Table 6.1. Background heterogeneity in backcross strains generated
Background Strain Bxl Bx2 Bx3 Bx4
WKY 47% 25% 5% 0%
SHRSP 62% 37% 18% 0%
Bx = Backcross
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line, in the available time frame. A graphical representation of the introgressed 
chromosome 14 segment and relative approximation of LVMI QTL is illustrated in Figure 
6.4.
Analysis of LVMI in F2 males at marker loci D14Woxl4  and D14Got33 {Chapter 3) 
identified a WKY allele dominant effect, which is shown in Figures 6.5a-b. A significant 
reduction in LVMI was noted between homozygote SHRSP (SS) and heterozygote 
WKY/SHRSP (WS) animals, with no significant difference between homozygote WKY 
(WW) and WS heterozygotes. Based on this observation, backcross 4 males on a SHRSP 
background (SHRSPoiaBxQ were expected to have a lower LVMI in comparison to the 
respective SHRSP parental strain. SBP measurements and LVMI calculated from 
echocardiographic B-mode and M-mode images are shown in Figures 6.6a-b. In Figure 
6.6a, SBP measurements for both SHRSP and SHRSPGiaBX4  are equivalent with no 
significant differences observed between the strains. Despite comparable haemodynamic 
profiles, Figure 6.6b illustrates a significantly reduced LVMI in SHRSPGiaBX4  animals, 
compared to age matched SHRSP. A significant increased weight is observed in 
SHRSPGiaBX4  at 10 weeks of age, however by 18 weeks there is no significant difference in 
body mass between the two strains (Figure 6.7). At the time of writing this thesis, 
reciprocal congenic strain production was at the stage of intercross breeding to fix the 
homozygous congenic segment, however due to time constraints phenotypic examination of 
these animals could not be completed and therefore is not included in this chapter.
6.4 DISCUSSION
Data relating to the production of congenic strains is presented in this study, 
providing initial evidence in support of LVMI QTL within a region of rat chromosome 14 
identified in Chapter 3. Introgressing a segment approximating to a 56 Mb region of 
chromosome 14 from WKY into the genetic background o f SHRSP resulted in a 
significantly reduced LVMI in comparison to age matched SHRSP, highlighting the 
importance of this region in the genetic control and development o f LV hypertrophy. It is 
important to note the LVMI reduction observed in this study occurs in the absence of any
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51Mb
107Mb
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SHRSP
QTL 1
QTL 2
GlaBX4
(a)
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17
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21
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32
43
64
D14Rat54 WW SS
D14Rat75 WW SS
D14Woxl8 
D14WoxlO DI4Wox8 
D14Arbl7 D14nigh3 
DI4Woxl2 
D14Woxl4 1WW SS
D14Got33
WW SS
D14Rat41 WW SS
D14Rat24 WW SS
D14RatllO WW SS
Chromosome 14 WKY SHRSPG lal4a Glal4a
(b) (c)
Figure 6.4 A diagram of chromosome 14 showing QTLl and QTL2. The region of 
chromosome 14 encompassing both LVMI QTL spans approximately 56 million base pairs 
(Mb). This region is heterozygous WKY/SHRSP in backcross 4 animals (SHRSPciasx#); 
the remaining genome is homozygous SHRSP (a). A depiction of the anticipated fixed 
homozygous WKY (b) and SHRSP (c) chromosome 14 strains are also illustrated to 
highlight the difference between these fixed strains and the heterozygous SHRSPoiaBX4 .
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Figure 6.5 Single factor ANOVA analysis of LVMI at marker loci (a) D14Woxl4  
for homozygous (WW, n=12), homozygous (SS, n=26) and heterozygous (WS, 
11=27) and (b) D14Got33 (WW, n=16; SS, n=21; WS, n=27). At both marker loci, 
there is no statistical difference between WW and WS. Analysis of SS and WS at 
both marker loci shows a recessive SHRSP allele effect: D14Woxl4\ ^  P<0.001,
F= 14.65; D14Got33; *, P<0.001, F=14.9. Data shown is mean ±SEM with post hoc 
Bonferroni adjustment for multiple comparisons.
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Figure 6.6 Analysis o f (a) SBP and (b) LVMI in SHRSPGiaBX4 and parental SHRSP strains. 
There is no significant difference in SBP between SHRSP aged 10 and 18-weeks (n=10, 
n=8 respectively) and SHRSPGiaBX4 at 10 and 18-weeks of age (n=10, n=6 respectively). 
Gravimetric estimated LVMI is significantly reduced in SHRSP GiaBX4 strain at both time 
points (P=0.018, P=0.0041 respectively), compared to age matched parental SHRSP. All 
data shown are mean ±SEM, analysis by unpaired student t-test.
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Figure 6.7 Analysis o f SHRSPoiaBX4 and parental SHRSP body weights. At 10 weeks of 
age, body weight in SHRSPGiaBX4 (n=10) is statistically higher (P=0.012, n=10), compared 
to age matched parental SHRSP (n=10) with no statistical difference observed at 18 weeks 
of age between SHRSP (n=8) and SHRSPGiaBX4  (n=6). All data shown are mean ±SEM, 
analysis by unpaired student t-test.
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significant blood pressure difference between the strains. The SHRSPGiaBX4 strain are 
unique in this respect, as findings from other groups (Cicila et a l,  1998; Garrett et a l,
2000) show differences in cardiac mass and LVM are consistently associated with a parallel 
reduction in blood pressure, in the other hypertensive congenic rat models.
Cardiovascular physiology alone does not explain sequent cardiac remodelling mechanisms 
in response to pressure overload, therefore a priori it is reasonable to assume loci 
influencing heart weight (independent of blood pressure regulation) exist within the 
genome. Innes et a l (1998) has previously shown that a QTL (Lvm-1) on chromosome 2 
near D2Mghl5 influences LVMI, but not blood pressure in Fi (SHR x Fischer 344 (F344)) 
animals. The association of this locus with the SHR genotype is recessive in relation to 
increased LVMI as F2 animals homozygous for the SHR allele for Lvm-1 had significantly 
greater LVMI than rats homozygous or heterozygous for the F344 allele. This particular 
QTL lies is at the edge of a well-established blood pressure QTL, therefore from these 
results alone it is difficult to ascertain the actual effect blood pressure exerts on LVMI in 
the absence of further evidence (e.g. a congenic strain for heart weight independent of BP 
and body weight). Harrap et a l  (2002) has gone some way to address this with the 
development o f a genetic model of cardiac and cardiomyocyte hypertrophy, without 
hypertension (HHR strain) using selectively bred rats with large hearts and low blood 
pressure from a second-generation cross o f SHR and F344 strains. Recently Harrap’s 
laboratory confirmed the Lvml QTL with further QTL analyses and fine mapping of the 
region, identifying a number of putative candidate genes (Nicolantonio et a l,  2006). 
Nonetheless, this QTL is still to be validated by physiology and phenotypic evidence. The 
application of gene expression profiling and/or the generation of a fixed congenic and 
substrain congenic line may facilitate detection of biological in situ effects relating to 
candidate genes as well as identification of gene-gene and gene-environment interactions.
A seminal microarray experiment, combining the application of congenic strain production 
with genome wide expression analysis was the identification of the Cd36 gene on rat 
chromosome 4; a gene responsible for defective fatty acid and glucose metabolism (Aitman 
et a l, 1999). This study included investigation of over 10,000 cDNA probe sets in SHR,
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BN and congenic strain SHR 4 (in which a 36cM region of rat chromosome 4 of BN was 
introgressed into a SHR background). A deficiency in Cd36 was identified in the SHR 
strain in addition to other differentially expressed genes. Moreover, they established 
multiple coding sequence variants in Cd36 cDNA and negligible protein product, in SHR 
adipocyte plasma membrane. The group continued study with the gene, to develop 
transgenic mice expressing Cd36, characterised by reduced plasma triglycerides and fatty 
acids (Aitman et a l,  1999). Further work included radiation hybrid mapping of 70 other 
genes, also differentially expressed between the SHR and BN strains (Wallace et a l,  2002)
McBride et a l  (2003) and Garrett et a l  (2005) also used congenic substitution mapping in 
conjunction with microarray technology to identify candidate genes of positional and 
functional interest. Our group identified a significant reduced expression of glutathione S- 
transferase mu-type 1 (a gene involved in oxidative stress defence) in a congenic strain 
(SP.WKYGla2c*; SHRSP background with a portion of chromosome 2 introgressed) 
compared to the parental SHRSP strain. Garrett et a l successfully localised a previously 
identified blood pressure QTL to within a 117 kb region on rat chromosome 9, by 
production of substrain congenic strains and high resolution mapping combined with gene 
expression profiling, thereby reducing the region of interest and excluding a previously 
identified candidate gene. In using the congenic substrain approach, there is a possibility 
that the phenotype of interest may be lost due to continued reduction of the congenic 
region. Nevertheless, with careful dissection of larger congenic segments, congenic 
substrain production allows closer inspection of the phenotype and underlying genetic 
components. Combining methods o f both gene array systems with congenic substrains 
provides greater power to identify candidate genes and allows in depth analysis of 
background associated effects and interactions.
Therefore, production of congenic strains offers an extremely powerful resource for 
investigating the functional and physiological differences associated with QTL effects on a 
primary phenotype of interest, allowing facilitation of QTL isolation. In addition, genetic 
analysis of the phenotype can be further tested with the production of substrain congenic 
lines, which used in parallel with gene expression systems such as microarray may reduce
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the number of candidate genes and biological pathways for investigation. Due to time 
constraints, data for the fixed congenic strain is not presented here, however it is anticipated 
that future assessment o f the fixed congenic strains will support the echocardiographic 
estimations of LVM observed in the SHRSPGiaBX4 strain. Generation of reciprocal strains 
will then allow for further study into the importance of genetic background in the context of 
LVMI.
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CH APTER 7 
GENOM E W IDE EXPRESSION ANALYSIS
7.1 INTRODUCTION
Recent complementary advances, in both knowledge and technology have greatly 
facilitated the study of gene expression resulting in the identification of genes and 
biological interactions within the context o f disease progression. Microarray technology is 
a powerful means to examine thousands of RNA transcripts concurrently, allowing 
exploration o f genome complexity at a fundamental level (The chipping forecast, 1999).
The use o f high throughput gene expression to investigate experimental animal models of 
human disease, affords the opportunity to establish links between genotype and phenotype 
of complex traits. Moreover, the versatility of design by experimental condition and 
various analysis methods, allow for a comprehensive approach to candidate gene 
identification, on a genome wide scale.
Over the last few years, advances in technology, online resources and data analysis has 
resulted in several successful cardiovascular directed microarray experiments. A seminal 
paper from Aitman et al. (1999) indicated the potential of genome wide expression analysis 
for candidate gene identification, using a combined approach of cDNA microarray and a 
congenic strain, identifying a gene involved in defective fatty acid and glucose metabolism 
“ Cd36. Following on from the work of Aitman et a l (1999), other laboratories have since 
used microarray technology to detect genes that may contribute towards a disease 
phenotype of interest. In particular, our group identified glutathione S-transferase mu-type 
1 (Gstml) as a putative positional and physiological candidate gene involved in the defence 
against oxidative stress (McBride et a l 2003).
Heart specific microarray experiments to date have mainly focussed on cardiac hypertrophy 
in the context o f heart failure or single gene disorders such as familial hypertrophic 
cardiomyopathy (FHC) (Rajan et a l, 2006; Schiekofer et a l, 2006; Kong et a l, 2005; Rysa 
et a l 2005). Rysa era/. (2005) analysed gene expression in 12-, 16-, and 20-month-old 
SHR and age-matched WKY using cDNA microarray and identified LVH in SFIR was 
associated with increased expression of hypertrophy-associated genes, including contractile 
protein and natriuretic peptide genes. Recently, Schiekofer et a l (2006) conducted a
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detailed comparative analysis of gene expression between 2.5-month-old control mice and 
two transgenic mouse models with familial hypertrophic cardiomyopathy (FHC) associated 
mutations in alpha-tropomyosin. Their results showed 754 genes (from a total of 22,600) 
were differentially expressed between the control and FHC hearts. The transgenic models 
used in this study exhibited a varying degree of observed hypertrophy - FHC alpha-TM175 
mice have patchy areas o f ventricular disorganization and mild hypertrophy, whereas FHC 
alpha-TM180 mice show severe hypertrophy and fibrosis, with a short lifespan of 
approximately 6 months. Between transgenic groups, 266 genes were differentially 
expressed, with the largest increased expression in the secreted/extracellular matrix class 
and the most significant decreased expression in the metabolic enzymes group (Rajan et a l, 
2006). There has been no definitive study thus far, in which investigation of the shift from 
a healthy to pathogenic phenotype with respect to genotype and in the context of 
environmental stimuli.
Experimental design and sensitive statistical methods of data analysis are fundamentally 
important to the success of any study however microarray is particularly dependant on the 
quality of analysis, mainly due to the limited biological replicates per experiment, the large 
number of genes identified and the background noise of data (Breitling et a l,  2004). A 
quick and simple method to identify differentially expressed genes from microarray 
experiments, which is based on calculating rank products (RP), was developed by Breitling 
et a l  (2004). In particular, RP can provide reliable analysis o f results in small datasets 
providing a stringent method of analysing large numbers of genes more reliably than 
previously used statistical approaches, such as t-test and significance analysis of microarray 
(Tusher et a l,  2001). However the investigation of interactive effects, such as genotype 
and environmental factors, cannot be tested with the RP statistical method. An alternative 
statistical approach is two-way ANOVA, which offers both the identification of main 
effects between factors o f investigation and the detection o f genes based on an interaction 
between two (or more) specific conditions (Pavlidis, 2003).
The main objective o f this study is to identify differentially expressed genes in cardiac 
tissue taken from hypertensive and normotensive 21 week old male rats in the presence and
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absence of dietary salt manipulation, using a genome wide expression approach. The use of 
a two-way experimental design has also enabled the application o f more than one statistical 
approach, which will allow the identification of differentially expressed genes by RP 
method and ANOVA.
7.2 METHODS
7.2.1 Experimental Animals, Dietary Manipulation and Phenotypic Measurement
12 male rats aged 18 weeks (SHRSP, n = 6; WKY, n=6) were given 1% salt water 
(SHRSP, n = 3; WKY, n=3) or plain drinking water (SHRSP, n = 3; WKY, n=3) ad libitum 
over a 3 week period. At 21 weeks of age, systolic blood pressure (SBP) was measured by 
tail-cuff plethysmography, as described in Chapter 2.3.1. Body weight of each rat was 
measured prior to sacrifice; cardiac and left ventricle (LV) + septum weight was measured 
after removal of the heart, as described in Chapter 2.3.3. Whole heart and LV + septum 
weight were indexed to body mass in order to obtain CMI and LVMI respectively.
7.2.2 RNA Extraction and Microarray Experiment
RNA was extracted using Qiagen RNeasy Maxi kit and quantified using a
NanoDrop® ND-1000 Spectrophotometer as described in detail in Chapter 2.6.1. A TEST- 
3 Affymetrix chip was run for 2 samples to assess cRNA quality on a transcript level after 
biotin labeling o f heart tissue, starting from 5.0 pg total RNA. Biotinylated amplified 
target cRNA was prepared and hybridised to the Affymetrix GeneChip® Rat Genome 230 
2.0 Array set (which is comprised of 31,000 probe sets, analyzing over 30,000 transcripts 
and variants from over 28,000 rat genes). Following hybridisation, the microarray was 
washed, stained and scanned (see Chapter 2.8.1 for detailed description).
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7.2.3 M icroarray  D ata Analysis
Data was normalized using Robust Multichip Average (RMA) (Irizarry et a l ,  2003) 
as described in Chapter 2.82. Cluster analysis was used to partition samples on the basis of 
variance. The Rank Product (RP) method of analysis was used to determine the 
significance o f each gene (Breitling et a l , 2004). An additional statistical analysis method 
was used to test for interactions between stain and environment; 2-way analysis of variance 
(ANOVA). Figure 7.1 illustrates the two-way factor design template used in this 
experiment. Data was imported to Ingenuity Pathways Analysis 
(https://analysis.ingenuity.com) and functional and network pathways o f significance 
generated. A diagram key for data output from Ingenuity Pathway Analysis is given in 
Figure 7.2. Networks were graded as significant using hypergeometric distribution, 
calculated via the Fisher's Exact Test for 2 x 2  contingency tables. A numerical value was 
assigned as a score and used to rank networks according to how relevant they are to genes 
in the input dataset.
7.3 RESULTS
Daytime averaged haemodynamic and cardiac parameters for representative SHRSP 
and WKY strains are given in Figures 7.3a-c. SBP, CMI and LVMI are significantly 
increased in SHRSP compared to WKY at 21 weeks of age with and without dietary salt 
manipulation (P<0.001, P<0.001, P<0.001, respectively). After 1% salt loading, CMI and 
LVMI increase significantly in salt versus non-salt groups. SBP is unaltered in WKY salt 
versus no salt group, with an increase trend observed in SHRSP after salt loading that does 
not reach significance.
Ill order to consider data structure as a further quality control measure, cluster analysis of 
normalised data was carried out and charted using Sammon mapping and Manhattan 
distance metric plots, the results are shown in Figures 7.4 and 7.5a-b. Sammon maps 
provide a useful method of visualizing data as a measure o f quality control; Figure 7.4 
illustrates four distinct homogeneous data groups clustered by gene expression.
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( a )
(P)
Conditions
Salt Strain
Strain
A
B
A, strain A,salt B,strain B,salt
# #1 W #
Salt Effect
lEiteraction
Interaction ( + strain effect)
Figure 7.1 (a) A two-way factor design template. Combinations of experimental 
conditions are represented in boxes detailing the number o f biological replicates [3]. (b) 
Examples of various effects that can be identified by ANOVA. Grey dotted lines indicate a 
‘baseline’ level (adapted from Pavlidis, 2003).
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Figure 7.2 Diagram key for Ingenuity Pathway Analysis data output.
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Figure 7.4 Sammon Plot. Groups are prefix annotated NS (non-salt), S (salt) and colour 
coded: WKY NS, red; WKY S, black; SHRSP NS, blue; SHRSP S, green. Relative 
distances shown are Euclidean, a mathematical distance used to represent a distance 
between two points in a straight line as measured with a ruler, which can be validated by 
Pythagoras theorem. In using this formula as a distance. Euclidean space becomes a metric 
space allowing visualisation of data from a high dimensional space (e.g. 3 dimensional) to a 
2 dimensional or 1 dimensional graph. Data subsets of genes or sample datasets of gene 
expression values are grouped together (clustered) based on their similarities; the larger the 
Euclidean distance, the smaller the similarity. This plot shows similarities within datasets, 
grouping by colour in clusters, thus illustrating separate homogenous data groups.
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distributions for sample groups. Figures 7.5a-b, illustrates distance partition clustering by 
group. Samples cluster within a relatively short distance to biological replicates, in 
distinctive groups. The validity of these groupings was further confirmed by genetic 
profiling, compiled by separation on the basis o f strain and dietary salt intake, for a total of 
2,215 differentially expressed genes. These data are illustrated as Venn diagrams shown in 
Figures 7.6a-b. The majority of significant changes occurred in the SHRSP group after 3 
weeks 1% salt stimuli (798 genes differentially expressed) and in the WKY salt (s) versus 
SHRSP (s) groups (566 genes differentially expressed) with 90 genes differentially 
expressed between WKY (s) and non-salt (ns) groups.
A list of differentially expressed genes on chromosome 14 identified from RP analysis, is 
given in Table 7.1. Ingenuity Pathway Analysis was used to generate networks from RP 
data for each sample group comparison, based on a level of scoring by means of right tailed 
Fisher's Exact Test; 80 networks were identified, outlined in Table 7.2. Data was filtered to 
illustrate the highest ranked network for a single group comparison and the number of 
common overlapping genes, shown in Figure 7.7. A list of genes, from these identified 
networks is given in Table 7.3; the highest ranking network pathway for each group 
comparison is illustrated in Figures 7.8a-d, 7.9a-d, 7.10a-d and 7.1 la-d.
Two-way ANOVA analysis was used to specifically investigate interactions between strain 
and salt. A diagram of probe sets identified as significant for an interaction event is shown 
in Figure 7.12. From the total of genes analysed, 31 genes were significantly differentially 
expressed at <0.05 and positive for an interaction between strain and salt. Further filtering 
was achieved by removal of duplicate probe sets and those showing a flat line pattern of 
expression; a list o f 17 differentially expressed genes Is given in Table 7.5. Alignment of 
these genes with cited cardiac mass QTL data (http://rgd.mcw.edu) identified 7 genes 
corresponding to a LVMI or CMI QTL region, indicated in Table 7.5 by an asterisk. A full 
list o f current cited heart weight and LVMI QTL are given in Appendix VI. The majority 
o f genes identified from ANOVA analysis are transcriptional regulators, growth factors and 
transporter proteins.
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Table 7.1 Differentially expressed genes mapping to chromosome 14
Probe Set Gene
Symbol
tFDR *Fold
Change
Entrez 
Gene ID 
(Human)
Entrez 
Gene ID 
(Mouse)
Entrez 
Gene ID 
(Rat)
WKY (ns) 
vs.
SHRSP (ns)
1367555 at ALB 0.00000 6.0005 213 11657 24186
1367816 at HOP 0,00247 -2.4572 84525 74318 171160
1370962 at CIPARl 0.00569 -2.1053 25849 231440 286894
1398390 at CXCL13 0.00588 2.3985 10563 55985 498335
1395327 at SCARB2 0.05864 1.6057 950 12492 117106
WKY (s) 
vs. 
SHRSP (s)
1367555 at ALB 0.00043 6.4770 213 11657 24186
1370962 at CIPARl 0.00613 -2.1612 25849 231440 286894
1368379 at SCARB2 0.03983 -1.6872 950 12492 117106
1398390 at CXCL13 0.05188 2.3541 j 10563 55985 498335
SHRSP (s) 
vs.
SHRSP (ns)
1384985 at CIPARl 0.01933 2.5048 25849 231440 286894
1395327 at SCARB2 0.03516 1.9145 950 12492 117106
WKY (s) 
vs. 
WKY (ns)
1370830 at EGFR 0.01899 -1.98322 1956 13649 24329
*A positive fold change indicates an increased expression and a negative fold 
change indicates a decreased expression, in the first sample group of the comparison 
shown
tA  false discovery rate <0,05 is considered significant
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Table 7.2 Netwoi ks identified from RP analysis for each sample group comparison
Analysis
Com parison
Score Focus
Gene
No.
^Highest Ranking Functions
55 34 Cardiovascular System Development and Function, Cancer, Cell Death
55 35
Lipid Metabolism, Small Molecule 
Biochemistry, Carbohydrate Metabolism
24 20
Cellular Development, Embryonic 
Development, Cardiovascular System 
Development and Function
19 18
Cancer, Cellular Growth and Proliferation, Cell 
Cycle
17 17
Tissue Morphology, Cellular Growth and 
Proliferation, Cellular Movement
15 16
Lipid Metabolism, Small Molecule 
Biochemistry, Cardiovascular Disease
15 16 Cell Cycle, Cell Death, Cancer
15 16
Cell Death, Organismal Survival, 
Haematological Disease
15 15
Endocrine System Disorders, Metabolic 
Disease, Gene Expression
WKY (ns) 14 15 Lipid Metabolism, Molecular Transport, Small Molecule Biochemistryvs.
SHRSP (ns) 14 15 Metabolic Disease, Carbohydrate Metabolism, Lipid Metabolism
13 13
Cell-To-Cell Signalling and Interaction, Immune 
Response, Immune and Lymphatic System 
Development and Function
13 14
Cellular Growth and Proliferation, DNA 
Replication, Recombination, and Repair, 
Cellular Movement
13 14 Gene Expression, Cellular Development, Behaviour
11 13 Cell Morphology, Cell-To-Cell Signalling and Interaction, Tissue Development
1 1 Nucleic Acid Metabolism, Small Molecule Biochemistry, Amino Acid Metabolism
1 1
Viral Infection, Cell Death, Cell-To-Cell 
Signalling and Interaction
1 1
Lipid Metabolism, Small Molecule 
Biochemistry, Connective Tissue Development 
and Function
1 1 Cancer, Cell-To-Cell Signalling and Interaction, Cellular Assembly and Organization |
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Analysis
Com parison
Score Focus
Gene
No.
*Highest Ranking Functions
1 1
Cellular Assembly and Organization, Cancer, 
Cell Cycle
1 1
Cancer, Neurological Disease, Tumour 
Morphology
1 1
Cell Death, Cell Morphology, Cellular 
Development
52 34
Cancer, Connective Tissue Disorders, 
Immunological Disease
52 35
Cellular Movement, Cellular Growth and 
Proliferation, Cancer
52 35 Cell Cycle, Cell Death, Cancer
18 19
Lipid Metabolism, Small Molecule 
Biochemistry, Carbohydrate Metabolism
17 17
Endocrine System Disorders, Gene Expression, 
Carbohydrate Metabolism
17 17
Lipid Metabolism, Molecular Transport, Small 
Molecule Biochemistry
WKY (s) 15 17
Haematological System Development and 
Function, Tissue Morphology, Haematological 
Disease
15 16 Cell Cycle, Cancer, Cell Deathvs. 
SHRSP (s) 14 16
Cellular Growth and Proliferation, Tissue 
Development, Cellular Development
14 16
Cellular Growth and Proliferation, Cellular 
Movement, Cell Cycle
14 15
Cellular Growth and Proliferation, Cell Cycle, 
Cellular Development
13 15
Metabolic Disease, Endocrine System 
Disorders, Lipid Metabolism
13 15
Cell-To-Cell Signalling and Interaction, 
Haematological System Development and 
Function, Tissue Morphology
13 15
Cell Morphology, Cell Death, Immune and 
Lymphatic System Development and Function
13 15
Cellular Development, Connective Tissue 
Development and Function, Gene Expression
13 15
Gene Expression, Cellular Growth and 
Proliferation, DNA Replication, Recombination, 
and Repair
11 14
Immune Response, Haematological System 
Development and Function, Immune and 
Lymphatic System Development and Function
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Analysis
Comparison
Score Focus
Gene
No.
*Highest Ranking Functions
WKY (s) 
vs. 
SHRSP (s) 
Cont.
11 14
Cellular Growth and Proliferation, Cellular 
Function and Maintenance, Cellular Movement
1 1 Cancer, Cellular Movement, Lipid Metabolism
1 1 RNA Post-Transcriptional Modification
1 1
Lipid Metabolism, Small Molecule 
Biochemistry, Connective Tissue Development 
and Function
1 1
Cellular Compromise, Renal and Urological 
Disease, Cell-To-Cell Signalling and Interaction
1 1 Embryonic Development, Tissue Development
1 0
Cell Morphology, Cellular Assembly and 
Organization, Genetic Disorder
SHRSP (s) 
vs.
SHRSP (ns)
51 35
Cancer, Cell Death, Reproductive System 
Disease
51 32
Cell-To-Cell Signalling and Interaction, Tissue 
Development, Cancer
51 35
Cell Death, Behaviour, Nervous System 
Development and Function
51 35
Cell Death, Cell-To-Cell Signalling and 
Interaction, Cancer
23 22
Cellular Growth and Proliferation, Cancer, Cell 
Death
19 20
Cell Cycle, Developmental Disorder, Cellular 
Growth and Proliferation
15 17
Cellular Growth and Proliferation, Cancer, 
Haematological Disease
14 16
Cell Death, Infectious Disease, Cell-To-Cell 
Signalling and Interaction
14 16
Cellular Development, Lipid Metabolism, 
Molecular Transport
12 15
Cell Cycle, Cancer, Cellular Growth and 
Proliferation
12 14
Carbohydrate Metabolism, Lipid Metabolism, 
Small Molecule Biochemistry
12 15
Cellular Movement, Skeletal and Muscular 
System Development and Function, Cancer
12 15
Cellular Development, Cellular Growth and 
Proliferation, Developmental Disorder
11 14
DNA Replication, Recombination and Repair, 
Cellular Growth and Proliferation
SHRSP (s) 
vs.
SHRSP (ns)
10 13 Cancer, Cell Cycle, Cellular Development
10 12
Cell Death, Cellular Development, Tissue 
Morphology
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Analysis
Com parison
Score Focus
Gene
No.
*Highest Ranking Functions
SHRSP (s) 
vs.
SHRSP (ns)
10 13
Cell-To-Cell Signalling and Interaction, Cancer, 
Cellular Growth and Proliferation
9 12
Protein Synthesis, DNA Replication, 
Recombination, and Repair, Free Radical 
Scavenging
1 1
Viral Infection, Cell Death, Cell-To-Cell 
Signalling and Interaction
1 1 RNA Post-Transcriptional Modification
1 1 No function assigned
1 1
Carbohydrate Metabolism, Molecular Transport, 
Small Molecule Biochemistry
1 1 Embryonic Development, Tissue Development
1 0
Cell Morphology, Cellular Assembly and 
Organization, Genetic Disorder
1 1
Cell Death, Cell Morphology, Cellular 
Development
WKY (s) 
vs. 
WKY (ns)
31 17
Developmental Disorder, Cellular Development, 
Cancer
22 13
Cellular Movement, Haematological System 
Development and Function, Immune Response
19 12 Gene Expression, Cancer, Cell Cycle
2 1
Developmental Disorder, Genetic Disorder, 
Skeletal and Muscular Disorders
2 1
Molecular Transport, Cardiovascular Disease, 
Genetic Disorder
2 0
Molecular Transport, Small Molecule 
Biochemistry, Cardiovascular System 
Development and Function
2 1
Cellular Assembly and Organization, RNA 
Post-Transcriptional Modification
2 1
Gene Expression, Embryonic Development, 
Genetic Disorder
2 1
Cancer, Cell-To-Cell Signalling and Interaction, 
Reproductive System Disease
T h e  three highest ranking functions for networks
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1
WKY (ns) vs SH RSP (ns) 
WKY (s) vs SH RSP (s) 
WKY (s) vs WKY (ns) 
SH RSP (s) vs SH RSP (ns)
Figure 7.7 Overlapping network analyses from rank product data showing the highest 
ranked network for each group comparison. Each node represents one network with edges 
(lines) indicating a link between networks and the number o f common genes shared.
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Table 7.3 List of 119 genes identified from highest significant network
Nam e Affym etrix *FDR
q-value
Entrez ID 
Human
Entrez ID 
M ouse
Entrez 
ID Rat
ACTAI 1369928 at 0 58 11459 29437
1370857 at 0.00127273 59 11475 81633
ACTB
A F F X R a tb e ta -  
actin M at 0.14163934 60 11461 81822
ACTC 1385797 at 0.69494658 70 11464 29275
ACTGl 1384581 at 0.92746177 71 11465 287876
ACTG2 1386869 at 0.20855856 72 11468 25365
ACTNl 1398294 at 0.25465753 87 109711 81634
ACTR2 1379687 at 0.66546157 10097 66713 289820
ACTR3 1395886 at 0.49142731 10096 74117 81732
ADAM TSl 1368223 at 0.25516418 9510 11504 79252
AK2 1386954 at 0.74862845 204 11637 24184
ALAS2 1367985 at 0.00942149 212 11656 25748
ANGPTl 1381487 at 0.54105848 284 11600 89807
ARPCIB 1386925 at 0.66031382 10095 11867 54227
ARPC2 1375137 at 0.89988413 10109 76709 301511
ATRX 1393798 at 0.01675325 546 22589 246284
BGN 1367594 at 0.19494318 633 12111 25181
■’c s a i ü b  y 1371263 a at 0.19648649 817 108058 24246
CAMK4 1375598 at 0.49061892 814 12326 25050
CAPl 1368808 at 0.73846179 10487 12331 64185
CAVl 1370131 at 0.33156109 857 12389 25404
CAV2 1370135 at 0.62566017 858 12390 363425
CDC25B 1370034 at 0.35063492 994 12531 171103
CDKNIA 1388674 at 0.38461539 1026 12575 114851
CDR2 1374139 at 0.39858543 1039 12585 308958
CEACAMl 1374620 at 0.46080819
CHI3L1 1392171 at 0.4566302 1116 12654 89824
CL1C4 1377765 at 0.14193548 25932 29876 83718
COL18A1 1388143 at 0.32709677 80781 12822 85251
COL4A1 1372439 at 0.5695814 1282 12826 290905
COL5A1 1369955 at 0.40283862 1289 12831 85490
COL5A2 1373463 at 0.79124895 1290 12832 85250
COL5A3 1368347 at 0.9550375 50509 53867 60379
COL6A3 1396055 at 0.66516957 1293 12835 367313
COL8A2 1394748 at 0.92057272 1296 329941 313592
CSDA 1370376 a at 1.07134191 8531 56449 83807
CSPG2 1388054 a at 0.40215543 1462 13003 114122
C ISC 1374778 at 0.67668744 1075 13032 25423
CXADR 1374273 at 0.13636364 1525 13052 89843
CXCL12 1387655 at 0.03534091 6387 20315 24772
CYR61 1368290 at 0.25561047 3491 16007 83476
DDIT4 1368025 at 0.79391449 54541 74747 140942
DDRl 1370216 at 0.73873338 780 12305 25678
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Nam e Affym etrix *FDR
q-value
Entrez ID 
Human
Entrez ID 
M ouse
Entrez 
ID Rat
EGFR 1370830 at 0.01898701 1956 13649 24329
EGLNl 1392603 at 0.67870739 54583 112405 308913
EGRl 1368321 at 0.00474748 1958 13653 24330
EMPl 1369736 at 0.21987552 2012 13730 25314
ENOl 1367575 at 0.91049345 2023 13806 24333
ERBB3 1377821 at 0.35663778 2065 13867 29496
ERBB4 1369353 at 1.03590673 2066 13869 59323
F3 1369182 at 0.7380332 2152 14066 25584
FBLN2 1389533 at 0.75501725 2199 14115 282583
FBNl 1387351 at 0.77134371 2200 14118 83727
FGFl 1387301 at 0.1696 2246 14164 25317
FOS ' 1375043 at 0.00181818 2353 14281 314322
FZD2 1398304 at 0.55638298 2535 57265 64512
GART 1390787 at 1.02706078 2618 14450 288259
GATA4 1370293 at 0.54332842 2626 14463 54254
GCNTl 1368770 at 0.87343997 2650 14537 64043
GDF15 1370153 at 0.45682171 9518 23886 29455
GHR 1373803 a at 0.54104755 2690 14600 25235
1369640 at 0.02844697 2697 14609 24392
GSN 1371414 at 1.04079017 2934 227753 296654
HBPl 1368549 at 0.95428331 26959 73389 27080
HESl 1387036 at 1.02397237 3280 15205 29577
HES5 1375713 at 0.49213321 388585 15208 79225
. H E Y 2 . . 1384515 at 0.8891105 23493 15214 155430
HLA-DMB 1382788 at 0.96416454 3109 14999115000 294273
HLA-DQAl 1370822 at 0.75113789 3117 14960 309621
HLA-DQBl 1371033 at 0.17670886 3119 14961 309622
HLA-DRBl 1370383 s at 0.36174168 3123 14969 294270
HSPAIB 1368247 at 0.4926899 3304 15511 24472
IDIl 1368878 at 0.48716636 3422 319554 89784
IER3 1388587 at 0.443213 8870 15937 294235
IL13 1369618 at 1.02719088 3596 16163 116553
IL2RB 1387394 at 0.96190977 3560 16185 25746
JAGl 1368725 at 0.88236255 182 16449 29146
JUN 1369788 s at 0.04929619 3725 16476 24516
KLF2 1386041 a at 0.52783094 10365 16598 306330
KLF6 1387060 at 0.82655139 1316 23849 58954
LAMAS 1396159 at 0.66575298 3911 16776 140433
LAMC2 1379889 at 0.70679985 3918 16782 192362
LOXLl 1388902 at 0.66940386 4016 16949 315714
LOXL2 1391450 at 0.74439365 4017 94352 290350
MAF 1392566 at 0.02945076 4094 17132 54267
MMP14 1378225 at 0.80846134 4323 17387 81707
MTIA 1371237 a at 0.50195251 4489 17748 24567
MYC 1368308 at 1.01916269 4609 17869 24577
MYCN 1376648 at 0.62007361 4613 18109 298894
MYH6 1393540 at 0.04861601 4624 17888 29556
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Nam e Affym etrix *FDR
q-value
Entrez ID 
Human
Entrez ID 
M ouse
Entrez 
ID Rat
MYH7 1392401 s at 0.00490909 4625 140781 29557
MYH9 1387402 at 0.24830389 4627 17886 25745
' NÔV 1376734 at 0 4856 18133 81526
P4HA1 1370954 at 0.73718992 5033 18451 64475
PDL1M7 1370347 at 0.62469722 9260 67399 286908
PLS3 1371139 at 0.95615059 5358 102866 81748
RBM3 1371583 at 0.81596344 5935 19652 114488
RBPl 1367939 at 1.06364791 5947 19659 25056
RTN4 1388027 a at 0.05511831 57142 68585 83765
S100A6 1367661 at 1.03470305 6277 20200 85247
SIOOB 1386903 at 0.17585635 6285 20203 25742
SCD2 1367668 a at 0.90184156 20250 83792
SERPINEl 1392264 s at 0.59016255 5054 18787 24617
SERPINE2 1372440 at 0.38010638 5270 20720 29366
SLC16A6 1376267 at 0.00488636 9120 104681 303772
SRF 6722 20807 445445
STAT3 1370224 at 0.04814229 6774 20848 25125
SYCP3 1376785 _at 0.84487931 50511 20962 25561
TFRC 1371113 a at 0.26249169 7037 22042 64678
TO FBI 1370082 _at 0.103 7040 21803 59086
TGM2 1387776 at 0.17464052 7052 21817 56083
TIMPl 1367712 at 0.44976109 7076 21857 116510
TNFRSF12A 1371785 at 0.45662597 51330 27279 302965
1379936 at 0.01916667 7168 22003 24851
TPM3 1398303 s at 0.40008955 7170 59069 117557
TPM4 1368838 at 1.04469602 7171 326618 24852
UBE2V2 1372143 at 0.91174146 7336 70620 287927
WBSCRl 1397675 at 0.2138326 7458 22384 288599
YY l 1398564 at 0.01796791 7528 22632 24919
*FDR signifies false discovery rate. Genes highlighted in grey, indicate shared 
between networks and empty cells represent no equivalent data.
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Figure 7.12 Representation of two-way ANOVA results for strain-salt interaction. Thirty 
one probe sets were initially identified as significantly for an interaction event and plotted 
to illustrate fold changes between groups. Multiple represented probe sets were removed 
from the list. A probe set plot displaying a straight line i.e. the overall fold change was 
close to ±1, was removed. An example o f this can be seen in panel (iii) probe set 
137224l_at and probe set 1388337_at, with a fold change across all groups of 1.09 and - 
1.002 respectively, reflecting very little differential expression between the groups. In 
panel (iv) probe set 1387796_at shows no change in WKY expression after salt 
manipulation, but shows a large increase after salt exposure in SHRSP, indicated by the 
upturned incline for SHRSP (s).
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Table 7.4 Two-way ANOVA strain-salt interaction
Probe Set 
ID
Gene Symbol Chromosome
Location
UniGene
ID
Entrez Gene 
ID
P - value
1367553 X at Hbb* lq22 36966 24440 0.007
1367985 at Alas2* Xq21 32517 25748 0.03
1368182 at Acsl6 10q22 33697 117243 0.01
1368303 at Per2* 9q36 25935 63840 0.01
1370462 at Hmmr 10ql2 92304 25460 0.01
1371643 at Ccnd1 * lq42 22279 58919 0.01
1372248 at Sesnl 20ql3 22395 294518 0.01
1372500 at Tmod3* 8q24 146101 300838 0.03
1373058 at Tmem30a 8q31 161918 300857 0.01
1374139 at Cdr2* Iq35-q36 3537 308958 0.02
1375911 at RGD735140 3q36 11612 362219 0.01
1386953 at H sd lIb l 13q27 888 25116 0.03
1387036 at Hesl Hq22 19727 29577 0.01
1387351 at Fbnl* 3q36 12759 83727 0.02
1387656 at Slc4al 10q32 32202 24779 0.02
1387796 at A loxl5 10q24 11318 81639 0.01
1388608 X at Hba-al 10ql2 107334 25632 0.02
* Genes mapping to cited heart weight QTL regions
2 1 0
7.4 DISCUSSION
The use of microarray gene expression profiling in whole heart tissue of age 
matched animals with and without dietary salt manipulation, was used successfully to gain 
some insight into the identity and expression levels of cardiac genes associated with an 
adaptive response to hypertension (in the absence of environmental stimuli) and salt intake 
(in the presence and absence o f hypertension). In addition, two contrasting analytical 
methods were used to assess normalised data and produce gene pathways of potential 
interest for individual strains and interactions between genotype-environmental stimuli.
An interesting result from the phenotype data of SHRSP and WKY before and after 1% salt 
intake is increased CMI and LVMI in both strains after salt, despite no parallel increase in 
SEP. This finding lends credence to the hypothesis that blood pressure independent 
gene(s) may interact with environmental factors to influence cardiac weight. However, it’s 
also important to note that SEP was measured by tail cuff plethysmography, which 
although a validated method is not as accurate or consistent for data acquisition of blood 
pressure as radiotelemetry.
From the list of positional genes of interest identified on chromosome 14, Egfr forms part 
of the most significant network pathway for group WKY (s) vs. WKY (ns). Growth factor 
regulation and signaling affects tissue remodelling through autocrine/paracrine mechanisms 
(Lauffenburger et a l,  1998) and is central to myocardial extracellular matrix homeostasis 
(Mauviel, 1993). Several groups have shown that Egfr receptor transactivation by heparin- 
binding EGF (HB-EGF) is a primary factor in hypertrophic cardiomyocyte signaling and 
cell co-ordinated remodelling within the myocardium (Yoshioka et a l,  2005).
Tgfpl was identified as the most significant network pathway in group SHRSP (s) vs. 
SHRSP (ns). Tgfj3I is induced by injury and is normally involved in repair however 
excessive or prolonged signaling of this pathway has been shown as a factor in pathologic 
fibrosis, scarring and matrix deposition in a variety of diseases, including cardiac 
hypertrophy (Ju & Dixon, 1996, Lim et a l,  2005). In this network pathway, gene
2 1 1
expression is increased in SHRSP (s) compared to SHRSP (ns) in all genes with the 
exception of germ cell nuclear antigen {Gcnal; a marker of steroidogenic cells) and 
T p m la .
From RP network analysis, Jpm i cr was identified as interacting between salt and strain. 
There are currently eight reported missense mutations in Tpmla^ associated with varying 
degrees of FHC (Thierfelder et a l,  1994; Jongbloed et a l,  2003). In this study, Tpmlcç is 
upregulated in WKY (s) vs. SHRSP (s) and down regulated in SHRSP (s) vs. SHRSP (ns), 
indicating salt is an important regulatory control factor. Prabhakar et a l (2001) developed 
transgenic mouse lines encoding a FHC mutation in Tpm la, in a troponin T binding region. 
They showed expression o f mutant tropomyosin leads to a parallel decrease in endogenous 
Tpm la, without altering expression of other contractile proteins. Observed disease- 
associated changes, in particular functional differences in diastolic performance and 
increased sensitivity to calcium, were detected within 1 month, resulting in death within 5 
months. This report demonstrates the importance of T pm la  gene expression and 
sarcomeric function, consequently resulting in a hypertrophic response.
Genes identified from both RP and two-way ANOVA analyses as interacting between 
strain and salt, were Fbnl, Alas2 and Hesl. Known mutations in Alas2 isoforms involved 
in catalysing the first and rate-limiting step in the haeme synthesis pathway, lead to 
ineffective erythropoiesis and typify X-linked sideroblastic anemia (Fontenay et ah, 2006). 
Fbnl mutations are associated with Marfan syndrome, an autosomal dominant connective 
tissue disorder characterized by pleiotropic characteristics involving the skeletal, ocular, 
and cardiovascular systems (Coucke et a l,  2006). More recently, mutations in Tgfj31 
(which acts directly to control transcription factor H esl) has been described as an important 
factor relating to Marfan syndrome in Fbnl negative patients (Disabella et a l, 2006), 
adding further weight that overlapping network analysis of RP, although Fnot designed to 
identify interacting genes, is an important tool for studying large datasets.
There are numerous factors to consider prior to a genome wide expression study - probe 
selection (including high hybridization stringency and low susceptibility to gene
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polymorphisms), study design and data analysis (Watson A., Mazumder, Stewart & 
Balasubramanian, 1998; Privalis, 2003). Ambiguity regarding probe sets from both types 
of microarray platforms, united with their respective and well documented experimental 
noise, such as compression of gene expression ratios (Yuen et a l ,  2002) requires a cautious 
approach to data analysis and interpretation, therefore the application o f more than one 
statistical approach may be useful. This microarray experiment was carried out in animals 
with an established pathology, making it difficult to distinguish between primary target and 
secondary target effects from direct and/or indirect association of pathways, using RP 
analysis only. The processes governing any observed changes in gene expression may be a 
cardiac hypertrophic adaptive response to pressure overload in the SHRSP or alternatively a 
protective reaction to salt stimuli in the normotensive WKY. For this reason the addition of 
a more complex analytical approach was desirable.
Increasing the level o f stringency in any study introduces a potential for failure to spot 
genes of interest, due to variation observed within groups. An example of this is the 
number of interactions identified from manual breakdown of RP data using Ingenuity 
Pathway Analysis but missed by two-way ANOVA for example T pm la. A further 
complication of using a more complex analytical method in small sample groups is the 
number o f false positive results identified as significant. An illustration of this, are probe 
sets identified as interacting yet showing little differential expression between groups (a flat 
line when plotted relative to other data groups). In conclusion, a genome wide expression 
stratagem is a powerful tool for investigating genotype in conjunction with a phenotype of 
interest and provides a basis for identification of genes and pathways which may be 
stimulated and/or suppressed by environmental stimuli. This work can be systematically 
followed up by confirmation of genes identified, functional analysis of significant 
genes/pathways identified and the inclusion o f a congenic strain to localise region/genes of 
interest to current study.
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CHAPTER 8
GENERAL DISCUSSION
Cardiovascular diseases in man are determined by a network array o f genes and 
environmental factors, interacting at various stages in development and throughout the 
lifetime of the individual. Previously used strategies such as linkage analysis in families 
segregating for rare Mendelian disorders or investigation of putative candidate genes have 
had a limited success in identifying the major genetic determinants of multifactorial 
diseases. Practical difficulties add to the complexity in direct study of the genetic 
determinants o f such complex traits and have been a driving force behind the development 
o f similar but fundamentally simpler paradigms, such as experimental animal models. In 
particular, crosses between hypertensive and normotensive inbred rat strains have led to the 
identification of chromosomal regions containing QTL for several cardiovascular related 
phenotypes.
The research described in this thesis included re-evaluation of data from a previously 
reported genome wide in F2 crosses derived from Glasgow colonies of SHRSP and WKY 
rat strains. In addition, stringent QTL analysis and high fidelity phenotyping was carried 
out, to identify QTL containing genetic determinants for cardiac and left ventricular 
hypertrophy. There are several features of the QTL mapping strategies used in this thesis, 
which make them particularly appropriate for congenic production, fine mapping and 
ultimately identification of primary genes. Firstly, in contrast to previous studies, which 
used only a single analysis, the use of more than one QTL analysis package offered a more 
robust localisation of, and confidence in QTL identified. Secondly, the use of MRI was 
demonstrated as an additional means of reproducible high fidelity phenotyping of animals 
and subsequent congenic strains, which provides a more accurate assessment of the heart, 
in particular in small animal groups and characterisation of rat strains. Thirdly, preliminary 
data from congenic strains give confidence in QTL regions identified that may harbour 
gene(s) influencing the development of left ventricular hypertrophy in SHRSP. Finally, the 
current study also combined a genome wide expression approach to candidate gene 
identification in the absence o f a fixed congenic strain, using 2 different analytical 
strategies, which identified several gene pathways o f interest for follow up study in 
conjunction with the continued production and phenotyping of congenic strains.
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The results from this thesis confirm the congenic SP.WKYGIa2a strain has an equivalent 
LVMI to the parental SHRSP, despite an approx. 20mmHg reduction in SBP, consistent 
with previous unpublished results from our group. Relative wall thickness differences 
identified indicate a different pattern of remodelling in the congenic strain previously not 
reported; concentric remodelling in the SP.WKYGla2a, as opposed to concentric 
hypertrophy observed in the SHRSP. Preliminary data from phenotype analysis of male 
SHRSPbx4 congenic animals indicates a reduced LVMI despite equivalent SBP to the 
parental SHRSP. In order to identify the significance of this finding, a more precise and in 
depth cardiac phenotyping of parental rat strains and fixed congenic strains on both genetic 
backgrounds is necessary. The validation of MRI as an improved tool for measuring left 
ventricle mass and LV geometry will provide a more superior and robust method for rodent 
cardiac phenotyping, and offers the potential for assessment o f cardiac function including 
structure, contractility and perfusion. In human studies, the quality of information collected 
for patients has been shown to impact on the power of results achieved (Kuznetsova et a l,  
2002; Wingfield et a l, 2002), therefore any improvement in this area will add to the 
knowledge o f physiological characteristics and promote a more exact and uniform 
quantification of disease.
Given the results of the current study, the demonstrated propensity for high fidelity 
phenotyping coupled with the rapidly increasing availability of appropriate genetic 
resources for the rat, including dense genetic and physical maps and access to microarray 
data there can be little doubt that identified QTL will be completely dissected over time. In 
particular, phenotype and gene expression comparison of age matched animals differing 
only by genotype and/or diet can be tested using statistical approaches such as rank product 
(RP) and two-way ANOVA. High fidelity phenotyping of blood pressure and the 
production o f congenic strains, was successfully used by our group previously to confirm 
two identified BP QTL on rat chromosome 2 (Clark et a l,  1996) and verify the application 
of a speed congenic strategy to dissect QTL in the rat (Jeffs et a l,  2000). Furthermore, the 
combined use o f microarray technology and substrain congenic animals resulted in the 
identification of a positional and functional candidate gene, glutathione-s-transferase-mu- 
type-1.
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In the post genomic era, there is a greater understanding of the human genome as well as a 
wide assortment o f pharmacological and mechanical therapies available for the treatment of 
cardiovascular diseases (Murray et a l,  2003, Wald et a l,  2003). The use of comparative 
mapping to identify regions of shared synteny between species is one route of investigation 
together with the analysis of differences in response or outcome by "candidate gene", in 
both animals and humans. These areas of therapeutics and genomics can benefit from an 
inter-relationship between human and experimental pharmacogenetics. As with many 
association studies, preliminary data does not always translate well to larger groups, 
nevertheless strong evidence has been presented by Chasman et a l (2004) by way of 
haplotype analysis used to generate a pharmacogenetic profile for patients receiving 
cholesterol reducing, statin therapy. A poorer cholesterol-lowering response to Pravastatin 
was reported in 7% of patients carrying a particular haplotype o f the HMG CoA reductase 
gene (14% fall versus 19%). Another example is determination o f genotype at the CYP2C9 
locus with respect to warfarin treatment, since carriers for functional variants (>20% of the 
population) require lower doses for optimal anticoagulation, and homozygotes (although 
rare), may be have a greater risk o f bleeding when given a typical dose. The full potential 
o f this field will only be realised with further work and although it is unlikely this will 
ultimately lead to an individually tailored prognosis and therapy for patients, it may allow 
for a less generic treatment, by specific targeting of the genetic aspect or involved pathway.
In this thesis, several candidate genes were identified by both comparative mapping and 
genome wide expression profiling. Further investigation is required to confirm or refute 
functional relevance o f these genes to CMI and LVMI in the SHRSP. The effect of dietary 
salt intake on Dbp gene expression in WKY is of interest, in particular as micro array 
phenotype data from 21 week old animals, indicates no SBP increase in the WKY after 1% 
salt challenge, but a significant increase in CMI and LVMI. Gene networks and pathways 
of interest generated from microarray analysis can be taken forward and explored in more 
depth using a combination of congenic strains (currently in production), congenic substrain 
lines and functional genomics, to localise QTL and dissect the underlying genetic elements 
influencing heart and LV weight. Quantitative RT-PCR investigation o f the most
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significant genes identified from both RP and two-way ANOVA statistics will allow for 
validation of microarray results and sequencing will allow a full characterisation of these 
genes in the SHRSP and WKY strains. Further, the production of congenic substrain 
animals may enable filtering o f data and the study of epistatic interactions and localised 
regions of gene activity, in comparison to parental and congenic strains. Additionally, 
functional studies such as RNA interference (RNAi) and/or gene transfer will facilitate 
investigation o f candidate genes in vivo prior to the production o f knockout or phenotype 
rescue transgenic animal models.
In conclusion, the production of congenic strains to confirm, both a previously identified 
and second newly identified QTL involved in the development of concentric left ventricular 
hypertrophy in the SHRSP in this study, should enable the translation from experimental 
model to human cardiovascular disease. This information will also lead to an improved 
understanding of the genes and biochemical pathways involved in pathogenesis of cardiac 
hypertrophy and in turn may lead to the continued development of preventative medicine 
and/or therapies directed against complex traits, which are major causes of morbidity and 
mortality worldwide.
218
REFERENCES
Aiello, E. A., Villa-Abrille, M. C., Escudero, E. M., Poitiansky, E. L., Perez, N. G., de 
Hurtado, M. C., & Cingolani, H. E. 2004, "Myocardial hypertrophy of normotensive 
Wistar“Kyoto rats", AJP - Heart and Circulatory Physiology, vol. 286, no. 4, p. H I229- 
H1235.
Ahmad, F., Seidman, J. G., & Seidman, C. E. 2005, "The genetic basis for cardiac 
VQmoàé[\\\^\ Annu.Rev.Genomics Plum Genet, vol. 6, pp. 185-216.
Akkad, A. A., Halligan, A. W., Abrams, K., & Al Azzawi, F. 1997, "Differing responses in 
blood pressure over 24 hours in normotensive women receiving oral or transdermal 
estrogen replacement therapy", Ohstet.Gynecol, vol. 89, no. 1, pp. 97-103.
Al Shafei, A. I., Wise, R. G., Gresham, G. A., Carpenter, T. A., Hall, L. D., & Huang, C. L. 
2002, "Magnetic resonance imaging analysis of cardiac cycle events in diabetic rats: the 
effect of angiotensin-converting enzyme inhibition", J  Physiol, vol. 538, no. Pt 2, pp. 555- 
572.
Anan, R., Greve, G., Thierfelder, L., Watkins, H., McKenna, W. J., Solomon, S., Vecchio, 
C., Shono, H., Nakao, S., Tanaka, H., & . 1994, "Prognostic implications of novel beta 
cardiac myosin heavy chain gene mutations that cause familial hypertrophic 
cardiomyopathy", J  Clin Invest, vol. 93, no. 1, pp. 280-285.
Andress, D. L. 2005, "Vitamin D treatment in chronic kidney disease", Semin.Dial, vol.
18, no. 4, pp. 315-321.
Annest, J. L., Sing, C. F., Biron, P., & Mongeau, J. G. 1979, "Familial aggregation of blood 
pressure and weight in adoptive families. II. Estimation of the relative contributions of 
genetic and common environmental factors to blood pressure correlations between family 
members". Am J  Epidemiol, vol. 110, no. 4, pp. 492-503.
Annest, J. L., Sing, C. F., Biron, P., & Mongeau, J. G. 1983, "Familial aggregation of blood 
pressure and weight in adoptive families. III. Analysis of the role o f shared genes and 
shared household environment in explaining family resemblance for height, weight and 
selected weight/height indices", Hw J  Epidemiol, vol. 117, no. 4, pp. 492-506.
Arnett, D. K., Strogatz, D. S., Ephross, S. A., Hames, C. G., & Tyro 1er, H. A. 1992, 
"Greater incidence of electrocardiographic left ventricular hypertrophy in black men than in 
white men in Evans County, Georgia", Ethn.Dis, vol. 2, no. 1, pp. 10-17.
Arnett, D. K., Tyroler, H. A., Burke, G., Hutchinson, R., Howard, G., & Heiss, G. 1996, 
"Hypertension and subclinical carotid artery atherosclerosis in blacks and whites. The 
Atherosclerosis Risk in Communities Study. ARIC Investigators", Arch.Intern Med, vol. 
156, no. 17, pp. 1983-1989.
219
Ashton, N. & B aiment, R. J. 1991, "Sexual dimorphism in renal function and hormonal 
status of New Zealand genetically hypertensive rats", Acta Endocrinol (Copenh), vol. 124, 
no. 1, pp. 91-97.
August, P. & Oparil, S. 1999, "Hypertension in women", Journal o f  Clinical Endocrinology 
Metabolism, vol. 84, no. 6, pp. 1862-1866.
Bachmann, H., Horacek, U., Leowsky, M., & Hirche, H. 1987, "[Blood pressure in children 
and adolescents aged 4 to 18. Correlation of blood pressure values with age, sex, body 
height, body weight and skinfold thickness (Essen Blood Pressure Study)]", 
Monatsschr.Kinderheilkd., vol. 135, no. 3, pp. 128-134.
Baima, J., Nicolaou, M., Schwartz, P., DeStefano, A. L., Manolis, A., Gavras, I., Laffer, C., 
Elijovich, F., Farrer, L., Baldwin, C. T., & Gavras, H. 1999, "Evidence for linkage between 
essential hypertension and a putative locus on human chromosome 17", Hypertension, vol. 
34, no. 1, pp. 4-7.
Barlassina, C., Lanzani, C., Manunta, P., & Blanchi, G. 2002, "Genetics of Essential 
Hypertension: From Families to Genes", Journal o f  the American Society o f  Nephrology, 
vol. 13, no. 90003, p. S155-S164.
Bastarrika, G., Sprengel, U., Saenz, d. B., Romero, C., Alegria, E., Benito, A., & Barba, J. 
2005, "[Cardiac magnetic resonance: clinical applications]", An.Sist.Sanit.Navar., vol. 28, 
no. 1, pp. 49-58.
Bauwens, F. R., Duprez, D. A., De Buyzere, M. L., De Backer, T. L., Kaufman, J. M., Van 
Hoecke, J., Vermeulen, A., & Clement, D. L. 1991, "Influence of the arterial blood pressure 
and nonhemodynamic factors on left ventricular hypertrophy in moderate essential 
hypertension", Am J  Cardiol, vol. 68, no. 9, pp. 925-929.
Beaglehole, R., Salmond, C. E., Hooper, A., Huntsman, J., Stanhope, J. M., Cassel, J. C., & 
Prior, I. A. M. 1977, "Blood pressure and social interaction and Tokelau and migrants in 
New Zealand", JC hron Dis, vol. 30, pp. 803-812.
Benarroch, E. E. 1993, "The central autonomic network: functional organization, 
dysfunction, and perspective", Mayo Clin Proc., vol. 68, no. 10, pp. 988-1001.
Berne, R. & Levy, M. 1997, in”Cardiovascular Physiology”, ed. St. Louis, MO: Mosby, 
ch. 10, p. 225.
Bhatnagar, D., Anand, I. S., Durrington, P. N., Patel, D. J., Wander, G. S., Mackness, M. I., 
Creed, F., Tomenson, B., Chandrashekhar, Y., & Winterbotham, M. "Coronary risk factors 
in people from the Indian subcontinent living in west London and their siblings in India", 
Lancet, vol. 345, no. 8947, pp. 405-409.
Bhopal, R., Unwin, N., White, M., Yallop, J., Walker, L., & Alberti, K. G. 1999, 
"Heterogeneity o f coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and 
European origin populations: cross sectional study", BMJ, vol. 319, no. 7204, pp. 215-220.
2 2 0
Bie, P., Wamberg, S., & Kjolby, M. 2004, "Volume natriuresis vs. pressure natriuresis", 
Acta Physiologica Scandinavica, vol. 181, no. 4, pp. 495-503.
Bihoreau, M. T., Gauguier, D., Kato, N., Hyne, G., Lindpaintner, K., Rapp, J. P., James, M. 
R., & Lathrop, G. M. 1997, "A linkage map of the rat genome derived from three F2 
crosses", Genome Res, vol. 7, no. 5, pp. 434-440.
Bogin, E., Massry, S. G., & Harary, I. 1981, "Effect of parathyroid hormone on rat heart 
cells", J  C/m Invest, vol. 67, no. 4, pp. 1215-1227.
Bonne, G., Carrier, L., Richard, P., Hainque, B., & Schwartz, K. 1998, "Familial 
hypertrophic cardiomyopathy: from mutations to functional defects". Circulation Research, 
vol. 83, no. 6, pp. 580-593.
Booz, G. W. & Baker, K. M. 1996, "Role of type 1 and type 2 angiotensin receptors in 
angiotensin Il-induced cardiomyocyte hypertrophy", Hypertension, vol. 28, no. 4, pp. 635- 
640.
Boutin-Ganache, I., Picard, S., & Deschepper, C. F. 2002, "Distinct gene-sex interactions 
regulate adult rat cardiomyocyte width and length independently", Physiol Genomics, vol. 
12, no. 1, pp. 61-67.
Brand, E., Chatelain, N., Keavney, B., Caulfield, M., Citterio, L., Connell, J., Grobbee, D., 
Schmidt, S., Schunkert, H., Schuster, H., Sharma, A. M., & Soubrier, F. 1998, "Evaluation 
of the angiotensinogen locus in human essential hypertension: a European study". 
Hypertension, vol. 31, no. 3, pp. 725-729.
Brede, M., Hadamek, K., Meinel, L., Wiesmann, F., Peters, J., Engelhardt, S., Si mm. A., 
Haase, A., Lohse, M. J., & Hein, L, 2001, "Vascular hypertrophy and increased P70S6 
kinase in mice lacking the angiotensin II AT(2) receptor". Circulation, vol. 104, no. 21, pp. 
2602-2607.
Breitling, R., Armengaud, P., Amtmann, A., & Herzyk, P. 2004, "Rank products: a simple, 
yet powerful, new method to detect differentially regulated genes in replicated microarray 
experiments", FEBSLetters, vol. 573, no. 1-3, pp. 83-92.
Brockway, B. P., Mills, P. A., & Azar, S. H. 1991, "A new method for continuous chronic 
measurement and recording o f blood pressure, heart rate and activity in the rat via radio­
telemetry", Clin Exp Hypertens A, vol. 13, no. 5, pp. 885-895.
Brooks, V. L. & Osborn, J. W. 1995, "Hormonal-sympathetic interactions in long-term 
regulation of arterial pressure: an hypothesis", AJP  - Regulatory, Integrative and 
Comparative Physiology, vol. 268, no. 6, p. R1343-R1358.
Brown, D. M., Matise, T. C., Koike, G., Simon, J. S., Winer, E. S., Zangen, S., 
McLaughlin, M. G,, Shiozawa, M., Atkinson, O. S., Hudson, J. R., Jr., Chakravarti, A., 
Lander, E. S., & Jacob, H. J. 1998, "An integrated genetic linkage map o f the laboratory 
rat", Mamm.Genome, vol. 9, no. 7, pp. 521-530.
2 2 1
Bukoski, R, D., Ishibashi, K., & Bian, K. 1995, "Vascular actions of the calcium-regulating 
hormones", Semin.Nephrol, vol. 15, no. 6, pp. 536-549.
Bunag, R. D. 1983, "Facts and fallacies about measuring blood pressure in rats", Clin Exp 
Hypertens A, vol. 5, no. 10, pp. 1659-1681.
Bunag, R. D. & Teravainen, T, L. 1991, "Tail-cuff detection of systolic hypertension in 
different strains o f ageing rats", Mech. Ageing Dev., vol. 59, no. 1-2, pp. 197-213.
Burnstock, G. 1986, "The changing face of autonomic neurotransmission",
Scand, vol. 126, no. 1, pp. 67-91.
Cameron, V. A. & Ellmers, L. J. 2003, "Minireview: Natriuretic Peptides during 
Development of the Fetal Heart and Circulation", Endocrinology, vol. 144, no. 6, pp. 2191- 
2194.
Carretero, O. A. & Oparil, S. 2000, "Essential Hypertension : Part I: Definition and 
Etiology", Circulation, vol. 101, no. 3, pp. 329-335.
Chan, J. C., Knudson, O., Wu, F., Morser, J., Dole, W. P., & Wu, Q. 2005, "Hypertension 
in mice lacking the proatrial natriuretic peptide convertase corin", 
Proc.Natl.Acad.Sci.U.S.A, vol. 102, no. 3, pp. 785-790.
Chen, J., Song, S. K., Liu, W., McLean, M., Allen, J, S., Tan, J., Wickline, S. A., & Yu, X. 
2003, "Remodeling o f cardiac fiber structure after infarction in rats quantified with 
diffusion tensor MRI", AJP  - Heart and Circulatory Physiology, vol. 285, no. 3, p. H946- 
H954.
Chen, Y. F. & Meng, Q. C. 1991, "Sexual dimorphism of blood pressure in spontaneously 
hypertensive rats is androgen dependent". Life Sci., vol. 48, no. 1, pp. 85-96.
Chitayat, D., Grix, A., Balfe, J. W., Abramowicz, J. S., Garza, J., Fong, C. T., Silver, M. 
M., Sailer, D. N., Jr., Bresnick, G. H., Giedion, A., Lachman, R. S., & Rimoin, D. L. 1997, 
"Brachydactyly-short stature-hypertension (Bilginturan) syndrome: report on two families", 
Am J  M ed Genet, vol. 73, no. 3, pp. 279-285.
Churchill, G. A. & Doerge, R. W. 1994, "Empirical threshold values for quantitative trait 
mapping". Genetics, vol. 138, no. 3, pp. 963-971.
Cicila, G. T. & Lee, S. J. 1998, "Identifying candidate genes for blood pressure quantitative 
trait loci using differential gene expression and a panel of congenic strains", Hypertens Res, 
vol. 21, no. 4, pp. 289-296.
Cicila, G. T., Choi, C., Dene, H., Lee, S. J., & Rapp, J. P. 1999, "Two blood 
pressure/cardiac mass quantitative trait loci on chromosome 3 in Dahl rats", 
Mamm.Genome, vol. 10, no. 2, pp. 112-116.
2 2 2
Clark, J. S., Jeffs, B., Davidson, A. O., Lee, W. K., Anderson, N. H., Bihoreau, M. T., 
Brosnan, M. J., Devlin, A. M., Kelman, A. W., Lindpaintner, K., & Dominiczak, A. F.
1996, "Quantitative Trait Loci in Genetically Hypertensive Rats: Possible Sex Specificity", 
Hypertension, vol. 28, no. 5, pp. 898-906.
Colditz, G. A., Willett, W. C., Stampfer, M. J., Rosner, B., Speizer, F. E., & Hennekens, C. 
H. 1987, "Menopause and the risk of coronary heart disease in women", N .EnglJM ed, vol. 
316, no. 18, pp. 1105-1110.
Cooper, R. & Rotimi, C. 1997, "Hypertension in blacks". Am J  Hypertens, vol. 10, pp. 
804-812.
Cooper, R. S., Wolf-Maier, K., Luke, A., Adeyemo, A., Banegas, J. R., Forrester, T., 
Giampaoli, S., Joffres, M., Kastarinen, M., Primatesta, P., Stegmayr, B., & Thamm, M. "An 
International Comparative Study o f Blood Pressure in Populations o f European vs. African 
Descent", BMC Med, vol. 3, p. 2.
Cordell, H. J. 2002, "Epistasis: what it means, what it doesn't mean, and statistical methods 
to detect it in humans". Human Molecidar Genetics, vol. 11, no. 20, pp. 2463-2468.
Coucke, P., Van Acker, P., & De Paepe, A. 2006, "Mutation analysis of the FBNl gene in 
patients with Marfan syndrome". Methods Mol Med, vol. 126, pp. 81-95.
Crowley, J. J., Huang, C. L., Gates, A. R., Basu, A., Shapiro, L. M., Carpenter, T. A., & 
Hall, L. D. 1997, "A quantitative description of dynamic left ventricular geometry in 
anaesthetized rats using magnetic resonance imaging", Exp Physiol, vol. 82, no. 5, pp. 887- 
904.
Cruickshank, J. K., Jackson, S. H. D., Beevers, D. G., Bannan, L. T., Beevers, M., & 
Stewart, V. L. 1985, "Similarity of blood pressure in blacks, whites and Asians in England: 
The Birmingham Factory study", J  Hypertension, vol. 3, pp. 365-371.
Davidson, A. O., Schork, N., Jaques, B. C., Kelman, A. W., Sutcliffe, R. G., Reid, J. L., & 
Dominiczak, A. F. 1995, "Blood pressure in genetically hypertensive rats. Influence of the 
Y chromosome", Hypertension, vol. 26, no. 3, pp. 452-459.
de Simone, G., Wallerson, D. C., Volpe, M., & Devereux, R. B. 1990, "Echocardiographic 
measurement of left ventricular mass and volume in normotensive and hypertensive rats. 
Necropsy validation". Am J  Hypertens, vol. 3, no. 9, pp. 688-696.
de Simone, G., Devereux, R. B., Roman, M. J., Ganau, A., Saba, P. S., Alderman, M. H., & 
Laragh, J. H. 1994, "Assessment of left ventricular function by the midwall fractional 
shortening/end-systolic stress relation in human hypertension", J  Am CollCardioL, vol. 23, 
no. 6, pp. 1444-1451.
De Wardener, H. E. 2001, "The Hypothalamus and Hypertension", Physiological Reviews, 
vol. 81, no. 4, pp. 1599-1658.
223
Deng, A. Y. & Rapp, J. P. 1995, "Locus for the inducible, but not a constitutive, nitric 
oxide synthase cosegregates with blood pressure in the Dahl salt-sensitive rat", J  C/m 
Invest, vol. 95, no. 5, pp. 2170-2177.
Deng, A. Y., Dene, H., & Rapp, J. P. 1997, "Congenic strains for the blood pressure 
quantitative trait locus on rat chromosome 2", Hypertension, vol. 30, no. 2 Pt 1, pp. 199- 
202 .
Deschepper, C. P., Masciotra, S., Zahabi, A., Boutin-Ganache, I., Picard, S., & 
Reudelhuber, T. L. 2001, "Functional alterations o f the Nppa promoter are linked to cardiac 
ventricular hypertrophy in WKY/WKHA rat crosses". Circulation Research, vol. 88, no. 2, 
pp. 223-228.
Devereux, R. B., Lutas, E. M., Casale, P. N., Kligfield, P., Eisenberg, R. R., Hammond, I. 
W., Miller, D. H., Reis, G., Alderman, M. H., & Laragh, J. H. 1984, "Standardization of M- 
mode echocardiographic left ventricular anatomic measurements", J  Am CollCardioL, vol. 
4, no. 6, pp. 1222-1230.
Devereux, R. B. 1987, "Cardiac involvement in essential hypertension. Prevalence, 
pathophysiology, and prognostic implications", Med Clin North Am, vol. 71, no. 5, pp. 813- 
826.
Devereux, R. B., de Simone, G., Koren, M. J., Roman, M. J., & Laragh, J. H. 1991, "Left 
ventricular mass as a predictor of development of hypertension". Am J  Hypertens, vol. 4, 
no. 11, pp. 603S-607S.
Devereux, R. B., de Simone, G., Ganau, A., Koren, M. J., & Roman, M. J. 1993, "Left 
ventricular hypertrophy associated with hypertension and its relevance as a risk factor for 
complications", y  Pharmacol, vol. 21 Suppl 2, p. S38-S44.
Devereux, R. B., de Simone, G., Ganau, A., & Roman, M. J. 1994, "Left ventricular 
hypertrophy and geometric remodeling in hypertension; stimuli, functional consequences 
and prognostic implications", J  Hypertens Suppl, vol. 12, no. 10, p. S117-S127.
Devereux, R. B., Wallerson, D. C., de Simone, G., Ganau, A., & Roman, M. J. 1994, 
"Evaluation o f left ventricular hypertrophy by M-mode echocardiography in patients and 
experimental animals", Am J  Card Imaging, vol. 8, no. 4, pp. 291-304.
Devereux, R. B. & Roman, M. J. 1995, "Evaluation of the heart and arterial tree in 
hypertension", y  CarJ/ovn.s'e Risk, vol. 2, no. 1, pp. 4-15.
Devereux, R. B., Roman, M. J., Liu, J. E., Lee, E. T., Wang, W., Fabsitz, R. R., Welty, T. 
K., & Howard, B. V. 2003, "An appraisal of echocardiography as an epidemiological tool. 
The Strong Heart Study", Ann Epidemiol, vol. 13, no. 4, pp. 238-244.
Di Nicolantonio, R., Kostka, V., Kwitek, A., Jacob, H., Thomas, W. G., & Harrap, S. B. 
2006, "Fine mapping of Lvml : a quantitative trait locus controlling heart size 
independently of blood pressure", Pulm.Pharmacol Ther., vol. 19, no. 1, pp. 70-73.
224
Dickhuth, H. H., Reindeil, H., Lehmann, M., & Keul, J. 1985, "Capacity for regression of 
the athletic heart", Z.KardioL, vol. 74 Suppl 7, pp. 135-143.
Diez-Roux, A. V., Nieto, F. J., & Muntaner, C. 1997, "Neighbourhood environments and 
coronary heart disease: A multilevel analysis". Am J  Epidemiol, vol. 146, pp. 48-63.
Disabella, E., Grasso, M., Marziliano, N., Ansaldi, S., Lucchelli, C., Porcu, E., Tagliani, 
M., Pi lotto. A., Diegoli, M., Lanzarini, L., Malattia, C., Pelliccia, A., Ficcadenti, A., 
Gabrielli, O., & Arbustini, E. 2006, "Two novel and one known mutation of the TGFBR2 
gene in Marfan syndrome not associated with FBNl gene defects", E urJH um  Genet, vol. 
14, no. 1, pp. 34-38.
Doerge, R. W. & Churchill, G. A. 1996, "Permutation tests for multiple loci affecting a 
quantitative character", Genetics, vol. 142, no. 1, pp. 285-294.
Doerge, R. W. 2002, "Mapping and analysis of quantitative trait loci in experimental 
populations", Nat.Rev.Genet, vol. 3, no. 1, pp. 43-52.
Dominiczak, A.F. & Lindpaintner, K. 1994, “Genetics of hypertension: a current 
appraisal”. News in Physiological Sciences, vol. 9, pp. 246-251.
Dominiczak, A. F., Devlin, A. M., Lee, W. K., Anderson, N. H., Bohr, D. F., & Reid, J. L. 
1996, "Vascular Smooth Muscle Polyploidy and Cardiac Hypertrophy in Genetic 
Hypertension", Hypertension, vol. 27, no. 3, pp. 752-759.
Dominiczak, A. F., Devlin, A. M., Brosnan, M. J., Anderson, N. H., Graham, D., Clark, J.
S., McPhaden, A., Hamilton, C. A., & Reid, J. L. 1997, "Left ventricular hypertrophy and 
arterial blood pressure in experimental models o f hypertension". Adv.Exp Med Biol, vol. 
432, pp. 23-33.
Dominiczak, A. F. & McBride, M. W. 2003, "Genetics of common polygenic stroke", 
Nat.Genet, vol. 35, no. 2, pp. 116-117.
Dominiczak, A. F., Brain, N., Charchar, F., McBride, M., Hanlon, N., & Lee, W. K. 2004, 
"Genetics of hypertension: lessons learnt from mendelian and polygenic syndromes", Clin 
Exp Hypertens, vol. 26, no. 7-8, pp. 611-620.
Dominiczak, A. F., Graham, D., McBride, M. W., Brain, N. J., Lee, W. K., Charchar, F. J., 
Tomaszewski, M., Delies, C., & Hamilton, C. A. 2005, "Corcoran Lecture. Cardiovascular 
genomics and oxidative stress", Hypertension, vol. 45, no. 4, pp. 636-642.
Dueland, S., Bouillon, R., Van Baelen, H., Pedersen, J. L, Helgerud, P., & Drevon, C. A. 
1985, "Binding protein for vitamin D and its metabolites in rat mesenteric lymph", AJP - 
Legacy, vol. 249, no. 1 Pt 1, p. E1-E5.
Durand, J. B. 1999, "Genetic basis of cardiomyopathy", Curr Opin.CardioL, vol. 14, no. 3, 
pp. 225-229.
225
Dzau, V. J. 1988, "Vascular renin-angiotensin system in hypertension. New insights into 
the mechanism o f action of angiotensin converting enzyme inhibitors". Am J  Med, vol. 84, 
no. 4A, pp. 4-8,
Ed 1er, 1. & Hertz, C. H. 2004, "The use of ultrasonic reflectoscope for the continuous 
recording of the movements of heart walls. 1954", Clin Physiol Funct.Imaging, vol. 24, no. 
3, pp. 118-136.
Ekins, R., Chu, F., & Micallef, J. 1989, "High specific activity chemiluminescent and 
fluorescent markers: their potential application to high sensitivity and 'multi-analyte' 
immunoassays", JBiolumin.Chemilumin., vol. 4, no. 1, pp. 59-78.
Ely, D. L. & Turner, M. E. 1990, "Hypertension in the spontaneously hypertensive rat is 
linked to the Y chromosome", Hypertension, vol. 16, no. 3, pp. 277-281.
Espiner, E. A., Richards, A. M., Yandle, T. G., & Nicholls, M. G. 1995, "Natriuretic 
hormones", Endocrinol Metah Clin North Am, vol. 24, no. 3, pp. 481-509.
Shen, R., Fan, J. B., Campbell, D., Chang, W., Chen, J., Doucet, D., Yeakley, J., Bibikova, 
M., Wickham, G. E., McBride, C., Steemers, F., Garcia, F., Kermani, B. G., Gunderson, K., 
& Oliphant, A. 2005, "High-throughput SNP genotyping on universal bead arrays", 
Mutat.Res, vol. 573, no. 1-2, pp. 70-82.
Farrall, M. 2004, "Quantitative genetic variation: a post-modern view", Hum.Mol.Genet, 
vol. 13 Spec No 1, p. R1-R7.
Feigenbaum, H. 1996, "Echocardiographic tissue diagnosis", European Heart Journal, vol. 
17, no. 1, pp. 6-7.
Feinleib, M., Garrison, R. J., Fabsitz, R., Christian, J. C., Hrubec, Z., Borhani, N. O., 
Kannel, W. B., Rosenman, R., Schwartz, J. T., & Wagner, J. O. 1977, "The NHLBI twin 
study of cardiovascular disease risk factors: methodology and summary o f results", Am J  
Epidemiol, vol. 106, no. 4, pp. 284-285.
Feng, J. A., Perry, G., Mori, T., Hayashi, T., Oparil, S., & Chen, Y. F. 2003, "Pressure- 
independent enhancement of cardiac hypertrophy in atrial natriuretic peptide-deficient 
mice". Clinical and Experimental Pharmacology and Physiology, vol. 30, no. 5-6, pp. 343- 
349.
Fischer, M., Baessler, A., Hense, H. W., Hengstenberg, C., Muscholl, M., Holmer, S., 
Doring, A., Broeckel, U., Riegger, G., & Schunkert, H. 2003, "Prevalence of left 
ventricular diastolic dysfunction in the community: Results from a Doppler 
echocardiographic-based survey of a population sample", European Heart Journal, vol. 24, 
no. 4, pp. 320-328.
Foley, R. N., Parfrey, P. S., Harnett, J. D., Kent, G. M., O'Dea, R., Murray, D. C., & Barre, 
P. E. 1998, "Mode o f dialysis therapy and mortality in end-stage renal disease", Journal o f  
the American Society o f  Nephrology, vol. 9, no. 2, pp. 267-276.
226
Franco, F., Thomas, G. D., Giroir, B., Bryant, D., Bullock, M. G., Chwialkowski, M. C., 
Victor, R. G., & Peshock, R. M. 1999, "Magnetic resonance imaging and invasive 
evaluation of development o f heart failure in transgenic mice with myocardial expression of 
tumor necrosis factor-alpha". Circulation, vol. 99, no. 3, pp. 448-454.
Friesen, R. H., Wurl, J. L., & Charlton, G. A. 2000, "Haemodynamic depression by 
halothane is age-related in paediatric patients", Paediatr.Anaesth., vol. 10, no. 3, pp. 267- 
272.
Frohlich, E. D., Dunn, F. G., & Messerli, F. H. 1983, "Pharmacologic and physiologic 
considerations o f adrenoceptor blockade". Am J  Med, vol. 75, no. 4A, pp. 9-14.
Frohlich, E. D. 2001, "Local hemodynamic changes in hypertension: insights for 
therapeutic preservation of target organs", Hypertension, vol. 38, no. 6, pp. 1388-1394.
Gaasch, W. H., Levine, H. J., Quinones, M. A., & Alexander, J. K. 1976, "Left ventricular 
compliance: mechanisms and clinical implications", 4m  J , vol. 38, no. 5, pp. 645- 
653.
Gabe, I. T. 1965, "Arterial Blood Flow by Analogue Solution of the Navier-Stokes 
Equation", Physics in Medicine and Biology no. 2, pp. 271-280.
Gairard, A., Pernot, F., Bergmann, C., & van Overloop, B. 1994, "Ions, parathyroids, and 
genetic hypertension". Am J  M ed Sci.,yo\. 307 Suppl 1, p. S126-S129.
Gamba, G. 2005, "Role of WNK kinases in regulating tubular salt and potassium transport 
and in the development o f hypertension", AJP - Renal Physiology, vol. 288, no. 2, p. F245- 
F252.
Ganau, A., Devereux, R. B., Pickering, T. G., Roman, M. J., Schnall, P. L., Santucci, S., 
Spitzer, M. C., & Laragh, J. H. 1990, "Relation o f left ventricular hemodynamic load and 
contractile performance to left ventricular mass in hypertension". Circulation, vol. 81, no.
1, pp. 25-36.
Ganau, A,, Devereux, R. B., Roman, M. J., de Simone, G., Pickering, T. G., Saba, P. S., 
Vargiu, P., Simongini, I., & Laragh, J. H. 1992, "Patterns of left ventricular hypertrophy 
and geometric remodeling in essential hypertension", J  Am CollCardioL, vol. 19, no. 7, pp. 
1550-1558.
Ganten, D., Unger, T., & Lang, R. E. 1987, "Brain peptides and blood pressure control", 
Verh.Dtsch.Ges.Inn.Med, vol. 93, pp. 418-421.
Ganten, U., Schroder, G., Witt, M., Zimmermann, F., Ganten, D., & Stock, G. 1989,
"Sexual dimorphism o f blood pressure in spontaneously hypertensive rats: effects of anti­
androgen treatment", J  Hypertens, vol. 7, no. 9, pp. 721-726.
Garcia, E. A., Newhouse, S., Caulfield, M. J., & Munroe, P. B. 2003, "Genes and 
hypertension", Curr Pharm Des, vol. 9, no. 21, pp. 1679-1689.
227
Garner, C., Lecomte, E., Visvikis, S., Abergel, E., Lathrop, M., & Soubrier, F. 2000, 
"Genetic and Environmental Influences on Left Ventricular Mass : A Family Study", 
Hypertension, vol. 36, no. 5, pp. 740-746.
Garrett, M. R., Saad, Y., Dene, H., & Rapp, J. P. 2000, "Blood pressure QTL that 
differentiate Dahl salt-sensitive and spontaneously hypertensive rats". Physiol Genomics, 
vol. 3, no. 1, pp. 33-38.
Garrett, M. R., Zhang, X., Dukhanina, O. L, Deng, A. Y., & Rapp, J. P. 2001, "Two linked 
blood pressure quantitative trait loci on chromosome 10 defined by dahl rat congenic 
strains", Plypertension, vol. 38, no. 4, pp. 779-785.
Garrett, M. R., Meng, H., Rapp, J. P., & Joe, B. 2005, "Locating a blood pressure 
quantitative trait locus within 117 kb on the rat genome: substitution mapping and renal 
expression analysis", Hypertension, vol. 45, no. 3, pp. 451-459.
Gel 1er, D. S., Farhi, A., Pinkerton, N., Fradley, M., Moritz, M., Spitzer, A., Meinke, G., 
Tsai, F. T., Sigler, P. B., & Lifton, R. P. 2000, "Activating mineralocorticoid receptor 
mutation in hypertension exacerbated by pregnancy", Science, vol. 289, no. 5476, pp. 119- 
123.
George, T. C., Carl, C., Howard, D., Soon, J. L., & John, P. R. 1999, "Two blood 
pressure/cardiac mass quantitative trait loci on Chromosome 3 in Dahl rats". Mammalian 
Genome, vol. 10, no. 2, pp. 112-116.
Gibbons, R. J. & Araoz, P. A. 2005, "The year in cardiac imaging", J  Am Coll.Cardiol, 
vol. 46, no. 3, pp. 542-551.
Gibbs, R. A., Weinstock, G. M., Metzker, M. L., Muzny, D. M., Sodergren, E. J., Scherer, 
et a l  2004, "Genome sequence of the Brown Norway rat yields insights into mammalian 
evolution", Nature, vol. 428, no. 6982, pp. 493-521.
Goetz, R. M., Morano, I., Calovini, T., Studer, R., & Holtz, J. 1994, "Increased expression 
of endothelial constitutive nitric oxide synthase in rat aorta during pregnancy", 
Biochem.Biophys.Res Commun., vol. 205, no. 1, pp. 905-910.
Gong, M., Zhang, H., Schulz, H., Lee, Y. A., Sun, K., Bahring, S., Luft, F. C., Nürnberg, 
P., Reis, A., Rohde, K., Ganten, D., Hui, R., & Hubner, N. 2003, "Genome-wide linkage 
reveals a locus for human essential (primary) hypertension on chromosome 12p", Human 
Molecular Genetics, vol. 12, no. 11, pp. 1273-1277.
Gordon, T., Kannel, W. B., Hjortland, M. C., & McNamara, P. M. 1978, "Menopause and 
coronary heart disease. The Framingham Study", Annals o f  Internal Medicine, vol. 89, no. 
2, pp. 157-161.
Graham, D., McBride, M. W., Brain, N. J., & Dominiczak, A. F. 2004, 
"Congenic/Consomic models of hypertension", Methods Mol Med, vol. 108, pp. 3-16.
228
Grim, C. E., Wilson, T. W., Nicholson, G. D., Hassel, T. A., Fraser, H. S., Grim, C. M., & 
Wilson, D. M. 1990, "Blood pressure in blacks. Twin studies in Barbados", Hypertension, 
vol. 15, pp. 803-809.
Gross, V., Tank, J., Obst, M., Plehm, R., Blumer, K. J., Diedrich, A., Jordan, J., & Luft, F. 
C. 2005, "Autonomic Nervous System and Blood Pressure Regulation in RGS2-deficient 
Mice", AJP  - Regulatory, Integrative and Comparative Physiology p. 00246.
Gustavsen, P. FI., Hoegholm, A., Bang, L. E., & Kristensen, K. S. 2003, "White coat 
hypertension is a cardiovascular risk factor: a 10-year follow-up study", J  Hum Hypertens, 
vol. 17, no. 12, pp. 811-817.
Hacia, J. G., Fan, J. B., Ryder, O., Jin, L., Edgemon, K., Ghandour, G., Mayer, R. A., Sun, 
B., Hsie, L., Robbins, C. M., Brody, L. C., Wang, D., Lander, E. S., Lipshutz, R., Fodor, S. 
P., & Collins, F. S. 1999, "Determination of ancestral alleles for human single-nucleotide 
polymorphisms using high-density oligonucleotide arrays", Nat.Genet, vol. 22, no. 2, pp. 
164-167.
Haley, C. S. & Knott, S. A. 1992, "A simple regression method for mapping quantitative 
trait loci in line crosses using flanking markers". Heredity, vol. 69, no. 4, pp. 315-324.
Hansson, J. H., Schild, L., Lu, Y., Wilson, T. A., Gautschi, I., Shimkets, R., Nelson- 
Williams, C., Rossier, B. C., & Lifton, R. P. 1995, "A de novo missense mutation of the 
beta subunit o f the epithelial sodium channel causes hypertension and Liddle syndrome, 
identifying a proline-rich segment critical for regulation o f channel activity", 
Proc.NatlAcad.Sci. U.S.A, vol. 92, no. 25, pp. 11495-11499.
Hara, Y., Tagawa, M., Ejima, H., Orima, H., Yamagami, T., Umeda, M., Komori, S., & 
Washizu, M. 1995, "Regression of hypertrophic osteopathy following removal of 
intrathoracic neoplasia derived from vagus nerve in a dog", J  Vet.M edSet, vol. 57, no. 1, 
pp. 133-135.
Harburg, E., Erfurt, J. C., & Chape, C. 1973, "Socioecological stressor areas and African- 
white blood pressure: Detroit", J  Chronic Dis, vol. 26, pp. 595-611.
Harrap, S. B., Louis, W. J., & Doyle, A. E. 1984, "Failure of psychosocial stress to induce 
chronic hypertension in the rat", J  Hypertens, vol. 2, no. 6, pp. 653-662.
Harrap, S. B., Danes, V. R., Ellis, J. A., Griffiths, C. D., Jones, E. F., & Delbridge, L. M. 
2002, "The hypertrophic heart rat: a new normotensive model of genetic cardiac and 
cardiomyocyte hypertrophy". Physiol Genomics, vol. 9, no. 1, pp. 43-48.
Harris, E. L., Phelan, E. L., Thompson, C. M., Millar, J. A., & Grigor, M. R. 1995, "Heart 
mass and blood pressure have separate genetic determinants in the New Zealand genetically 
hypertensive (GH) rat", J  Hypertens, vol. 13, no. 4, pp. 397-404.
229
Harshfield, G. A., Alpert, B. S., Pulliam, D. A., Somes, G. W., & Wilson, D. K. 1994, 
"Ambulatory blood pressure recordings in children and adolescents". Pediatrics, vol. 94, 
no. 2 Pt 1, pp. 180-184.
He, F. J. & MacGregor, G. A. 2003, "Cost of poor pressure control in the UK: 62000 
unnecessary deaths per year", J  Human Hypertens, vol. 17, pp. 455-457.
Helmer, O. M. 1965, "The renin-angiotensin system and its relation to hypertension", 
Prog.Cardiovasc Dis, vol. 8, no. 2, pp. 117-128.
Hess, P., Clozel, M., & Clozel, J. P. 1996, "Telemetry monitoring o f pulmonary arterial 
pressure in freely moving rats", JAppl.Physiol, vol. 81, no. 2, pp. 1027-1032.
Higgins, C. B., Holt, W., Pflugfelder, P., & Sechtem, U. 1988, "Functional evaluation of 
the heart with magnetic resonance imaging", Magn Reson.Med, vol. 6, no. 2, pp. 121-139.
Hilbert, P., Lindpaintner, K., Beckmann, J. S., Serikawa, T., Soubrier, F., Dubay, C., 
Cartwright, P., De Gouyon, B., Julier, C., Takahasi, S., & . 1991, "Chromosomal mapping 
o f two genetic loci associated with blood-pressure regulation in hereditary hypertensive 
rats". Nature, vol. 353, no. 6344, pp. 521-529.
Hinderliter, A. L., Sherwood, A., Blumenthal, J. A., Light, K. C., Girdler, S. S., 
McFetridge, J., Johnson, K., & Waugh, R. 2002, "Changes in hemodynamics and left 
ventricular structure after menopause", Am J  Cardiol, vol. 89, no. 7, pp. 830-833.
Hinojosa-Laborde, C., Chapa, I., Lange, D., & Haywood, J. R. 1999, "Gender differences 
in sympathetic nervous system regulation". Clinical and Experimental Pharmacology and 
Physiology, vol. 26, no. 2, pp. 122-126.
Hinojosa-Laborde, C., Craig, T., Zheng, W., Ji, H., Haywood, J. R., & Sandberg, K. 2004, 
"Ovariectomy Augments Hypertension in Aging Female Dahl Salt-Sensitive Rats", 
Hypertension, vol. 44, no. 4, pp. 405-409.
Hoehe, M. R., Kopke, K., Wendel, B., Rohde, K., Flachmeier, C., Kidd, K. K., Berrettini, 
W. H., & Church, G. M. 2000, "Sequence variability and candidate gene analysis in 
complex disease: association o f {micro} opioid receptor gene variation with substance 
dependence", Human Molecular Genetics, vol. 9, no. 19, pp. 2895-2908.
Horan, M. J. & Lenfant, C. 1990, "Epidemiology of blood pressure and predictors of 
hypertension", Hypertension, vol. 15, no. 2 SuppI, p. 120-124.
Hughes, T. A. 2006, "Regulation of gene expression by alternative untranslated regions", 
Trends Genet, vol. 22, no. 3, pp. 119-122.
Ibsen, K. K. 1984, "Blood-pressures in offspring o f hypertensive parents", Acta 
Paediatr.Scand, vol. 73, no. 6, pp. 842-847.
230
Ichiham, S., Senbonmatsii, T., Price E Jr, Ichiki, T., Gaffney, F. A., & Inagami, T. 2001, 
"Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac 
fibrosis in chronic angiotensin Il-induced hypertension". Circulation, vol. 104, no. 3, pp. 
346-351.
lemitsu, M., Miyauchi, T., Maeda, S., Sakai, S., Fujii, N., Miyazaki, H., Kakinuma, Y., 
Matsuda, M., & Yamaguchi, I. 2003, "Cardiac hypertrophy by hypertension and exercise 
training exhibits different gene expression of enzymes in energy metabolism", Hypertens 
Res, vol. 26, no. 10, pp. 829-837.
Ikeuchi, M., Tsutsui, H., Shiomi, T., Matsusaka, H., Matsushima, S., Wen, J., Kubota, T., 
& Takeshita, A. 2004, "Inhibition of TGF-beta signaling exacerbates early cardiac 
dysfunction but prevents late remodeling after infarction", Cardiovasc Res, vol. 64, no. 3, 
pp. 526-535.
Innes, B. A., McLaughlin, M. G., Kapuscinski, M. K., Jacob, H. J., & Harrap, S. B. 1998, 
"Independent genetic susceptibility to cardiac hypertrophy in inherited hypertension", 
Hypertension, vol. 31, no. 3, pp. 741-746.
Inomata, H., Watanabe, T., lizuka, Y., Liang, Y. Q., Mashimo, T., Nabika, T., Ikeda, K., 
Yanai, K., Gotoda, T., Yamori, Y., Isobe, M., & Kato, N. 2005, "Identification of 
quantitative trait loci for cardiac hypertrophy in two different strains o f the spontaneously 
hypertensive rat", Hypertens Res, vol. 28, no. 3, pp. 273-281.
Irizarry, R. A., Ooi, S. L., Wu, Z., & Boeke, J. D. 2003, "Use of mixture models in a 
microarray-based screening procedure for detecting differentially represented yeast 
mutants", Stat.Appl.Genet Mol B io l, vol. 2, no. 1, p. Article 1.
Iwamoto, R., Yamazaki, S., Asakura, M., Takashima, S., Hasuwa, H., Miyado, K., Adachi,
S., Kitakaze, M., Hashimoto, K., Raab, G., Nanba, D., Higashiyama, S., Hori, M., 
Klagsbrun, M., & Mekada, E. 2003, "Heparin-binding EGF-like growth factor and ErbB 
signaling is essential for heart function", Proc.NatlAcad.Sci.U.S.A, vol. 100, no. 6, pp. 
3221-3226.
Jacob, H. J., Lindpaintner, K., Lincoln, S. E., Kusumi, K., Bunker, R. K., Mao, Y. P., 
Ganten, D., Dzau, V. J., & Lander, E. S. 1991, "Genetic mapping o f a gene causing 
hypertension in the stroke-prone spontaneously hypertensive rat". Cell, vol. 67, no. 1, pp. 
213-224.
Jacob, H. J., Brown, D. M., Bunker, R. K., Daly, M. J., Dzau, V. J., Goodman, A., Koike, 
G., Kren, V., Kurtz, T., Lernmark, A., & . 1995, "A genetic linkage map of the laboratory 
rat, Rattus norvegicus", Nat.Genet, vol. 9, no. 1, pp. 63-69.
Jansen, R. C. 1993, "Interval mapping of multiple quantitative trait loci". Genetics, vol. 
135, no. 1, pp. 205-211.
Jeffs, B., Negrin, C. D., Graham, D., Clark, J. S., Anderson, N. H., Gauguier, D., & 
Dominiczak, A. F. 2000, "Applicability of a "Speed" Congenic Strategy to Dissect Blood
231
Pressure Quantitative Trait Loci on Rat Chromosome 2", Hypertension, vol. 35, no. 1, pp. 
179-187.
Jiang, C. & Zeng, Z. B. 1995, "Multiple trait analysis of genetic mapping for quantitative 
trait loci", Genetics, vol. 140, no. 3, pp. I l l  1-1127.
John, S. W., Krege, J. H., Oliver, P. M., Hagaman, J. R., Hodgin, J. B., Pang, S. C., Flynn, 
T. G., & Smithies, O. 1995, "Genetic decreases in atrial natriuretic peptide and salt- 
sensitive hypertension". Science, vol. 267, no. 5198, pp. 679-681.
Jongbloed, R. J., Marcelis, C. L., Doevendans, P. A., Schmeitz-Mulkens, J. M., Van 
Dockum, W. G., Geraedts, J. P., & Smeets, H. J. 2003, "Variable clinical manifestation of a 
novel missense mutation in the alpha-tropomyosin (TPM l) gene in familial hypertrophic 
cardiomyopathy", JA m  Coll.Cardiol, vol. 41, no. 6, pp. 981-986.
Jones, E. F., Harrap, S. B., Calafiore, P., & Tonkin, A. M. 1992, "Development and 
validation o f echocardiographic methods for estimating left ventricular mass in rats", Clin 
Exp Pharmacol Physiol, vol. 19, no. 5, pp. 361-364.
Ju, H. & Dixon, I. M. 1996, "Extracellular matrix and cardiovascular diseases", Can.J 
Cardiol, vol. 12, no. 12, pp. 1259-1267.
Julier, C., Delepine, M., Keavney, B., Terwilliger, J., Davis, S., Weeks, D. E., Bui, T., 
Jeunemaitre, X., Velho, G., Froguel, P., Ratcliffe, P., Corvol, P., Soubrier, F., & Lathrop,
G. M. 1997, "Genetic susceptibility for human familial essential hypertension in a region of 
homology with blood pressure linkage on rat chromosome 10", Hum Mol Genet, vol. 6, no. 
12, pp. 2077-2085.
Kaganovsky, E., Belkin, V., Barhum, Y., Schaper, J., Schaper, W., & Kessler-Icekson, G. 
2001, "Occurrence and distribution of atrial natriuretic peptide-containing cells in the left 
ventricle o f hypertensive rats. Effect of antihypertensive treatment". Cell Tissue Res, vol. 
303, no. 1, pp. 57-67.
Kannel, W. B., Gordon, T., Castelli, W. P., & Margolis, J. R. 1970, "Electrocardiographic 
left ventricular hypertrophy and risk o f coronary heart disease. The Framingham study", 
Annals o f  Internal Medicine, vol. 72, no. 6, pp. 813-822.
Kannel, W. B. 1983, "Prevalence and natural history of electrocardiographic left ventricular 
hypertrophy". Am J  Med, vol. 75, no. 3 A, pp. 4-11.
Kannel, W. B. & Wilson, P. W. 1995, "Risk factors that attenuate the female coronary 
disease advantage", Arch.Intern Med, vol. 155, no. 1, pp. 57-61.
Karet, F. E. & Lifton, R. P. 1997, "Mutations contributing to human blood pressure 
variation", Recent Prog.Horm.Res, vol. 52, pp. 263-276.
232
Katoh, Y., Klein, K. L., Kaplan, R. A., Sanborn, W. G., & Kurokawa, K. 1981,
"Parathyroid hormone has a positive inotropic action in the rat", Endocrinology, vol. 109, 
no. 6, pp. 2252-2254.
Kim, S. D. & Piano, M. R. 2000, "The Natriuretic Peptides: Physiology and Role in Left- 
Ventricular Dysfunction", Biological Research For Nursing, vol. 2, no. I, pp. 15-29.
Kishimoto, I., Rossi, K., & Garbers, D. L. 2001, "A genetic model provides evidence that 
the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular 
myocyte hypertrophy", Proc.NatlAcad.Sci. U.S.A, vol. 98, no. 5, pp. 2703-2706.
Kloss, S., Rodenbach, D., Bordel, R., & Mulsch, A. 2005, "Pluman-antigen R (HuR) 
expression in hypertension: downregulation of the mRNA stabilizing protein HuR in 
genetic hypertension". Hypertension, vol. 45, no. 6, pp. 1200-1206.
Knapp, S. J. & Bridges, W. C. 1990, "Using molecular markers to estimate quantitative trait 
locus parameters: power and genetic variances for unreplicated and replicated progeny", 
Genetics, vol. 126, no. 3, pp. 769-777.
Knowles, J. W., Esposito, G., Mao, L., Hagaman, J. R., Fox, J. E., Smithies, O., Rockman,
H. A., & Maeda, N. 2001, "Pressure-independent enhancement of cardiac hypertrophy in 
natriuretic peptide receptor A-deficient mice", JC /w  Invest, vol. 107, no. 8, pp. 975-984.
Kong, S. W., Bodyak, N., Yue, P., Liu, Z., Brown, J., Izumo, S., & Kang, P. M. 2005, 
"Genetic expression profiles during physiological and pathological cardiac hypertrophy and 
heart failure in rats". Physiol Genomics, vol. 21, no. 1, pp. 34-42.
Kong, S. W., Bodyak, N., Yue, P., Liu, Z., Brown, J., Izumo, S., & Kang, P. M. 2005, 
"Genetic expression profiles during physiological and pathological cardiac hypertrophy and 
heart failure in rats". Physiological Genomics, vol. 21, no. 1, pp. 34-42.
Koren, M. J., Devereux, R. B., Casale, P. N., Savage, D. D., & Laragh, J. H. 1991,
"Relation of left ventricular mass and geometry to morbidity and mortality in 
uncomplicated essential hypertension". Annals o f  Internal Medicine, vol. 114, no. 5, pp. 
345-352.
Kurisu, S., Ozono, R., Oshima, T., Kambe, M., Ishida, T., Sugino, H., Matsuura, H., 
Chayama, K., Teranishi, Y., Iba, O., Amano, K., & Matsubara, H. 2003, "Cardiac 
angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis". 
Hypertension, vol. 41, no. I, pp. 99-107.
Kurtz T.W., St Letzin, E.M . & Pravenet M. 1994,’’Development of hypertension strains”, 
in Textbook o f  Hypertension, ed. Swales, J.D. Ch.22A, pp441-447. Oxford: Blackwell.
Lander, E. S. & Botstein, D. 1989, "Mapping mendelian factors underlying quantitative 
traits using RFLP linkage maps", Genetics, vol. 121, no. 1, pp. 185-199.
233
Lander, E. S. & Schork, N. J. 1994, "Genetic dissection of complex traits", Science, vol. 
265, no. 5181, pp. 2037-2048.
Landry, D. W., Levin, H. R., Gallant, E. M., Ashton, R. C., Jr., Seo, S., D'Alessandro, D., 
Oz, M. C., & Oliver, J. A. 1997, "Vasopressin deficiency contributes to the vasodilation of 
septic shock", Circulation, vol. 95, no. 5, pp. 1122-1125.
Lane, D. A. & Lip, G. Y. H. 2001, "Ethnic differences in hypertension and blood pressure 
control in the UK", QJM, vol. 94, no. 7, pp. 391-396.
Langenickel, T. H., Pagel, I., Buttgereit, J., Tenner, K., Lindner, M., Dietz, R., 
Willenbrock, R., & Bader, M. 2004, "Rat corin gene; molecular cloning and reduced 
expression in experimental heart failure", AJP - Heart and Circulatory Physiology, vol. 
287, no. 4, p. H1516-H1521.
Lauffenburger, D. A., Oehrtman, G. T., Walker, L., & Wiley, H. S. 1998, "Real-time 
quantitative measurement o f autocrine ligand binding indicates that autocrine loops are 
spatially localized", Proc.NatlAcad.Sci. U.S.A, vol. 95, no. 26, pp. 15368-15373.
Laurent, D., Allergrini, P. R., & Zierhut, W. 1995, "Different left ventricular remodelling 
and function in two models of pressure overload as assessed in vivo by magnetic resonance 
imaging", J  Hypertens, vol. 13, no. 6, pp. 693-700.
Lavoie, J. L. & Sigmund, C. D. 2003, "Minireview: Overview of the Renin-Angiotensin 
System—An Endocrine and Paracrine System", Endocrinology, vol. 144, no. 6, pp. 2179- 
2183.
Lee, L. G., Connell, C. R., & Bloch, W. 1993, "Allelic discrimination by nick-translation 
PCR with fluorogenic probes". Nucleic Acids Res, vol. 21, no. 16, pp. 3761-3766.
Levin, A. & Li, Y. C. 2005, "Vitamin D and its analogues: do they protect against 
cardiovascular disease in patients with kidney disease?", Kidney Int., vol. 68, no. 5, pp. 
1973-1981.
Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. 1990, 
"Prognostic implications o f echocardiographically determined left ventricular mass in the 
Framingham Fleart Study", N .EnglJM ed, vol. 322, no. 22, pp. 1561-1566.
Levy, D., Wilson, P. W., Anderson, K. M., & Castelli, W. P. 1990, "Stratifying the patient 
at risk from coronary disease: new insights from the Framingham Heart Study", Am Heart 
J, vol. 119, no. 3 Pt 2, pp. 712-717.
Lewontin, R. C. 1972, "The apportionment of human diversity", Evol Biol, vol. 6, pp. 381- 
398.
Li, M., Ma, J., Cheng, R., Dupont, R., Williams, N., Crews, K., Payne, T., & Elston, R. 
2003, "A genome-wide scan to identify loci for smoking rate in the Framingham Heart 
Study population", BMC Genetics, vol. 4, no. Suppl 1, p. S I03.
234
Lifton, R. P., DIuhy, R. G., Powers, M., Rich, G. M., Cook, S., Uiick, S., & Laloiiel, J. M. 
1992, "A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid- 
remediable aldosteronism and human hypertension". Nature, vol. 355, no. 6357, pp. 262- 
265.
Lifton, R. P., Dluhy, R. G., Powers, M., Ulick, S., & Lalouel, J. M. 1992, "The molecular 
basis of glucocorticoid-remediable aldosteronism, a Mendelian cause of human 
hypertension", Trans.Assoc.Am Physicians, vol. 105, pp. 64-71.
Lifton, R. P. 1995, "Genetic determinants of human hypertension",
Proc.NatlAcad.Sci. U.S.A, vol. 92, no. 19, pp. 8545-8551.
Lifton, R. P. 1996, "Molecular genetics of human blood pressure variation". Science, vol. 
272, no. 5262, pp. 676-680.
Lim, J. Y., Park, S. J., Hwang, H. Y., Park, E. J., Nam, J. H., Kim, J., & Park, S. I. 2005, 
"TGF-betal induces cardiac hypertrophic responses via PKC-dependent ATF-2 activation", 
J  Mol Cell Cardiol, vol. 39, no. 4, pp. 627-636.
Lindpaintner, K. 1992, "Genetic linkage analysis in hypertension: principles and practice", 
J  Hypertens, vol. 10, no. 2, pp. 121-124.
Linzbach, A. J. 1960, "Heart failure from the point of view of quantitative anatomy", Am J  
Cardiol, vol. 5, pp. 370-382.
Lip, G. Y. & Beevers, D. G. 1995, "Alcohol, hypertension, coronary disease and stroke", 
Clin Exp Pharmacol Physiol, vol. 22, no. 3, pp. 189-194.
Lipshutz, R. J., Fodor, S. P., Gingeras, T. R., & Lockhart, D. J. 1999, "High density 
synthetic oligonucleotide arrays", Nat.Genet, vol. 21, no. 1 Suppl, pp. 20-24.
Livak, K. J., Flood, S. J., Marmaro, J., Giusti, W., & Deetz, K. 1995, "Oligonucleotides 
with fluorescent dyes at opposite ends provide a quenched probe system useful for 
detecting PCR product and nucleic acid hybridization", PCR Methods A pp l, vol. 4, no. 6, 
pp. 357-362.
Llamas, B., Jiang, Z., Rainville, M. L., Picard, S., & Deschepper, C. F. 2005, "Distinct 
QTLs are linked to cardiac left ventricular mass in a sex-specific manner in a normotensive 
inbred rat inter-cross", Mamm.Genome, vol. 16, no. 9, pp. 700-711.
Loganathan, R., Bilgen, M., Al Hafez, B., & Smirnova, I. V. 2006, "Characterization of 
alterations in diabetic myocardial tissue using high resolution MRI", Int.J Cardiovasc 
Imaging, vol. 22, no. 1, pp. 81-90.
London, G. M., Fabiani, F., Marchais, S. J., de Vernejoul, M. C., Guerin, A. P., Safar, M. 
E., Metivier, F., & Llach, F. 1987, "Uremic cardiomyopathy: an inadequate left ventricular 
hypertrophy". Kidney Int., vol. 31, no. 4, pp. 973-980.
235
Lovenberg, W. 1987, "Animal models for hypertension research", Prog.Clin Biol Res, vol. 
229, pp. 225-240.
Luft, F. C. 1999, "Bad genes, good people, association, linkage, longevity and the 
prevention of cardiovascular disease". Clinical and Experimental Pharmacology and 
Physiology, vol. 26, no. 7, pp. 576-579.
Lyons, L. A., Laughlin, T. F., Copeland, N. G., Jenkins, N. A., Womack, J. E., & O'Brien,
S. J. 1997, "Comparative anchor tagged sequences (CATS) for integrative mapping of 
mammalian genomes", Nat.Genet, vol. 15, no. 1, pp. 47-56.
Maduell, F., Navarro, V., Torregrosa, E., Rius, A., Dicenta, F., Cruz, M. C., & Ferrero, J.
A. 2003, "Change from three times a week on-line hémodiafiltration to short daily on-line 
hémodiafiltration", Kidney International, vol. 64, no. 1, pp. 305-313.
Mann, G. V., Roels, A. A., Price, D. L., & Merrill, J. M. 1962, "Cardiovascular disease in 
African pygmies", JC hron Dis, vol. 15, pp. 341-371.
Mann, G. V., Shafer, R., Anderson, R. S., & Stanstead, H. H. 1964, "Cardiovascular disease 
in the Masai", J  Atherosclerosis Res, vol. 4, pp. 289-312.
Manning, W. J., Wei, J. Y., Fossel, E. T., & Burstein, D. 1990, "Measurement of left 
ventricular mass in rats using electrocardiogram-gated magnetic resonance imaging". Am J  
Physiol, vol. 258, no. 4 P t2 , p. H1181-H1186.
Mansfield, T. A., Simon, D. B., Farfel, Z., Bia, M., Tucci, J. R., Lebel, M., Gutkin, M., 
Vialettes, B., Christofilis, M. A., Kauppinen-Makelin, R., Mayan, H., Risch, N., & Lifton, 
R. P. 1997, "Multilocus linkage o f familial hyperkalaemia and hypertension, 
pseudohypoaldosteronism type II, to chromosomes lq31-42 and 17pl l-q2I", Nat.Genet, 
vol. 16, no. 2, pp. 202-205.
Marcus, R., Krause, L., Weder, A. B., Dominguez-Meja, A., Schork, N. J., & Julius, S.
1994, "Sex-specific determinants of increased left ventricular mass in the Tecumseh Blood 
Pressure Study", Circulation , vol. 90, no. 2, pp. 928-936.
Markel, P. D., Fulker, D. W., Bennett, B., Corley, R. P., DeFries, J. C., Erwin, V. G., & 
Johnson, T. E. 1996, "Quantitative trait loci for ethanol sensitivity in the LS x SS 
recombinant inbred strains: interval mapping", Behav.Genet, vol. 26, no. 4, pp. 447-458.
Maron, B. J., Gardin, J. M., Flack, J. M., Gidding, S. S., Kurosaki, T. T., & Bild, D. E.
1995, "Prevalence o f Hypertrophic Cardiomyopathy in a General Population of Young 
Adults : Echocardiographic Analysis of 4111 Subjects in the CARDIA Study", Circulation, 
vol. 92, no. 4, pp. 785-789.
Masaki, H., Kurihara, T., Yamaki, A., Inomata, N., Nozawa, Y., Mori, Y., Murasawa, S., 
Kizima, K., Maruyama, K., Horiuchi, M., Dzau, V. J., Takahashi, H., Iwasaka, T., Inada, 
M., & Matsubara, H. 1998, "Cardiac-specific overexpression o f angiotensin II AT2
236
receptor causes attenuated response to ATI receptor-mediated pressor and chronotropic 
effects", J  Clin Invest, vol. 101, no. 3, pp. 527-535.
Masciotra, S., Picard, S., & Deschepper, C. F. 1999, "Cosegregation Analysis in Genetic 
Crosses Suggests a Protective Role for Atrial Natriuretic Factor Against Ventricular 
Flypertrophy", Circulation Research, vol. 84, no. 12, pp. 1453-1458.
Masubuchi, Y., Kumai, T., Uematsu, A., Komoriyama, K., & Hirai, M. 1982, 
"Gonadectomy-induced reduction of blood pressure in adult spontaneously hypertensive 
Acta Endocrinol (Copenh), vol. 101, no. 1, pp. 154-160.
Matsumoto, K., Yamada, T., Natori, T., Ikeda, K., Yamada, J., & Yamori, Y. 1991, 
"Genetic variability in SHR (SHRSR), SHRSP and WKY strains", Clin Exp Hypertens A, 
vol. 13, no. 5, pp. 925-938.
Mauviel, A., Qiu, C. Y., Dong, W., Evans, C. H., & Ditto, J. 1993, "Transcriptional 
interactions of transforming growth-factor-beta with pro-inflammatory cytokines", Curr 
Biol, vol. 3, no. 12, pp. 822-831.
McBride, M. W., Carr, F. J., Graham, D., Anderson, N. H., Clark, J. S., Lee, W. K., 
Charchar, F. J., Brosnan, M. J., & Dominiczak, A. F. 2003, "Microarray analysis of rat 
chromosome 2 congenic strains". Hypertension, vol. 41, no. 3 Pt 2, pp. 847-853.
McIntyre, M., Hamilton, C. A., Rees, D. D., Reid, J. L., & Dominiczak, A. F. 1997, "Sex 
Differences in the Abundance o f Endothelial Nitric Oxide in a Model of Genetic 
Hypertension", Hypertension, vol. 30, no. 6, pp. 1517-1524.
Medina, A., Bodick, N., Goldberger, A. L., Mahon, M. M., & Lipsitz, L. A. 1997, "Effects 
of Central Muscarinic-1 Receptor Stimulation on Blood Pressure Regulation", 
Hypertension, vol. 29, no. 3, pp. 828-834.
Mein, C. A., Caulfield, M. J., Dobson, R. J., & Munroe, P. B. 2004, "Genetics of essential 
hypertension", Hum.Mol.Genet, vol. 13 Spec No 1, p. R169-R175.
Merin, R. G. 1975, "Effect of anesthetics on the heart", Surg.Clin North Ain, vol. 55, no. 4, 
pp. 759-774.
Merlo, J., Asplund, K., Lynch, J., Rastam, L., & Dobson, A. 2004, "Population Effects on 
Individual Systolic Blood Pressure: A Multilevel Analysis of the World Health 
Organization MONICA ?ro]cct", American Journal o f  Epidemiology, vol. 159, no. 12, pp. 
1168-1179.
Messerli, F. H. 1983, "Clinical determinants and consequences o f left ventricular 
hypertrophy", Am J  Med, vol. 75, no. 3A, pp. 51-56.
Meyer, P. 1965, "[The renin-angiotensin system]", Pathol.Biol, vol. 13, no. 19, pp. 934- 
939.
237
Miall, W. E., Kass, E. H., Ling, J., & Stuart, E. L. 1962, "Factors influencing arterial blood 
pressures in the general population in Jamaica", BMJ, vol. 2, pp. 497-506.
Mikhail, N. & Cope, D. 2004, "The JNC-7 guidelines and the optimal target for systolic 
blood pressure", Hypertension, vol. 43, no. 5, p. e31.
Mongeau, J. G., Biron, P., & Sing, C. F. 1986, "The influence o f genetics and household 
environment upon the variability of normal blood pressure: the Montreal Adoption 
Survey", Clin Exp Hypertens A, vol. 8, no. 4-5, pp. 653-660.
Mongeau, J. G. 1989, "Heredity and blood pressure", Semin.Nephrol, vol. 9, no. 3, pp. 208- 
216.
Mori, T., Chen, Y. F., Feng, J. A., Hayashi, T., Oparil, S., & Perry, G. J. 2004, "Volume 
overload results in exaggerated cardiac hypertrophy in the atrial natriuretic peptide 
knockout mouse", Cardiovasc Res, vol. 61, no. 4, pp. 771-779.
Morrison, A. C., Cooper, R., Hunt, S., Lewis, C. E., Luke, A., Mosley, T. H., & 
Boerwinkle, E. 2004, "Genome scan for hypertension in nonobese African Americans: The 
national heart, lung, and blood institute family blood pressure program", American Journal 
o f  Hypertension, vol. 17, no. 9, pp. 834-838.
Mulatero, P., Veglio, F., Pilon, C., Rabbi a, F., Zocchi, C., Limone, P., Boscaro, M., Sonino, 
N., & Fallo, F. 1998, "Diagnosis of Glucocorticoid-Remediable Aldosteronism in Primary 
Aldosteronism: Aldosterone Response to Dexamethasone and Long Polymerase Chain 
Reaction for Chimeric Gene", Journal o f  Clinical Endocrinology Metabolism, vol. 83, no.
7, pp. 2573-2575.
Mune, T., Rogerson, F. M., Nikkila, H., Agarwal, A. K., & White, P. C. 1995, "Human 
hypertension caused by mutations in the kidney isozyme o f 11 beta-hydroxysteroid 
dehydrogenase", Nat.Genet, vol. 10, no. 4, pp. 394-399.
Nabika, T., Nara, Y., Ikeda, K., Endo, J., & Yamori, Y. 1991, "Genetic heterogeneity of the 
spontaneously hypertensive rat". Hypertension, vol. 18, no. 1, pp. 12-16.
Nabika, T., Ito, T., Kitada, K., Serikawa, T., Mashimo, T., Soubrier, F., Julier, C., Ohno,
Y., Saruta, T., Tanase, H., Masuda, J., Yamori, Y., & Nara, Y. 1997, "Comparative 
mapping o f novel simple sequence repeat markers in a hypertension-related region on rat 
chromosome 1", Mamm.Genome, vol. 8, no. 3, pp. 215-217.
Nabika, T., Kobayashi, Y., & Yamori, Y. 2000, "Congenic Rats For Hypertension: How 
Useful Are They For The Hunting Of Hypertension Genes?", Clinical and Experimental 
Pharmacology and Physiology, vol. 27, no. 4, pp. 251-256.
Nadeau, J. H. 1989, "Maps of linkage and synteny homologies between mouse and man", 
Trends Genet, vol. 5, no. 3, pp. 82-86.
238
Nagaoka, A., Iwatsuka, H., Suzuoki, Z., & Okamoto, K. 1976, "Genetic predisposition to 
stroke in spontaneously hypertensive rats", AJP - Legacy, vol. 230, no. 5, pp. 1354-1359.
Nahrendorf, M., Hiller, K.-H., Hu, K., Ertl, G., Haase, A., & Bauer, W. R. 2003, "Cardiac 
magnetic resonance imaging in small animal models of human heart failure". Medical 
Image Analysis, vol. 7, no. 3, pp. 369-375.
Nara, Y., Nabika, T., Ikeda, K., Sawamura, M., Endo, J., & Yamori, Y. 1991, "Blood 
pressure cosegregates with a microsatellite of angiotensin I converting enzyme (ACE) in F2 
generation from a cross between original normotensive Wistar-Kyoto rat (WKY) and 
stroke-prone spontaneously hypertensive rat (SHRSP)", Biochem.Biophys.Res Commun., 
vol. 181, no. 3, pp. 941-946.
Nash, W. G. & O'Brien, S. J. 1982, "Conserved regions of homologous G-banded 
chromosomes between orders in mammalian evolution: carnivores and primates", 
Proc.NatlAcad.Sci. U.S.A, vol. 79, no. 21, pp. 6631-6635.
Naveh-Many, T., Bell, O., Silver, J., & Kilav, R. 2002, "Cis and trans acting factors in the 
regulation o f parathyroid hormone (PTH) mRNA stability by calcium and phosphate", 
FEBSLett., vol. 529, no. 1, pp. 60-64.
Nunez, D. J., Clifford, C. P., al Mahdawi, S., & Dutka, D. 1996, "Hypertensive cardiac 
hypertrophy—is genetic variance the missing link?", Br.J Clin Pharmacol, vol. 42, no. 1, 
pp. 107-117.
Oakey, R. J., Watson, M. L., & Seldin, M. F. 1992, "Construction of a physical map on 
mouse and human chromosome 1: comparison of 13 Mb of mouse and 11 Mb of human 
DNA", Hum Mol Genet, vol. 1, no. 8, pp. 613-620.
Ogawa, Y., Nakao, K., Mukoyama, M., Hosoda, K., Shirakami, G., Aral, H., Saito, Y., 
Suga, S., Jougasaki, M., & Imura, H. 1991, "Natriuretic peptides as cardiac hormones in 
normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis 
and secretion of brain natriuretic peptide". Circulation Research, vol. 69, no. 2, pp. 491- 
500.
Okamoto, K. & Aoki, K. 1963, "Development of a strain of spontaneously hypertensive 
rats", Jpn.Circ J, vol. 27, pp. 282-293.
Oldham, P. D., Pickering, G., Roberts, J. A., & Sowry, G. S. 1960, "The nature of essential 
hypertension", Lancet, vol. 1, pp. 1085-1093.
Oostlander, A. E., Meijer, G. A., & Ylstra, B. 2004, "Microarray-based comparative 
genomic hybridization and its applications in human genetics". Clinical Genetics, vol. 66, 
no. 6, pp. 488-495.
Ordunez-Garcia, P. O., Espinosa-Brito, A. D., & Cooper, R. S. 1998, "Hypertension in 
Cuba: Evidence o f a narrow African-white difference", J  Hum Hypertens, vol. 12, pp. 111- 
116.
239
Park, C. W , Oh, Y. S., Shin, Y. S., Kim, C. M., Kim, Y. S., Kim, S. Y., Choi, E. J ,  Chang, 
Y, S., & Bang, B. K. 1999, "Intravenous calcitriol regresses myocardial hypertrophy in 
hemodialysis patients with secondary hyperparathyroidism", Am J  Kidney Dis, vol. 33, no.
1, pp. 73-81.
Parzy, E., Fromes, Y., Wary, C., Vignaux, O., Giacomini, E., Leroy-Willig, A., & Carlier,
P. G. 2003, "Ultrafast multiplanar determination of left ventricular hypertrophy in 
spontaneously hypertensive rats with single-shot spin-echo nuclear magnetic resonance 
imaging", J  Hypertens, vol. 21, no. 2, pp. 429-436.
Pease, A. C., Solas, D., Sullivan, E. J., Cronin, M. T., Holmes, C. P., & Fodor, S. P. 1994, 
"Light-generated oligonucleotide arrays for rapid DNA sequence analysis", 
Proc.Natl.Acad.Sci.US.A, vol. 91, no. 11, pp. 5022-5026.
Perera, G. A., Gearing, F. R., & Schweitzer, M. D. 1972, "A family study of primary 
hypertension—final report", J  Chronic Dis, vol. 25, no. 3, pp. 127-132.
Pfeffer, J. M., Pfeffer, M. A., Mirsky, L, & Braunwald, E. 1982, "Regression of left 
ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the 
spontaneously hypertensive rat", Proc.NatlAcad.Sci. U.S.A, vol. 79, no. 10, pp. 3310-3314.
Pfeuler, A., Busjahn, A., Vergopoulos, A., Knoblauch, H., Urata, H., Osterziel, K. J.,
Menz, M., Wienker, T. F., Faulhaber, H. D., & Steinmetz, A. 1998, "Chymase gene locus is 
not associated with myocardial infarction and is not linked to heart size or blood pressure", 
The American Journal o f  Cardiology, vol. 82, no. 8, pp. 979-981.
Pickering, G. 1965, "Hypertension: natural history, diagnosis, prognosis and management", 
Med Times, vol. 93, pp. 939-955.
Piepho, H. P. 2001, "A quick method for computing approximate thresholds foi- 
quantitative trait loci detection". Genetics, vol. 157, no. 1, pp. 425-432.
Pines, A., Fisman, E. Z., Shapira, I., Drory, Y., Weiss, A., Eckstein, N., Levo, Y., 
Averbuch, M., Motro, M., Rotmensch, H. H., & Ayalon, D. 1996, "Exercise 
echocardiography in postmenopausal hormone users with mild systemic hypertension". Am 
J  Cardiol, vol. 78, no. 12, pp. 1385-1389.
Poetz, O., Schwenk, J. M., Kramer, S., Stoll, D., Templin, M. F., & Joos, T. O. 2005, 
"Protein microarrays: catching the proteome". Mechanisms o f  Ageing and Development, 
vol. 126, no. 1, pp. 161-170.
Porter, K.R., Bonneville, M. A. 1973, in “An Introduction to the Fine Structure of Cells and 
Tissues”, 4th edition, Philadelphia, PA: Lea & Febiger.
Poulter, N., Khaw, K. T., Hopwood, B. E. C., Mugambi, M., Peart, W. S., & Sever, P. S. 
1984, "Salt and blood pressure in various populations", Pharmacol, vol. 6, p.
S197-S203.
240
Poulter, N. R., Khaw, K. T., & Hopwood, B. E. 1990, "The Kenyan Luo migration study: 
Observations on the initiation of a rise in blood pressure", BMJ, vol. 300, pp. 967-972.
Prabhakar, R., Boivin, G. P., Grupp, I. L., Ho it, B., Arteaga, G., Solaro, J. R., &
Wieczorek, D. F. 2001, "A familial hypertrophie cardiomyopathy alpha-tropomyosin 
mutation causes severe cardiac hypertrophy and death in mice", J  Mol Cell Cardiol, vol. 
33, no. 10, pp. 1815-1828.
Prakash, E. S., Madanmohan, & Pal, G. K. 2004, "What is the ultimate goal in neural 
regulation of cardiovascular ïunetÀonT', Advances in Physiology Education, vol. 28, no. 3,
pp. 100-101.
Pravenec, M., Gauguier, D., Schott, J. J., Buard, J., Kren, V., Bila, V., Szpirer, C., Szpirer, 
J., Wang, J. M., Huang, H., & . 1995, "Mapping of quantitative trait loci for blood pressure 
and cardiac mass in the rat by genome scanning o f recombinant inbred strains", J  Clin 
Invest, vol. 96, no. 4, pp. 1973-1978.
Pravenec, M., Gauguier, D., Schott, J. J., Buard, J., Kren, V., Bila, V., Szpirer, C., Szpirer, 
J., Wang, J. M., Huang, H., St Lezin, E., Spence, M. A., Flodman, P., Printz, M., Lathrop, 
G. M., Vergnaud, G., & Kurtz, T. W. 1996, "A genetic linkage map o f the rat derived from 
recombinant inbred strains", Mamm.Genome, vol. 7, no. 2, pp. 117-127.
Pravenec, M., Zidek, V., Simakova, M., Kren, V., Krenova, D., Horky, K., Jachymova, M., 
Mikova, B., Kazdova, L., Aitman, T. J., Churchill, P. C., Webb, R. C., Hingarh, N. H., 
Yang, Y., Wang, J. M., Lezin, E. M., & Kurtz, T. W. 1999, "Genetics of Cd36 and the 
clustering o f multiple cardiovascular risk factors in spontaneous hypertension", J  C/m 
Invest, vol. 103, no. 12, pp. 1651-1657.
Pripp, U., Hall, G., Csemiczky, G., Eksborg, S., Landgren, B. M., & Schenck-Gustafsson, 
K. 1999, "A randomized trial on effects of hormone therapy on ambulatory blood pressure 
and lipoprotein levels in women with coronary artery disease", J  Hypertens, vol. 17, no. 10, 
pp. 1379-1386.
Raj an, S., Williams, S. S., Jagatheesan, G., Ahmed, R. P., Fuller-Bicer, G., Schwartz, A., 
Aronow, B. J., & Wieczorek, D. F. 2006, "Micrarray analysis of gene expression during 
early stages o f mild and severe cardiac hypertrophy", Physiological Genomics, vol. 26, 
no.3, pp. 72-102.
Rapp, J. P. 1983, "A paradigm for identification of primary genetic causes of hypertension 
in rats", Hypertension, vol. 5, no. 2 Pt 2, p. 1198-1203.
Rapp, J. P. 1991, "Dissecting the primary causes of genetic hypertension in rats". 
Hypertension, vol. 18, no. 3 Suppl, p. 118-128.
Rapp, J. P., Garrett, M. R., & Deng, A. Y. 1998, "Construction of a double congenic strain 
to prove an epistatic interaction on blood pressure between rat chromosomes 2 and 10", J  
Clin Invest, vol. 101, no. 8, pp. 1591-1595.
241
Rapp, J. P. 2000, "Genetic Analysis of Inherited Hypertension in the Rat", Physiological 
Reviews, vol. 80, no. 1, pp. 135-172.
Ray, K., Wang, X. K., Zhao, M., & Cooke, N. E. 1991, "The rat vitamin D binding protein 
(Gc-globulin) gene. Structural analysis, functional and evolutionary correlations",
Chem., vol. 266, no. 10, pp. 6221-6229.
Reckelhoff, J. P., Zhang, H., & Granger, J. P. 1998, "Testosterone exacerbates hypertension 
and reduces pressure-natriuresis in male spontaneously hypertensive rats", Hypertension, 
vol. 31, no. 1 Pt 2, pp. 435-439.
Reckelhoff, J. F., Zhang, H., Srivastava, K., & Granger, J. P. 1999, "Gender differences in 
hypertension in spontaneously hypertensive rats: role of androgens and androgen receptor". 
Hypertension, vol. 34, no. 4 Pt 2, pp. 920-923.
Reckelhoff, J. F., Zhang, H., & Srivastava, K. 2000, "Gender differences in development of 
hypertension in spontaneously hypertensive rats: role of the renin-angiotensin system", 
Hypertension, vol. 35, no. 1 Pt 2, pp. 480-483.
Reckelhoff, J. F. 2001, "Gender Differences in the Regulation of Blood Pressure", 
Hypertension, vol. 37, no. 5, pp. 1199-1208.
Reddy, K. S. 2004, "Cardiovascular disease in non-Western countries", N .E nglJ Med, vol. 
350, no. 24, pp. 2438-2440.
Rodriguez, C. J., Sciacca, R. R., Diez-Roux, A. V., Boden-Albala, B., Sacco, R. L., 
Homma, S., & DiTullio, M. R. 2004, "Relation between socioeconomic status, race- 
ethnicity, and left ventricular mass: the Northern Manhattan study". Hypertension, vol. 43, 
no. 4, pp. 775-779.
Rosengren, A., Hawken, S., Ounpuu, S., Sliwa, K., Zubaid, M., Almahmeed, W. A., 
Blackett, K. N., Sitthi-amorn, C., Sato, H., Yusuf, S., & INTERHEART, i. 2004, 
"Association o f psychosocial risk factors with risk of acute myocardial infarction in 11119 
cases and 13648 controls from 52 countries (the INTERHEART study): case-control 
study", Lancet, vol. 364, no. 9438, pp. 953-962.
Rubattu, S. & Volpe, M. 2001, "The atrial natriuretic peptide: a changing view", J  
Hypertens, vol. 19, no. 11, pp. 1923-1931.
Rushmer, R. F. 1955, "Initial Phase of Ventricular Systole: Asynchronous Contraction", 
AJP  - Legacy, vol. 184, no. 1, pp. 188-194.
Rysa, J., Leskinen, H., lives, M., & Ruskoaho, H. 2005, "Distinct upregulation of 
extracellular matrix genes in transition from hypertrophy to hypertensive heart failure", 
Hypertension, vol. 45, no. 5, pp. 927-933.
Saeed, M., Watzinger, N., Krombach, G. A., Lund, G. K., Wend land, M. F., Chujo, M., & 
Higgins, C. B. 2002, "Left Ventricular Remodeling after Infarction: Sequential MR
242
Imaging with Oral Nicorandil Therapy in Rat Model", Radiology, vol. 224, no. 3, pp. 830- 
837.
Sagnella, G. A. 1998, "Measurement and significance of circulating natriuretic peptides in 
cardiovascular disease", Clin Sci.(Lond), vol. 95, no. 5, pp. 519-529.
Sahn, D. J., DeMaria, A., Kisslo, J., & Weyman, A. 1978, "Recommendations regarding 
quantitation in M-mode echocardiography: results of a survey o f echocardiographic 
measurements", Circulation, vol. 58, no. 6, pp. 1072-1083
Samani, N. J., Swales, J. D., Jeffreys, A. J., Morton, D. B., Naftilan, A. J., Lindpaintner, K., 
Ganten, D., & Brammar, W. J. 1989, "DNA fingerprinting of spontaneously hypertensive 
and Wistar-Kyoto rats: implications for hypertension research", J  Hypertens, vol. 7, no. 10, 
pp. 809-816.
Samani, N. J. 2003, "Genome scans for hypertension and blood pressure regulation", 
American Journal o f  Hypertension, vol. 16, no. 2, pp. 167-171.
Sawyer, J. R. & Hozier, J. C. 1986, "High resolution of mouse chromosomes: banding 
conservation between man and mouse", Science, vol. 232, no. 4758, pp. 1632-1635.
Schalla, S., Higgins, C. B., Chujo, M., & Saeed, M. 2004, "Effect of potassium-channel 
opener therapy on reperfused infarction in hypertrophied hearts: demonstration of 
preconditioning by using functional and contrast-enhanced magnetic resonance imaging", J  
Cardiovasc Pharmacol Ther. , vol. 9, no. 3, pp. 193-202
Schena, M., Shalon, D., Davis, R. W., & Brown, P. O. 1995, "Quantitative monitoring of 
gene expression patterns with a complementary DNA microarray", Science, vol. 270, no. 
5235, pp. 467-470.
Schena, M. 1996, "Genome analysis with gene expression microarrays". Bioessays, vol. 18, 
no. 5, pp. 427-431.
Scherthan, H., Seisenberger, C., Greulich, K., & Winnacker, E. L. 1994, "Mapping of the 
murine nuclear factor I/X gene (Nfix) to mouse chromosome 8 C l-2 by FISH", Genomics, 
vol. 22, no. 1, pp. 247-249.
Schiekofer, S., Shiojima, I., Sato, K., Galasso, G., Oshima, Y., & Walsh, K. 2006, 
"Microarray analysis of Aktl activation in transgenic mouse hearts reveal transcript 
expression profiles associated with compensatory hypertrophy and failure", Physiological 
Genomics, vol. 26, no.3, pp. 234-297.
Schillaci, G., Verdecchia, P., Borgioni, C., Ciucci, A., & Porcellati, C. 1998, "Early cardiac 
changes after menopause". Hypertension, vol. 32, no. 4, pp. 764-769.
Schillaci, G., Verdecchia, P., Porcellati, C., Cuccurullo, O., Cosco, C., & Perticone, F. 
2000, "Continuous relation between left ventricular mass and cardiovascular risk in 
essential hypertension", Hypertension, vol. 35, no. 2, pp. 580-586.
243
Schlieper, G., Kim, J. H., Molojavyi, A., Jacoby, C., Laussmann, T., Flogel, U., Godecke, 
A., & Schrader, J. 2004, "Adaptation of the myoglobin knockout mouse to hypoxic stress", 
AJP  - Regulatojy, Integrative and Comparative Physiology, vol. 286, no. 4, p. R786-R792.
Schluter, K. D., Weber, M., & Piper, H. M. 1995, "Parathyroid hormone induces protein 
kinase C but not adenylate cyclase in adult cardiomyocytes and regulates cyclic AMP 
levels via protein kinase C-dependent phosphodiesterase activity", BiochemJ, vol. 310 ( Pt 
2), pp. 439-444.
Schork, N. J. 1997, "Genetics of complex disease: approaches, problems, and solutions".
Am JRespir.Crit Care Med, vol. 156, no. 4 Pt 2, p. S103-S109.
Schwartzkopff, B. & Strauer, B. E. 2000, "Coronary reserve and aiteriolosclerosis in 
hypertensive heart disease", Z.Kardiol , vol. 89 Suppl 9, p. IX/132-IX/135.
Sebkhi, A., Zhao, L., Lu, L., Flaley, C. S., Nunez, D. J., & Wilkins, M. R. 1999, "Genetic 
determination of cardiac mass in normotensive rats: results from an F344xWKY cross". 
Hypertension, vol. 33, no. 4, pp. 949-953.
Senbonmatsu, T., Ichihara, S., Price E Jr, Gaffney, F. A., & Inagami, T. 2000, "Evidence 
for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo 
pressure overload", Y C/m Invest, vol. 106, no. 3, p. R25-R29.
Sharma, P., Middelberg, R. P., Andrew, T., Johnson, M. R., Christley, H., & Brown, M. J. 
2006, "Heritability of left ventricular mass in a large cohort of twins", J  Hypertens, vol. 24, 
no. 2, pp. 321-324.
Sharma, U. C., Pokharel, S., Evelo, C. T. A., & Maessen, J. G. 2005, "A systematic review 
of large scale and heterogeneous gene array data in heart failure", Journal o f  Molecular and 
Cellular Cardiology, vol. 38, no. 3, pp. 425-432.
Shen, R., Fan, J. B., Campbell, D., Chang, W., Chen, J., Doucet, D., Yeakley, J., Bibikova, 
M., Wickham, G. E., McBride, C., Steemers, F., Garcia, F., Kermani, B. G., Gunderson, K., 
& Oliphant, A. 2005, "High-throughput SNP genotyping on universal bead arrays", 
Mutat.Res, vol. 573, no. 1-2, pp. 70-82.
Shimkets, R. A., Warnock, D. G., Bositis, C. M., Nelson-Williams, C., Hansson, J. H., 
Schambelan, M., Gill, J. R., Jr., Ulick, S., Mil ora, R. V., Findling, J. W., & . 1994,
"Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit 
of the epithelial sodium channel". Cell, vol. 79, no. 3, pp. 407-414.
Shoji, T., Shinohara, K., Kimoto, E., Emoto, M., Tahara, H., Koyama, H., Inaba, M., 
Fukumoto, S., Ishimura, E., Miki, T., Tabata, T., & Nishizawa, Y. 2004, "Lower risk for 
cardiovascular mortality in oral 1 alpha-hydroxy vitamin D3 users in a haemodialysis 
population", Nephrol Dial.Transplant., vol. 19, no. 1, pp. 179-184.
Silva, J. A., Jr., Araujo, R. C., Baltatu, O., Oliveira, S. M., Tschope, C., Fink, E.,
Hoffmann, S., Plehm, R., Chai, K. X., Chao, L., Chao, J., Ganten, D., Pesquero, J. B., &
244
Bader, M. 2000, "Reduced cardiac hypertrophy and altered blood pressure control in 
transgenic rats with the human tissue kallikrein gene", FASEB J, vol. 14, no. 13, pp. 1858- 
1860.
Siri, F. M., Jelicks, L. A., Leinwand, L. A., & Gardin, J. M. 1997, "Gated magnetic 
resonance imaging of normal and hypertrophied murine hearts". Am J  Physiol, vol. I l l ,  no.
5 Pt 2, p. H2394-FI2402.
Slama, M., Ahn, J., Peltier, M., Maizel, J., Chem la, D., Varagic, J., Susie, D., Tribouilioy, 
C., & Frohlich, E. D. 2005, "Validation of echocardiographic and Doppler indexes of left 
ventricular relaxation in adult hypertensive and normotensive rats", AJP  - Heart and 
Circulatory Physiology, vol. 289, no. 3, p. HI 131-Hl 136.
Snieder, H., Hayward, C. S., Perks, U., Kelly, R. P., Kelly, P. J., & Spector, T. D. 2000, 
"Heritability o f Central Systolic Pressure Augmentation : A Twin Study", Hypertension, 
vol. 35, no. 2, pp. 574-579.
Sola, S., White, R. D., & Desai, M. 2006, "MRI of the heart: promises fulfilled?",
Cleve.Clin J  Med, vol. 73, no. 7, pp. 663-670.
Somsen, R. J. M., Jennings, J. R., & Van der Molen, M. W. 2004, "The cardiac cycle time 
effect revisited: Temporal dynamics of the central-vagal modulation of heart rate in human 
reaction time tasks". Psychophysiology, vol. 41, no. 6, pp. 941-953.
Souzeau, E., Llamas, B., Belanger, S., Picard, S., & Deschepper, C. F. 2006, "A genetic 
locus accentuates the effect of volume overload on adverse left ventricular remodeling in 
male and female rats", Hypertension, vol. 47, no. 1, pp. 128-133.
Staessen, J., Bulpitt, C. J., Fagard, R., Lijnen, P., & Amery, A. 1989, "The influence of 
menopause on blood pressure", J  Hum Hypertens, vol. 3, no. 6, pp. 427-433.
Stewart, P. M., Krozowski, Z. S., Gupta, A., Milford, D. V., Howie, A. J., Sheppard, M. C.,
6  Whorwood, C. B. 1996, "Hypertension in the syndrome of apparent mineralocorticoid 
excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene", Lancet, 
vol. 347, no. 8994, pp. 88-91.
Stober, T., Sen, S., Anstatt, T., Freier, G., & Schimrigk, K. 1985, "Direct evidence of 
hypertension and the possible role of post-menopause oestrogen deficiency in the 
pathogenesis of berry aneurysms", J  Neurol, vol. 232, no. 2, pp. 67-72.
Stoll, M., Kwitek-Black, A. E., Cowley, A. W., Jr., Harris, E. L., Harrap, S. B., Krieger, J. 
E., Printz, M. P., Provoost, A. P., Sassard, J., & Jacob, H. J. 2000, "New target regions for 
human hypertension via comparative genomics". Genome Res, vol. 10, no. 4, pp. 473-482.
Stubbs, L., Rinchik, E. M., Goldberg, E., Rudy, B., Handel, M. A., & Johnson, D. 1994, 
"Clustering of six human 1 Ip 15 gene homologs within a 500-kb interval of proximal mouse 
chromosome 7", Genomics, vol. 24, no. 2, pp. 324-332.
245
Sugino, H., Ozono, R., Kurisu, S., Matsuura, H., Ishida, M., Oshima, T., Kambe, M., 
Teranishi, Y., Masaki, H., & Matsubara, H. 2001, "Apoptosis is not increased in 
myocardium overexpressing type 2 angiotensin II receptor in transgenic mice". 
Hypertension, vol. 37, no. 6, pp. 1394-1398.
Sutherland, D. J., Ruse, J. L., & Laidlaw, J. C. 1966, "Hypertension, increased aldosterone 
secretion and low plasma renin activity relieved by dexamethasone", Can.Med Assoc J ,  vol. 
95, no. 22, pp. 1109-1119.
Sutton, A. L. M. & MacDonald, P. N. 2003, "Vitamin D: More Than a "Bone-a-Fide" 
Hormone", Molecular Endocrinology, vol. 17, no. 5, pp. 777-791.
Swales, J. D. 1994, "Guidelines for treating hypertension: improved care or retarded 
progress?". Am J  Hypertens, vol. 7, no. 10 Pt 1, pp. 873-876.
Swan, G. E. & Carmelli, D. 2002, "Evidence for genetic mediation of executive control: a 
study of aging male tWms", J  Gerontol.B Psychol.Sci.Soc Sci., vol. 57, no. 2, pp. 133-143.
Swan, L., Birnie, D. H., Padmanabhan, S., Inglis, G., Connell, J. M. C., & Hillis, W. S. 
2003, "The genetic determination o f left ventricular mass in healthy adults", European 
Heart Journal, vol. 24, no. 6, pp. 577-582.
Takahashi, N. O. B. U. & Smithies, O. L. I. V. 1999, "Gene Targeting Approaches to 
Analyzing Hypertension", Journal o f  the American Society o f  Nephrology, vol. 10, no. 7, 
pp. 1598-1605.
Takahashi, N., Hagaman, J. R., Kim, H. S., & Smithies, O. 2003, "Minireview: Computer 
Simulations o f Blood Pressure Regulation by the Renin-Angiotensin System", 
Endocrinology, vol. 144, no. 6, pp. 2184-2190.
Tanase, H., Yamori, Y., Hansen, C. T., & Lovenberg, W. 1982, "Heart size in inbred strains 
of rats. Part 2. Cardiovascular DNA and RNA contents during the development of cardiac 
enlargement in rats", Hypertension, vol. 4, no. 6, pp. 872-880.
Teng, M., Wolf, M., Ofsthun, M. N., Lazarus, J. M., Hernan, M. A., Camargo, C. A., Jr., & 
Thadhani, R. 2005, "Activated injectable vitamin D and hemodialysis survival: a historical 
cohort study". Journal o f  the American Society o f  Nephrology, vol. 16, no. 4, pp. 1115- 
1125.
The chipping forecast. 1999, Nat Genet, vol. 21, no. 1, pp 1-60.
Thierfelder, L., Watkins, H., MacRae, C., Lamas, R., McKenna, W., Vosberg, H. P., 
Seidman, J. G., & Seidman, C. E. 1994, "Alpha-tropomyosin and cardiac troponin T 
mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere", Cell, 
vol. 77, no. 5, pp. 701-712.
Thierry-Paimer, M., Doherty, A., Bayorh, M. A., & Griffin, K. 2003, "Dahl salt-sensitive 
rats excrete 25-hydroxyvitamin D into urine", JNutr., vol. 133, no. 1, pp. 187-190.
246
Tingleff, J., Munch, M., Jakobsen, T. J., Torp-Pedersen, C., Olsen, M. E., Jensen, K. H., 
Jorgensen, T., & Kirchoff, M. 1996, "Prevalence of left ventricular hypertrophy in a 
hypertensive population", European Heart Journal, vol. 17, no. 1, pp. 143-149.
Toka, IT. R., Bahring, S., Chitayat, D., Melby, J. C., Whitehead, R., Jeschke, E., Wienker,
T. F., Toka, O., Schuster, H., & Luft, F. C. 1998, "Families with Autosomal Dominant 
Brachydactyly Type E, Short Stature, and Severe Hypertension", Annals o f  Internal 
Medicine, vol. 129, no. 3, pp. 204-208.
Tomson, J. & Lip, G. 2005, "Blood pressure demographics: nature or nurture genes or
environment?", BMC Medicine, vol. 3, no. 1, p. 3.
Tran, K. L., Lu, X., Lei, M., Feng, Q., & Wu, Q. 2004, "Upregulation of corin gene 
expression in hypertrophic cardiomyocytes and failing myocardium", AJP  - Heart and 
Circulatory Physiology, vol. 287, no. 4, p. H1625-H1631.
Troy, B. L., Pombo, J., & Rackley, C. E. 1972, "Measurement of left ventricular wall 
thickness and mass by echocardiography", Circulation, vol. 45, no. 3, pp. 602-611.
Tsujita, Y., Iwai, N., Tamaki, S., Nakamura, Y., Nishimura, M., & Kinoshita, M. 2000, 
"Genetic mapping of quantitative trait loci influencing left ventricular mass in rats",XJP - 
Heart and Circulatory Physiology, vol. 279, no. 5, p. H2062-H2067.
Tusher, V. G., Tibshirani, R., & Chu, G. 2001, "Significance analysis of microarrays 
applied to the ionizing radiation response", Proc.NatlAcad.Sci. U.S.A, vol. 98, no. 9, pp. 
5116-5121.
Ulick, S., Tedde, R., & Mantero, F. 1990, "Pathogenesis of the type 2 variant of the 
syndrome o f apparent mineralocorticoid excess". Journal o f  Clinical Endocrinology 
Metabolism, vol. 70, no. 1, pp. 200-206.
Urbina, E. M., Gidding, S. S., Bao, W., Pickoff, A. S., Berdusis, K., & Berenson, G. S. 
1995, "Effect of Body Size, Ponderosity, and Blood Pressure on Left Ventricular Growth in 
Children and Young Adults in the Bogalusa Heart Study", Circulation, vol. 91, no. 9, pp. 
2400-2406.
Van Vliet, B. N., Chafe, L. L., Antic, V., Schnyder-Candrian, S., & Montani, J. P. 2000, 
"Direct and indirect methods used to study arterial blood pressure", Journal o f  
Pharmacological and Toxicological Methods, vol. 44, no. 2, pp. 361-373.
Verhaaren, H. A., Schieken, R. M., Mosteller, M., Hewitt, J. K., Eaves, L. J., & Nance, W. 
E. 1991, "Bivariate genetic analysis of left ventricular mass and weight in pubertal twins 
(the Medical College o f Virginia twin study)". Am J  Cardiol, vol. 68, no. 6, pp. 661-668.
Vincent, M., Kaiser, M. A., Orea, V., Lodwick, D., & Samani, N. J. 1994, "Hypertension in 
the spontaneously hypertensive rat and the sex chromosomes". Hypertension, vol. 23, no. 2,
pp. 161-166.
247
Visscher, P. M., Thompson, R., & Haley, C. S. 1996, "Confidence intervals in QTL 
mapping by bootstrapping". Genetics, vol. 143, no. 2, pp. 1013-1020.
Wakeland, E., Morel, L., Achey, K., Yui, M., & Longmate, J. 1997, "Speed congenics: a 
classic technique in the fast lane (relatively speaking)", Immunol. Today, vol. 18, no. 10, pp. 
472-477.
Walker, R., Kessar, P., Blanchard, R., Dimasi, M., Harper, K., DeCarvalho, V., Yucel, E.
K., Patriquin, L., & Eustace, S. 2000, "Turbo STIR magnetic resonance imaging as a 
whole-body screening tool for métastasés in patients with breast carcinoma: preliminary 
clinical experience", J  Magn Reson.Imaging, vol. 11, no. 4, pp. 343-350.
Wallace, C. A., Ali, S., Glazier, A. M., Norswoithy, P. J., Carlos, D. C., Scott, J., Freeman, 
T. C., Stanton, L. W., Kwitek, A. E., & Aitman, T. J. 2002, "Radiation hybrid mapping of 
70 rat genes from a data set of differentially expressed genes", Mamm.Genome, vol. 13, no. 
4, pp. 194-197.
Wang, D. G., Fan, J. B., Siao, C. J., Berno, A., Young, P., Sapolsky, R., Ghandour, G., 
Perkins, N., Winchester, E., Spencer, J., Kruglyak, L., Stein, L., Hsie, L., Topaloglou, T., 
Hubbell, E., Robinson, E., Mittmann, M., Morris, M. S., Shen, N., Kilburn, D., Rioux, J., 
Nusbaum, C., Rozen, S., Hudson, T. J., Lipshutz, R., Chee, M., & Lander, E. S. 1998, 
"Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms 
in the human genome". Science, vol. 280, no. 5366, pp. 1077-1082.
Ward, R. H. 1983, "Genetic and sociocultural components of high blood pressure". Am J  
Phys.Anthropol, vol. 62, no. 1, pp. 91-105.
Warden, C. H., Yi, N., & Fisler, J. 2004, "Epistasis among genes is a universal 
phenomenon in obesity:: evidence from rodent models", Nutrition, vol. 20, no. 1, pp. 74-77.
Watkins, H., Thierfelder, L., Anan, R., Jarcho, J., Matsumori, A., McKenna, W., Seidman, 
J. G., & Seidman, C. E. 1993, "Independent origin of identical beta cardiac myosin heavy- 
chain mutations in hypertrophic cardiomyopathy", Am J  Hum Genet, vol. 53, no. 6, pp. 
1180-1185.
Watkins, H., Conner, D., Thierfelder, L., Jarcho, J. A., MacRae, C., McKenna, W. J., 
Maron, B. J., Seidman, J. G., & Seidman, C. E. 1995, "Mutations in the cardiac myosin 
binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy", 
Nat.Genet, vol. 11, no. 4, pp. 434-437.
Watson, A., Mazumder, A., Stewart, M., & Balasubramanian, S. 1998, "Technology for 
microarray analysis o f gene expression", Curr Opin.Biotechnol, vol. 9, no. 6, pp. 609-614.
Watzinger, N., Maier, R., Reiter, U., Reiter, G., Fuernau, G., Wonisch, M., Fruhwald, F.
M., Schumacher, M., Zweiker, R., Rienmueller, R., & Klein, W. 2005, "Clinical 
applications of cardiovascular magnetic resonance", Curr Pharm Des, vol. 11, no. 4, pp. 
457-475.
248
Weinberger, M, H. 1996, "Sait sensitivity of blood pressure in humans". Hypertension, vol. 
27, no. 3 Pt 2, pp. 481-490.
Weiner, C. P., Knowles, R. G., Nelson, S. E., & Stegink, L. D. 1994, "Pregnancy increases 
guanosine 3',5'-monophosphate in the myometrium independent o f nitric oxide synthesis". 
Endocrinology, vol. 135, no. 6, pp. 2473-2478.
White, P. C. 1994, "Disorders of aldosterone biosynthesis and action", N .E nglJ Med, vol.
331.110. 4, pp. 250-258.
Wienberg, J. & Stanyon, R. 1995, "Chromosome painting in mammals as an approach to 
comparative genomics", Curr Opin.Genet Dev., vol. 5, no. 6, pp. 792-797.
Willaims, B., Poulter, N. R., Brown, M. J., Davis, M., Mclnnes, G. T., Potter, J. F., Sever,
P. S., McG Thom, S., & British Hypertension Society 2004, "Guidelines for management 
of hypertension: report o f the fourth working party of the British Hypertension Society, 
2004-BHS IV", J  Hum Hypertens, vol. 18, no. 3, pp. 139-185.
Wilson, T. W. & Grim, C. E. 1991, "Biohistory of slavery and blood pressure differences in 
blacks today. A hypothesis". Hypertension, vol. 17, no. suppl I, p. I.
Wise, R. G., Huang, C. L., Gresham, G. A., Al Shafei, A. I., Carpenter, T. A., & Hall, L. D. 
1998, "Magnetic resonance imaging analysis of left ventricular function in normal and 
spontaneously hypertensive rats", J  Physiol, vol. 513 ( Pt 3), pp. 873-887.
Wise, R. G., Huang, C. L., Al Shafei, A. I., Carpenter, T. A., & Hall, L. D. 1999, 
"Geometrical models of left ventricular contraction from MRI o f the normal and 
spontaneously hypertensive rat heart", Phys.Med Biol, vol. 44, no. 10, pp. 2657-2676.
Woodman, S. E., Park, D. S., Cohen, A. W., Cheung, M. W., Chandra, M., Shirani, J.,
Tang, B., Jelicks, L. A., Kitsis, R. N., Christ, G. J., Factor, S. M., Tanowitz, H. B., & 
Lisanti, M. P. 2002, "Caveolin-3 knock-out mice develop a progressive cardiomyopathy 
and show hyperactivation of the p42/44 MAPK cascade", J  Biol Chem., vol. 277, no. 41, 
pp. 38988-38997.
Wu, F. & Wu, Q. 2003, "Corin-mediated processing of pro-atrial natriuretic peptide in 
human small cell lung cancer cells". Cancer Res, vol. 63, no. 23, pp. 8318-8322.
Xiang, W., Kong, J., Chen, S., Cao, L. P., Qiao, G., Zheng, W., Liu, W., Li, X., Gardner, D. 
G., & Li, Y. C. 2005, "Cardiac hypertrophy in vitamin D receptor knockout mice: role of 
the systemic and cardiac renin-angiotensin systems", rt/M J  Physiol Endocrinol Metab, vol.
288 . 110. l,p .E 125-E132.
Yamori, Y., Tomimoto, K., Ooshima, A., Hazama, F., & Okamoto, K. 1974, "Proceedings: 
Developmental course of hypertension in the SHR-substrains susceptible to hypertensive 
cerebrovascular lesions", Jpn.Heart J, vol. 15, no. 2, pp. 209-210.
249
Yamori, Y., Horie, R., Sato, M., & Ohta, K. 1976, "Proceedings: Prophylactic trials for 
stroke in stroke-prone SHR: effect o f sex hormones", Jpn.Heart J, vol. 17, no. 3, pp. 404- 
406.
Yamori, Y., Nara, Y., Kihara, M. Horie, R. & Ooshima, A. 1981, “Sodium and other 
dietary factors in exerimenta! and human hypertension: the Japanese experience”, in 
Frontiers in Hypertension Research, eds. Laragh, J.H., Buhler, F.R. & Seldin, D.W. pp46- 
48. New York: Springer-Verlag.
Yamori, Y. & Lovenberg, W. 1987, “Spontaneously hypertensive rats”, Hypertension, vol 
9 (Suppl I), I-13-I-14.
Yamori, Y., Fukuda, S., Tsuchikura, S., Ikeda, K., Nara, Y., & Horie, R. 1991, "Stroke- 
prone SHR (SHRSP) as a model for osteoporosis", Clin Exp Hypertens A, vol. 13, no. 5, pp. 
755-762.
Yamori, Y & Swales, J.D. 1994, “The spontaneously hypertensive rat”, in Textbook o f  
Hypertension, ed. Swales, J.D. Ch.l.pp447-455. Oxford: Blackwell.
Yamori, Y. 1999, "Implication of hypertensive rat models for primordial nutritional 
prevention of cardiovascular diseases". Clinical and Experimental Pharmacology and 
Physiology, vol. 26, no. 7, pp. 568-572.
Yan, W., Wu, F., Morser, J., & Wu, Q. 2000, "Corin, a transmembrane cardiac serine 
protease, acts as a pro-atrial natriuretic peptide-converting enzyme", 
Proc.Natl.Acad.Sci.U.S.A, vol. 97, no. 15, pp. 8525-8529.
Ye, P. & West, M. J. 2003, "Cosegregation analysis of natriuretic peptide genes and blood 
pressure in the spontaneously hypertensive rat", Clinical and Experimental Pharmacology 
and Physiology, vol. 30, no. 12, pp. 930-936.
Yoshioka, J., Prince, R. N., Huang, H., Perkins, S. B., Cruz, F. U., MacGillivray, C., 
Lauffenburger, D. A., & Lee, R. T. 2005, "Cardiomyocyte hypertrophy and degradation of 
connexin43 through spatially restricted autocrine/paracrine heparin-binding EGF", 
Proc.Natl.Acad.Sci.U.S.A, vol. 102, no. 30, pp. 10622-10627.
Young, J. H., Parler, P., Bristol, B., & Klag, M. J. "The coming epidemic: hypertension in 
rural Kyrgyzstan, Central Asia", J  Hum Hypertens.
Yu, H., Harrap, S. B., & Di Nicolantonio, R. 1998, "Cosegregation of spontaneously 
hypertensive rat renin gene with elevated blood pressure in an F2 generation", J  Hypertens, 
vol. 16, no. 8, pp. 1141-1147.
Yuen, P. K., Li, G., Bao, Y., & Muller, U. R. 2003, "Microfluidic devices for fluidic 
circulation and mixing improve hybridization signal intensity on DNA arrays". Lab Chip., 
vol. 3, no. 1, pp. 46-50.
250
Zaman, M. A., Oparil, S., & Calhoun, D. A. 2002, "Drugs targeting the renin-angiotensin- 
aldosterone system", Nat.Rev.Drug Discov., vol. 1, no. 8, pp. 621-636.
Zeng, Z. B. 1994, "Precision mapping of quantitative trait loci", Genetics, vol. 136, no. 4, 
pp. 1457-1468.
Zhang, L., Summers, K. M., & West, M. J. 1996, "Cosegregation of genes on chromosome 
5 with heart weight and blood pressure in genetic hypertension", Clin Exp Hypertens, vol. 
18, no. 8, pp. 1073-1087.
Zhang, Q. Y., Dene, H., Deng, A. Y., Garrett, M. R., Jacob, H. J., & Rapp, J. P. 1997, 
"Interval mapping and congenic strains for a blood pressure QTL on rat chromosome 13", 
Mamm.Genome, vol. 8, no. 9, pp. 636-641.
Zittermann, A., Schleithoff, S. S., & Koerfer, R. 2007, "Vitamin D and vascular 
calcification", Curr Opin.Lipidol, vol. 18, no. 1, pp. 41-46.
Zhou, R., Pickup, S., Glickson, J. D., Scott, C. H., & Ferrari, V. A. 2003, "Assessment of 
global and regional myocardial function in the mouse using cine and tagged MRI", Magn 
Reson.Med, vol. 49, no. 4, pp. 760-764.
Zhou, C., Ziegler, C., Birder, L. A., Stewart, A. F., & Levitan, E. S. 2006, "Angiotensin II 
and stretch activate NADPH oxidase to destabilize cardiac Kv4.3 channel mRNA", 
Circulation Research, vol. 98, no. 8, pp. 1040-1047.
251
APPENDIX I
Suppliers of all the chemicals and reagents used
Chemical Reagents Suppliers
Absolute Ethanol 
Advantage RT for PCR kit 
Agarose
Antibody (goat), Anti-streptavidin, 
biotinylated
Antibody, IgG, Goat, reagent grade 
Ammonium Acetate, 7.5M 
Ammonium persulphate 
Blue dextran
Bovine Serum Albumin (BSA) 
Bromophenol blue 
Buffer tablets 
Cellulose patches 
Chloroform
Concentrated hydrochloric acid 
Cresol Red 
Decon 75
dNTPs/deoxynucleoside triphosphates
ddNTPs/dideoxynucleoside triphosphates
DNA, Herring Sperm
Dimethyl sulfoxide
EDTA
Ethanol
Ethidium bromide 
Formamide
GENESCAN-350 Tamra
Sigma
Clontech Laboratories Inc. 
Gibco BRL 
Vector Laboratories
Sigma
Sigma
BDH
Perkin-Elmer 
Gibco BRL 
Sigma 
BDH
Data Sciences Int.
Fisher Scientific
BDH
Sigma
Decon Laboratories Ltd.
Pro mega
Perkin-Elmer
Promega
Sigma
Bio-Rad
Sigma
Sigma
BDH
Perkin-Elmer
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Chemical Reagents Suppliers
Ambion
Sigma
Zeneca Ltd.
Qiagen
Amersham
Vetapharma
BDH
Glycogen
Goat IgG, Reagent Grade 
Halothane
HotStartTaq DNA polymerase 
Hybond-N+ membrane 
Hypnorm©
Isoamylalcohol
1OX kinase buffer 
Long Ranger 5% stock gel solution 
Magnesium chloride/MgC12 
Magnesium acetate 
Megascript T7 Kit
MES free acid monohydrate SigmaUltra 
MES sodium salt 
Metaphor agarose 
NaCl
Nucleotides, labeled, Biotin-11-CTP/UTP Sigma 
[a-^^P]dCTP Amersham
[a-^^P]dATP Amersham
1 OX PGR buffer Qiagen
Oligo B2, control oligo for anti sense probe MWG Biotech 
array, HPLC purified 
PBS, pH 7.2
Phenol/chloroform/isoamyl alcohol 
Phenol, water-saturated in Tris buffer 
Phycoerythrin-streptavidin 
Powered milk 
Polyoxyethylene 
Primers (including T7-(dT)24)
Ready Reaction mix
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Promega
Bio Whittaker
Promega
Sigma
Ambion
Sigma
Sigma
FMC
Ambion
Gibco BRL 
Ambion 
Life Sciences 
Molecular Probes 
Premier Beverages 
Life Technologies 
MWG Biotech 
Perkin-Elmer
Chemical Reagents Suppliers
Resin AG 501-X8 
RNase solution 
RNeasy Maxi kit 
0.9% Saline 
20X SSC
SDS (sodium dodecyl sulphate) powder
Sigmacote
Sodium acetate
Sodium chloride
Sodium hydroxide pellets
Sodium hypochlorite
SSPE (20X)
Sucrose
Superscript choice system
Tartrazine
lOXTBE
TEMED
TEMED
Terminal deoxynucleotidyl
transferase/TdT
TdT buffer
lOX Thermophilic buffer 
Tris base 
Tween-20, 10%
Ultra-pure formamide 
Universal Taqman mastermix 
Urea 
VetBond
Water, DEPC-treated
Water, nuclease-free (not DEPC-treated)
Bio-Rad
Promega
Qiagen
Baxter Scientific
National Diagnostics
Bio-Rad
Sigma
Sigma
Fisher Scientific 
Fisher Scientific 
Sigma
BioWhittaker 
Fisher Scientific 
Gibco BRL 
Sigma
National Diagnostics
Sigma
Amresco
Promega
Promega 
Promega 
Bio-Rad 
Pierce Chemical 
Amresco
Applied Biosystems 
Sigma
3M Animal Care Products
Ambion
Ambion
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Chemical Reagents Suppliers
Xylene cyanol Sigma
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List of ail reagents used in preparation of solutions
10% Ammonium Persulphate (10 ml)
1 g APS dissolved in 10 ml sterile distilled water. Store at 4°C.
Chloroform  Isoamylalcohol m ixture (250 ml)
240 ml chloroform added to 10 ml isoamylalcohol. Store at 4°C wrapped in light resistant 
bottle.
dNTPs (200 pi, 25 mm)
5 pi of each dGTP, dATP, dTTP, and dCTP (provided in 100 mm stock solutions) added to 
180 pi sterile distilled water. Store frozen. 
dNTPs (1, OOOpl, 1 mm)
10 pi o f each dGTP, dATP, dTTP, and dCTP (provided in 100 mm stock solutions) added 
to 960 pi o f sterile distilled water. Store frozen.
0.5M EDTA, pH 8.0 (1 L)
186.1 g EDTA dissolved in 1 L sterile distilled water, pH adjusted with sodium hydroxide 
pellets. Sterilised by autoclave. Store at room temperature.
70%  Ethanol (100 ml)
70 ml of 100% ethanol mixed with 30 mi sterile distilled water.
90% Ethanol (100 ml)
90 ml of 100% ethanol added to 10 ml of water.
80% Ethanol (100ml)
80ml of 100% ethanol added to 20ml of water 
2X Form am ide Loading Buffer (10 ml)
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9 ml formamide, 160 pi bromophenol blue, 160 pi xylene cyanol, 680 pi sterile distilled 
water. Store at 4°C.
10 mg/mm G oat IgG  stock
Resuspend 50 mg in 5 ml PBS. Store at 4°C.
2X Hybridisation Buffer (50ml)
8.3ml of 12X MES stock, 17.7ml of 5M NaCl, 4.0ml of 0.5M EDTA, 0.1ml of 10% Tween 
20, 19.9ml of water.
Non-Stringent W ash Buffer (Buffer A)
300 ml o f 20X SSPE, 1.0 ml o f 10% Tween-20, and 698 ml of water. Filter through a 0.2 
pm filter. After filtering, add 1.0 ml 5% Antifoam.
PC R  M aster Mix (15 pi, n= l) fluorescent
Contains 2 pi of lOX buffer (Qiagen), 1 pi of polioxyethylene, 4 pL of dNTPs (1 mm), 
6.96 pi o f sterile distilled water, 0.04 pi of HotStartTaq polymerase (Qiagen), and 0.5 pi of 
each primer (20 pm), preparation is ready for PCR in a thermal cycler.
PCR M aster Mix (10 pi, n= l) non-fluorescent
Contains 4 pi 5X Red, 2 pi lOX Promega thermophilic buffer, 1.2 pi 25 mm MgCb, 1.1 pi
2.5 mm dNTPs, 1.6 pi sterile distilled water and 0.08 pi Taq polymerase. The Taq was 
added immediately prior to the PCR reaction to avoid dénaturation. Can be stored frozen 
until required without the polymerase enzyme.
Phenol choroform  isoamylalcohol (200 ml)
100 ml water saturated phenol mixed with 100 ml chloroform isoamylalcohol mixture. 
Store at 4°C, in light resistant bottle.
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8%  Polyaciylam ide Gel Mix (100 ml)
32 ml SequaGel concentrate, 58 ml SequaGel diluent, and 10 ml SequaGel buffer mixed 
together.
Post-Hybridisation W ash Solution (1 L)
10 ml 20% SDS, 20 X SSC and 890 ml sterile distilled water mixed together.
P rim er Solution (500 pL, 20 pm) for fluorescent PCR
100 pi of each primer (forward and reverse) mixed with 300 pi o f sterile distilled water. 
Store frozen.
P rim er Solution (5 pi, n= l) for non-fluorescent PCR
0.8 pi of each 6 pm primer (forward and reverse) mixed with 3.4 pi sterile distilled water. 
Final addition of a few particles of tartrazine to aid identification. Can be stored frozen until 
required.
Proteinase K Solution
5 ml Proteinase K (Qiagen) added to 10 ml DNAse free water.
5X Red (10 ml)
6.5 g sucrose dissolved in 10 ml sterile distilled water. Addition of 1 pi cresol red for 
colour. Store at 4°C.
5X RNA Fragm entation Buffer
4.0 ml IM Tris acetate pH 8.1(Trizma base, Ph adjusted with glacial acetic acid), 0.64 g 
MgOAc, 0,98 g KOAc, DEPC-treated water to a total volume of 20 ml.
Single S tranded cDNA Synthesis (Clontech RT for PC R  kit)
5X reaction buffer 4.0 pi, dNTP mix (10 mM each) 1.0 pi , Recombinant RNase inhibitor 
0.5 pi and MMLV reverse transcriptase 1.0 pi
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0.4% SDS (500 ml)
2 g SDS powder dissolved in 500 ml sterile distilled water by heating to 68°C in 
microwave.
10% SDS (1 L)
500 ml 20% SDS mixed with 500 ml sterile distilled water.
3M Sodium Acetate, pH 6.0 (1 L)
408.1 g sodium acetate dissolved in 1 L of sterile distilled water. pH adjusted with glacial 
acetic acid. Sterilised by autoclave.
1% Sodium Chloride (1 L)
10 g sodium chloride dissolved in 1 L sterile distilled water.
4M Sodium Chloride.
117 g sodium chloride dissolved in 500 ml sterile distilled water. Sterilised by autoclave. 
0.4M Sodium Hydroxide (1 L)
16 g sodium hydroxide pellets dissolved with stirring in 1 L sterile distilled water.
2 X SSC (1 L)
100 ml 20 X SSC mixed with 900 ml sterile distilled water.
2X Stain Buffer (250 ml)
41.7 ml 12X MES stock buffer, 92.5 ml 5M NaCl, 2.5 ml 10% Tween-20, 112.8 ml water. 
Filter through a 0.2 pm filter. After filtering, add 0.5 ml of 5% Anti-foam.
Stringent Wash Buffer (Buffer B)
For 1000ml. 83.3 ml of MES stock buffer, 5.2 ml of 5M NaCl, 1.0 ml of 10% Tween 20,
910.5 ml of water. Filter through a 0.2 pm filter.
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Suspension Buffer (500 ml)
25 ml IM Tris (pH 8.0), 100 ml 0.5M EDTA (pH 8.0), and 375 ml sterile distilled water 
mixed together.
IX TBE (1 L)
100 ml lOX TBE mixed with 900 ml sterile distilled water.
TE (20 ml).
200 pi IM Tris (pH 8.0), 40 pL 0.5M EDTA (pH 8.0), and 19.76 ml sterile distilled water 
mixed together.
IM  Tris, pH 8.0 (1 L).
121.1 g Tris base dissolved in 1 L sterile distilled water. pH adjusted with concentrated 
hydrochloric acid. Sterilised by autoclave.
Solution for extraction of DNA from rat tails (20 ml).
1 ml IM  Tris (pH 8.0), 100 ml 0.5M EDTA (pH 8.0), 1 ml 10% SDS and 14 ml sterile 
distilled water mixed together.
Taqman PCR reaction Mastermix
2 pi housekeeping gene probe, 2 pi target gene probe, 8 pi Taqman Universal mastermix 
and 2 pi sterile distilled water.
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APPENDIX II 
Raw Phenotype Data
Codes as follows: Cross G refers to F2 hyrbids (n=134) with a SHRSP grandfather, Cross 
H a WKY grandfather. CMI is cardiac mass indexed to body weight; LVMI is left 
ventricular mass indexed to body weight; PRA is plasma renin activity; SBP and DBP 
values are means after salt loading period (Clark et ah, 1996).
Cross CMI
mg/g
LVMI
mg/g
PRA SBP(s)
mmHg
DBP(s)
mmHg
Sex
G1 5.91 4.8 1.3 147.93 100.07 F
G2 3.35 2.66 6.8 173.3 120 F
G3 3.34 2.79 3.7 168.56 115.73 F
G4 3.53 2.81 1.8 163.95 112.8 F
G5 3.4 2.71 5.2 171.57 117.94 F
G6 3.26 2.72 1.8 181.96 126.13 M
G7 3.92 3.12 0.35 211.33 146.46 F
G8 3.63 2.82 0.25 173.61 119.66 F
G9 3.32 2.73 0.23 154.98 105.26 F
GIO 3.16 2.37 2.1 168.69 116.4 M
G il 3.37 2.61 1.2 182.11 125.52 M
G12 3.86 3.33 0.82 194.9 132.74 M
G13 3.87 3.16 0.1 209.57 146.95 M
G14 3.77 3.3 3.1 193.91 130.44 M
G15 3.74 3.22 0.37 196.82 132.08 M
G16 3.2 2.79 0.22 204.7 141.06 M
G17 3.96 3.3 0.1 181.66 126 F
G18 4.1 3.5 0.65 203 147.03 F
G21 3.78 3.22 1.6 182.6 128.11 M
G22 3.25 2.76 0.34 183.01 126.24 M
G43 4.28 3.68 0.1 159.54 104.61 F
G44 3.76 3.07 0.33 235.43 166.98 F
G26 4.15 3.69 2.4 178.47 134.1 F
G27 3.43 2.8 0.26 153.41 105.07 F
G28 4.71 4.05 1.7 229.25 162.76 F
G30 3.47 2.74 0.6 165.65 112.18 F
261
Cross CMI
mg/g
LVMI
mg/g
PRA SBP(s)
mmHg
DBP(s)
mmHg
Sex
G32 3.55 2.92 0.58 167.62 112.33 F
G33 4.64 3.51 0.61 175.99 115.19 F
G34 3.3 2.7 0.2 193.36 134.83 M
G35 3.16 2.69 0.49 177.07 120.62 M
G36 3.78 3.22 0.52 223.34 155.43 M
G37 3.74 3 0.19 199.14 132.27 M
G39 3.56 2.77 0.69 177.33 119.71 M
G40 3.19 2.6 0.16 173.83 117.53 M
G41 3.29 2.65 0.1 206.23 143.5 M
G46 4.19 3.33 0.5 181.56 122.72 F
G48 4.34 3.14 0.1 199.53 134.46 M
G49 4.14 3.08 0.36 218.61 147.9 M
G50 3.8 2.58 0.92 170.99 115.65 M
G52 4.47 3.43 0.1 194.44 131.1 F
G53 3.95 2.73 0.28 159.68 110.63 F
G54 4.39 3.27 0.21 244.01 170.6 M
G55 3.82 2.79 0.1 189.85 127.71 M
G57 4.26 3.06 0.38 166.2 114.01 F
G58 4.42 2.91 0.72 162.63 108.55 F
HI 3.19 2.4 2.2 182.448 121.36 M
H2 3.82 2.66 0.52 173.9 116.38 M
H3 4.19 3.1 0.5 170.983 114.61 F
H4 3.41 2.42 1.3 167.894 116.83 M
H5 3.64 2.64 0.7 171.023 118.01 M
H6 4.07 2.99 0.7 174.969 118.2 M
H7 3.73 2.7 1.5 180.502 125.24 M
H8 3.39 2.52 0.3 177.21 123.59 M
H9 4.14 3 1.3 166.44 115 F
HIO 3.72 2.62 1.9 - - M
H ll 3.89 2.83 1.1 197.24 131.1 M
H12 4.49 3.28 1.5 180.05 118.27 M
H13 3.99 2.83 1.2 154.6 99.64 F
H14 3.98 2.82 1.8 170.43 115.4 F
H41 3.41 2.57 2 171.41 115.38 M
H42 3.43 2.57 1.4 184.29 126.14 M
H17 3.68 2.79 2.5 171.58 116.29 F
H18 3.86 2.77 0.9 171.92 116.88 F
H19 3.37 2.4 1.9 151.35 105.22 F
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Cross CM I
mg/g
LVM I
mg/g
PRA SBP(s)
mmHg
DBP(s)
mmHg
Sex
H20 3.18 2.31 2.3 167 116.39 M
H21 3.68 2.68 1.6 199.74 135.84 M
H22 3.61 2.58 0.21 160.85 109.01 F
H23 3.3 2.33 2.3 142.83 99.82 F
H24 3.39 2.46 3.3 161.88 111.93 F
H25 3.68 2.59 1.3 158.58 106.15 F
H28 3.49 2.68 0.57 189.71 129.97 M
H29 2.8 1.97 0.61 183.31 124.1 M
H30 3.74 2.7 - 196.18 132.32 M
H31 3.26 2.31 0.5 181.19 125.53 M
H32 3.09 2.29 - 169.3 112.14 F
H33 3.74 2.43 0.1 163.61 112.33 F
H34 3.29 2.34 2.9 170.37 117.78 M
H35 3.76 2.7 2.4 164.09 114.46 F
H36 4.13 2.83 1.2 180.34 124.34 F
H38 3.61 2.57 2.1 159.35 108.25 F
H39 3.88 2.76 0.1 163.24 109.41 F
H40 3.93 2.81 4.1 187.25 126.51 F
H43 3.19 2.22 2.7 171.48 116.49 M
H44 4.16 3.04 4.1 170.51 115.89 F
H46 2.94 2.32 1.4 157.02 107.12 F
H47 3.31 2.48 0.4 168.8 120.5 F
H48 3.83 2.79 0.41 148.13 103.54 M
H49 3.58 2.73 0.1 189.18 113.11 M
H50 3.35 2.36 3.1 147.89 99.01 F
H51 3.66 2.42 0.7 157.84 107.68 F
G59 - 279.44 208.54 F
G60 4.71 3.1 0.1 165.24 113.75 F
G62 3.733 2.866 0.23 169.88 113.32 F
G64 3.761 2.906 0.1 176.35 121.12 M
G65 4.356 3.208 0.81 234.68 169.95 M
G66 4.245 2.775 0.16 187.52 130.55 M
G67 4.188 2.938 0.1 205.54 143.4 M
G68 3.9 2.927 0.9 192.62 135.62 M
G71 4.921 3.448 0.27 209.08 143.05 M
H52 3.09 2.25 0.3 170.12 115.17 M
H53 3.35 2.48 0.37 183.13 123.7 M
H55 3.55 2.39 0.44 157.99 106.39 F
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Cross CMI
mg/g
LVMI
mg/g
PRA SBP(s)
mmHg
DBP(s)
mmHg
Sex
H56 3.9 2.95 0.31 160.72 105.85 F
H57 3.52 2.66 0.26 161.68 109.37 F
H58 3.74 2.74 0.58 149.04 98.2 F
H59 3.5 2.77 0.87 170.84 115.6 F
H60 3.36 2.42 1.3 172.21 118.8 M
H61 3.45 2.61 3.5 174.57 119.1 M
H62 3.32 2.48 1.9 185.04 130.09 M
H63 3.38 2.62 0.72 195.45 136.94 F
H64 3.84 2.93 0.57 180.21 123.68 F
H65 3.19 2.4 2.4 172.51 119.77 M
H66 3.29 2.33 1.5 154.33 106.87 F
H67 3.76 2.71 1.2 162.85 111.92 F
H68 3.6 2.73 1.6 187.56 130.49 M
H69 4.38 3.15 0.54 174.53 123.98 M
H70 3.6 2.52 1.2 163.64 113.47 M
H71 3.88 2.85 1.4 159.64 108.61 M
H72 3.58 2.43 0.4 160.68 114.12 M
H73 3.55 2.51 0.81 160.14 108.87 M
H81 4.01 3.04 0.61 208.65 140.74 F
H82 4.14 2.82 0.23 185.9 120.91 F
H88 3.68 2.62 0.7 194.02 134.96 F
H74 3.97 2.79 3.5 197.82 136.73 M
H75 4.04 2.86 3.8 165.66 113.89 F
H76 3.67 2.52 2.6 148.57 99.68 F
H77 3.82 2.59 1.6 150.9 101.94 F
H78 4.11 2.9 3.9 166.16 111.04 F
H79 3.99 2.8 0.65 183.02 124.58 F
H84 3.8 2.66 14.5 141.48 96.49 F
H86 3.68 2.52 0.51 156.51 106.03 F
H91 2.71 1.94873 - 156.05 106.43 F
H89 3.71244 2.60888 - 172.27 118.99 M
H90 3.56483 2.59057 - 172.92 118.58 M
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Raw Chromosome 14 Genotype Data
Microsatellite marker and genotype codes for data is given below. The symbol 
indicates missing data. Heterozygote -  0; homozygote WKY -  1; homozygote SHRSP 2.
%a 1tHQ 1tHA
00
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A
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1
A
rr
1
A
1oTp
A
ioTf
A
1
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tH
1
tHA
G1 2 2 2 2 2 2 2 2 2 2 2 2 2
G2 2 2 1 1 1 1 1 1 1 1 1 1 0 0
G3 2 2 1 2 2 2 2 1 2 - - 1 - -
G4 2 2 1 1 1 1 1 1 1 1 1 1 0
G5 1 0 0 0 - 0 0 0 0 0 0 0 1 1
G6 1 1 2 1 1 1 1 1 1 1 - 2 2 1
G7 1 1 2 1 1 1 1 1 1 1 1 2 2 1
G8 1 - - 1 1 1 1 1 1 1 - 0 0 1
G9 1 0 0 0 0 0 0 0 0 2 0 1 1 1
GIO 1 1 1 1 - 1 1 1 1 1 1 1 1 1
G i l - 1 1 1 1 1 1 1 1 1 - 1 1 1
G12 - 2 2 2 2 2 2 2 2 2 2 1 1 1
G13 1 2 2 2 2 2 2 2 2 2 2 1 1
G14 - 1 1 1 1 1 1 1 1 1 1 1 1
G15 - 2 - 2 2 2 2 2 2 2 2 2 2 1
G16 0 0 1 1 1 1 1 1 1 1 1 1 1 1
G17 - 0 0 0 0 0 0 0 0 0 2 2 2
G18 - 1 1 1 1 1 1 1 1 1 1 1 1 1
G21 - 2 2 2 2 2 2 2 2 2 2 2 2
G22 - 1 1 1 1 1 1 1 1 1 1 1 1 1
G43 - 0 0 0 0 0 2 0 0 0 0 1 1 1
G44 - 0 0 0 0 0 2 0 0 1 1 1 2
G26 - 0 0 0 0 0 2 0 0 0 0 0 0 1
G27 - 1 1 1 1 1 1 1 1 1 1 1 1 1
G28 - 1 0 1 1 1 1 1 1 1 - 1 1
G30 - 2 2 2 2 2 2 2 2 2 2 2 2 1
G32 - - 0 0 - 0 0 0 0 0 0 0 0 1
G33 - 1 1 2 2 2 2 2 2 2 2 2 2
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TP
aI
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tH1
tHA
IT-iA
Tp1
tHA
ITp
1-4A
1-41
Tp1-4A
I
1-4A
01-41
1-4A
G34 - 2 - 2 2 2 2 2 2 2 2 2 2 2
G35 - 0 0 0 0 0 0 0 0 0 0 0 0 0
G36 - 2 2 2 2 2 2 2 2 2 2 1 1
G37 1 1 - 1 1 1 1 1 1 1 1 1 1 2
G39 0 0 0 0 0 0 0 0 0 0 0 0 0 0
G40 2 2 2 2 2 2 2 2 2 2 2 2 1 1
G41 2 2 - 2 2 2 2 2 2 2 2 2 2 1
G46 2 2 2 2 2 2 2 2 2 2 2 2 1 1
G48 1 1 1 1 1 1 1 1 1 1 - 2 2 1
G49 2 2 - 2 2 2 2 2 2 2 2 2 0 1
G50 1 1 - 1 1 1 1 1 1 1 1 1 1
G52 1 1 - 1 I 1 1 1 1 1 1 1 1 1
G53 2 2 2 2 2 2 2 2 2 2 2 2 2
G54 1 1 1 1 1 1 1 1 1 1 1 1 0 1
G55 1 - 1 1 1 - 1 1 1 2 2 2 2
G57 - 0 •“ - 0 0 0 0 0 0 0 0 0 1
G58 1 0 0 0 0 0 - 0 0 0 - 0 0 1
H I 1 1 1 1 - 1 1 1 1 1 1 1 1 1
H2 2 2 2 2 2 2 2 2 2 2 - 2 1 1
H3 2 2 2 2 2 2 2 2 2 2 2 2 1
H4 - 2 - 1 1 - - 1 - 1 - - 0 1
H5 1 1 2 2 2 2 2 2 2 2 2 2 2 1
H6 2 - 2 2 2 2 2 2 2 2 2 2 2
H7 0 0 0 0 0 0 0 0 0 0 0 0 0 1
H8 2 2 2 2 2 2 2 2 2 2 1 - 2 1
H9 1 1 1 1 1 1 1 1 1 1 1 0 0 1
HIO 1 1 1 1 1 1 1 1 1 1 1 1 1 2
H l l 0 0 0 0 0 0 0 0 0 0 0 0 0 0
H12 - 2 2 - 2 2 2 2 2 2 2 2 2 0
H13 1 1 1 1 1 1 1 Î 1 1 1 1 1 1
H14 1 1 1 1 1 1 1 1 1 1 1 1 0
H41 1 - 2 2 2 2 2 2 2 2 1 2 2 1
H42 1 - 1 1 1 1 1 1 1 1 1 0 0 1
H17 - 1 0 0 0 0 0 0 0 0 1 0 0 1
H18 2 2 2 2 2 2 2 2 2 2 2 2 2 2
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H19 2 1 1 1 1 1 1 1 1 1 - 1 1 1
H20 1 1 1 1 - 1 1 1 1 1 1 1 1 1
H21 1 1 0 0 0 0 0 0 0 0 1 0 0 0
H22 2 2 2 2 2 2 2 2 2 2 2 - 2 2
H23 2 - 2 2 2 2 - 2 2 2 1 2 1 0
H24 1 1 1 1 1 1 1 1 1 1 1 1 1 2
H25 0 0 0 0 0 0 0 0 0 0 0 0 0
H28 1 0 0 0 0 0 0 0 0 0 0 1 1 2
H29 1 1 1 1 1 1 1 1 1 1 1 1 0 0
H30 2 2 2 2 2 2 2 2 2 2 2 2 2 2
H31 1 1 - 1 1 1 1 1 1 1 1 0 0 2
H32 1 1 1 1 1 1 1 1 1 1 1 1 0 2
H33 1 1 1 1 1 1 1 1 1 1 0 0 0 1
H34 - 0 0 0 0 0 0 0 0 1 0 0 0 2
H35 0 2 2 2 2 1 1 1 1 1 1 1 1 1
H36 2 1 1 1 1 1 1 1 1 1 2 2 2 0
H38 2 1 0 1 1 1 1 1 1 1 1 - 0 1
H39 1 0 0 0 0 0 0 0 0 0 0 0 0 0
H40 1 2 2 2 2 2 2 2 2 2 2 2 2 1
H43 1 2 2 2 2 2 2 2 2 0 1 1 1 1
H44 2 1 - 1 1 1 1 1 1 Î 1 1 0 2
H46 1 1 1 1 1 1 1 1 1 - 1 2 1
H47 0 2 1 1 - 1 1 1 1 1 1 1 1 2
H48 2 2 2 2 2 2 2 2 2 2 - 2 2 0
H49 2 0 0 0 0 0 0 0 0 1 - 1 2 1
H50 0 2 1 1 1 1 - 1 1 1 1 1 1 2
H51 2 1 2 2 2 2 2 2 2 2 2 2 2 1
G59 - 0 0 0 0 0 0 0 0 0 - 0 1 1
G60 “■ 2 2 2 2 2 2 2 2 2 2 2 2 2
G62 1 - 0 0 0 0 0 0 0 0 0 0 0 2
G64 0 - 0 0 0 0 0 0 0 0 0 - 0 0
G65 2 - 2 2 2 2 2 2 2 2 2 2 2 0
G66 1 1 1 1 1 1 1 1 1 2 2 2 2 -
G67 2 2 2 2 2 2 2 2 2 2 1 2 1 2
G68 2 2 2 2 2 2 2 2 2 2 1 2 1 2
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G71 - 2 2 2 2 2 2 2 2 2 2 - 1 0
H 52 1 1 1 1 1 1 1 1 1 1 1 1 1 1
H 53 - 1 1 1 1 1 1 1 1 1 1 1 1 1
H 55 0 0 - 0 0 0 0 0 0 0 0 1
H 56 2 2 1 1 1 1 1 1 1 1 1 1 1 1
H 57 0 1 1 1 1 1 1 1 1 1 1 1 1 1
H 58 - 1 1 1 1 1 1 1 1 1 1 1 1 0
H 59 - - 0 0 0 0 0 0 0 1 1 0 1 1
H 60 1 1 1 1 1 1 1 1 1 1 1 1 1 1
H61 1 1 1 1 1 1 1 1 1 1 1 1 1 1
H 62 1 1 1 1 1 1 1 1 1 1 1 1 1
H 63 1 1 1 1 1 1 1 1 1 1 1 1 1 1
H 64 2 2 2 2 2 2 2 2 2 2 2 2 1
H 65 2 1 1 1 1 1 1 1 1 1 1 1 1 0
H 66 1 1 1 1 1 1 1 1 1 1 1 1 1 1
H 67 0 0 0 0 0 0 0 0 0 0 0 0 0 1
H 68 2 2 1 1 1 1 1 1 1 1 1 1 1 2
H 69 2 2 2 2 2 2 2 2 2 2 2 2 2 2
H 70 - 2 2 2 2 2 2 2 2 2 2 2 2 1
H71 - 0 0 0 0 0 0 0 0 0 1 0 0 2
H 72 0 - 1 1 1 1 1 1 1 1 2 1 2 1
H 73 0 2 2 2 2 - 2 2 2 2 2 0 2 2
H81 - 2 - 2 2 2 2 2 2 2 2 0 2 1
H 82 - 1 1 1 1 1 1 1 1 1 1 1 2 1
H 88 0 1 2 2 2 2 1 2 2 2 2 0 2 0
H 74 - 1 1 1 1 1 1 1 1 1 1 1 1 2
H 75 0 2 0 0 0 0 0 0 0 0 0 0 0 1
H 76 2 1 2 2 2 2 2 2 2 2 2 2 2 0
H 77 0 0 0 0 0 0 0 0 0 0 0 0 0 1
H 78
H 79 - 2 2 2 2 2 2 2 1 2 2 2 2 1
H 84 1 - 1 1 1 1 1 1 2 1 1 1 0 2
H 86 2 2 - 2 2 2 2 2 2 2 2 2 2 0
H91 1 1 0 0 0 0 0 0 0 0 0 0 0 1
H 89 0 0 0 0 0 0 0 0 0 0 1 0 1 0
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APPENDIX III
Genes located in regions of synteny between rat chromosome 14, mouse chromosome 
5 and human chromosome 4.
Gene Description
similar to vomeronasal 2, receptor, 2
hypothetical protein LQC689413
similar to putative pheromone receptor
similar to vomeronasal 2, receptor, 1
similar to putative pheromone receptor Go-VN13C (predicted)
similar to vomeronasal 2, receptor, 1
similar to putative pheromone receptor
similar to vomeronasal 2, receptor, 1
similar to putative pheromone receptor (predicted)
similar to vomeronasal 2, receptor, 16
similar to putative pheromone receptor (predicted)
similar to ribosomal protein LI3A
similar to putative pheromone receptor (predicted)
similar to Ankyrin repeat domain 13 (predicted)
hypothetical protein LOC689585
similar to putative pheromone receptor (predicted)
similar to vomeronasal 2, receptor, 1
similar to vomeronasal 2, receptor, 1
similar to vomeronasal 2, receptor, 1
similar to karyopherin (importin) alpha 2
similar to putative pheromone receptor (Go-VN2)
similar to putative pheromone receptor (Go-VN2)
similar to putative pheromone receptor
similar to putative pheromone receptor
similar to vomeronasal 2, receptor, 1
similar to vomeronasal 2, receptor, 2
similar to vomeronasal 2, receptor, 1
similar to vomeronasal 2, receptor, 11
similar to Glycoprotein 25L precursor (GP25L)
similar to D 1081.9
Fibroblast growth factor receptor-like 1
solute carrier family 26 (sulfate transporter), member 1
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Gene Description
similar to RIKEN cDNA 3Q1QQ01K23 gene
cyclin G associated kinase
complexin 1
ring Finger protein 3 (predicted)
similar to RIKEN cDNA 4732482E20 (predicted)__________
ATP synthase, H+ transporting, mitochondrial FO complex,
subunit e____________________________________________
phosphodiesterase 6B, cGMP, rod receptor, beta polypeptide
(predicted)__________________________________________
similar to glyceraldehyde-3-phosphate dehydrogenase
(predicted) _____________________________
similar to GPI7 (predicted)_____________________________
down-regulator of transcription 1________________________
similar to Sarcoma antigen NY-SAR-41 (predicted)________
transmembrane emp24 protein transport domain containing 5
metal response element binding transcription factor 2_______
hypothetical protein LOC689871
similar to RIKEN cDNA 2900024C23 (predicted)_________
ribosomal protein L5__________________________________
similar to RuvB-like 2
similar to DNA helicase_______________________________
similar to RuvB-like 2________________________________
similar to 4QS ribosomal protein S26____________________
ubiquitin-conjugating enzyme E2D 2 
hypothetical protein LOC689944
growth factor independent 1____________
similar to Expressed sequence AW0602Q7
FKBP-associated protein
hypothetical protein LOC689986
similar to H43E16.1
similar to BTB (POZ) domain containing 8
similar to hypothetical protein A33Q042H22
abhydrolase domain containing 7 (predicted)
bromodomain, testis-specific
transforming growth factor, beta receptor III
hypothetical protein LOC690086
similar to ribosomal protein SI 1 (predicted)
cell division cycle 7 (S. cerevisiae) (predicted)
similar to UPFQ197 protein Cl lorflO homolog
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Gene Description
similar to HFMl, ATP-dependent DNA helicase homolog
similar to H02F09.3
hypothetical protein LOC690213
zinc finger protein 644 (predicted)
hypothetical protein LQC69Q24Q
hypothetical protein LOC690245
BarH-class homeodomain transcription factor
hypothetical protein LOC690395
LOC501317
similar to spermatogenesis associated glutamate (E)-rich 
protein 4d_______________________________________
similar to spermatogenesis associated glutamate (E)-rich 
protein 4d  ^ ________
similar to RIKEN cDNA 5031410106
similar to glutamate receptor, ionotropic, N-methyl D- 
aspartate-like lA  (predicted)_____________________
hypothetical protein LQC689797
similar to zinc finger CCCH type, antiviral 1
hypothetical protein LQC690525
similar to spermatogenesis associated glutamate (E)-rich 
protein 4d _______
hypothetical gene supported by BC082068 (predicted)
similar to spermatogenesis associated glutamate (E)-rich 
protein 4d_______________________________________
similar to glutamate receptor, ionotropic, N-methyl D- 
aspartate-like lA______________________________
similar to spermatogenesis associated glutamate (E)-rich 
protein 4d (predicted)_____________________________
similar to glutamate receptor, ionotropic, N-methyl D- 
aspartate-like lA (predicted)______________________
similar to RIKEN cDNA 5031410106
leucine rich repeat containing 8 family, member D
leucine rich repeat containing 8 family, member C
similar to T-cell activation leucine repeat-rich protein 
(predicted)____________________________________
similar to ATP-binding cassette, sub-family G (WHITE), 
member 3
similar to ATP-binding cassette transporter ABCG3
similar to ubiquitin-conjugating enzyme E2 variant 1
similar to Hypothetical protein E430029F06 (predicted)
similar to ATP-binding cassette, subfamily G, member 3 
(predicted)______________________________________
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Gene Description
similar to ATP-binding cassette, sub-family G (WHITE), 
member 3 (predicted)______________________________
similar to 60S ribosomal protein L38
ATP-binding cassette, sub-family G (WHITE), member 3 
similar to THQ complex subunit 2 (Tho2)_____________
similar to polycystic kidney disease 2 (predicted)
secreted phosphoprotein 1
matrix extracellular phosphoglycoprotein with ASARM motif 
(bone)_______________________________________________
integrin binding sialoprotein
dentin matrix protein 1
dentin sialophosphoprotein
SPARC-like 1 (mast9, hevin)
nudix (nucleoside diphosphate linked moiety X)-type motif 9 
dehydrogenase/reductase (SDR family) member 8
hydroxysteroid (17-beta) dehydrogenase 13
similar to NADH-ubiquinone oxidoreductase B9 subunit
(Complex I-B9) (CI-B9) _______________________
kelch-like 8 (Drosophila) (predicted)__________________
AF4/FMR2 family, member 1 (predicted)______________
hypothetical protein LOC68Q289_____________________
similar to hypothetical protein MGC26744_____________
sodium-dependent organic anion transporter____________
similar to protein Tyr phosphatase ________________
similar to NADH:ubiquinone oxidoreductase B 15 subunit
(predicted)_______________________________________
mitogen activated protein kinase 10_______
similar to 40S ribosomal protein S25_______________
similar to RIKEN cDNA 2310005N03
Rlio GTPase activating protein 24
similar to proliferating cell nuclear antigen (predicted) 
similar to mKIAAl 108 protein
WD repeat and FYVE domain containing 3 (predicted)_____
CDP-diacylglycerol synthase 1 ____________
NK6 transcription factor related, locus 1 (Drosophila)______
similar to ribosomal protein L36________________________
similar to SET protein (Phosphatase 2A inhibitor I2PP2A) (I- 
2PP2A) (Template-activating factor I) (TAF-I) (Liver
regeneration-related protein LRRGR0QQ02)______________
similar to hypothetical protein 49334Q8F15_______________
273
Gene Description
similar to RIKEN cDNA 3830405G04
mitochondrial ribosomal protein S18C (predicted)
similar to DNA helicase HEL308
similar to 60S ribosomal protein L7a (Surfeit locus protein 3)
similar to peptidylprolyl isomerase D
heparanase
similar to 23 lQ0Q2F18Rik protein
placenta-specific 8 (predicted)
C0P9 (constitutive photomorphogenic) homolog, subunit 4 
(Arabidopsis thaliana) _____________ _________________
similar to hypothetical protein
SEC31-like 1 (S. cerevisiae)
similar to RIKEN cDNA 2610318G18 (predicted)
hypothetical protein LQC68II53
similar to RIKEN cDNA 2310057D15
heterogeneous nuclear ribonucleoprotein D-like
heterogeneous nuclear ribonucleoprotein D
similar to ASFl anti-silencing function 1 homolog A
similar to ribosomal protein S17 (predicted)
similar to ribosomal protein L21
similar to 40S ribosomal protein SA (p40) (34/67 IcDa laminin 
receptor) (predicted)___________________________________
similar to Elongation factor 2 (EF-2)
hypothetical protein LOC685087
hypothetical protein LQC68510Q
protein kinase, cGMP-dependent, type II
bone morphogenetic protein 3
similar to CG8138-PA
similar to glyceraldehyde-3-phosphate dehydrogenase
fibroblast growth factor 5
PR domain containing 8 (predicted)
similar to Antxr2 protein
glucokinase activity, related sequence 2
similar to MGC1Q646 protein
similar to 40S ribosomal protein S19 (predicted)
similar to SPANX-N2 protein
progestin and adipoQ receptor family member III
BMP-2 inducible kinase 
annexin A3
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Gene Description
Fraser syndrome 1 homolog (human) (predicted)___________
mitochondrial ribosomal protein LI (predicted)____________
CCR4-N0T transcription complex, subunit 6-like (predicted) 
similar to Small inducible cytokine B13 precursor (CXCL13) 
(B lymphocyte chemoattractant) (CXC chemokine BLC) 
similar to DNA segment, Chr 5, ERATO Doi 577, expressed
(predicted)__________________________________________
similar to DNA segment, Chr 5, ERATO Doi 577, expressed 
(predicted)__________________________________________
similar to FRAME family member 8_____________________
similar to CDNA sequence BC061212 (predicted)__________
similar to NEDD4-binding protein 1 (N4BP1)____________
similar to FRAME family member DJl 198FI6.2___________
similar to FRAME family member DJl 198H6.2___________
similar to FRAME family member 1 ____________
similar to FRAME family member 3
similar to DNA segment, Chr 5, ERATO Doi 577, expressed
(predicted)__________________________________________
similar to DNA segment, Chr 5, ERATO Doi 577, expressed
(predicted)__________________________________________
similar to CDNA sequence BC061212 (predicted) 
similar to DNA segment, Chr 5, ERATO Doi 577, expressed
(predicted)__________________________________________
similar to preferentially expressed antigen in melanoma
similar to FRAME family member 9____________________
similar to DNA segment, Chr 5, ERATO Doi 577, expressed
(predicted)__________________________________________
similar to homolog of yeast ribosome biogenesis regulatory
protein RRS1 (predicted)______________________________
similar to FRAME family member DJl 198H6.2___________
similar to DNA segment, Chr 5, ERATO Doi 577, expressed
(predicted)__________________________________________
similar to DNA segment, Chr 5, ERATO Doi 577, expressed
(predicted)__________________________________________
similar to CDNA sequence BC061212___________________
similar to DNA segment, Chr 5, ERATO Doi 577, expressed 
(predicted)__________________________________________
similar to FRAME family member 8____________________
similar to DNA segment, Chr 5, ERATO Doi 577, expressed
(predicted)__________________________________________
similar to CDNA sequence BC061212 (predicted)_________
cyclin G2 (predicted)_________________________________
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Gene Description
cyclin I (predicted)
septin 6 (predicted)
hypothetical LOC289501 (predicted)
similar to PDZ domain actin binding protein Shroom 
similar to 60S ribosomal protein LI2_____________
similar to RIKEN cDNA 4932413014 gene (predicted) 
similar to genethonin 1___________________________
hypothetical protein LOC68614Q
similar to TSH receptor suppressor element-binding protein-1; 
TSEP-1 (predicted)____________________________________
scavenger receptor class B, member 2
nucleoporin 54
ADP-ribosyltransferase 3
chemokine (C-X-C motif) ligand 11
chemokine (C-X-C motif) ligand 10
chemokine (C-X-C motif) ligand 9
SDAl domain containing 1
N-acylsphingosine amidohydrolase (acid ceramidase)-like 
(predicted)________________________________________
protein phosphatase, EF hand calcium-binding domain 2 
(predicted)______________________________________
vesicle docking protein
similar to Late endosomal/lysosomal Mpl-interacting protein 
(Pl4)________________________________________
similar to RNA-binding protein isoform G3BP-2a
cyclin-dependent kinase-like 2 (CDC2-related kinase) 
THAP domain containing 6 (predicted)____________
ring finger and CHY zinc finger domain containing 1 
similar to ribosomal protein L21_________________
similar to FRAME family member DJl 198H6.2
castration induced prostatic apoptosis-related protein 1 
betacellulin
amphiregulin
epiregulin
hypothetical protein LQC688741
similar to Epigen protein (predicted)
similar to methylenetetrahydrofolate dehydrogenase (NAD) 
(EC 1.5.1.15) / methenyItetrahydrofblate cyclohydrolase (EC 
3.5.4.9) precursor - mouse (predicted)____________________
chemokine (C-X-C motif) ligand 2
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Gene Description
chemokine (C-X-C motif) ligand 1
similar to Enol protein
gene model 1960, (NCBI)
hypothetical protein LOC688833
chemokine (C-X-C motif) ligand 4
chemokine (C-X-C motif) ligand 7
chemokine (C-X-C motif) ligand 5
similar to Ras association (RalGDS/AF-6) domain family 6
similar to alpha-fetoprotein
afamin
alpha-fetoprotein
albumin
similar to 60S ribosomal protein L8_______________
similar to ankyrin repeat domain protein 17 isoform b 
(predicted) ____________ ________
similar to hypothetical protein FLJ38991 (predicted)
hypothetical protein LQC689097
a disintegrin-like and metalloprotease (reprolysin type) with 
thrombospondin type 1 motif, 3 (predicted)______________
neuropeptide FF receptor 2
group specific component
LRRGT00190
solute carrier family 4, member 4
deoxycytidine kinase
MOBl, Mps One Binder kinase activator-like lA (yeast) 
(predicted)______________________________________
G-rich RNA sequence binding factor 1
rap2 interacting protein x
charged amino acid rich leucine zipper 1
similar to microsomal glutathione S-transferase 3 (predicted) 
immunoglobulin joining chain_________________________
enamel in (predicted)
ameloblastin
similar to Protein UNQ689/PR01329 homolog precursor
mucin 10, submandibular gland salivary mucin
variable coding sequence A1
variable coding sequence A2
PR-Vbetal
similar to peptidylprolyl isomerase D
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Gene Description
RSD-6
casein kappa
follicular dendritic cell secreted
APIN precursor
similar to zinc finger DAZ interacting protein 1
hypothetical LOC289530 (predicted)
casein delta
casein gamma
hypothetical protein LOC689604
casein beta
casein alpha si
similar to ribosomal protein L30 (predicted)
hypothetical protein LOC689650
sulfotransferase, estrogen preferring
estrogen sulfotransferase
sulfotransferase family ID, member 1
sulfotransferase family IB, member 1
UDP glucuronosyltransferase 2 family, polypeptide A 1 
UDP glucuronosyltransferase 2 family, polypeptide A3 
(predicted) __________
UDP glycosyltransferase 2 family, polypeptide B
similar to UDP glucuronosyltransferase 2 family, polypeptide 
A3
similar to T-cell activation kelch repeat protein
similar to UDP-glucuronosyltransferase 2B2 precursor 
(UDPGT) (3-hydroxyandrogen specific) (UDPGTr-4) 
(RLUG23)_____________________________________
similar to UDP-glucuronosyltransferase 2B3 precursor 
(UDPGT) (Testosterone, dihydrotestosterone, and beta- 
estradiol specific) (17-beta-hydroxysteroid specific) 
(UDPGTr-3) (RLUG38)_________________________
UDP glycosyltransferase 2 family, member 3
UDP-glucuronosyltransferase 2 family, member 5
UDP glycosyltransferase 2 family, polypeptide B4
UDP-glucuronosyltransferase
similar to UDP-glucuronosyltransferase
similar to heterogeneous nuclear ribonucleoprotein A3 
(predicted)____________________________________
liver UDP-glucuronosyltransferase, phenobarbitai-inducible 
form
similar to UDP-glucuronosyltransferase 2B1 precursor.
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Gene Description
microsomal (UDPGTR-2) (predicted)
similar to Rho GTPase activating protein 11A
similar to heat shock protein 1, alpha
UDP glycosyltransferase 2 family, polypeptide BIO (predicted) 
similar to Expressed sequence AI788959 (predicted)_________
splicing factor YT521-B
transmembrane protease, serine l ie  (predicted)
similar to 60S ribosomal protein L23a
airway trypsin-like 5
similar to RIKEN cDNA 47324Q6DQ1 gene (predicted)
similar to RIKEN cDNA 9930032022 gene__________
transmembrane protease, serine 11 d________________
airway trypsin-like 3_____________________________
gonadotropin releasing hormone receptor
similar to RIKEN cDNA 5730469D23 (predicted)
similar to stem cell adaptor protein STAP-1
centromere protein C 1_________________
similar to bactin2
similar to Phosphoglycerate kinase 1______
similar to 60S ribosomal protein L9 (predicted)_____________
EphA5_______________________________________________
steroid 5 alpha-reductase 2-like 2 (predicted)
hypothetical protein LQC690Q95_________________________
similar to Ferritin light chain 1 (Ferritin L subunit 1)_________
latrophilin 3 ______________
similar to Importin 7 (Imp7) (Ran-binding protein 7) (RanBP7)
similar to RIKEN cDNA 5730434103 gene (predicted)_______
insulin-like growth factor binding protein 7 _________
similar to RAN guanine nucleotide release factor 
polymerase (RNA) II (DNA directed) polypeptide B
(predicted)___________________________________________
MMR HSRl domain containing protein RGD1359460
RE 1-silencing transcription factor_______________________
similar to DlErtd622e protein (predicted)_________________
serine protease inhibitor, Kazal type 2____________________
similar to 4QS ribosomal protein S2 ______________
homeobox only domain________________________________
similar to testicular haploid expressed gene product isoform 2 
ADP-ribosylation factor-like 9
279
Gene Description
similar to signal recognition particle,72 kPa subunit
phosphoribosylaminoimidazole carboxylase, 
phosphoribosylaminoribosylaminoimidazole 
succinocarboxamide synthetase
phosphoribosyl pyrophosphate amidotransferase
similar to 2-aminoadipic 6-semialdehyde dehydrogenase 
(predicted)______________________________________
hypothetical LOC289568 (predicted)
similar to KIAAQ635 gene product (predicted)
SEC3-like 1 (S. cerevisiae)
hypothetical protein LOC679526
neuromedin U
similar to phosducin-like 2 (predicted)
clock homolog (mouse)
TP A regulated locus
similar to SRD5A2L
hypothetical gene supported by NM_Q5333Q (predicted)
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog________________________________________
similar to CO 1249-PA
platelet derived growth factor receptor, alpha polypeptide
genomic screened homeo box 2 (predicted)
cysteine-rich hydrophobic domain 2 (predicted)
similar to keratin associated protein 10-7
ligand of numb-protein X 1 (predicted)
FIPl like 1 (S. cerevisiae)
similar to Seel family domain containing protein 2 (Syntaxin 
binding protein 1-like 1) (Neuronal Seel)_________________
RAS-like family 11 member B
similar to ubiquitin specific protease 46 (predicted)
similar to WW domain binding protein 11
hypothetical protein LOC680197
spermatogenesis associated 18
similar to Beta-sarcoglycan (Beta-SG) (43 kDa dystrophin- 
associated glycoprotein) (43DAG)_____________________
similar to hypothetical protein MGC38937
DCNl, defective in cullin neddylation 1, domain containing 4 
(S. cerevisiae) (predicted)______________________________
similar to RIKEN cDNA C130090K23 (predicted)
OCIA domain containing 1_______
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Gene Description
similar to 2510Q02A14Rik protein (predicted)
zygote arrest 1
solute carrier family 10 (sodium/bile acid cotransporter 
family), member 4_______________________________
similar to RIKEN cDNA 5033405K12 (predicted)
similar to Phospholipid hydroperoxide glutathione peroxidase, 
mitochondrial precursor (PHGPx) (GPX-4)________________
tec protein tyrosine kinase
TXK tyrosine kinase
NIPA-like domain containing 1 (predicted)
cyclic nucleotide gated channel alpha 1
similar to nuclear transcription factor, X-box binding-like 1
conn
similar to Acidic leucine-rich nuclear phosphoprotein 32 
family member A (Leucine-rich acidic nuclear protein)
similar to synaptonemal complex central element protein 2
similar to type IV putative aminophospholipid transporting 
ATPase
similar to 4QS ribosomal protein S2
similar to myosin, light polypeptide 6, alkali, smooth muscle 
and non-muscle
COMM domain containing 8 (predicted)
gamma-aminobutyric acid (GABA-A) receptor, subunit beta 1
olfactory receptor pseudo gene 1604
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 
4
similar to Gamma-aminobutyric-acid receptor alpha-2 subunit 
precursor (GABA(A) receptor)
similar to 60S ribosomal protein L7a
gamma-aminobutyric acid A receptor, gamma 1
hypothetical protein LOC680769
glucosamine-6-phosphate deaminase 2 (predicted)
similar to expressed sequence AA407526 isoform a (predicted)
similar to YIP IB (predicted)
potassium channel tetramerisation domain containing 8 
(predicted)_____________________________________
similar to 60 kDa heat shock protein, mitochondrial precursor 
(Hsp60) (60 kDa chaperonin) (CPN60) (Heat shock protein 
60) (HSP-60) (Mitochondrial matrix protein PI) (HSP-65)
similar to Ab2-076 (predicted)
similar to acety 1-Coenzyme A acetyltransferase 2
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similar to Ac 1591
similar to 60 kDa heat shock protein, mitochondrial precursor 
(Hsp60) (60 kDa chaperonin) (CPN60) (Heat shock protein 
60) (HSP-60) (Mitochondrial matrix protein PI) (HSP-65)
similar to CGI 2206-PA, isoform A (predicted)____________
ATPase, aminophospholipid transporter (APLT), class I, type 
8A, member 1 (predicted)
similar to MGC68837 protein (predicted)
hypothetical protein LOC680948
similar to Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH)
hypothetical protein LOC680994
hypothetical protein LOC681008
similar to glyceraldehyde-3-phosphate dehydrogenase 
similar to solute carrier family 30 (zinc transporter), member 9 
transmembrane protein 33_______________________________
paired-like homeobox 2b (predicted)
similar to hypothetical protein (predicted)
ubiquitin carboxy-terminal hydrolase LI
hypothetical protein LOC681146
similar to amyloid beta (A4) precursor protein-binding, family
B, member 2 (predicted)________________________________
similar to NOLIR protein; Williams-Beuren syndrome critical 
region protein 2 0 _____________________________________
hypothetical protein LOC681183
similar to ribosomal protein S23 (predicted)______
hypothetical RNA binding protein RGD 1359713 
cholinergic receptor, nicotinic, alpha polypeptide 9
similar to RIKEN cDNA 2410Q04L22___________
ras homolog gene family, member H
similar to mKIAA1413 protein (predicted)_______
similar to KIAA0648 protein (predicted)
similar to ribosomal protein LI4
huntingtin interacting protein 2 (predicted)
similar to RIKEN cDNA 1110003E01
UDP-glucose dehydrogenase
lipoic acid synthetase
ribosomal protein L9
klotho beta (predicted)
replication factor C 1____________
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WD repeat domain 19 (predicted)
similar to Heterogeneous nuclear ribonucleoprotein A1 (Helix- 
destabilizing protein) (Single-strand RNA-binding protein)
(hnRNP core protein A l) (HDP)_________________________
similar to Mitochondrial carrier triple repeat 1 (predicted) 
kelch-like 5 (Drosophila) ___________________________
hypothetical protein LOC498365
similar to RIKEN cDNA 9130QQ5N14 (predicted)
toll-like receptor 6
toll-like receptor 10 (predicted)
Kruppel-like factor 3 (basic) (mapped)
hypothetical protein LOC685077
similar to 60S ribosomal protein L29 (P23) (predicted) 
hypothetical protein LQC685112_________________
TBCl domain family, member 1 (predicted)
similar to H3 histone, family 3B__________
hypothetical protein LOC685134
phospho glucomutase 1 (predicted)
similar to serine/threonine/tyrosine interacting protein 
similar to 3110Q47P20Rik protein (predicted)_______
similar to RIKEN cDNA 0610040J01
similar to expressed sequence AA536743 (predicted)
similar to nidogen-2_______________________________
similar to membrane protein NBRl__________________
similar to glyceraldehyde-3-phosphate dehydrogenase 
(phosphorylating) (EC 1.2.1.12)- mouse
mitochondrial carrier triple repeat 2 (predicted)________
similar to CGI 7293-PA____________________________
similar to CGI 7293-PA____________________________
similar to type I interferon receptor beta chain-associated 
similar to lin-9 homo log
similar to Reticulocalbin-1 precursor
similar to reticulocalbin
similar to similar to RIKEN cDNA 4930555G01_________
similar to cDNA sequence AY358078 (predicted)
similar to reticulocalbin________________________________
similar to RIKEN cDNA 493Q555GQ1
similar to Discs large homolog 5 (Placenta and prostate DLG)
(Discs large protein P-dlg) ___________________
hypothetical protein LOC685573________________________
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hypothetical protein LOC685598
hypothetical protein LOC685615
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APPENDIX IV 
Body weights (g) as genotyped
WW w s  ss
D14Woxl4 362.9±6.7g 360.48±5.58g 356.48±13.4g
D14Got33 363.9±6.32g 359.76±10.06g 344.25±6.79g
Taqman output -  P-actin gene and GAPDH gene
Strain P-actin
(CT)
GAPDH
(CT)
WKY 21.2593 17.3142
WKY 20.6447 17.2603
WKY 21.6301 17.2321
WKY 22.0733 17.7561
WKY 20.5314 17.1643
WKY 21.5487 17.8546
SHRSP 22.0050 17.1953
SHRSP 23.0103 17.1898
SHRSP 20.6415 17.2227
SHRSP 23.3812 17.2333
SHRSP 22.4896 17.1989
SHRSP 23.7895 17.3246
WKY CT Values for D b p  in Aorta
Dbp
(CT)
GAPDH
(CT)
Dbp
(CT)
GAPDH
(CT)
16 weeks 21 weeks
38.5539 16.5392 37.1875 16.8403
34.2732 16.7670 36.9845 16.8254
37.7171 16.9213 37.2898 16.8351
33.7612 16.5486 35.0097 16.417
38.1302 16.8108 36.2345 16.6781
34.3274 16.5915 35.9987 16.5354
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APPENDIX V
Background Markers for Genotyping and Sequencing
Tm
“C
Marker Size
(bp)
Left Right
ACTTGGTGAAGAAGAG GATTTACTGTGCCTGTGG
50 DlMit3 120 TCAGGG TTTT
TTGTCTGTAAGTATGCA
50 DSMghl 153 CATGTGG GATGAGCAGGGGCATGTC
GAAGGGTACAGTCTGG AAGGCTCCTACTCCAGGT
50 D8Woxl6 208 GAAAG CTA
AAGGCAGCTTGTAAGC GCTCATTCTGGTGCAAAA
50 D8Wox3 150 CTGGG CGC
CCTTTGCGGGGTGTTGT ACCAACAATGCGACAGA
50 D9Woxl3 278 A GAAT
GACATTAAGGGGTCTTC TATCTTTGCAACGCTGAG
50 D12Woxl 401 CTAAG G
ATTTACAAACAGGGAA CCAATTCTTCCCAAGAAT
52 DlMghlS 111 GAAAGTGT AGTCC
TAGTGGGGACAATGCT ACTCAGATGTATAATTGA
52 DlWox37 146 ATCTC CTGACTG
TTCGGACTCAGTCTTGA GCCTTCCTAGAATACTTG
52 DlWox4 160 TTTGG GT
TCTGAGCATTGAGGGTT AACACAAGACCTCAGGA
52 D5Rat4 152 ATTGTT GCG
TCAAACAATACATGTA ACAATGGAGTCTCCTTTT
52 D7Mitl 1 92 CGTGCC ATGC
TCCACCCTTAGAAAGC CTGCTTTTCTGGGAGACT
52 D7Ratl41 117 ACAGA GG
TGTAGGTATACATGCTA CATACTCCTCATCACCTA
52 D7Wox27 189 TACACCG AGATAG
TTATACCTCCAAGAGAT ACCAGTAGTATCTGTGCA
52 D9Woxl5 194 GAAGG GTTG
GTATCTGATGCCCTCTT CAAGTTTCTCTGGATGTT
54 D18Wox3 226 CTGG CTTC
TGTGCTGTTCATAACCC TGGTGGAGACAGAGATGC
55 DlMghl9 166 CAA TG
ATAAGCCAGCCCCCATT CCTACTGAAAGTGAAATG
55 DlM Itll 275 C TCTGG
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TTCTCCCCTTTTCAGTC AGGGGATTAGAAGCCTCT
55 DlRat97 157 CCT GC
TGAGCCTGGGCACTAT GGACAGGGACTGGAATC
55 D1W0XÎ4 206 GTAG ATC
GACATGGTGAGTGAAG TGAGGCTATCCTGAGCTA
55 DlWox21 104 ACCC ACTC
CCCTTCCTCAAGATTGT CTCCTACAAGTGGTTCTTT
55 D4Mghl5 145 TTCC GACC
TTCTGTATTAACCACAG AAGCCAGCCCAAAGTAA
55 D4Mit2 215 AAAGAAGC ATG
CAGGAATGGGACCCAA GAGCAAGTGACTAGCTCT
55 D4Mit9 97 AAAT GG
GATAGGTGGATATATG GCTGTGCTCATTTATCTGC
55 D4Woxl 105 ACAGACAG C
TCACGTGTGTTCTCAAG TCATCGCCATGTTCAACT
55 D4Woxl6 189 ATCC ATTG
CCCTCTAAGGTCAGCA TCAGGAAACCTGTTCTTG
55 D4Woxl7 149 AGGT AGATA
AGGGAGTGGCAGCATT GAGATAGTTCAGAAGAA
55 D4Wox21 138 TAG ACCCATG
CCCTTCTACAGTGACTC GGGCGCAATTAGTACTCT
55 D5Got43 150 ATATTTGC GATTT
CGÀTCTÂAGÀCÀCACA TTCAGTGTTTGCTCACAA
55 D5Got73 TGTGCAT GGA
GGAAGGAGACAGAAAC CTCGCTTGTAGTGTCAGA
55 D5Got79 175 TCCGA ACTGG
TGAGCCTTTCTCAGGGT AAAATTCAGCATGGGGAC
55 D5Got86 215 CAT AG
CACCTCGACCAACACC TTAATCCCAACTGTGACA
55 DSMghl 5 159 AAC TTCG
GCATACAGCTTTACAGT AGACAAGGGACATGCTCG
55 DSMghl 6 133 GCTGC AG
CTCACAAAACTTGACTG TCAAGATGCTATGGAAAA
55 D5Mgh6 155 AAATTGC GCC
TCTGCATTGAAACTAAT TTGCACACATTGGAATGT
55 D5Mit2 201 CTAAATCC CA
CTACTGGCCGTAGTGTT CCACTGTGGTTGCTGTTC
55 D5Mit9 127 TGC AG
TGTGCACACGTACCTGA CCATGATTACCTTTCACC
55 D5Rat229 ACA CG
TTCCCTAAGAGCAGGT AGCTACATGGTAAGGCTC
55 D5Uia4 250 GATATG TGTC
TTCCCTAAGAGCAGGT CATGGTAAAGGCTCTGTC
55 D5Uia6 246 GATATG TGA
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TGGGTAGGTCGTGTCTT CCTGGTTAGAGGAGGGAG
55 D5Woxl4 227 CTC TC
GGTAGAGGTGAGTGGA CCTCCTCAGCTCTGCTAG
55 D5Woxl5 ATGAA TC
154- CAGCCTTCATTCTCACA TGACTTCTGTGAGCTCCT
55 D5Woxl6 160 C AC
CCTGCTGTTTCTGACTC AGCATCCAAGACTGGGTG
55 D5Wox4 157 cc C
TTGGTGGTGCTGCATCT CTTAAGGCAATATAGGAA
55 D5Wox7 169 ATTG ACTAC
ACAGCTGGAATCCTCTG GAGCTAGCCATGCAGGAA
55 D7Mit7 260 GG AC
GAGTTAACCCAACAAC CCCAAATGCAGCAGTCTA
55 D8Mgh4 152 TCTAAGCC CA
CAACTCCTGCAGGTTGT CCAGCAGCTACCTCTTCC
55 D8Mgli6 150 CCT AG
GCAGTGTGAGAGGAAA GAAGTCCTCACCTGTGTT
55 D8Wox22 181 GTGTC GAG
GAGATGGAGAAACAGG TCTTCCTGGAATCAATGT
55 D8Wox5 252 GACC GG
GCATAATGGAAGAAGA TCCATGCATGTGTATCTG
55 D9Mit4 204 CAACTACC CA
ACTCACTCAACTCTACC AGAAAGGAGGGGGTTGTT
55 DllRat31 153 ATCAAAA GT
GTGTGCCATATATACAT CTGAGACATAATATTTTC
55 D12Mit3 154 GCATGC ccccc
TAACCTCCAAAGGACC CTAGATAAGGTGTATGTG
55 D12Wox2 194 TCTC GCTC
TCCCTTGGTTTATTTTG CCTCCTCGTGCTGGAAGT
55 D17Mit5 290 CCA AG
TCATCCAGTTGAGCAG AGAGTCTGGTAAAGTGGT
55 D17Wox5 104 GAAGC GTG
CAAGGGAGTAGGTGTG TGCATCAGTGCTTACTGT
55 D17Wox7 CCTA GG
AAAGCCAAGGTCTTAA
55 D18Mit8 146 CTGAAGC TCGACCACACACCTCCCT
CCTTTCTTTGGGGAAAA CTGACATGCATCTGCTAT
55 D19Woxl 127 AGC ATGG
GCAAGAGGCTTACATA AGCCAGCTAATGTGTCAA
55 D19Woxl2 127 ATAGCA GTG
ACGCAAATCAAACCAG CATCCCCATCTTCGTCCA
55 D20Wox6 144 CC G
GGAACCTGCACAATCA CCATCTACTCCAGTCCTT
56 D5Rat95 160 TGTG GGTT
288
Tm
“C
Marker Size
(bp)
Left Right
AGGAAAAGCATATAGA TTTACTTACTAGGGCATG
58 DlW oxl? 81 ACACGC GGAT
ATTGTATATTCCAGACT AATTGATGTGACATTATT
58 DlWox2 123 AGC TTCATTG
GCGATTATATTGTCACC
58 DlWox34 140 TTCC GGTAATCAGGCGCTCTCC
ATAGGAATAAAGAGTG CAGTTAGCATAGAAAGCA
58 D6Mgh5 106 CACGTTTG AAGGG
TTCTGATGGCTAAGCTG
58 D6Woxl3 271 TTG GCTCCACCCTGCAAGTAC
TGCCCCAAAAAGGAAA TCAGCTTCATACGGAAGC
58 D7MitlO 171 AAC AA
ACAAAAAGATGAAAGG GAAGGCCACTGGTCTCTG
58 D8Gotl51 263 TTGGC TTAC
CGGAAAGGGAATAACA CACGAGCATGGTGCATAC
58 D9Wox21 136 ATCG AC
AAGGTTGGCAGTTTCCC ACCATTTATGTGCCCAGA
58 D19Mit2 200 AG TG
CAAGGACTGAGTGCAT TTCTCTCTTGCTAGCTGCC
60 DlWox20 118 GCTC A
CTCAAGCCTCAGGCATC AAGGACGTTATCCATTTT
60 D4Mghl7 132 TG GGG
AGGACAGGTTTTTGGG
60 D4Mitl4 150 CTTT TCTGCCGCCACCTTAGAG
TCATCCCAGGCCATAA
60 D6Mit3 111 AGAG ACGGTCACACAGTGGCCT
AGCAAAGCAAGTTAGC AATTTTAAGGAAAGAGGC
60 D7Mgh9 126 AGATCC CTGG
ACCTCAGGTCCCAGGA AGGTAAGCCAGTGGATGC
60 D7Mitl 182 GTG TT
GTAGAAGGTTCTGCAA GGGTCCCAACTGCATCAG
60 D7Woxl 80 AACATGC CC
CTTTGATACTGTACCAA AATGTCAGGATGGCAGAG
60 DSMghlO 142 CAGCACC AC
GCACACACACCCCCTTC CATGGATTTGATTCCTGG
60 D8Wox2 158 AC AC
CTCCTGCCTGGGTAACC CCTCTTCTGGGCTTCTTAG
60 D9Wox2 162 TG G
CTTGTATTGACACCCAT GGATGCAAAGCATATCCT
60 D10Wox26 170 GTGC GAG
CACTTCCCAAATGCTAG AGAGAAAATATGTGGAC
60 D13Mghl 147 CGT AGAAGCC
CACACTGGTTCATCCAC GAAGCAGGTGATCCTAGA
60 D13Mgh6 112 AGG GTGA
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AGCAGCGGTATCTCCA GGGTGACGGAGACAGAG
60 D15Mgh6 216 GTGT AAA
GACCTCCAGGATTGGT ACAACCCATGAGGCAGAC
60 D16Mghl 237 GAGA AG
TCATTTCTGCTTCTTTCC CTGCAGGAAGGAAAGCA
60 D16Mgh2 151 TATGG AAC
CGGCTCAGAGTTACTA TTACCAATACAAGTGCGA
60 D16Woxl5 171 AATAGGT GTTT
GCCAAGGCTACATAAT CACACTCCCATTCAGCCC
60 D16Wox4 100 GATACCC CTC
TAAGGTCCCTCCAGACT TGGGCAGAGAACAGCAG
60 D17Mit3 186 CCA TC
ATCTGTGTGCGAGTGCG
60 D17WoxlO 147 T CTGGCGAAGTGACGTGAG
TAAGGACCCCTGATACT AGATCTTTGTCAAATTCA
60 D17Wox21 153 CTGG TGGC
120- CCTAGGCAGTAGTTACC
60 D18Mgh4 210 ATGTGC TGTTTCTGTTGCCCTCGAG
CAAACAATTCTAAAAC CACCTACTACTGACGGCA
60 D18Woxl 101 AAAAAGTG GG
CTCTCCCTTCAGTCCCA TCCTAGAGCCCCTTTTCA
60 D20Mghl 136 TTG CA
GATGAGTCTCTCCCCAG GTCTAGCCTGGGCAACCT
60 D20Wox8 132 CC TC
ACTCCAACACCCAGTC GCCAAAGCATCTCCCTAT
60 DXMit4 188 AACC CA
TGGTGGCTCACAACAG CCAGTCATACTGCATCTG
61 D6Gotl31 220 ACAG CAATA
GATTCCAGGTTGTGGCA ATGCATGCATGGAGTTTG
62 D19Rat4 360 AGT TG
CATATTTCCCCCAATCC CGGATCTCCATATGTACT
64 D13Mgh4 143 TGT TGTACA
TTCCATCTACTGCTGTT TCTGCCTTCTCACATGAA
62 DlM itl4 112 TAGGG CA
CTGATTACCAGGTCACC TCTAACAGCTGTAGCAAC
58 DlWox27 150 TTAAG TGG
CAGGAGCTGTCTGGGA GAACACTAGAGAAACTA
52 D4Mghl6 259 CTTC GGCAGGC
TCACAAGTTTGTGTGCC AAAGCAAGTTTTAGGATA
55 D6Mit4 225 TGA GCAGG
TTGAGAAGCGTTAAAA TTGGTTTCCAGGGTGAGA
56 D6Wox21 120 TATGTG A
TGTGGCAAGTACATAC CTCTACCTGCCTGGTCTA
60 D7Wox2 180 ATCCC GC
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ACAACTCCCATCTCTTG GCTTTCAAACACCACAGG
60 D9Mitl 130 AGAGG GT
GGTGTAGGTTCGTCTGT CGGTGCTCATAAAAGGGA
60 DlOMghll 140 CAGG AA
CTTGGATGAAGAAGTC CAAAGACCCTTTTGAGAG
59 D10Wox2 192 TCCAC AAC
GAAGTCTTCACTTTTAC GACCCTTTTGAGAGAACT
54 D10Wox3 176 TTGTGG TTTG
AACAGTCAAAAGAGAT AAACAAATGATGTACATG
61 DllMgh6 100 ATCCAGGG CATACA
GCATATGGGAGTTTTGC CCAGTTGCAGATGATTTC
59 D llR atl7 150 GTG CA
GGATTGAGGGTGGGGT TTCAACAACCACCTCACT
54 D12Mgh3 124 AAGT TCC
TTCAGATTAGTATAGGC GAGACCCTCAACCTGTGC
54 D15Mgh2 148 AGGGTCC AT
AGACCCAGGGTAGGCA GATTACAATTCTGTCCAA
52 D15Mgh3 146 TTTT GTCACG
103- CCTGGGAATTTCATTCT AGCTGTCCTCTGACCTTC
56 D16Woxl 122 TGG ACA
GCCACACTTGGTGATCT TATTGTCTGGGTTTGCTCT
57 D16Woxl2 131 AGC CT
AGTAGACAGGAGTGGG CTCTTTGGGCAGCTTACA
58 D17Woxl3 134 AAGGA TT
ATAATCCAATCAGGGC AGACACATTCACTTCCAG
59 D17Wox20 185 TTAAC GTC
CCAGAACGATTACCCTC CCTCAGGACCAGACACTA
62 D18Woxl8 149 ACC CG
TGAGCCCTAGGTTCAAC ACAAAAGCTGCTAGGTTT
60 D19Mit5 97 ACC GAGG
TGCTCACTTCACAACTG CCTTCTCCAAAGCACCAA
60 DXMit5 215 GCT AA
TGGGAACATCCATATC TGAGCCATTTGCAAAGAG
60 D13Mgh3 120 ATTCA G
ACCCTAAGGCTCTGTCT CTTTGGATAGTAATGAGT
60 D4Wox24 194 CAAA GCTTTG
TACCGTTATCAATGAAA GATCTGAATACTTATGTG
59 D8Wox21 324 GAGTCTA CCCTC
GCTGTTGTCCTCAAATT GGTCTCAGAAGGTATACC
58 D9Wox20 107 TTCTC CATAG
TCACAGAGACCATGGA GACCCTTATTCTCTCCCTC
54 D13Mghl6 140 GCAG CC
GAAAAATACTTCCACA AAAGTCAAGCCCTGGAGT
54 D20Wox5 259 CACTAATG G
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ACATCAACCCCATTAG AACCTCATCCTCATCCAA
57 D4Gotl2 170 ATTTCA AAAG
GACCTGACCTGTTGTGG
57 D15Mit3 200 GAT GTTGCTCTCTGGCCTCCTC
CCTTTGCTCTGAGCCTG AGAGAAAAAGAAAAGGG
52 DlMgh5 155 G AAAACG
GCTACTGCCTTGCCCTC TCACATTTTACCTGTAGTT
55 DlWox32 188 A GGAA
GGGGAAGTTTTAGGAA AGGGAATGAAAATACAA
55 Dlmitl 146 GTCCC CACGC
GATCCAGCTCACATCTA CCAAATGCTCTTGCAGTC
50 D4Mgh7 145 ATCCC AA
TCCCAACTCTCCCTTAC TGTCTTGGAAGAAAGAAA
52 D7Mgh5 229 CG GAAGG
TGAAGAGTTTTACTGGG TGGACCAGGCAAGTTCTC
55 D8Mgh7 191 TAGCTCC TT
TGAGACTTGTATTCACT CTATCCCTGTCTCTGTGTC
55 D9mit3 156 CCTCCC TACCA
GCCAGATATAAGATGA CCACAGTCATTGAGTTAT
55 D9woxl8 178 TTAGTCTG TGGT
CCTGGACACTAATCCTA GGGTAGGTCTGAGGGAA
55 D13Wox4 180 TCTTG GG
AGGCTTTGATTGCAGG AAAGAGCTGTCGTCCACA
55 D16woxl0 118 AAG AC
GGCTTGTGTGGACACCT AAAGAGCAGGGAAGAGA
55 D16mitl 164 GTA CAGG
CACATGTTTACTTTCTA CCCCTCTTCTGGACTTCAT
55 D18woxI2 148 AGCATTTG AG
TCACAATAAAAAACTC AGTCTGTGCCCTGTTCCC
55 D18woxl6 152 CTCCAAC A
GGTATGGGAGTAACAT GGACACATACAGTAAGCA
55 D19Wox2 129 GACCTC CATGC
TGCCCGTCTCTGTTACT CAAGAACCCTGAGGCAAT
55 D 19wox8 111 CAT AA
AGGAAATGGGTTTCAG CAGGATTCTGTGGCAATC
55 D20wox3 125 TTCC TG
GATCGTCCAGCATCGTG GTTGGTGCTACTCAAGAT
55 Dxwox3 130 G CGG
TTCGAGAATATGTGGCT GTTAGGGAACACCGGTGA
56 D3Mit7 128 GCA GG
ACTTGAGTTGATGGCTT AGAGGATGCCTCTGAAGC
60 D3Ratl28 127 GGC AA
GATTGCAGAATGACTG ACCCTTTGCCTCCATTCTC
60 D3Ratl33 130 GCAT T
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CTCAATGCCTGCATCTG CAGGTGTAGCCTTCTCAC
52 D3Ratll4 131 AAG ACA
ATCCCAGCACTGCATA AGGATGTCAGGAACGCA
60 D3Rat59 170 AACC GAT
GTAAGTGGCTCCAGTTT CCTGGGTTCGATTCCTAA
58 D3Rat35 154 GGG CA
GCTCAGCATGCATCTTC CAGTCTAGGCAACTGAGA
54 D3Rat94 160 TTG CACTG
CCCCAATCTTCATCTAA TGGGAGCAGAAGAATCTC
56 DBRatBO 162 CCC TCA
GAAAGCAATGGCATCC TATTATTGTGTATTTTGGG
57 DSMghl 5 165 TGAT CATGC
GAAAGCAATGGCATCC TATTATTGTGTATTTTGGG
58 DSMghl 4 124 TGAT CATGC
CTCGCACTAAGAGGGC GATCCACAATACTCACAT
58 D3Got83 125 ACTG GTGAAAT
GCAAAGAGATGCACAT AAAAAACCAACCCCCTTC
60 D3Mit4 124 CTGG C
TTCTACTTGGGGATTTC ACTTTGACGTTGAATGGT
60 D3Woxl9 145 TTGAT TGA
TACCTGAAATGCCCACC CTGCCTCAGAAAATAAGG
60 D3Gotl25 156 CT TGGA
CTTTTTGGGAAAAGCA TCGATCTTAGAGCACACC
60 D3Gotl41 151 AAAAGC ATG
CCACAAAAAAGCATCC GGAGAGAATCTACCAACT
59 D3Gotl29 130 AAACA GTTGC
AGCCATGACATTGTCTT GAACTTTTTGAATGGGAT
59 D3Mgh5 178 CTGG AAAGAA
CACAAAAACGTCCCTTT GATCACTGCACTCGTGTA
57 D3Gotl32 147 CCT TTGTTC
GATCTTATCTGCCTCTT ATCTGAACTCCATTGACT
55 D3Gotl20 156 T ACG
GGCCCTGCCTCAGAAA CCCACCCTTAGGTTTCTTG
55 D3Gotl21 154 ATAA TGT
CTTTTTGGGAAAAGCA TCGATCTTAGAGCACACC
60 D3Gotl41 121 AAAAGC ATG
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APPENDIX VI
Cited Cardiac mass QTL
Chr
No.
Start Pos. Stop Pos. *QTL Flanking
markers
LOD
score
P-va lue
1 135159025 176894238 QTL 23 DlMgh9,
DlMit2
4.6 0.0004
1 181664764 263910134 QTL35 DlRatl55,
DlMghl4
5.7
1 87443392 153756953 QTL 16 DlRatl89,
DlRatl58
2.7
1 103228034 37184 QTL 32 DlRat29,
DlRatl88
5.2
1 103228034 37184 QTL 36 DlRat29,
DlRatl88
4.1
1 103228034 37184 QTL 32 DlRat29,
DlRatl88
5.2
1 209484615 239484615 QTL 7 DlRat73,
DlRat92
5.32 0.0001
2 146178185 35064 QTL 29 D2Mghl5,
D2Rat64
3.50
2 77461812 156192873 QTL 22 D2Mit6,
D2Mgh7
4.3 0.0008
2 24474448 163154228 QTL 38 D2Ratl82,
D2Rat40
2
2 24474448 163154228 QTL 39 D2Ratl82,
D2Rat40
2.26
2 24474448 212168914 QTL 41 D2Ratl82,
D2Rat55
2.73
2 24474448 212168914 QTL 42 D2Ratl82,
D2Rat55
2.82
2 105274088 170210328 QTL 14 D2Mgh26,
Eefla2
2.1
3 21353078 51353078 QTL 8 D3Mgh7 7.03 0.0001
3 1 19010302 QTL 10 D3Mgh9 7.34 0.0001
3 26674019 6373336 QTL 43 D3Mit9,
D3Mghl6
6.6 2.9E-08
3 26674019 6373336 QTL 46 D3Mit9,
D3Mghl6
5.4 5.5E-06
3 26674019 6373336 QTL 48 D3Mit9, 
DSMghl 6
4 0.0001
3 21197575 35034292 QTL 13 D3Ratl00,
D3Mcol6
2.5
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No.
Start Pos. Stop Pos. *QTL Flanking
markers
LOD
score
P-value
3 103497433 133497433 QTL 17 D3Ratl60 2
3 58879349 87777490 QTL 25 D3Rat27,
D3Rat38
4.8 0.0001
3 21353078 51353078 QTL 8 D8Ratl20,
D8Ratl49
7.03 0.0001
4 129019956 159019956 QTL 18 D4Ratl95 2.6
5 135083701 165083701 QTL 24 D5Ratl73,
D5WoxlO
3.5
6 QTL 47 D6Mgh4,
D6Mit4
2.9 0.001
7 47266045 107884993 QTL 6 D7Ratl36,
D7Arbl6
4.09
7 47985908 125333398 QTL 27 D7Rat9,
D7Ratl07
3.45
7 105547152 108809845 QTL 1 D7UIA1,
D7Mcol
2.7
7 47266045 107884993 QTL 6 D6Mit5,
D6Mgh6
4.09
8 98905540 126436679 QTL 19 D8Ratl30,
D8Rat3
2.6
8 57427796 58611955 QTL 3 D8Ratl49,
D8Rat36
3.97
8 74716950 36003 QTL 2 D8Ratl59,
D8Ratl4
3.65
8 103174717 106194717 QTL 40 D8Ratl64,
D8Mgh3
1.89
8 29565716 103691902 QTL 30 D8Rat51,
D8Mghl5
3.77
9 77170798 105579863 QTL 53 D9Mco6,
D9Uia6
3.3 0.0001
9 3587583 37414784 QTL 4 D9Ratl01,
D9Rat26
3.55
9 24732014 54732014 QTL 11 D9Ratl25 3.1 0.00089
9 12522363 37414784 QTL 20 D9Rat36,
D9Rat26
3.9
9 21568480 77454334 QTL 28 D9Rat70,
D9Uia6
7.3
9 77254082 105889541 QTL 21 D9Uia6,
D9Mco6
2.7
10 29975240 10466 QTL 31 DlOMghll,
DlOMitl
3.8461
10 29975240 10466 QTL 44 D10Mgh6,
DlOMghl
4.8 3.7x10'"
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No.
Start Pos. Stop Pos. *QTL Flanking
markers
LOD
score
P-value
10 56944071 34813 QTL 33 D10Ratl56,
D10Ratl6
2.8
10 53806591 83806591 QTL 51 DlOWoxl 1, 
D10Wox6
3
10 23806740 53806740 QTL 50 D10Wox3, 
DlOWoxl 1
6.6
10 23806740 53806740 QTL 44 D10Wox3, 
DlOWoxl 1
4.8 3.7E-05
12 28893568 46007684 QTL 5 D12Mgh5,
D12Rat22
3.78
12 28893568 46007684 QTL 5 D13Wox6 3.78
13 28893568 46007684 QTL 45 D13Wox6 3.6 0.002
13 28893568 46007684 QTL 45 D13Wox6 3.6 0.002
17 9988754 35473 QTL 34 D17Rat2,
D17Rat58
8.7
17 76740345 92705174 QTL 26 D17Rat39,
D17Rat52
3.71
17 65811231 81723321 QTL 15 D17Wox9,
D17Rat44
6.5
19 1 21799962 QTL 9 D19Ratl8 4.27 0.0001
19 1 21799962 QTL 12 D19Ratl8 3.33 0.00053
19 1 21799962 QTL 9 D19Ratl8 4.27 0.0001
*QTL number is arbitrarily assigned by Rat Genome Database.
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